{
  "responseHeader":{
    "status":0,
    "QTime":18,
    "params":{
      "q":"(Background: \"lung cancer\"^4 OR \"lung carcinoma\" OR \"small-cell lung carcinoma\" OR \"SCLC\" OR \"non-small-cell lung carcinoma\" OR \"NSCLC\" OR Doc_title: \"lung cancer\"^4 OR \"lung carcinoma\" OR \"small-cell lung carcinoma\" OR \"SCLC\" OR \"non-small-cell lung carcinoma\" OR \"NSCLC\") AND (Background: ERBB2^4 OR \"NEU\" OR \"NGL\" OR \"HER2\" OR \"TKR1\" OR \"CD340\" OR \"HER-2\" OR \"MLN 19\" OR \"HER-2/neu\" OR Doc_title: ERBB2^4 OR \"NEU\" OR \"NGL\" OR \"HER2\" OR \"TKR1\" OR \"CD340\" OR \"HER-2\" OR \"MLN 19\" OR \"HER-2/neu\") AND (Background: \"treatment\" OR \"therapy\" OR \"Surgery\" OR \"Radiotherapy\" OR \"Chemotherapy\" OR \"Targeted therapy\" OR \"Bronchoscopy\" OR \"Palliative care\")"}},
  "response":{"numFound":274,"start":0,"docs":[
      {
        "Meeting_name":" A case series of ERBB2 indel driver mutations in non-small cell lung cancer identified by cell-free circulating tumor DNA NGS",
        "Background":"['Background', ' In-frame insertions between codons 775 and 881 in exon 20 of the ERBB2 gene, of which a 12 base pair YVMA insertion is the most common, are activating mutations in 2%-4% of non-small cell lung cancers (NSCLC), and have also been reported in exon 19 and 20 in breast cancer. These driver mutations are not captured with IHC or FISH staining because in the majority of cases, the ERBB2 gene is not amplified and HER2 protein is not overexpressed. Next generation sequencing (NGS) of circulating cell-free DNA (cfDNA) provides a non-invasive means of identifying these potential driver mutations.Method', ' Guardant360TM is a targeted cfDNA NGS panel using hybrid capture and complete exon sequencing for single nucleotide variant detection in 70 genes, copy number amplifications (CNA) in 16 genes, and fusions in six genes and indels in EGFR, ERBB2 and MET exon 14 skipping. De-identified pathology and genotyping reports were reviewed for consecutive patients in which ERBB2 indels were identified in clinical practice.Results', ' Guardant360 identified ERBB2 indels in 27 of 2,093 (1.3%) of non-squamous NSCLC cases, with a single concomitant ERBB2 gene amplification. For this ERBB2 indel series, pathology reports revealed no patients with HER2 amplification via IHC or FISH, nor ERBB2 point mutation via NGS, but were only available in 25% of cases. Eight of the ERBB2 indels were confirmed by tissue NGS reports with zero false positives (100% PPV). 80% of ERBB2 indels were the common p.Tyr772_Ala775dup (YVMA insertion) in exon 20 followed by other insertions in codons 772 through 814. A single ERBB2 exon 20 p.Leu755_Glu757delinsProLys net deletion at 3.9% mutant allele fration (MAF) was noted in one patient, for whom outcome data was available. Initial tissue was IHC negative for HER2 overexpression at the referring hospital where the archival tissue biopsy was exhausted and so could not be sequenced. Based on the cfDNA finding of ERBB2 indel, the patient was switched from cytotoxic chemotherapy to trastuzumab with objective response on PET/CT and a repeat Guardant360 showed the ERBB2 indel MAF had dropped below the test limit of detection. After four months the patient progressed and it was decided to switch to ado-emtansine trastuzumab (T-DM1) in late November.Results', ' ERBB2 indels can be identified without tissue in NSCLC patients with 100% PPV in this modest cfDNA series. In a patient whose tissue was not available for sequencing, an objective response with trastuzumab was obtained.']",
        "Doc_id":"AACR_2016-2240",
        "Doc_title":" A case series of ERBB2 indel driver mutations in non-small cell lung cancer identified by cell-free circulating tumor DNA NGS",
        "_version_":1606189013979365376},
      {
        "Meeting_name":" Concomitant mutation and amplification of the ERBB2 (HER2) gene in human tumors.",
        "Background":"['Background', '  Amplification of the ERBB2 (HER2) gene is a well-known genetic aberration in many tumor entities. Up to 20% of breast and gastric cancer show ERBB2 gene amplification and anti-HER2 targeting therapies are well established for these tumors. In other tumor entities such as lung cancer, colorectal cancer and bladder cancer the fraction of ERBB2 amplified tumors is considerably lower. In contrast to breast cancer, these tumors show heterogeneity of ERBB2 amplification in a substantial proportion. Oncogenic EGFR mutation with subsequent EGFR amplification is a common phenomenon in lung cancer. In analogy, primary ERBB2 mutation could explain the observed heterogeneity of ERBB2 amplification in some tumors. Methods', '  100 tumors showing ERBB2 amplification by fluorescence in situ hybridization were examined for ERBB2 mutation', ' 50 breast cancer samples, including 10 cases with borderline gene amplification, 10 cases with heterogeneous gene amplification and 11 samples of metastatic lesions as well as 15 colorectal carcinomas, 12 gastric carcinomas, 12 non-small cell lung cancers and 10 urothelial carcinomas. Tumor DNA was extracted and examined for mutations in the tyrosine kinase domain (exons 18-23) of the ERBB2 gene by Sanger sequencing. Results', '  ERBB2 mutation was found in two metastatic lesions of breast cancer, two lung cancers and two colorectal cancers. In five of these cases short in-frame insertions in exon 20 were found. In one case of a breast cancer lung metastasis a missense mutation in exon 19 (p.L755S) was detected. The semi-quantitative chromatograms show an overrepresentation of the mutations indicating a selective amplification of the mutated allele. Conclusions', '  In certain tumor entities the heterogeneity of ERBB2 amplification indicates a late genetic event. The finding of a concomitant mutation in ERBB2 amplified tumors might explain the heterogeneity in some of these tumors. The effect of a primary oncogenic ERBB2 mutation might be increased by selective amplification of the mutated allele resulting in an additional growth advantage. If ERBB2 amplified tumors with a primary ERBB2 mutation also benefit from an HER2 targeted therapy needs to be elucidated.']",
        "Doc_id":"ASCO_133558-144",
        "Doc_title":" Concomitant mutation and amplification of the ERBB2 (HER2) gene in human tumors.",
        "_version_":1606188998316785664},
      {
        "Meeting_name":" Custom (Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies) trial.",
        "Background":"['Background', '  CUSTOM is the first completed prospective clinical trial using molecular selection for treatment assignments into multiple targeted therapy arms and in multiple cancer histological subtypes concurrently.  Methods', '  All patients with advanced NSCLC, SCLC or TM were eligible to participate in the study. Oncogenic mutations, amplifications or translocations in 12 genes detected in CLIA-certified laboratories were used to assign patients to 1 of 5 biomarker/treatment groups per histological subtype', ' EGFR mutations/erlotinib; KRAS, NRAS, HRAS or BRAF mutations/AZD6244; PIK3CA, AKT or PTEN mutations/MK2206; ERBB2 mutations or amplifications/lapatinib; and KIT or PDGFRA mutations/sunitinib; or to standard-of-care therapy. For each arm, the study was conducted as an optimal two-stage phase II trial in favor of a response rate of 40% or more.  Results', '  668 patients were enrolled at two academic institutions. The most frequent genetic alterations in NSCLC were KRAS and EGFR mutations (25.2 and 19.7% respectively), ALK rearrangements 7.8%, HER2 amplifications 2.7% and mutations in PIK3CA 2.5%, BRAF 1.9%, HRAS 1.5%, ERBB2 1.7%, AKT1 0.4%, and NRAS 0.7%. PTEN mutation analysis was only feasible in 13 patients with NSCLC of which 3 were positive (23%). The most frequent genetic alterations in SCLC were mutations in PIK3CA 6.5%, ERBB2 amplifications 5.3% and mutations in HRAS 3.4%, AKT1 2.2%, BRAF 2% and KRAS 2%. The most frequent genetic alterations in TMs were HER2 amplifications 7.7% and mutations in HRAS 4.7%, PIK3CA 1.4% and EGFR 1.4%. Only 6.2% (n=42) of patients met criteria for enrollment into the treatment arms of the study. Efficacy analyses including response rates will be presented.  Conclusions', '  CUSTOM is the first completed prospective clinical trial demonstrating the feasibility of conducting efficacy analyses of multiple biomarker-matched therapies in multiple cancer histological subtypes concurrently. CUSTOM is also the largest prospective molecular profiling study of patients with SCLC and TMs. Clinical trial information', ' NCT01306045.']",
        "Doc_id":"ASCO_108629-132",
        "Doc_title":" Custom (Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies) trial.",
        "_version_":1606189037647822848},
      {
        "Meeting_name":" An analysis of ERBB2 alterations (amplifications and mutations) found by next-generation sequencing (NGS) in 2000+ consecutive solid tumor (ST) patients.",
        "Background":"['Background', '  Testing for ERBB2 amplification by FISH and IHC is routine in breast and gastro-esophageal cancer. There are 3 approved and multiple targeted therapies in clinical trials that rely on the results of these tests. ERBB2 amplification and activation by mutation/fusion has also been described in a wide variety of other ST. As these alterations are not routinely tested for but may predict response to anti-ERBB2 agents we sought to determine their frequency in an unselected cohort of specimens from advanced ST patients.    Methods', '  We reviewed genomic profiles from the first 2,223 formalin-fixed, paraffin-embedded specimens received and analyzed by our CLIA-certified lab (Foundation Medicine) with our NGS platform. 3,230 exons in 182 cancer-related genes and 14 genes frequently rearranged were assayed for base pair substitutions, small insertions/deletions (indels), amplifications, and rearrangements.   Results', '  110/2,223 (4.9%) specimens had 116 ERBB2 alterations', ' 67 (58%) amplifications, 29 (25%) substitutions, 16 (14%) indels, 2 (2%) splice site variants and 2 (2%) translocations, including a potential fusion. Six samples (5%) had multiple alterations, and two had both ERBB2 substitution and amplification.  14 ST types had evidence of ERBB2 alterations including 29% of esophageal, 20% of uterine, 14% of breast, and 12% of stomach carcinomas. 6% of all lung cancer samples had ERBB2 alterations. Amplifications predominated, but lung specimens had predominantly indels. Durable responses exist to anti-ERBB2 agents in STs with activating ERBB2 mutations.  Conclusions', '  Use of a broad NGS panel identifies an unprecedented number of actionable genomic changes including a significant rate of ERBB2 alterations across 14 different solid tumor types. The discovery of unanticipated ERBB2 amplifications and activating mutations in a wide variety of ST highlights the need to study a broad range of genes at a high level of sensitivity and specificity when searching for novel targets of therapy. Widespread use of this approach could provide more treatment options and enable more rapid accrual to ongoing and planned trials of agents targeting pathways under study.']",
        "Doc_id":"ASCO_114501-132",
        "Doc_title":" An analysis of ERBB2 alterations (amplifications and mutations) found by next-generation sequencing (NGS) in 2000+ consecutive solid tumor (ST) patients.",
        "_version_":1606188981924397056},
      {
        "Meeting_name":" Clinical and molecular profiling of surgically resected small-cell lung cancer",
        "Background":"['Background', '  NCCN and Japanese guidelines suggest surgery for patients with c-stage I small-cell lung cancer (SCLC). However, the clinical impact of surgery with other variables on patients with early-stage SCLC has yet to be determined. Thus clarification of the clinical and molecular profile of SCLC is required. Methods', '  We reviewed the clinical courses of 149 patients with SCLC who had undergone surgery at 16 institutes from January, 2003 through January, 2013. Eighty-nine paraffin-embedded tissue samples were subjected to immunohistochemistry using 8 antibodies, and to next-generation sequencing system (NGS) using MiSeq and TruSight Tumor Panel (Illumina) loading 26 genes (UMIN registration No. 000010116/10117). Results', '  Median relapse-free survival (RFS) and overall survival (OS) were 16.6 (95%CI=7.1-26.2), and 36.7 (17.3-56.2) months, respectively. Multivariate analysis revealed that OS was longer in patients without interstitial pneumonitis (IP) (HR=0.372, 95%CI=0.181-0.767, p=0.007), without history of malignancy (HR=0.446, 0.229-0.868, p=0.017), with preoperative diagnosis (HR=0.401, 0.210-0.767, p=0.006), with c-stage II and under (HR=0.204, 0.065-0.640, p=0.006), and with p-stage IA (HR=0.294, 0.142-0.605, p=0.001). Of the 89 patients whose samples were available, MED12 and TGF-RII were highly expressed in nucleus and cytoplasm, respectively in 92% and 61%. Multivariate analysis demonstrated that high expression of either c-Kit or HER2 in tumors is an independent factor for longer OS (HR=0.396, 95%CI=0.209-0.752, p=0.005). None of the tumors expressed ALK. There was no relationship between the expression of c-Met, EGFR, and VEGFRII and either of RFS or OS. Thirty-five samples were subjected to NGS so far. However, no druggable mutations of BRAF, EGFR, ERBB2, KRAS, KIT, PDGFRA, PIK3CA, FOXL2, GNAQ, GNAS, and FGFR2 were found. Conclusions', '  These results indicate that i) complication of IP and history of malignancy might be major decision factors of surgery, and', ' ii) patients with c-stage II should be considered for surgery in a prospective trial. Immunohistochemistry results assist us in gaining a better understanding of the biology of SCLC.']",
        "Doc_id":"ASCO_125324-144",
        "Doc_title":" Clinical and molecular profiling of surgically resected small-cell lung cancer",
        "_version_":1606189014759505920},
      {
        "Meeting_name":" Clinical significances of ErbB family receptors, Myc, and mitogen-activated protein kinase (MAPK) in patients with early-stage non-small cell lung cancer.",
        "Background":"['Background', '  EGFR deregulation has been extensively studied in non small-cell lung cancer (NSCLC), but less is known about the expression and role of other ErbB receptors and their downstream signal transductions. Myc and MAPK are key downstream components of the EGFR pathway and have significant roles in cell survival, proliferation, and growth. The purpose of this study is to determine the prognostic value of  EGFR,  ErbB2,  ErbB3, ErbB4, Myc and MAPK  by immunohistochemistry (IHC) in early stage NSCLC. Methods', '  109 NSCLC were evaluated', ' median age was 67 years (range 4084); Male/Female', '93/16; squamous (SCC)/adenocarcinoma (ADC)/BAC/other', ' 52/36/3/18; smoker/never smoker', '100/9, and stage I/II/III', '67/17/25.  The tumors with 10% positive cells were classified positive, further confirmed by Receiver Operating Characteristic (ROC) analysis. Kaplan-Meier estimates of survival and time to recurrence were calculated for clinical and biologic variables using Cox model for multivariate analysis  Results', '  EGFR and EbrB3 were associated with SCC (p<0.0001 and p=0.004, respectively) whereas ErbB2 and Myc with ADC (p=0.004 and p<0.0001, respectively) . EGFR and ErbB3 were significantly associated (p=0.003), as well as MAPK and ErbB4 (p=0.02). At  a median follow-up of 75 months the contemporary overexpression of EGFR, ErbB2 and MAPK was associated with shorter disease free survival (DFS) (HR=5.4, p=0.002)  and overall survival (OS) (HR=8.9, p<0.0001). At multivariate analysis adjusting for stage, the co-expression of EGFR, ErbB2 and MAPK was an independent predictor for worse DFS and OS (HR=5.7, p=0.004; HR=8.67, p<0.001, respectively).  Conclusions', '  Our results suggest that in early stage NSCLC, the co-expression of EGFR, ErbB2 and MAPK  predicted a worse prognosis. ErbB3, ErbB4 and Myc were not prognostic factors. Such features may have important implications for future targeted therapies. We thank  Italian Association for Cancer Research (AIRC) for supporting the study.']",
        "Doc_id":"ASCO_100326-114",
        "Doc_title":" Clinical significances of ErbB family receptors, Myc, and mitogen-activated protein kinase (MAPK) in patients with early-stage non-small cell lung cancer.",
        "_version_":1606188984143183872},
      {
        "Meeting_name":" Outcomes with chemotherapies and molecular characteristics of HER2-mutant lung cancers.",
        "Background":"['Background', '   Human epidermal growth factor receptor 2 (HER2, ERBB2) mutations occur in 3% of lung adenocarcinomas and are increasingly being identified with the growing adoption of multiplex next-generation genotyping. HER2-mutant lung cancers impart a distinct natural history with a median overall survival from stage IV diagnosis of 1.6 years (Kris JAMA 2014). While case reports and series have shown activity of HER2-targeted agents in these patients, little is known about outcomes of systemic treatments.  Methods', '   Patients with stage IV HER2-mutant lung cancers at Memorial Sloan Kettering were reviewed. Patient demographics, types of HER2 mutations, survival, and duration of systemic treatments were documented.   Results', '    37 patients with HER2-mutant lung cancers were identified', ' median age 62; majority were women (n = 24), never smokers (n = 21), and had adenocarcinomas (n = 36, 1 adenosquamous). A 12bp in-frame insertion in exon 20 (p.A775_G776insYVMA c.2324_2325ins12) was present in 23 (62%, 95% CI 45-78%) patients. In addition, there were four 9bp insertions, one 6bp insertion, and five 3bp insertions in exon 20, and four single base pair substitutions (3 exon 20, 1 exon 8). The median overall survival from date of diagnosis of stage IV disease was 2.3 years (95% CI 1.2-2.7). The median duration of all chemotherapy was 8 months (range 0.8-43 months). Median duration of treatment was 6 months for pemetrexed platinum/bevacizumab, 3 months for taxane platinum/bevacizumab, 4 months for gemcitabine, 4 months for vinorelbine, 5 months for mitomycin vinblastine. The median duration of targeted therapy was 3 months for trastuzumab, 4 months for small molecule HER2 tyrosine kinase inhibitors, 3 months for erlotinib. No objective responses were noted with trastuzumab (n = 2) or lapatinib (n = 4) alone.  Conclusions', '   Most HER2-mutant lung tumors demonstrate an identical 12bp in-frame insertion (YVMA) in exon 20. In our cohort, the median duration of treatment with chemotherapy was double that of HER2-targeted therapies. Pemetrexed-containing regimens had the longest duration of treatment. As we search for better targeted therapies for patients with HER2-mutant lung cancers, chemotherapy remains an important component of care.']",
        "Doc_id":"ASCO_151022-156",
        "Doc_title":" Outcomes with chemotherapies and molecular characteristics of HER2-mutant lung cancers.",
        "_version_":1606189006808154113},
      {
        "Meeting_name":" Activating ERBB4 mutations in non-small cell lung cancer",
        "Background":"['Genes encoding the ErbB receptor tyrosine kinases (EGFR/ERBB1, ERBB2, ERBB3, and ERBB4) are key regulators of cellular proliferation, survival, and differentiation, and thus represent potent proto-oncogenes. In particular, mutations or copy number variations of EGFR or ERBB2 are present in human malignancies and serve as predictive markers for targeted therapies. Recent efforts to comprehensively characterize the mutational landscape of human cancers have identified frequent somatic mutations in ERBB4 in various cancer types, such as non-small cell lung cancer (NSCLC), melanoma, and colorectal cancer. However, the significance of mutated ERBB4 in cancer remains elusive.Here, we have functionally characterized nine ERBB4 mutations previously identified in lung adenocarcinoma. Four out of the nine mutations, Y285C, D595V, D931Y and K935I, were found to be activating, increasing both basal and ligand-induced ErbB4 phosphorylation. According to structural analysis, the four activating mutations were located at critical positions at the dimerization interfaces of the ErbB4 extracellular (Y285C, D595V) and kinase (D931Y and K935I) domains. Consistently, the mutations enhanced ErbB4 dimerization and increased the trans activation in ErbB4 homodimers and ErbB4/ErbB2 heterodimers. The expression of the activating ERBB4 mutants promoted survival of NIH 3T3 cells in the absence of serum. Interestingly, serum starvation of NIH 3T3 cells expressing the ERBB4 mutants only moderately increased the phosphorylation of canonical ErbB signaling pathway effectors Erk1/2 and Akt as compared to wild-type ERBB4. In contrast, the mutations clearly enhanced the proteolytic release of signaling-competent ErbB4 intracellular domain.These results suggest the presence of activating, oncogenic mutations of ERBB4 in non-small cell lung cancer.']",
        "Doc_id":"AACR_2015-139",
        "Doc_title":" Activating ERBB4 mutations in non-small cell lung cancer",
        "_version_":1606188985749602304},
      {
        "Meeting_name":" Defining the spectrum and \"overlap\" of HER2 aberrations in lung cancers",
        "Background":"['Background', '   Human epidermal growth factor receptor 2 (HER2, ERBB2) aberrations have been identified as oncogenic drivers and potential therapeutic targets in lung cancers. The molecular associations of HER2 protein overexpression, HER2 gene amplification and HER2mutation in lung cancers have not been distinctly defined. To explore these associations, Memorial Sloan Kettering and the University of Colorado combined their data on HER2 in lung cancers.  Methods', '   Tumor specimens from 175 patients with lung adenocarcinomas with no prior targeted therapy were evaluated for the presence of HER2 overexpression, HER2 amplification and mutation. Overexpression was assessed by immunohistochemistry (IHC) using the 4B5 Ventana antibody. Amplification was assessed by fluorescence in-situ hybridization (FISH) using FDA approved probe sets (PathVysion, Abbott and HER2 IQFISH pharmDx, Dako) and defined as HER2/CEP17 ratio  2.0. Mutation was assessed by fragment analysis and mass spectrometry genotyping for indels and recurrent point mutations in exon 20, respectively. The frequencies of HER2 overexpression, HER2 amplification and mutation were calculated and their concordance examined.  Results', ' HER2 amplification by FISH was detected in 5 of 175 (3%) cases, and 46 (26%) showed polysomy (HER2 copy  4 but HER2/CEP17 ratio < 2). HER2 overexpression (2+, 3+) on IHC was not detected in the 25 specimens tested to date and negative IHC correlated with negative results on FISH. HER2 mutation was detected in 4 of 145 (3%) specimens, including 3 identical 12bp insertions [(p.A775_G776insYVMA (c.2324_2325ins12)] and a 9bp insertion, all in exon 20. None of the HER2 mutant cases were amplified and 3 had polysomy.  Conclusions', ' HER2 mutations are not associated with HER2 amplification or HER2 protein overexpression suggesting a distinct entity and therapeutic target. HER2-positive lung cancers may not be an adequate term and patient cohorts for the study of HER2 targeted agents should be defined by the specific HER2 aberrations present.  Funded in part by Boehringer-Ingelheim, NCI 1 RC2 CA148394-01, NCI P50CA058187, and NCI CCSG P30CA046934.']",
        "Doc_id":"ASCO_149120-156",
        "Doc_title":" Defining the spectrum and \"overlap\" of HER2 aberrations in lung cancers",
        "_version_":1606189003257675777},
      {
        "Meeting_name":" Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer.",
        "Background":"['Growth factor receptors (GFRs) are amenable to therapeutic intervention in cancer and it is important to select patients appropriately.One of the mechanisms for activation of GFRs is gene amplification (GA) but discrepancies arising from the difficulties associated with data interpretation and the lack of agreed parameters confound the comparison of results from different laboratories. Here, we attempt to establish appropriate conditions for standardization of the determination of GA in a panel of GFRs. A NSCLC tissue microarray panel containing 302 samples was screened for alterations at ALK,FGFR1, FGFR2, FGFR3, ERBB2, IGF1R, KIT, MET and PDGFRA by FISH, immunostaining and/or real-time quantitative RT-PCR. Strong amplification was found for FGFR1, ERBB2, KIT/PDFGRA and MET, with frequencies ranging from 1 to6%. Thresholds for overexpression and GA were established. Strong immunostaining was found in most tumors with ERBB2, MET and KIT amplification, although some tumors underwent strong immunostaining in the absence of GA. KIT and PDFGRA were always co-amplified, but only one tumor showed PDGFRA overexpression, indicating that KIT is the main target.Amplification of FGFR1 predominated in squamous cell carcinomas, although the association with overexpression was inconclusive. Interestingly, alterations at ALK,MET, EGFR, ERBB2 and KRAS correlated with augmented levels of phospho-S6 protein, suggesting activation of the mTOR pathway, which may prove useful to pre-select tumors for testing.Overall, here, we provide with parameters for the determination of GA at ERBB2, MET, KIT, and PDGFRA which could be implemented in the clinic to stratify lung cancer patients for specific treatments.']",
        "Doc_id":"AACR_2013-3034",
        "Doc_title":" Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer.",
        "_version_":1606189042072813568},
      {
        "Meeting_name":" Ultra-deep next generation sequencing (NGS) of plasma cell-free DNA (cfDNA) from patients with advanced lung cancers",
        "Background":"['Introduction', ' Noninvasive genotyping using plasma cfDNA from cancer patients has the potential to obviate the need for some biopsies while also characterizing disease heterogeneity. This study was undertaken to develop an ultra-deep plasma NGS panel for patients with non-small cell lung cancers (NSCLC).Methods / Results', ' Plasma was prospectively collected from 51 patients with advanced, progressive NSCLC and a known oncogenic driver from prior tumor genotyping. We performed ultra-deep NGS on extracted cfDNA using a customized Illumina library preparation, hybrid capture panel covering 37 lung cancer related genes (complete exons and partial introns), and ultra-deep sequencing (HiSeq4000). Mean sequencing depth was 50,000X (150 million, 150bp reads per sample). After specialized consensus-based error correction for low allele frequency (AF) genomic alterations, the median unique DNA molecules per position were 3,500. The mean sequence error rate was reduced by 20-fold to 0.002%, enabling the confident call of a driver mutation as low as 0.03%. In a subset of cases, paired plasma droplet digital PCR (ddPCR) was performed for common EGFR and KRAS mutations using a validated assay.Blinded to tumor genotype, plasma NGS detected SNVs (EGFR, KRAS, BRAF), indels (EGFR, ERBB2), and fusions (ALK, ROS1) as well as significant copy number gains (CNG) (ERBB2, MET). Sensitivity of cfDNA for the detection of known oncogenic drivers was 88% (45/51). A single false positive driver mutation was identified in a case with a known EGFR mutation in tumor; plasma NGS found both EGFR exon 19 del (0.88% AF) and KRAS G12D (2.65% AF), and plasma ddPCR confirmed the presence of both mutations (2.2% and 2.0% AF). Evaluation for an occult second primary is ongoing. In 22 EGFR, ALK, or ROS1 cases with acquired resistance to targeted therapy, plasma genotyping detected a range of potential resistance mechanisms', ' EGFR T790M and C797S, ALK F1174C, ERBB2 CNG, MET CNG. In 16 cases with paired resistance biopsies, concordance for EGFR T790M status was 94% (15/16).18 cases with known EGFR or KRAS mutations underwent paired ddPCR. In 14 cases the driver mutation was detected using both assays with high concordance of the%AF (r = 0.91). The remaining 4 cases were negative with ddPCR but 3 were positive with NGS at low AF (0.04%, 0.08%, and 0.29%), and the specificity for each driver was 100%.Conclusions', ' Ultra-deep plasma NGS can detect a wide range of oncogenic drivers in NSCLC and may be more sensitive than established ddPCR assays. In the setting of acquired resistance to targeted therapy, plasma NGS reliably captured EGFR T790M and additional somatic alterations as potential resistance mechanisms.']",
        "Doc_id":"AACR_2016-4342",
        "Doc_title":" Ultra-deep next generation sequencing (NGS) of plasma cell-free DNA (cfDNA) from patients with advanced lung cancers",
        "_version_":1606189006484144128},
      {
        "Meeting_name":" Identifying HER2 mutation, amplification, and HER2 protein overexpression as therapeutic targets in lung cancers.",
        "Background":"['Background', ' We have previously shown that human epidermal growth factor receptor 2 (HER2, ERBB2) mutation and amplification represent distinct molecular entities in lung cancers (Li J Thorac Oncol 2015). The optimal method for assessing HER2 status in lung cancers for targeted therapy remains undefined. Methods', ' Prospective next generation sequencing (NGS) was performed on lung adenocarcinoma specimens by Memorial Sloan Kettering-Integrated Mutation Profiling for Actionable Cancer Targets (MSK-IMPACT) for potentially actionable drivers across 410 cancer related genes in 2014-2015 encompassing HER2 mutation (indels and point mutations) and amplification (fold change  1.5). Specimens found to have HER2 mutations or amplification were further assessed by fluorescence in-situ hybridization (FISH) and immunohistochemistry (IHC). HER2 IQFISH pharmDx, Dako probe was used for FISH with HER2/CEP17 ratio  2.0 defined as positive. The 4B5 Ventana antibody was used for HER2 protein overexpression by IHC. Results of the various HER2 testing were compared. Results', ' A total of 776 lung adenocarcinomas underwent NGS and found 21 cases (3%) of HER2 mutation and 20 cases (3%) of HER2 amplification; only one case showed concurrent mutation and amplification (S310F, fold change 11.7). 12 mutant cases (57%) harbored an identical 12bp insertion in exon 20 (p.A775_G776insYVMA). FISH analysis of 34 samples (18 mutant, 14 amplified) was positive in 1 of 18 mutant and 14 of 14 NGS amplified cases. IHC analysis of 18 mutant cases ranged from 0 to 2+, and analysis of 12 amplified cases showed high correlation with IHC 3+. All cases of HER2 amplification by FISH or high level HER protein overexpression (IHC 3+) were captured by NGS. Conclusions', ' This independent study confirmed that HER2 mutation and HER2 amplification are distinct molecular targets in lung cancers. IHC and FISH are suitable methods for identifying HER2 amplification but are not surrogates for assessing HER2 mutation. NGS identified HER2 mutation and all cases of HER2 amplification or high level HER2 overexpression, and constitutes an ideal method of upfront screening for all HER2 alterations for selecting patients for HER2 targeted therapy.']",
        "Doc_id":"ASCO_171637-176",
        "Doc_title":" Identifying HER2 mutation, amplification, and HER2 protein overexpression as therapeutic targets in lung cancers.",
        "_version_":1606188983566467072},
      {
        "Meeting_name":" The molecular characters of acquired resistant non-small cell lung cancer cells to afatinib",
        "Background":"['[Background] The non-small cell lung carcinomas (NSCLCs) with activating epidermal growth factor receptor (EGFR) gene mutation show significant response to EGFR-tyrosine kinase inhibitors (TKIs). However, almost all of them acquire resistance to EGFR-TKIs due to various mechanisms, such as T790M mutation or MET amplification. Afatinib is an irreversible TKI for EGFR and HER2 and known to be effective to the EGFR T790M variant. However, a half of the patient responded afatinib acquire resistance by 12 months in clinical use. Thus, to unravel the mechanisms of the resistances and to overcome them are still important issues of EGFR-TKI treatment. In this study, we established various kinds of afatinib resistant cell lines with changing drug exposing condition as we previously reported (Shien K. et al Cancer Res. 2013). We also investigated these cell lines to understand mechanisms of afatinib resistances in NSCLC.[Materials and Methods] Afatinib resistant cell lines were established using four NSCLC cell lines with activating EGFR mutations by exposing afatinib with different procedures, escalation from 1 nM, escalation from 10 nM, intermittent 2 M and continuous 2 M procedures. These cell lines were investigated about previously reported resistant related features, T790M mutation, MET amplification, and epithelial to mesenchymal transition (EMT). ALDH1A1 and ABCB1 expression, which were putative stem cell markers, were also investigated. Proliferative inhibitions with various drugs were evaluated using MTS assay.[Results] There were no T790M mutations in all afatinib resistant cell lines. HCC827 sublines exposed afatinib with escalation from 1 nM and intermittent 2 M, and HCC4011 sublines showed MET amplification. HCC827 sublines exposed afatinib with escalation from 10 nM and continuous 2 M, and HCC4006 sublines showed EMT features. Furthermore, ALDH1A1 and ABCB1 expression were up-regulated in HCC827 afatinib resistant sublines with EMT features. Next, we examined the effect of afatinib or crizotinib for the afatinib resistant cell line with MET amplification. We found that combination therapy with afatinib and crizotinib was effective to the MET amplified cell. The combination exposure was continued to establish a resistant subline (HCC827-ACR) to combination therapy. The HCC827-ACR was also showed EMT features and up-regulation of stem cell markers.[Conclusions] As in the cases of reversible EGFR-TKI, MET amplification, EMT, and stem cell-like features were emerged in afatinib resistant cells. To develop strategies to resistant cells with stem cell-like property may be critical part to overcome EGFR-TKI resistance.']",
        "Doc_id":"AACR_2014-1834",
        "Doc_title":" The molecular characters of acquired resistant non-small cell lung cancer cells to afatinib",
        "_version_":1606189014498410497},
      {
        "Meeting_name":" A non-invasive liquid biopsy approach for therapeutic stratification of lung cancer patients.",
        "Background":"['Background', '   Liquid biopsies of circulating tumor DNA (ctDNA) may eliminate the need for invasive tissue biopsies and allow the detection of alterations in multiple metastatic lesions throughout the course of therapy. This is of particular importance in lung cancer, where a third of patients may have insufficient biopsies for molecular analyses and may be ineligible for approved targeted therapies. However, the fraction of ctDNA obtained from a blood sample is often low ( < 1.0%) and can be difficult to detect with current approaches. Additionally, most methods to detect ctDNA interrogate single hot spot mutations or a few genetic alterations.   Methods', '   To overcome these issues, we developed comprehensive ctDNA approaches to detect somatic sequence mutations, translocations, and amplifications at low allele frequencies in the circulation of cancer patients. These analyses span 63 well-established cancer genes, including BRAF, EGFR, ERBB2, PI3KCA,FGFR,KRAS and NRAS, translocations in ALK, EGFR, NTRK1,RET and ROS1, and amplification of MET and ERBB2. This comprehensive panel covers many recognized resistance mechanisms to targeted therapies and provides a method to understand patterns of intrinsic and acquired resistance in oncogene defined lung cancer. To evaluate this approach, we performed dilution series using tumor-derived DNA, containing well-characterized somatic mutations, in the presence of wild-type DNA in 3-5ml of plasma from 90 patients with late-stage lung cancer.   Results', '   We were able to detect sequence alterations at levels of > 0.01% with a specificity of > 99.9%. Further analyses demonstrated high concordance between the somatic sequence mutations and translocations identified in the tumor sample and those identified in the plasma, including alterations in driver genes as well as those related to acquired resistance to targeted therapies. 70 patients had serial samples, and within this cohort, we demonstrated evolution of resistance clones that predict radiographic increases in tumor burden.   Conclusions', '  These analyses provide a non-invasive platform to enable liquid biopsy detection of clinically relevant genetic alterations across a large number of genomic loci in lung cancer patients.']",
        "Doc_id":"ASCO_152938-156",
        "Doc_title":" A non-invasive liquid biopsy approach for therapeutic stratification of lung cancer patients.",
        "_version_":1606189000971780096},
      {
        "Meeting_name":" Nationwide genomic screening network for the development of novel targeted therapies in advanced non-small cell lung cancer (LC-SCRUM-Japan).",
        "Background":"['Background', '  Various driver gene alterations have emerged as critical targets for molecular therapies in non-small cell lung cancer (NSCLC), but these alterations other than EGFR mutations occur in rare populations. A nationwide genomic screening network in Japan (LC-SCRUM-Japan) was established in February 2013 for the development of novel targeted therapies against advanced NSCLCs harboring these rare alterations. Methods', '  Advanced non-squamous NSCLCs without EGFR mutations were eligible for inclusion in LC-SCRUM-Japan. The tumors were analyzed for ALK/RET/ROS1 fusions using RT-PCR, and detected fusions were confirmed by FISH. Between November 2013 and March 2014, fusion-negative tumors were further examined for other driver gene mutations using a next-generation sequencing (NGS) system (Ion PGM with Ion Torrent AmpliSeq Cancer Hotspot Panel, version 2), enabling the simultaneous analysis of 50 cancer-related genes. Results', '  As of December 26, 2014, a total of 188 institutions across Japan were participating and 1347 patients had been enrolled in LC-SCRUM-Japan. Among 1271 available samples, ALK/RET/ROS1 fusions were detected in 24 (2%)/31 (3%)/55 (4%) cases, respectively. The NGS analysis was performed in 201 cases without the fusions, and 82 cases (41%) had driver mutations, including 45 KRAS mutations (22%), 10 BRAF mutations (5%), 9 ERBB2 mutations (4%), 2 PIK3CA mutations (1%), and 1 NRAS mutation (0.5%). MET and ERBB2 amplifications were also detected by the NGS in 4 (2%) and 2 (1%) cases, respectively. Among a total of 198 cases harboring targetable gene alterations, 16 with RET fusions, 26 with ROS1 fusions, and 2 with BRAF mutations were enrolled in clinical trials for vandetanib (LURET study, Japan), crizotinib (OO12-01, East Asia), and dabrafenib (BRF113928), respectively. Conclusions', '  This nationwide and population enrichment screening system enabled various rare driver gene alterations to be efficiently detected in advanced NSCLC, thereby contributing to the rapid accrual of matched patients in clinical trials for targeted therapies.']",
        "Doc_id":"ASCO_148248-156",
        "Doc_title":" Nationwide genomic screening network for the development of novel targeted therapies in advanced non-small cell lung cancer (LC-SCRUM-Japan).",
        "_version_":1606188999705100288},
      {
        "Meeting_name":" Comparative surface proteomics of NCI-H2122 cells reveals distinct cell surface phenotype of a metastatic NSCLC cell line expressing oncogenic KRASG12C",
        "Background":"['Oncogenic KRAS mutations are found in 40% of non-small cell lung carcinomas (NSCLC). In order to expand the treatment options for NSCLC harboring oncogenic K-Ras, new therapeutic cell surface targets need to be identified and characterized. Towards this goal we carried out comparative cell surface analysis of the NSCLC cell line H2122-KRASG12C and the BL2122 cell line (i.e., control), which has been established from the peripheral blood lymphocytes of the same NSCLC patient. Here, we describe optimized hydrazide-based glycoproteomics for mapping of the cell surface proteome of the NSCLC H2122 cell line harboring oncogenic KRASG12C. Our comparative glycoproteomics revealed 632 proteins identified by LC-MS at the surface of both H2122-KRASG12C and BL2122 cell lines. Subtractive proteomics revealed 215 proteins detected solely at the H2122-KRASG12C cell surface while 214 proteins were found germane to the cell surface of BL2122 cells. A total of 203 proteins were commonly identified at the surface of both cell lines. Spectral counting based quantitation revealed 44 proteins showing  3-fold increase in their relative concentration at the cell surface of H2122-KRASG12C cells. Subsequent meta-analysis via Ingenuity Pathway Analysis (IPA) revealed significant activation of canonical pathways known to be involved in NSCLC biology (e.g., EGFR/neuregulin, and PI3K/AKT signaling). From a subset of proteins showing significant up-regulation at the surface of H2122-KRASG12C cells, we further cross-validated CD147 using immunofluorescence analysis (IFA) and Western blotting (WB). Interestingly, subsequent IFA confirmed the over-expression of CD147 at the cell surface of pancreatic KP-3, lung H2444, and colon SW620 cancer cell lines, each harboring constitutively activated KRAS. Importantly, amongst 215 proteins identified solely at the cell surface of H2122-KRASG12C cells, proteins upstream of K-Ras, epidermal growth factor receptor (EGFR), receptor tyrosine-protein kinase erbB-2 (ERBB2), receptor tyrosine-protein kinase erbB-3 (ERBB3), and disintegrin metalloproteinase domain-containing protein 17 (ADAM17) were unambiguously identified. Using WB analysis, we first confirmed the expression K-Ras in the membrane preparation of H2122-KRASG12C cells. Interestingly, insulin-like growth factor 1 receptor, (IGF1R), and mesothelin (MSLN) were also detected exclusively at the cell surface of the H2122-KRASG12C. We further cross-validated the expression of mesothelin using WB. Taken together, present approach greatly extends the known cell surface phenotype of the NSCLC H2122-KRASG12C cells and can be readily employed as a primary proteomic screen to provide the basis for discovery and characterization of novel cell surface therapeutic targets or diagnostic assays in cells/tissues harboring oncogenic K-Ras.']",
        "Doc_id":"AACR_2015-1829",
        "Doc_title":" Comparative surface proteomics of NCI-H2122 cells reveals distinct cell surface phenotype of a metastatic NSCLC cell line expressing oncogenic KRASG12C",
        "_version_":1606188971593826304},
      {
        "Meeting_name":" Contribution of miR-205 in gefitinib-resistant lung cancer cell lines",
        "Background":"['Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), gefitinib is effective therapies for patients with advanced non-small cell lung cancer (NSCLC). Treatment with gefitinib frequently induces drug resistance in NSCLC. Two mechanisms of acquired resistance have been validated in patients. Secondly mutations in EGFR itself, EGFR T790M and amplification of the MET oncogene are observed in resistance case. However, it remains unclear how MET over expression contributes to TKI resistant NSCLC. Recently, micro RNA (miRNA) expression is noted and analyzed because the concern of these molecules in cancer pathogenesis and drug resistance has been elucidated. Circulating tumor cell (CTC) and miRNA are focused as sensitive and non-invasive biomarkers for cancer diagnosis. In this study, we aimed at the miRNA in the gefitinib-resistant cell lines, and evaluated the miRNAs being associated with resistance of gefitinib. We established gefitinib resistant cell lines, in which MET is amplified, PC-9/MET and PC-9/MET-1K by a stepwise escalation of gefitinib concentrations in vitro. Microarray and real time PCR analysis indicated that miR-205 is significantly elevated in both resistant cell lines, and ErbB3 was a significant target. We examine further to reveal that relation between miR-205 and EGFR family, such as ErbB2 and ErbB3. Our results suggest that miR-205 may function as a gefitinib resistance in NSCLC.']",
        "Doc_id":"AACR_2014-1840",
        "Doc_title":" Contribution of miR-205 in gefitinib-resistant lung cancer cell lines",
        "_version_":1606189003431739393},
      {
        "Meeting_name":" Afatinib in patients with metastatic HER2-mutant lung cancers",
        "Background":"['Background', ' Human epidermal growth factor 2 (HER2, ERBB2) mutations have been identified as oncogenic drivers in 3% of lung cancers. Afatinib is an irreversible tyrosine kinase inhibitor of HER1 (EGFR), HER2 and HER4 and has been described in case reports to have activity in HER2-mutant lung cancers. However, there is little data to inform the clinical use of afatinib. Methods', ' We reviewed patients with metastatic HER2-mutant lung cancers treated with afatinib among 7 institutions between 2009 and 2016. The primary endpoint was investigator assessed overall response rate using RECIST v1.1. Other data collected included types of HER2mutations, duration of afatinib treatment and overall survival. Results', ' We identified 27 patients with metastatic HER2-mutant lung cancers treated with afatinib. Median age at diagnosis was 63 (range 40 to 84); majority were men (n = 16; 59%) and never-smokers (n = 18; 67%). All tumors were adenocarcinomas, and the majority were Stage IV at initial diagnosis (n = 16; 59%). A 12-base pair (bp) in-frame insertion YVMA in exon 20 (p.A775_G776insYVMA) was present in 16 patients (59%). In addition, there were three 9-bp insertions, two 3-bp insertions and two single bp substitutions (L755F and D769H) in exon 20; two single bp substitutions (S310F) in exon 8; one exon 17 V659E mutation; and one single-nucleotide polymorphism (Ile655Val). Median duration on afatinib was 2 months (range 1 to 27); median line of prior treatment was 3 (range 1 to 6). Eight patients had previously received trastuzumab prior to afatinib and one concurrently with afatinib. Overall response rate was 15% (n = 4; 95% CI 4 to 34%); the four partial responses lasted 5, 5, 6 and 10 months. The 3 longest partial responders had a 12-bp insertion in exon 20 (YVMA); the remaining partial responder had a 9-bp insertion in exon 20. Median overall survival from diagnosis date of metastatic disease was 23 months (95% CI 18 to 62). Conclusions', ' Afatinib produced partial responses in 15% of patients with metastatic HER2-mutant lung cancers, including insertion YVMA. Our findings confirm the activity of afatinib and provide data supporting a framework for its use in the care of patients with HER2-mutant lung cancers.']",
        "Doc_id":"ASCO_188714-199",
        "Doc_title":" Afatinib in patients with metastatic HER2-mutant lung cancers",
        "_version_":1606188980503576577},
      {
        "Meeting_name":" Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers",
        "Background":"['Background', ' Human epidermal growth factor receptor 2 (HER2, ERBB2) mutations occur in 2% of lung cancers, resulting in receptor dimerization and kinase activation with in vitro sensitivity to trastuzumab. Ado-trastuzumab emtansine is a HER2 targeted antibody drug conjugate linking trastuzumab with the anti-microtubule agent emtansine. Methods', ' Patients (pts) with HER2 mutant lung cancers were enrolled into a cohort of the basket trial of ado-trastuzumab emtansine in HER2amplified or mutant cancers, treated at 3.6mg/kg IV every 3 weeks. The primary endpoint was overall response rate (ORR) using RECIST v1.1. A Simon two stage optimal design was used with type I error rate under 2.7% (and a family wise error rate across baskets under 10%), power of 89%, H0 10%, H1 40%; the H0 will be rejected if 5 or more responses are observed in 18 pts. Other endpoints include duration of response (DOR), progression-free survival (PFS) and toxicity. HER2 testing was performed on tumor tissue by next generation sequencing (NGS), fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). Results', ' The cohort completed accrual with 18 pts treated. The median age was 63 (range 47-74 years), 72% were female, 39% were never smokers and all had adenocarcinomas. The median lines of prior systemic therapy was 2 (range 0-4). ORR was 33% (5/15 confirmed, 95% CI 12-62%) not including a partial response awaiting confirmation and 3 pts pending response evaluation. Median DOR was not reached (range 3 to 7+ mo), median PFS was 4mo (95% CI 3mo-not reached). Toxicities were mainly grade 1 or 2 including infusion reaction, thrombocytopenia and transaminitis, there were no dose reductions or treatment related deaths. There were 10 (56%) exon 20 insertions and 8 (44%) point mutations; responders were seen across mutation subtypes (A775_G776insYVMA, G776delinsVC, V659E, S310F). HER2amplification was negative for all pts by NGS and positive for 1 of 12 pts by FISH. There was no IHC3+ in 10 pts tested. Conclusions', ' Ado-trastuzumab emtansine is active and well tolerated in pts with HER2 mutant lung cancers. This study has met its primary endpoint. Further development in a multicenter study is warranted. Clinical trial information', ' NCT02675829']",
        "Doc_id":"ASCO_193079-199",
        "Doc_title":" Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers",
        "_version_":1606189008475389952},
      {
        "Meeting_name":" A comprehensive noninvasive approach for the stratification of lung cancer patients for targeted therapies.",
        "Background":"['Background', '  Cancer is a disease caused by the accumulation of genetic alterations which initiate and promote the uncontrolled growth and metastasis of cancer cells. These genetic alterations are the targets of multiple approved therapies, preferentially inhibiting cancer cells while limiting damage to normal cells. Given the advances in the efficacy of targeted therapies, current guidelines recommend molecular testing of specific genes to match patients with targeted therapies for which there is clinical benefit. However, approximately one-third of non-small cell lung cancer (NSCLC) patients lack tissue samples for analysis and are not eligible for targeted therapies. Circulating tumor DNA (ctDNA), shed into the blood from tumor tissue, contain alterations specific to the genetic profile of the malignancy in tissue and can stratify patients for targeted therapies through a liquid biopsy.  Methods', '  We have developed LungSelect, a ctDNA approach to interrogate clinically actionable genetic alterations in NSCLC that are recommended by clinical guidelines or targeted in late stage clinical trials. LungSelect uses digital next-generation sequencing approaches to comprehensively examine single-base mutations, insertions and deletions in BRAF, EGFR, ERBB2, KRAS and NRAS while assessing translocations in ALK, EGFR, NTRK1,RET and ROS1with a high degree of precision and accuracy.  Results', '  To evaluate the analytical sensitivity of LungSelect, we examined well characterized somatic mutations through a combination of tumor derived DNA and wild-type derived DNA at various levels of tumor contribution, achieving a lower limit of detection of > 0.01% with a specificity of > 99.9%. In addition, we examined the utility of LungSelect to detect these genetic alterations in late-stage lung cancer patients through comparison of plasma and matched tissue biopsy specimens. These analyses revealed a high concordance between the genetic alterations identified in plasma and matched tissue biopsies.  Conclusions', ' LungSelect comprehensively detects genetic alterations non-invasively, allowing for a greater proportion of patients to obtain the survival benefit associated with targeted therapies in NSCLC.']",
        "Doc_id":"ASCO_149700-156",
        "Doc_title":" A comprehensive noninvasive approach for the stratification of lung cancer patients for targeted therapies.",
        "_version_":1606189029706956800},
      {
        "Meeting_name":" Clinical next generation sequencing (NGS) to reveal high frequency of alterations to guide targeted therapy in lung cancer patients.",
        "Background":"['Background', '  Cancer genomic profiling via NGS in a clinical setting can reveal additional actionable genomic alterations (GA) in patients with lung cancer (LC) previously tested only by hotspot analysis and leading to unanticipated avenues of targeted treatment.  Methods', '  We performed an NGS-based diagnostic test (FoundationOne) to characterize all classes of GA across 3,320 exons of 182 cancer-related genes and 37 introns of 14 genes frequently rearranged in cancer on 386 LC FFPE specimens in a CLIA-certified lab (Foundation Medicine). Specimens included fine needle aspirates, core needle biopsies, and malignant effusions.  95% of cases were NSCLC (367/386). Actionable GAs are defined as those linked to targeted anti-cancer therapies approved or being evaluated in clinical trials.  NGS confirmed known hotspot results for EGFR, KRAS and EML4', 'ALK in 100% of cases.  Results', '    Genomic profiles were generated from 364/386 (94%) of lung cancer cases, identifying 1205 GA, averaging 3.31 alterations per tumor (range 0 to 10).  85% of tumors (310) harbored at least one actionable GA, with a mean of 1.79 GA per tumor (range 0 to 6). In 68% of tumors (248), at least one GA was detected that would be missed by current hotspot assays. ERBB2 harbored base substitutions or indels in 1.3% of cases.  BRAF and C-Kit were altered at frequencies of 2% and 1% respectively. The mTOR/PI3K pathway is likely to be activated via alterations in tumor suppressors STK11 (11%), NF1 (6%) and PTEN (4%), as well as by alterations of PIK3CA (10%) and in AKT1/2/3 (4%), suggesting possible benefit from mTOR/PI3K inhibitors.  The Hedgehog pathway (PTCH1/SMO/SUFU) was altered in 2% of cases.  ALK and RET were rearranged in 4% and 2% of cases, respectively, with several cases initially diagnosed negative by FISH testing.   Conclusions', '  Profiling the tumor genomes of 364 LC patients led to the identification of a series of GA not detectable by hotspot testing that could significantly inform targeted treatment decisions.  Moreover, actionable GA appeared in unexpected tumor type, i.e. an EGFR mutation in a SCLC, reinforcing the likely utility of clinical cancer genomic profiling for the personalized treatment of LC patients.']",
        "Doc_id":"ASCO_118079-132",
        "Doc_title":" Clinical next generation sequencing (NGS) to reveal high frequency of alterations to guide targeted therapy in lung cancer patients.",
        "_version_":1606189004042010624},
      {
        "Meeting_name":" Chemotherapy regulated microRNA-125/HER2 pathway as a novel therapeutic target for trastuzumab-mediated cellular cytotoxicity in small-cell lung cancer",
        "Background":"['Small-cell lung cancer (SCLC) accounts for 15% of all lung cancer cases and is a highly lethal disease. For the last several decades, the standard treatment for SCLC has been deadlocked, and new therapeutic strategies are urgently needed. Human epidermal growth factor receptor 2 (HER2) is a member of the HER family and has been reported to be overexpressed in 30% of SCLC cases with poor prognosis. However, the clinical relevance of HER2-targeted therapy for SCLC remains unclear. Here, we firstly identify that cytotoxic drugs induce significant HER2 overexpression through microRNA-125a (miR-125a) and miR-125b downregulation, which in turn act as a novel therapeutic target for trastuzumab-mediated cellular cytotoxicity in SCLC. In this study, we showed that treatment of the HER2-positive SCLC cells, SBC-3 and SBC-5, with cytotoxic drugs induced a significant upregulation of HER2. Cisplatin (CDDP) treatment of SCLC cells resulted in a significant downregulation of miR-125a and miR-125b. We confirmed that miR-125a and miR-125b bound to the 3-untranslated regions of HER2 mRNA, and that downregulation of miR-125a and miR-125b resulted in upregulation of HER2 in SCLC cells, suggesting a relationship between cytotoxic drug exposure and miR-125/HER2 dysregulation. Furthermore, using a calcein assay we demonstrated a significant synergistic cytotoxic effect of CDDP and trastuzumab that was mediated via antibody-dependent cellular cytotoxicity. Finally, we clearly demonstrated the synergistic anti-tumor effect of these agents in an orthotopic lung cancer model in vivo. Our result offer a novel therapeutic strategy for HER2-positive SCLC by using trastuzumab combined with cytotoxic drugs.']",
        "Doc_id":"AACR_2015-1334",
        "Doc_title":" Chemotherapy regulated microRNA-125/HER2 pathway as a novel therapeutic target for trastuzumab-mediated cellular cytotoxicity in small-cell lung cancer",
        "_version_":1606189029313740800},
      {
        "Meeting_name":" Targeting stepwise HER2 and VEGF can overcome multidrug resistance in small cell lung cancer",
        "Background":"['Small-cell lung cancer (SCLC) accounts for approximately 15% of primary lung cancer and has the poorest outcome of all its histological types. One of the major reasons of extreme aggressiveness of SCLC is that it recurs shortly after initial therapy with multidrug resistance (MDR) phenotype. However, standard therapeutic strategy for relapsed-SCLC has not been established yet. As one of the targetable receptor tyrosine kinases, human epidermal growth factor receptor 2 (HER2) was reported to be a negative prognostic factor in extensive-disease SCLC (Micke et al. Int J Cancer. 2001;92', '474-9). We found that HER2 was more frequently overexpressed in SCLC cell lines of Japanese origin (6/10) compared to those of Caucasian origin (0/3). We also detected HER2 expression in SCLC tissues in 7 out of 25 patients tested by our highly sensitive immunohistochemistry system. Moreover, we found that HER2 was upregulated when HER2-positive SCLC cells acquired MDR. Trastuzumab, a humanized monoclonal antibody against HER2, exerted differential levels of killing effect on HER2-positive parental and chemoresistant SCLC cells only when Fc receptor-positive natural killer (NK) cells coexisted. This result suggests that trastuzumab-induced SCLC cell-killing effect was caused mainly via antibody-dependent cell-mediated cytotoxicity (ADCC) but not via direct inhibition of HER2 signal. Among these cell lines, etoposide-resistant SCLC cells were most susceptible to trastuzumab in vitro and in vivo, and the antitumor effects of trastuzumab were not only dependent on the amount of HER2 expression on SCLC cells. We focused on cell-cell contact between SCLC cells and NK cells to determine the molecule affecting trastuzumab-mediated ADCC other than HER2. We found that intercellular adhesion molecule (ICAM)-1 was abundantly expressed on etoposide-resistant SCLC cells, and trastuzumab-mediated ADCC was canceled in the presence of an ICAM-1 functional blocking antibody. These results indicate that ICAM-1 expression on SCLC cell surface is indispensable to augment trastuzumab-mediated ADCC. Thus, trastuzumab could overcome etoposide-resistance in SCLC. On the contrary, irinotecan-resistant SCLC cells were still refractory to trastuzumab. The reason for this was thought that they not only lacked ICAM-1 expression but also came to produce abundant vascular endothelial growth factor (VEGF). Bevacizumab, a humanized monoclonal antibody against VEGF, treatment could significantly inhibit the in vivo growth of irinotecan-resistant xenografts through decreasing microvesseles in mice. These results suggest that bevacizumab-mediated antiangiogenesis is a promising therapeutic strategy to salvage irinotecan-resistance.Collectively, targeting stepwise HER2 and VEGF could overcome MDR in SCLC and bring about a favorable outcome for patients with relapsed-SCLC.']",
        "Doc_id":"AACR_2014-4506",
        "Doc_title":" Targeting stepwise HER2 and VEGF can overcome multidrug resistance in small cell lung cancer",
        "_version_":1606188992451051520},
      {
        "Meeting_name":" Whole genome and transcriptome sequencing of lung cancer",
        "Background":"['Background', ' Targeted therapy against driver mutations has revolutionized lung cancer management. The Personalized OncoGenomics (POG) program uses whole genome and transcriptome derived information to build pathways and identify potential therapeutic targets. We examined the lung adenocarcinoma (LUAD) patients enrolled in POG in order to identify novel cancer drivers and correlate the findings with clinical characteristics. Methods', ' Patients with advanced LUAD and survival > 6 months were eligible. Blood, archival and fresh tumour specimens were subjected to comprehensive DNA and RNA sequencing. SNV data were compared to the TCGA-LUAD cohort using the cBioPortal platform. Whole tumor transcriptome data were compared to matched normal blood specimens. Clinical characteristics were collected by chart review. Results', ' 30 POG LUAD cases were analyzed. Baseline characteristics; 47% female, median age 60, 57% never/light smokers, biopsy site - 50% lung, 50% metastatic lesion. High mutations rates in TP53, KRAS, NF1 were comparable to the TCGA-LUAD cohort. Four genes (GOLGA6L2, FAM186A, ARMCX4 and RBMXL3), were mutated 17-27% of the time in POG patients, while the rate in TCGA-LUAD was < 1%. Driver mutations (KRAS and EGFR) and known fusions (ROS1 and RET) were present in 63%.Other potential drivers included ERBB3, ERBB2, SDC', 'NRG1 fusion were identified. Copy number alterations and expression data revealed variations in cell cycle, mTOR, androgen receptor,HSP90, MET and Wee1 proteins, all potential targets for therapy. PD-L1 over-expression and a strong smoking signature were not mutually exclusive to EGFR copy gain and FGFR3 overexpression. Conclusions', ' The molecular signature of NSCLC is complex and involves multiple key oncogenic drivers. Whole genome sequencing and transcriptome data should be used together to map out the pathways of carcinogenesis and reliably identify targets for therapy.']",
        "Doc_id":"ASCO_190111-199",
        "Doc_title":" Whole genome and transcriptome sequencing of lung cancer",
        "_version_":1606189000018624512},
      {
        "Meeting_name":" Modeling acquired resistance to EGFR-directed therapies in mouse models of lung cancer.",
        "Background":"['Seventy percent of patients with Epidermal Growth Factor Receptor (EGFR) mutant lung cancer respond to treatment with the tyrosine kinase inhibitors (TKIs) erlotinib or gefitinib. Despite this high response rate, patients almost inevitably develop resistance to these drugs on average within a year of starting drug treatment. Acquired resistance to EGFR TKIs is most commonly due to the emergence of a secondary mutation (T790M) in EGFR (in 50% of cases), amplification of the genes encoding the ERBB2 and MET receptor tyrosine kinases in 12 and 5% of cases, respectively, and phenotypic transformation of the adenocarcinomas to small cell lung cancer (5% of cases). Previously, in an effort to develop strategies to overcome T790M-mediated resistance, we generated tetracycline-inducible transgenic mice that express the EGFRL858R+T790M in the lung epithelium. Upon administration of doxycycline these mice develop lung adenocarcinomas that are resistant to TKIs. However, the combination of the irreversible TKI afatinib and the EGFR antibody cetuximab showed dramatic responses in these transgenic mice. These preclinical studies led to a clinical trial of these agents, which has showing a promising 30% response rate in patients with EGFR mutant tumors resistant to TKIs. However, tumors also acquire resistance to this drug combination and the mechanisms of resistance to afatinib+cetuximab are currently unknown. We set out to identify these mechanisms using xenograft and transgenic mouse models of EGFR mutant lung cancer. Transgenic mice with EGFRL858R+T790M-induced tumors were treated with afatinib+cetuximab using an intermittent dosing strategy that we had previously used to generate erlotinib-resistant tumors in mice with EGFRL858R and EGFRDEL-induced tumors. 75% of mice develop afatinib+cetuximab resistant tumors after three month-long rounds of treatment. The same treatment strategy applied to xenografts harboring subcutaneous tumors induced by EGFRDEL+T790M gave rise to resistant tumors in 20% of cases. Analysis of the afatinib+cetuximab resistant tumors performed to date has not revealed additional mutations in the EGFR transgene, the ERBB2 kinase domain or KRAS. Additional sequencing studies and examination of signaling pathway alterations in the resistant tumors are ongoing. Uncovering mechanisms of resistance to this drug combination will allow the development of strategies to treat tumors that acquire resistance to EGFR-directed therapies.']",
        "Doc_id":"AACR_2013-933",
        "Doc_title":" Modeling acquired resistance to EGFR-directed therapies in mouse models of lung cancer.",
        "_version_":1606189020812935168},
      {
        "Meeting_name":" The GALAXY Trial(NCT01348126)",
        "Background":"['Background', ' Hsp90 is a molecular chaperone required for proper folding and activation of many cancer-promoting proteins and is recognized as a key facilitator of cancer cell growth and survival. In pre-clinical models, Hsp90 inhibition causes degradation of multiple client proteins and leads to cancer cell death. Ganetespib is a resorcinolic Hsp90 inhibitor that has shown potent anti-tumor activity in patients with lung, breast, and other cancers that had progressed on standard treatment agents. Moreover, combination of ganetespib with docetaxel results in synergistic antiproliferative effects in several human non-small cell lung carcinoma (NSCLC) tumor xenografts. Ganetespib is well tolerated and is devoid of severe liver or common ocular toxicities that have been observed with some other Hsp90 inhibitors. Diarrhea is the most common adverse event and is manageable with appropriate supportive care. In a recent report, ganetespib administered at 200 mg/m2 weekly showed activity in pretreated patients with advanced NSCLC patients with ELM4-ALK translocation and KRAS mutations. Methods', ' Stage 1 (240 subjects)', ' randomized, international open-label Phase 2B study in subjects that progressed on or after  one prior systemic therapy for stage IIIB or IV NSCLC', ' patients are prospectively stratified for ECOG performance status, histology, total LDH, interval since diagnosis, and smoking status. Co-primary endpoints are PFS in the ITT population, and PFS in patients with KRAS mutations. Main secondary endpoints include ORR, disease control rate, OS and clinical activity in different molecular subtypes, including BRAF, HER2, EGFR, EML4-ALK. Patients on the control arm are treated with docetaxel 75 mg/m2 on day 1 of a three-week cycle. In the combination arm, ganetespib 150 mg/m2 is given on day 1 (with docetaxel) and day 15 of a three-week cycle. At the time of submission 90 subjects had been enrolled in Stage 1.']",
        "Doc_id":"ASCO_95192-114",
        "Doc_title":" The GALAXY Trial(NCT01348126)",
        "_version_":1606189036798476289},
      {
        "Meeting_name":" Phenformin down-regulates mammary aromatase expression via the AMPK pathway in humanized aromatase expressing ERBB2 mice",
        "Background":"['Local mammary estrogen production may be vital for breast cancer development because about 70% of breast cancers occur in postmenopausal women. Aromatase is a key enzyme essential for estrogen biosynthesis, and aromatase inhibitors (AIs) are the most effective endocrine treatment for estrogen-responsive breast cancer in postmenopausal women. However, they are also accompanied a number of severe side-effects on bone and joints. Many researchers are currently focusing on developing the novel mammary-specific AIs to prevent or treat breast cancer to minimize the side effects of treatment. Phenformin, an antidiabetic drug, lowers serum glucose levels via activating the AMP-activated protein kinase (AMPK) pathway and reduces tumor burden and prolongs survival in non-small cell lung cancers. In vitro studies show that activated AMPK inhibits human mammary adipose tissue aromatase expression via suppression of binding of cAMP-responsive element binding protein (CREB) to aromatase promoters I.3/II, leading to decreased estrogen formation. We hypothesized that phenformin will be an effective adipose-specific AI for prevention and treatment of breast cancer. However, one of the major obstacles to define in vivo effects of phenformin on mammary aromatase expression is the lack of suitable mouse models because aromatase expression, present in the human breast, is absent in the mouse mammary gland. We developed a unique humanized aromatase mouse model (Aromhum) to mimic the human aromatase expression pattern and physiology in the mouse. We observed that tumorigenesis was accelerated in the mice overexpressing ERBB2 that were crossed with Aromhum mice (AE mice). Phenformin treatment (i.p., 70 mg/kg /day for 14 days) significantly decreased blood glucose levels by 37% in AE mice as compared to vehicle treatment. Phosphorylation of CREB, a downstream effector of the AMPK pathway, which mediates aromatase expression, was significantly decreased. Furthermore, after phenformin administration, mammary aromatase mRNA expression in AE mice was significantly decreased by 58% and estrogen response genes (SUSD3 and cyclin D1) were also reduced by about 65%. Real-time PCR showed that mammary AMPK1 mRNA expression is 10-fold higher compared with AMPK2 mRNA. Moreover, phenformin treatment significantly decreased AMPK1 mRNA levels by 53% but not AMPK2 mRNA expression in AE mice. Interestingly, daily oral phenformin treatment for 7 days significantly reduced mammary tumor volume of AE mice by 76%. In conclusion, phenformin decreased mammary aromatase expression and possible estrogen production, and reduced tumorigenesis via upregulation of the AMPK pathway in breast tissue of AE mice. This study provides justification for future testing of the adipose-specific preventive and therapeutic potential of the metabolic drug phenformin in postmenopausal breast cancer with minimal side-effects.']",
        "Doc_id":"AACR_2014-2102",
        "Doc_title":" Phenformin down-regulates mammary aromatase expression via the AMPK pathway in humanized aromatase expressing ERBB2 mice",
        "_version_":1606189000664547328},
      {
        "Meeting_name":" Modulation of ErbB receptors expression by histone deacetylase inhibitors increased the antitumor activity of an anti-ErbB3 monoclonal antibody in primary cultures from non-small cell lung cancer patients",
        "Background":"['In the last years several evidences suggested that ErbB3, a member of the HER family receptors, has a key role in the development and progression of several cancers including non-small cell lung cancer (NSCLC), and above all in the establishment of resistance to therapies, leading to major efforts towards the development of anti-ErbB3 therapies. We recently demonstrated in head and neck cancer cells that, depending on the ErbB3 expression level and on the tumor cell phenotype (epithelial vs mesenchymal), vorinostat, one of the two clinically approved histone deacetylase inhibitors (HDACi), differentially regulates HER receptors expression at the transcriptional level and/or by modulating protein degradation (Bruzzese F. et al. J Cell Physiol. 2011; 226(9)', '2378-90). Our group has developed a monoclonal antibody against ErbB3 called A3, that induces receptor internalization and degradation, inhibits growth and induces apoptosis only in cells overexpressing surface ErbB3 and potentiates the efficacy of EGFR TKIs (Noto A. et al. Oncotarget. 2013; 4(8)', '1253-65).In this study we first show, by using a set of malignant pleural effusion derived cell cultures from NSCLC patients (Mancini R. et al. PLOSone 2011; 6(7)', 'e21320) that the combination of the anti-ErbB3 antibody A3 with HDACi such as vorinostat or valproic acid (VPA), synergistically affect cell proliferation and induce apoptosis. Interestingly synergistic interaction was observed in both fully epithelial cells expressing all HER receptors including ErbB3, as well as in NSCLC cells that had undergone EMT and expressed very low levels of ErbB3. We provide evidences suggesting that differential modulation of ErbB receptors by HDACi is responsible for the observed synergism. We show in two epithelial cells expressing EGFR, ErbB2, and ErbB3 that either vorinostat or VPA time- and dose-dependent down-regulation the of all three receptors expression and signaling. On the contrary, in two A3-resistant mesenchymal cells expressing undetectable levels of ErbB3, we observe time- and dose-dependent increase of mRNA and protein levels as well as surface expression of ErbB3, paralleled by down-regulation of EGFR, ErbB2 and the the mesenchymal marker vimentin. Interestingly, ErbB3 induction was achieved also at low doses of both vorinostat and VPA, corresponding to a plasma level easily reached in patients treated with these agents.Our results suggest that the combination treatment of antibodies against ErbB3 and HDACi represents an attractive strategy that warrant further evaluation, even in combination with other agents, for the treatment of NSCLC patients.']",
        "Doc_id":"AACR_2014-5444",
        "Doc_title":" Modulation of ErbB receptors expression by histone deacetylase inhibitors increased the antitumor activity of an anti-ErbB3 monoclonal antibody in primary cultures from non-small cell lung cancer patients",
        "_version_":1606189013117435905},
      {
        "Meeting_name":" Clinicopathologic features of advanced RET fusion-positive lung cancers and outcomes in comparison to other fusion-positive lung cancers.",
        "Background":"['Background', '  Recurrent gene rearrangements are important drivers of lung cancer growth. While RET fusions are recognized as actionable targets, the clinicopathologic features of these drivers in advanced (stage IIIB/IV) disease and survival in comparison to ALK and ROS1 fusion-positive lung cancers are less well-characterized.  Methods', '  A FISH study using dual-color break-apart probes was performed to screen for RET fusions in patients (pts) with advanced lung ADCs that tested negative for mutations in EGFR, KRAS, NRAS, BRAF, MAP2K1, ERBB2, PIK3CA, or AKT, and fusions of ALK or ROS1. In pts with sufficient tissue, fusion partners were identified (RT-PCR/next-generation sequencing). Pathologic review of available tumor specimens and assessment of radiographic response via RECIST v1.1 were conducted. Overall survival (OS) and progression-free survival (PFS) were determined using Kaplan-Meier estimates. Comparisons to control groups of ALK and ROS1 fusion-positive lung cancers were performed (Mantel-Haenszel/log rank tests).  Results', '  17% (n=18/104, 95%CI 9-22%) of tumors from screened pts harbored a RET fusion (56% male, median age 61). Majority of pts had no history of chest RT [89%, n=16] and were never smokers [72% (n=13) <1, 22% (n=4) 1-15, and 6% (n=1) >15 pack-years]. In 8 pts with sufficient tissue, known upstream partners were identified in 7 pts (NCOA4, TRIM33, 6 KIF5B). An upstream partner not previously described in lung cancers (CLIP1) was found. Morphology in surgical specimens (n=8) was as follows', ' 63% (n=5) predominantly solid, 25% (n=2) predominantly cribriform, 13% (n=1) predominantly papillary. OS of RET (n=18) vs ALK (n=45; HR 0.84, 95%CI 0.34-2.08, p=0.71) and ROS1 (n=10; HR 1.59, 95%CI 0.34-7.31, p=0.55) fusion-positive lung cancers was similar. In patients who received first-line chemotherapy, PFS of RET (n=12) vs ALK (n=22; HR 0.53, 95%CI 0.25-1.13, p=0.10) and ROS1 (n=8; HR 1.19, 95%CI 0.34-4.17, p-0.78) fusion-positive lung cancers was similar.  Conclusions', '  Advanced RET fusion-positive lung cancers represent a distinct group of tumors with clinical outcomes comparable to ALK and ROS1 fusion-positive lung cancers.']",
        "Doc_id":"ASCO_134625-144",
        "Doc_title":" Clinicopathologic features of advanced RET fusion-positive lung cancers and outcomes in comparison to other fusion-positive lung cancers.",
        "_version_":1606189026337882112},
      {
        "Meeting_name":" Molecular profiling of small cell lung cancers in Japanese patients.",
        "Background":"['Background', '  Molecular abnormalities discovered in the last decade have led to a paradigm shift in the diagnosis and treatment of lung adenocarcinoma. But there have been few reports about molecular profiling of small cell lung cancers (SCLC). We conducted the Shizuoka Lung Cancer Mutation Study to analyze driver mutations in patients with thoracic SCLC malignancies.  Methods', '  We collected molecular profiling data of SCLC from the biobanking system in conjunction with the clinic, including the pathology lab, where 23 mutations in 9 genes (EGFR, KRAS, BRAF, PIK3CA, NRAS, MEK1, AKT1, PTEN and HER2), EGFR, MET, PIK3CA, FGFR1 and FGFR2 amplifications, and EML4-ALK translocations were assessed using pyrosequensing plus capillary electrophoresis, qRT-PCR, and RT-PCR, respectively. To evaluate mutation status for SCLC patients, we collected patient characteristics data from medical records. Results', '  Between July 2011 and July 2012, fifty small cell lung cancer patients were assessed in our biobanking system. Patient characteristics were as follows', ' median age (range) 70 (43 - 82) years; male 82%; smoker 96%; limited disease/extended disease 56/44%; small cell carcinoma/combined small cell carcinoma with adenocarcinoma 94/6%; surgically resected snap-frozen samples 8, formalin-fixed paraffin-embedded samples 40 and pleural effusion 7. We detected driver mutations in 8 cases (16%). Mutations found', ' EGFR 1 (2%), KRAS 1 (2%), PIK3CA 2 (4%), AKT1 1 (2%), MET amplification 1 (2%), PIK3CA amplification 6 (12%). EGFR and KRAS mutation were found in combined small cell carcinoma with adenocarcinoma. No significant differences in age, sex, disease extent at diagnosis or smoking status were found between patients with mutations and those without mutations. But serum neuron-specific enolase (NSE) levels were significantly higher in patients without mutations (p=0.03).  Conclusions', '  In our analysis, driver mutations were found in 16% of SCLC patients and PIK3CA amplification seemed to be relatively frequent in SCLC. Our results suggest that PIK3CA might become a target of treatment for SCLC patients.']",
        "Doc_id":"ASCO_116449-132",
        "Doc_title":" Molecular profiling of small cell lung cancers in Japanese patients.",
        "_version_":1606188985148768256},
      {
        "Meeting_name":" Docosahexaenoic acid inhibits heat shock protein 90 complex and client proteins by reducing intracellular ATP levels in breast and lung cancer",
        "Background":"['A major contributor to carcinogenesis is the molecular chaperone heat shock protein 90 (Hsp90). Hsp90 regulates the proper folding and stabilization of several client proteins, including human epidermal growth factor receptor 2 (ErbB2) and hypoxia-inducible factor 1 (HIF-1). ErbB2 is a member of the epidermal growth factor receptor (EGFR) family of receptor-proteins, and is a clinical target for the treatment of metastatic cancer, while HIF-1 is often stabilized and overexpressed in several cancers. The ability for Hsp90 to become a mature complex and to properly fold client proteins is dependent on adenosine triphosphate (ATP) binding with the co-chaperone, p23. Specific Hsp90 inhibitors, like geldanamycin, target the Hsp90 ATP-binding site to prevent formation of the mature complex. Although supplementation with docosahexaenoic acid (DHA; C22', '6 n-3) has not been shown to specifically target the Hsp90 ATP-binding site, the current study demonstrates a similar effect by DHA causing a reduction in available intracellular ATP levels. DHA is the longest, most unsaturated omega-3 polyunsaturated fatty acid (PUFA) existing in biological membranes and has been shown to possess anti-cancer activity in several cancer models. Studies from our laboratory have shown that DHA enrichment can reduce cancer cell metabolism and intracellular ATP levels in both breast and lung cancer models. In this study, a novel mechanism for the ability of DHA to inhibit the Hsp90 chaperone complex is defined. In vitro analyses of BT-474 human breast ductal carcinoma, as well as the A549 human lung adenocarcinoma cell lines were used to determine the impact of DHA-induced decreases of intracellular ATP levels. We found that the reduction in ATP levels by DHA treatment resulted in significant decreases in the association of Hsp90 and p23 in both cell lines. The decreased association of the Hsp90-p23 complex led to decreased levels of ErbB2 and HIF-1 client proteins, suggesting that DHA can modify Hsp90 chaperone function and attenuate client protein levels. Additionally, similar results were found when employing 2-deoxyglucose (2-DG), a glycolytic inhibitor, which confirms that DHA and 2-DG can disrupt Hsp90 molecular chaperone function by decreasing cellular ATP levels. Consistent with these observations, when using a dose of DHA that did not significantly reduce intracellular ATP levels, no change in the Hsp90-p23 chaperone complex or protein levels of ErbB2 and HIF-1 were seen. These results demonstrate a potential use for dietary intervention to improve cancer therapy in tumors that overexpress Hsp90 client proteins.']",
        "Doc_id":"AACR_2014-483",
        "Doc_title":" Docosahexaenoic acid inhibits heat shock protein 90 complex and client proteins by reducing intracellular ATP levels in breast and lung cancer",
        "_version_":1606189007324053504},
      {
        "Meeting_name":" Low dose Ganetespib (STA-9090) enhances radiotherapy effects on lung cancer cells by synergistically altering levels of cell cycle progression proteins",
        "Background":"['Radiotherapy is an important component for the curative management of locally advanced non-small cell lung cancer (LA-NSCLC); however radioresistance can hamper the efficacy of treatment. Biological innovations by combining molecular targeted therapy with radiation could potentially enhance radiotherapy efficacy. Hsp90 (heat shock protein 90) is a chaperone protein that assists other proteins in folding, stability and degradation. Since Hsp90 stabilizes a variety of client proteins required for survival of cancer cells, Hsp90 inhibitors are currently studied for their therapeutic benefit in the treatment of various types of malignancies. One drug in particular is Ganetespib, a potent second generation HSP90 inhibitor with minimal ocular and hepatic toxicities, has proven improved efficacy in Stage IV NSCLC in combination with docetaxel, and is now in phase III clinical testing (GALAXY-II). The purpose of our study is to determine if low dose (25 nM) Ganetespib in combination with irradiation can enhance the radiotherapeutic effects on human lung cancer cells. The experiments were conducted using Kras mutant H460 and A549 cells, and Kras wild type H1650 cells with p53 mutation. Cell survival was measured by clonogenic survival assay (CSA). Cell cycle distribution was analyzed by flow cytometry. Expression and activity of radiosensitivity related proteins was investigated by RPPA and western blotting. Our results demonstrated that Ganetespib reduced radiation clonogenic survival on lung cancer cells, and greatly attenuated DNA damage repair with irradiation as assessed by P53BP1 foci formation. Cell cycle analysis showed that Ganetespib dramatically increased G2/M arrest between 24-48 hours, which placed cells in the radiosensitive part of the cell cycle, thereby promoting subsequent apoptosis after 48 hours. On RPPA, while higher doses of Ganetespib (50-100 nM) completely attenuated the expression of important client growth factor and survival promoting proteins such as EGFR, Her-2, AKT, and mTOR, and enhanced expressed of apoptotic pathways proteins, radiation dose-dependently acted in concert with low dose Ganetespib to upregulate p21 and downregulate pRb levels that were not apparent with either drug or radiation alone. These results suggest that low dose Ganetespib can act as a potent radiosensitizer in the treatment of NSCLC by altering levels of cell cycle progression proteins. Ganetespib in combination with radiotherapy should be explored clinically in LA-NSCLC.']",
        "Doc_id":"AACR_2014-4902",
        "Doc_title":" Low dose Ganetespib (STA-9090) enhances radiotherapy effects on lung cancer cells by synergistically altering levels of cell cycle progression proteins",
        "_version_":1606189012837466112},
      {
        "Meeting_name":" HER2 as therapeutic target for overcoming ATP-binding cassette transporter-mediated chemoresistance in small cell lung cancer",
        "Background":"['Small Cell Lung Cancer (SCLC) easily acquires multidrug resistance after successful initial therapy. Overexpression of ATP-binding cassette (ABC) transporters is important for the multidrug resistance. Among them, ABCB1 and ABCG2 are known to be upregulated in chemoresistant SCLC. We found that human epidermal growth factor receptor 2 (HER2) expression is also upregulated in chemoresistant SBC-3/ETP, SBC-3/SN-38 and SBC-3/CDDP cells, compared to chemosensitive SBC-3 cells. Lapatinib, a tyrosine kinase inhibitor of HER2, could not suppress proliferation of these HER2-positive SCLC cells, but successfully restored chemosensitivity to etoposide and SN-38 in SBC-3/ETP and SBC-3/SN-38 cells, respectively. The reversal effect of lapatinib was thought to be caused by inhibition of drug efflux-pump functions of ABC transporters, and was producible with a clinically applicable concentration. Moreover, knocking down of HER2 by a small interfering RNA weakened the effect of lapatinib on ABCB1, indicating the involvement of HER2 in the inhibitory mechanisms. Notably, we demonstrated that caveolin-1 and Src play key roles in modulating ABCB1 function via HER2 inactivation. In SBC-3/ETP cells, dephosphorylation of HER2 by lapatinib activates Src and successively leads to increase caveolin-1 phosphorylation. Through this process, caveolin-1 dissociates from HER2 and strengthens association with ABCB1, and finally impairs the pump functions. Furthermore, we demonstrated that treatment by lapatinib in combination with etoposide or irinotecan significantly suppresses the growth of subcutaneous SBC-3/ETP and SBC-3/SN-38 tumors in mice, respectively. Collectively, these results indicate that combination therapy with lapatinib and cytotoxic agents could conquer ABC transporter-mediated chemoresistance in SCLC, especially in HER2-positive cases.']",
        "Doc_id":"AACR_2012-778",
        "Doc_title":" HER2 as therapeutic target for overcoming ATP-binding cassette transporter-mediated chemoresistance in small cell lung cancer",
        "_version_":1606188973818904576},
      {
        "Meeting_name":" Randomized, multicenter phase II study of erlotinib (E) or E plus fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' Inhibition of the EGFR pathway with E is an established therapy for second- and third-line NSCLC. Estrogen receptors (ERs) and aromatase are expressed in most NSCLC specimens. NSCLC growth is stimulated by estrogens, and this effect is blocked by antiestrogens (including F) in preclinical models (Weinberg et al. Cancer Res, 2005; Siegfried et al. Semin Oncol, 2009). An increased incidence (Slatore et al. J Clin Oncol, 2010) and risk of death (Chlebowski et al. Lancet, 2009) from NSCLC is reported in patients randomized to receive hormone replacement therapy. A reduced risk of death from lung cancer is found in breast cancer patients treated with antiestrogens (Bouchardy et al. Cancer, 2011). Extensive cross-talk occurs between ER and EGFR pathways in lung cancer (Stabile et al. Cancer Res, 2005; Marquez et al. Steroids, 2007). Methods', ' This Phase II clinical study evaluates whether F adds to antitumor efficacy of E.  Patients are randomized in a 2', '1 ratio to receive E (150 mg PO qd) + F (500 mg IM q2wk x 3, then q4wk) or E alone. Response rate is the primary endpoint, and secondary endpoints include correlation between clinical response and expression of ER, ER, EGF/HER-1 receptor and HER-2/neu biomarkers. Targeted enrollment is 102 patients.   Eligibility', ' Men and women (pre- and post-menopausal) with advanced NSCLC and at least one prior chemotherapy regimen (unless patient refuses) are eligible. Patients must have sufficient available tissue for study of biologic correlates, including EGFR mutation analysis and gene copy number and studies evaluating ER, ER and aromatase.  Current Enrollment', ' More than half of the study has been enrolled to date, with recruitment ongoing in the TORI network at sites located in Southern California, Nevada, Colorado and Indiana. Supported by NIH Lung Cancer SPORE P50-CA90388 and P50-CA090440, AstraZeneca, Genentech, Stiles Program.']",
        "Doc_id":"ASCO_81994-102",
        "Doc_title":" Randomized, multicenter phase II study of erlotinib (E) or E plus fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC).",
        "_version_":1606188996210196480},
      {
        "Meeting_name":" Development of nationwide genomic screening project (LC-SCRUM-Japan) contributing to the establishment of precision medicine in Japan.",
        "Background":"['Background', ' Most of targetable gene alterations are found only in 1-5% of non-small cell lung cancer (NSCLC) cases. Large scale screening systems for these rare populations are necessary for the development of molecular targeted therapies. Thus, a nationwide lung cancer genomic screening project in Japan (LC-SCRUM-Japan) has been operated since February 2013. Methods', ' Non-squamous NSCLCs without EGFR mutations were eligible for inclusion in this study. The tumors were analyzed for ALK/RET/ROS1 fusions using RT-PCR, and detected fusions were confirmed by FISH. Since March 2015, this nationwide project has been amended to an academic-industrial collaboration project with 14 pharmaceutical companies, and the samples were further subjected to a next-generation sequencing (NGS) system, Oncomine Comprehensive Assay, enabling the simultaneous analysis of 143 cancer-related genes. Results', ' As of December 31, 2015, 195 institutions across Japan were participating and 2161 patients had been enrolled. Among 1988 available samples, including 497 for the NGS analysis, ALK/RET/ROS1 fusions were detected in 37 (2%)/51 (3%)/86 (4%), respectively. The NGS analysis also showed that 269 cases (54%) had targetable gene alterations, including 82 KRAS mutations (17%), 36 ERBB2 mutations (7%), 28 BRAF mutations (6%), 22 PIK3CA mutations (4%), 6 NRAS mutations (1%), 6 MAP2K1 mutations (1%) and 2 FGFR2 fusions (0.4%). MET/ERBB2/FGFR1 amplifications were also detected by the NGS in 13 (3%)/11 (2%)/3 (1%) cases, respectively. Through this screening, the preplanned numbers of patient with RET and ROS1 fusions (n = 19 and 26, respectively) were successfully enrolled in clinical trials of vandetanib (LURET study in Japan) and of crizotinib (OO12-01 study in East Asia), respectively. Three patients with ERBB2 alterations and 2 with MET amplifications were also enrolled in genotype-matched ongoing trials. Conclusions', ' This nationwide screening system enables efficiently and successfully detecting various targetable gene alterations in NSCLC, thereby contributing to promote cancer precision medicine through the development of targeted therapies.']",
        "Doc_id":"ASCO_166878-176",
        "Doc_title":" Development of nationwide genomic screening project (LC-SCRUM-Japan) contributing to the establishment of precision medicine in Japan.",
        "_version_":1606189016056594432},
      {
        "Meeting_name":" Functional genomics of HER2 and HER3 mutations and response to neratinib",
        "Background":"['Selective kinase inhibitors, such as erolotinib and lapatinib, and monoclonal antibodies, such as cetuximab, trastuzumab and pertuzumab, targeting EGFR and ERBB2 have elicited significant response rates in lung cancer patients harboring mutant EGFR alleles and breast cancer patients whose tumors harbor gene amplification of ERBB2. To date, only a small number of ERBB2 and ERBB3 mutations have been reported and biologically characterized. Moreover, the therapeutic impact of ERBB2 or ERBB3 mutant alleles and their value as an actionable target in patients has not been validated. While ERBB2 itself cannot bind ligand, it is a potent receptor that integrates growth signals via homo- or heterodimerization with other ERBB family members.Genomic alterations increase ERBB2 kinase activity by constitutively activating the kinase domain, enabling ligand-independent receptor activation, by promoting enhanced dimerization or other mechanisms that have yet to be elucidated. Although ERBB3 has limited inherent kinase activity and cannot homodimerize, ligand stimulation promotes dimerization with active kinases like ERBB2 and EGFR that can phosphorylate ERBB2 which then promotes transformation.Thus genomic alterations in ERBB3 may be a key means of promoting oncogenic signaling despite the protein lacking robust enzymatic activity. We performed an analysis of 100 large-scale next generation sequencing datasets newly generated by our group (bladder), our institution (MSKCC-IMPACT), or found in recently published repositories (The Cancer Genome Atlas (TCGA), Broad, Genentech, Sanger, etc) to characterize the distribution and spectrum of mutations in the ERBB2 and ERBB3 genes. Data generated suggests that ERBB2 and ERBB3 mutations are highly prevalent in bladder cancer (each 10%), and recurrent, but with less frequency (<5%), in stomach, breast, colon and lung cancers. Hotspots include mutation of S310F and a cluster of residues in the kinase domain in ERBB2 and the V104M mutation in ERBB3. Preliminary analysis of 300 tumors demonstrated that ERBB2 and ERBB3 mutations present in a typically in a mutually exclusive pattern suggesting that these may be driver events with overlapping biologic effects. Generation and expression of several of these ERBB2 and ERBB3 mutants induced receptor activation, cell transformation and tumor growth in isogenic cell line and xenograft models. Treatment with the dual EGFR/HER2 inhibitor, neratinib, in isogenic cell lines abrogated colony formation in soft agar and receptor activation and downstream signaling. We hope to correlate the in vitro potency of specific ERBB2 and ERBB3 mutations with drug response in patients on ongoing or future clinical trials of targeted ERBB therapies and determine the whether lineage, subclonality and co-altered genes, if present, predict for drug resistance.']",
        "Doc_id":"AACR_2015-1101",
        "Doc_title":" Functional genomics of HER2 and HER3 mutations and response to neratinib",
        "_version_":1606189038759313409},
      {
        "Meeting_name":" Landscape of genomic alterations (GA) detected by next-generation sequencing (NGS) in non-small cell lung cancer (NSCLC) adenocarcinoma in Israel.",
        "Background":"['Background', '  Profiling lung cancer tumors for targetable GAs is the cornerstone for individualizing treatment for this disease. We hypothesized that NSCLC samples would be enriched in actionable GAs in targetable genes.  Methods', '  The analysis included all Israeli patients (pts) with NSCLC adenocarcinoma who underwent comprehensive NGS testing (FoundationOne) between 10/2011 and 12/2013.  NGS was performed on hybridization-captured adapter-ligated libraries using DNA extracted from NSCLC specimens. It covered 3,769 exons from 236 cancer-related genes and 47 introns from 19 genes commonly rearranged in cancer. GAs including base substitutions, small indels, copy number alterations, and select gene fusions were characterized for each pt sample. Actionable GAs were defined as those identifying anti-cancer targeted therapies (commercially available or in registered clinical trials). NGS was performed as a commercially available service;  the analysis was approved by the IRBs of all participating centers.  Results', '  The analysis included 58 pts. Median (range) age was 60 (20-82) yrs and 33 (57%) were lifelong non-smokers. At the time of NGS testing, 74% of pts were pre-tested for EGFR and ALK, and 3 and 1 pts were positive, respectively. Samples used for NGS originated from the primary tumor in 34 pts (59%) and from metastatic lesions in 24 pts (41%).  All 58 samples harbored  1 GA (mean', ' 3.2 GAs/tumor). The most frequent currently non-actionable GAs were identified in TP53 (53%) and RB1 (14 %). Fifty four pts  (93%) harbored  1 actionable GA (mean', ' 1.7 actionable GAs/tumor). The most common actionable GAs were KRAS (29 %), EGFR (26 %), and CDKN2A (14 %). Gene fusions included ALK and RET both at 7%, and a rare TACC3-FGFR3 fusion (2%). Notably, NGS identified GAs in EGFR and ALK in pts whose prior EGFR/ALK testing was negative (6/43 [14%] and 2/42 [5%], respectively). GAs in the ERBB2 gene were observed in 4 samples (7%); all had insertion mutations with no amplifications.  Conclusions', '  NGS of NSCLC samples revealed a high rate of actionable GAs in well-known anti-cancer targets, which were all mutually exclusive. Further analysis of this enhanced targetable GA rate appears warranted.']",
        "Doc_id":"ASCO_133087-144",
        "Doc_title":" Landscape of genomic alterations (GA) detected by next-generation sequencing (NGS) in non-small cell lung cancer (NSCLC) adenocarcinoma in Israel.",
        "_version_":1606188982468608000},
      {
        "Meeting_name":" Evaluation of liquid biopsies for molecular profiling in untreated patients with stage III/IV non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' Molecular profiling is limited by tumour heterogeneity and access to sufficient tissue for comprehensive analysis. Circulating tumour DNA (ctDNA) can be used as a minimally-invasive liquid biopsy for mutation detection, quantification and monitoring for personalised treatment strategies. Methods', ' We recruited 110 patients into a prospectively-designed study for Stage III/IV NSCLC patients intended to initiate 1stline platinum-based chemotherapy. Blood collections (10ml K2-EDTA) were performed prior to treatment and analysed by InVision (enhanced tagged-amplicon sequencing) using a 34-gene panel. Tissue biopsies, when available, were analysed by NGS (Ion-Torrent, Sanger) for concordance analysis. To evaluate correlation with outcome, repeat blood collections were performed in selected patients. Results', ' 110 NSCLC pts were included (61% male, 14% never-smoker, and 70% adenocarcinoma). ctDNA profiling detected mutations in 83 pts (79%). TP53 (44%), KRAS (17%), STK11 (18%; 11/19 with KRAS/STK11) and EGFR (10%) were the commonest abnormalities detected. Additionally, MET (6%), ERBB2 (6%), PIKC3A (6%) and BRAF (4%) mutations and EGFR, MET, ERBB2 amplifications were detected in 2% of patients, respectively. 20% of the mutations detected in ctDNA were observed at < 0.5% allele fraction, with 6% between 0.03%-0.25% AF. Tissue was available in 44 pts; somatic mutations were detected in 73%. Tissue & liquid concordance was 92.3%. 10 pts (23%) reported as tissue negative had a positive liquid biopsy. 33 advanced NSCLC patients were evaluated for longitudinal serial ctDNA monitoring up to cycle 4 of chemotherapy; the ratio of mutated molecules between D1 and D42 was significantly correlated with change in RECIST 1.1 measurement at D42 (p-value = 0.002625 CI 95% 0.298, 0.875). Conclusions', ' ctDNA can be used as a liquid biopsy for molecular profiling of NSCLC patients to detect clinically relevant and actionable mutations when tissue biopsy is unavailable. Liquid biopsies can be used longitudinally and may provide an early surrogate for response evaluation by radiographic RECIST.']",
        "Doc_id":"ASCO_193196-199",
        "Doc_title":" Evaluation of liquid biopsies for molecular profiling in untreated patients with stage III/IV non-small cell lung cancer (NSCLC).",
        "_version_":1606189007791718401},
      {
        "Meeting_name":" A phase I/II and pharmacologic study of MM-111 in patients with advanced, refractory HER2-positive (HER2+) cancers.",
        "Background":"['Background', ' The ErbB2/ErbB3 oncogenic heterodimer is the most potent ErbB receptor pairing with respect to strength of interaction, ligand-induced tyrosine phosphorylation, and downstream signaling through mitogen-activated protein kinase and phosphoinositide-3 kinase pathways. Recently, ErbB3 signaling has emerged as an important hypothesized mechanism of resistance to ErbB2 (HER2) targeted agents in clinical use (Sergina et al. Nature 2007; Garrett et al. SABCS 2009 abstract 63). MM-111 is a novel bispecific antibody fusion protein that specifically targets the ErbB2/ErbB3 heterodimer and blocks ligand binding to ErbB3. In HER2+ gastric, breast, ovarian, and lung cancer cell lines and xenografts, MM-111 inhibits ligand-induced ErbB3 phosphorylation, tumor cell cycle progression, and tumor growth. This first-in-human phase I-II study evaluates the safety and tolerability of MM-111 and provides preliminary efficacy data in HER-2+ advanced breast cancer (ABC). Methods', ' Patients (pts) aged  18 years with histologically confirmed HER2+ advanced solid tumors that have progressed or recurred on standard therapy or for which no standard therapy exists, and adequate performance status, bone marrow reserve, and organ function, are eligible for the phase I portion. Phase II is restricted to pts with HER2+ ABC who have progressed on prior trastuzumab or lapatinib therapy. Pts with stable central nervous system lesions are eligible. Phase I employs a standard 3 + 3 dose escalation design. Once the maximum tolerated (MTD) or feasible dose (MFD) is determined, up to 25 additional pts with HER2+ ABC will be enrolled, for a planned total of 40-49 pts in both phases. Primary endpoints are determination of MTD/MFD (phase I) and 6-month progression-free survival (phase II). Secondary endpoints include determination of dose-limiting toxicity, adverse event, pharmacokinetic, and immunogencity profiles of MM-111, as well as overall response and clinical benefit rates of MM-111 in HER2+ ABC. MM-111 is administered intravenously weekly in 4-week cycles. 8 pts have been enrolled in the phase I portion (7 ABC, 1 advanced gastric cancer), and enrollment in the phase I portion is ongoing.']",
        "Doc_id":"ASCO_42632-74",
        "Doc_title":" A phase I/II and pharmacologic study of MM-111 in patients with advanced, refractory HER2-positive (HER2+) cancers.",
        "_version_":1606189006197882881},
      {
        "Meeting_name":" Differences in mutation patterns of diagnostic versus post-chemotherapy samples in patients with metastatic non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' Many clinical trials in metastatic NSCLC patients who failed first-line chemotherapy have utilized pre-treatment, diagnostic tissues for marker assessment. BATTLE was a randomized, biopsy-driven clinical study in patients with metastatic NSCLC previously treated with systemic therapy. Fresh biopsies were obtained at the time of enrollment for biomarker evaluation. We hypothesized that molecular abnormalities found at the time of enrolment in BATTLE would differ from baseline, pre-chemotherapy, diagnostic tissue.    Methods', ' We isolated DNA (SPRI-TE-based DNA recovery and cleanup methodology) from 82 matched pre-chemotherapy and BATTLE formalin-fixed paraffin-embedded specimens. Mutations were assessed by MALDI-TOF MS (MassArray, Sequenom Inc) using a lung cancer panel of 16 genes/140 assays (AKT1, BRAF, CTNNB1, EGFR, ERBB2, FGFR3, HRAS, KRAS, MEK1, MEK2, MET, NRAS, PIK3CA, PIK3R1, PTEN, and STK11) and were compared between pre-chemotherapy versus BATTLE samples.  Results', ' Mutations were identified in 25 pre-chemotherapy samples (14 K-RAS, 5 EGFR, 3 PIK3CA, 1 STK11, 1 PTEN, 1 HRAS, 1 CTNNB1). Conversely, 29 BATTLE samples had at least one mutation (14 K-RAS, 7 EGFR, 5 PIK3CA, 2 STK11, 1 PTEN, 1 HRAS, 1 CTNNB1). For the matched pair analysis, 46 patients had wild-type tumors both in pre-chemotherapy and BATTLE samples. 11 patients had wild-type tumors in pre-chemotherapy samples, but had a mutation identified in BATTLE samples (4 K-RAS, 4 EGFR,  2 PIK3CA, 1 STK11). 7 patients had a mutation in pre-chemotherapy samples, but no mutations in BATTLE samples (4 K-RAS, 2 EGFR, 1 HRAS). The remaining 18 patients had mutations in both the pre-chemotherapy and BATTLE samples; of these, 2 had different mutations in the paired samples (both within the same genes, 1 KRAS, 1 PIK3CA). Overall, there was a 24% gene mutation discordance rate between pre-chemotherapy and BATTLE samples.  Conclusions', ' Profiling of fresh biopsies may more accurately reflect molecular abnormalities present in the tumor at the time of initiation of salvage therapy, underscoring the importance of real time tissue collection in biomarker-driven studies in this setting (V Foundation, DoD).']",
        "Doc_id":"ASCO_114230-132",
        "Doc_title":" Differences in mutation patterns of diagnostic versus post-chemotherapy samples in patients with metastatic non-small cell lung cancer (NSCLC).",
        "_version_":1606189010774917120},
      {
        "Meeting_name":" Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer patients with acquired resistance to erlotinib",
        "Background":"['Background', ' NSCLC p with EGFR mutations initially respond to EGFR tyrosine kinase inhibitors (TKIs) but ultimately relapse. Sub-genomic molecular studies indicate that the EGFR T790M mutation and the activation of MET, PI3K, AXL, HER2 and MAPK can lead to acquired resistance to EGFR TKIs. To date, no integrated comprehensive genomic investigation of EGFR TKI resistance has been reported.Methods', ' FFPE biopsies of erlotinib-sensitive and erlotinib-resistant tumors were obtained from 16 EGFR mutant NSCLC patients. The samples were analyzed by whole exome sequencing and whole transcriptome sequencing utilizing the Illumina HiSeq2500 platform. In addition, targeted gene sequencing was performed with the Illumina TruSeq Amplicon-Cancer Panel and run on the MiSeq system.Results', ' Erlotinib resistant NSCLC specimens harbored known resistance drivers, including EGFR T790M mutations (6/16; 38%), MET amplification (2/16; 13%), and AXL upregulation (3/16; 19%). Differential expression analysis between resistant and pre-treatment states revealed enrichment in the post-resistant tumors of ERBB2, and FGFR signaling pathways. Biopsies from patients that developed an EGFR T790M mutation post resistance exhibited enrichment in pathways associated with cell cycle, meiosis, telomere maintenance and transcriptional regulation. Copy number analysis demonstrated amplifications in the post-resistance setting that correlated significantly with progression free survival, including regions containing NFKBIA, NKX2-1, and TSC-1. There was also strong correlation between the copy number changes observed and the expression mRNA levels of specific genes. Of note, each resistant tumor exhibited greater copy number similarity to the corresponding matched pre-treatment sample compared to other tumors within the resistance cohort.Conclusions', ' We conducted the first ever comprehensive integrated genomic analysis of EGFR TKI resistant NSCLC patients, and identified both known and potentially novel drivers of EGFR TKI resistance. This study demonstrated the feasibility and utility of comprehensive genomic analysis in the clinical management of NSCLC receiving targeted therapy. Together, our data provide unprecedented insight into the molecular pathogenesis of escape from EGFR oncogene inhibition in NSCLC. We are now conducting a prospective observational study in additional NSCLC patients on targeted therapy.']",
        "Doc_id":"AACR_2014-954",
        "Doc_title":" Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer patients with acquired resistance to erlotinib",
        "_version_":1606189013879750656},
      {
        "Meeting_name":" Multiplex digital PCR analysis of EGFR mutations for lung cancer characterization and monitoring",
        "Background":"[\"Lung cancer is the most common cause of global cancer-related mortality, leading to over a million deaths each year, with adenocarcinoma the most common histological type. Recently, molecularly targeted therapies have dramatically improved the treatment of patients whose tumors are driven by somatically activated oncogenes such as mutated EGFR, BRAF or ERBB2, or translocated ALK, RET, or ROS1. In addition, circulating cell-free DNA in the blood is undergoing assessment as an accessible biomarker for dynamic monitoring of treatment efficacy and clonal evolution of the cancer patient's entire tumor burden. Thus a new paradigm for monitoring and resistance of solid tumors is currently under development\", ' sequencing the initial tumor biopsy for driver mutations followed by ultrasensitive detection of circulating tumor DNA (ctDNA) using methods such as digital PCR (dPCR).In recent years, dPCR has become the gold standard for precise quantification of nucleic acids, showing detection sensitivities unparalleled by other methodologies. Picodroplet-formatted dPCR compartmentalizes the sample (and one or more assay) into a large enough number of discrete reaction volumes (e.g. 10 million) such that there is at most one target molecule per reaction. Standard qPCR reagents (target-specific primers and fluorescent hydrolysis probes) and master mixes are used for endpoint PCR amplification, resulting in plateaued fluorescent signals only in target-containing compartments. This enables digital counting of the absolute number of target molecules present in the sample volume tested.Here we report the use of the RainDrop dPCR system together with multiplexed assays measuring the most common cancer-relevant mutations in EGFR. Multiplexed primer and probe sets were designed for wild-type EGFR, T790M and L858R point mutations, and exon 19 deletions in EGFR. Using spike-in plasmid controls and genomic DNA from lung cancer cell lines (H1975,H1650), we verified simultaneous detection and discrimination of all mutations across a broad dynamic range. Finally, we demonstrated application of the multiplexed EGFR assays on matched tumor and ctDNA samples from lung cancer patients.Sensitive quantification of EGFR mutations in lung cancer patients is critical for stratifying patients into different treatment regimens, and can potentially benefit EGFR mutation-positive patients by allowing dynamic non-invasive tracking of treatment efficacy and clonal evolution. Development of a multiplexed dPCR EGFR mutation assay should facilitate personalizing lung cancer therapy and treatment management, towards the goal of monitoring disease progression for better outcomes. The RainDrop system enables sensitive simultaneous dPCR detection of multiple mutations from the same sample, which is particularly important when available sample is limited, e.g. with tumor biopsies, FFPE samples, circulating tumor cells, and ctDNA in biological fluids.']",
        "Doc_id":"AACR_2016-3647",
        "Doc_title":" Multiplex digital PCR analysis of EGFR mutations for lung cancer characterization and monitoring",
        "_version_":1606188989968023552},
      {
        "Meeting_name":" Molecular profiling of 502 patient cohort with NSCLC using a 27 somatic gene panel.",
        "Background":"['Background', ' Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and a tumor with broad spectrum of targeted therapies already available or in clinical trials. Thus, molecular characterization of the tumor using the Next Generation Sequencing (NGS) technology, has become a key tool for NSCLC patients treatment decision and clinical management. Methods', ' The performance of a custom 23 gene multiplex amplification hot spot panel, based on Ion AmpliSeq Technology, was evaluated for the analysis of tumor DNA extracted from FFPE (Formalin Fixed Parraffin Embedded) tissue. Furthermore the Ion AmpliSeq RNA Fusion Lung Cancer Research Panel was used for fusion RNA transcript analysis. Tumors mutation spectrum was determined in a cohort of 502 patients with NSCLC using the aforementioned targeted gene panels. Results', ' The panel used for tumor DNA analysis in this study exhibit high rates (100%) of sensitivity, specificity and reproducibility at a mutation frequency of 3%. At least one DNA mutation was detected in 374 patients (74.5%) and an RNA fusion was identified in 16 patients, (3.2%). In total, alterations in a cancer driver gene were identified (including point mutations, gene rearrangements and MET amplifications) in 77.6% of the tumors tested. Among the NSCLC patients, 13.5% (68/502) presented a mutation in a gene with approved targeted therapy (EGFR, ALK ROS1) and 9.4% had an alteration in a gene related to emerging targeted therapies according the NCCN guidelines. These alterations include ERBB2, BRAF and MET mutations, MET amplification and RET rearrangements. The remaining 51.6% of the patients had a mutation in a gene that could be related to an off label therapy or give them access to a clinical trial. Conclusions', ' Thus the NGS panel validated is a reliable approach of clinical applicability for tumor molecular profile detection in NSCLC patients.']",
        "Doc_id":"ASCO_189381-199",
        "Doc_title":" Molecular profiling of 502 patient cohort with NSCLC using a 27 somatic gene panel.",
        "_version_":1606188989988995072},
      {
        "Meeting_name":" Anti-tumor effect of afatinib, an irreversible EGFR/HER2 dual inhibitor, in lung cancers harboring HER2 oncogene",
        "Background":"['HER2 is a member of the EGFR family of tyrosine kinase receptors and plays important roles in the pathogenesis of certain human cancers. In non-small cell lung cancer (NSCLC), HER2 amplification or mutations are reported. However, little is known about the benefit of HER2-targeted therapy for NSCLC harboring HER2 alteration. In this study, we investigated the anti-tumor effect of afatinib, an irreversible EGFR/HER2 dual inhibitor, in lung cancers harboring HER2 oncogene alteration, including the novel HER2 mutations in transmembrane domain which we recently identified. Ectopically overexpressing HER2 wild-type or mutant (G776V,Cins, A775insYVMA, G660D, and V659E) in normal bronchial epithelial cells, BEAS2B, showed constitutive autophosphorylation of HER2 and activation of downstream signaling. They were sensitive to afatinib, but insensitive to EGFR-TKI (gefitinib). Furthermore, we examined anti-tumor activity of afatinib and gefitinib in several NSCLC cell lines, and investigated the association between their genetic alteration and sensitivity to afatinib treatment. Afatinib down-regulated the phosphorylation of HER2, EGFR, and their downstream signalings, and induced anti-proliferative effect through a G1 arrest and apoptotic cell death in HER2 altered cells (H2170, Calu-3, and H1781). Whereas, HER2 non-dependent NSCLC cells (A549, H1299, and H1993) were insensitive to afatinib. Our results strongly suggest that afatinib is a therapeutic option for NSCLC patients with HER2 alteration.']",
        "Doc_id":"AACR_2015-2588",
        "Doc_title":" Anti-tumor effect of afatinib, an irreversible EGFR/HER2 dual inhibitor, in lung cancers harboring HER2 oncogene",
        "_version_":1606189030539526144},
      {
        "Meeting_name":" A new nationwide genomic screening system in Japan for the development of targeted therapies against advanced non-small lung cancers with rare driver mutations.",
        "Background":"['Background', '  A variety of targetable driver mutations other than EGFR mutations and ALKfusions occur in 1%-2% of NSCLCs. Efficient screening systems for these rare mutations are necessary for the successful development of targeted therapies.  Methods', '  In February 2013, a new nationwide genomic screening system (LC-SCRUM-Japan) was established in Japan to screen advanced non-squamous NSCLCs without EGFR mutations for primarily ALK/RET/ROS1fusions. In November 2013, this system was amended to further screen for other driver mutations in fusion-negative cancers after the primary screening. Ten nanograms of genomic DNA extracted from biopsy or cytology specimens were subjected to the Ion Torrent AmpliSeq Cancer Hotspot Panel, version 2, and Ion Torrent next-generation sequencing, enabling the simultaneous analysis of 2800 hotspot mutations in 50 cancer-related genes.  Results', '  As of January 31, 2014, a total of 158 institutions were participating and 507 patients were enrolled in LC-SCRUM-Japan. Among the 148 cases that were enrolled after the protocol amendment, ALK/RET/ROS1 fusions were detected in 1 (1%)/7 (5%)/8 (5%) cases, respectively, and 107 cases without fusions were transferred to the multiplex mutation screening. In the mutation screening, a total of 121 mutations were detected in 79 cases (74%), including 46 mutations in driver oncogenes in a mutually exclusive manner (23 KRAS mutations [21%], 7 BRAF mutations [7%], 5 ERBB2 mutations [5%], 2 PIK3CA mutations [2%] and 1 NRAS mutation [1%]). In addition, 43 TP53 mutations, 5 CDKN2A mutations, 4 MLH1 mutations, 2 PTEN mutations, 1 IDH1 mutation, 1 IDH2 mutation, 1 FBWX7 mutation, 1 SMAD4 mutation and 1 STK11 mutation were detected. Among them, a case with a BRAF V600E mutation was enrolled in a global phase II study of a BRAF inhibitor, dabrafenib (NCT01336634).  Conclusions', '  This screening system enabled rare fusions and mutations in driver oncogenes, especially RET, ROS1, KRAS, BRAF and ERBB2, to be detected precisely and more frequently in limited amounts of samples from advanced NSCLCs, thereby contributing to the enrollment of patients in clinical trials for targeted therapies.']",
        "Doc_id":"ASCO_130137-144",
        "Doc_title":" A new nationwide genomic screening system in Japan for the development of targeted therapies against advanced non-small lung cancers with rare driver mutations.",
        "_version_":1606188971634720768},
      {
        "Meeting_name":" Investigating novel resistance mechanisms to third generation EGFR TKI osimertinib in non-small cell lung cancer patients using next generation sequencing.",
        "Background":"['Background', ' Third generation epithelial growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib (AZD9291) has proven effective in Non-small cell lung cancer (NSCLC) patients who have developed EGFR T790M-mediated resistance to other EGFR TKIs. Unfortunately, a majority of patients still undergo progressed disease after receiving osimertinib treatment. Acquired EGFR C797S mutation has been identified as one major mechanism; however, resistance mechanisms of remaining cases are still largely unknown. Methods', ' Using next generation sequencing (NGS) targeting 416 cancer-relevant genes, we analyzed the mutation profiles of 99 NSCLC patients that were clinically resistant to osimertinib. Results', ' In addition to the notable EGFR C797 variants (22%), L792 mutations were identified in 10% of patients, and a further 7% cases carry L718 mutations. Further analysis of 14 patients with paired pre-treatment samples confirmed that these EGFR mutations were acquired during treatment. Interestingly, all L792 mutations are in cis with T790M and in trans with C797 mutations (when present in the same patient). 2 out of 10 L792-positive patients and 6 out of 7 L718-positive patients did not have co-existing C797 mutations, suggesting C797-, L792- and L718-mutated cells may represent different resistant clones. In vitro experiments demonstrated that L792 and L718 mutants also increase osimertinib IC50, and therefore confer their resistance. Besides secondary EGFR mutations, alterations in other key genes such as MET, KRAS, ERBB2 and PIK3CA may also contribute to osimertinib resistance. Notably, MET and KRAS amplifications are present only in patients without above EGFR secondary mutations. Conclusions', ' In this study, we identified secondary mutations on C797, L792 or L718 residues of EGFR in 29% of osimertinib-resistant patients. Combined with in vitro study, our data strongly suggest that L792 and L718 mutations are likely to alternatively cause osimertinib resistance. Furthermore, MET and KRAS amplification may serve as bypass resistance mechanisms in patients who are EGFR C797-, L792- and L718-wild type.']",
        "Doc_id":"ASCO_192596-199",
        "Doc_title":" Investigating novel resistance mechanisms to third generation EGFR TKI osimertinib in non-small cell lung cancer patients using next generation sequencing.",
        "_version_":1606189021620338688},
      {
        "Meeting_name":" Characterization of methylation profiles reveals distinct epigenomic patterns in SCLC and NSCLC",
        "Background":"['Background', ' Small cell lung cancer (SCLC) is a highly lethal malignancy characterized by rapid growth, early metastasis and poor prognosis. SCLC shows distinct molecular and clinical features when compared to other lung cancer subtypes. Previous analyses by us and others have identified genomic and proteomic differences between SCLC and Non-Small Cell Lung Cancer (NSCLC). Epigenetic alterations are some of the earliest events that could also lead to oncogenic changes and thus play an essential role in tumor initiation and progression. However, epigenetic differences between SCLC and NSCLC contributing to the alterations in gene and protein expression patterns, distinct biological features and therapeutic response have not been well characterized. Here, we investigate the differences in the methylation patterns of SCLC and NSCLC to provide novel insights into epigenetic associated gene alterations to identify potential therapeutic targets in SCLC.Material and Methods', ' A genome-wide DNA methylation profiling of SCLC and NSCLC cell lines was used for this investigation. We correlated DNA methylation status with gene expression and protein expression levels in 31 SCLC and 73 NSCLC lines to identify the relationship of epigenetic with genomic and proteomic features distinguishing SCLC from NSCLC.Results', ' SCLC and NSCLC lines exhibited different methylation profiles and we identified 484 genes that had a significant inverse correlation between methylation status and mRNA expression levels (Rho  -0.5 and FDR = 0.01), (genes regulated by methylation, GRM) that distinguished SCLC from NSCLC. Ingenuity pathway analysis of the 484 genes identified significant associations with neuregulin signaling, immune trafficking, integrin signaling, glioma invasiveness canonical pathways. Proteomic profiling by Reverse Phase Protein Array (RPPA) validated the different expression of some of the 484 genes identifying nine that were hypermethylated and downregulated at protein levels in SCLC compared to NSCLC lines (PTEN, CyclinD1, Caveolin, Notch3, TAZ, HSP27, STAT6 and both total and phosphorylated levels of receptor tyrosine kinases such Her2 and, MET).Conclusions', ' Genome wide methylation, mRNA expression, and detailed proteomic analyses have identified specific epigenic differences between SCLC and NSCLC that impact on important signaling pathways including widespread loss of PTEN function and receptor tyrosine kinase (RTK) expression in SCLCs which need to be considered in developing new rationale therapies for SCLC.']",
        "Doc_id":"AACR_2015-2961",
        "Doc_title":" Characterization of methylation profiles reveals distinct epigenomic patterns in SCLC and NSCLC",
        "_version_":1606188974895792128},
      {
        "Meeting_name":" Regional screening network for characterization of the molecular epidemiology of non-small cell lung cancer (NSCLC) and implementation of personalized treatment.",
        "Background":"['Background', '    Personalized treatment of genetically stratified subgroups has the potential to substantially improve outcome in NSCLC. A major challenge now is to implement high-quality molecular diagnostics and personalized treatment strategies in routine clinical practice also outside of highly specialized academic centers.   Methods', '    We have established a molecular screening network in the catchment area of our comprehensive cancer center encompassing about 2.5 million inhabitants in March 2010 after review of the local ethics committee (10-242). Lung adenocarcinoma (AD) was screened centrally for ALK translocations, mutations in KRAS, EGFR, BRAF and PIK3CA and for amplification of ERBB2. Squamous cell carcinoma (SQ) was analyzed for FGFR1 amplifications.   Results', '    2032 NSCLC samples were acquired of which 1782 in the Cologne-Bonn area indicating a capture rate of 60-70% of all NSCLC samples in the area. Material was suitable for molecular analysis in 77%. Distribution of histological subtypes was as expected (AD 63.4%, SQ 26.7, large cell carcinoma 1.4%, adenosquamous cell carcinoma 1.8%, carcinoid 0.1%, NSCLC NOS 6.7%. In AD the following frequencies of genetic lesions were detected', ' KRAS (32%), EGFR (13%), ALK (3%), BRAF (2%), PIK3CA (2%), ERBB2 (2%). EGFR mutations were highly enriched in the lepidic and micropapillary subtype of AD (30-32%), whereas the solid subtype only harboured a very small amount of the tested oncogenic lesions. In SQ FGFR1 amplification was detected in 78/500. Overall 40% of all NSCLC samples harboured potentially tractable oncogenic lesions. All patients with ALK translocations received crizotinib when clinically indicated. 75% of the stage IIIB/IV patients with activating EGFR mutations received EGFR-TKI treatment. In addition, clinical trials have been initiated to provide personalized treatment options to all patients with tractable genetic lesions.   Conclusions', '    High-quality molecular diagnostics and identification of patients for personalized treatment approaches is feasible in daily clinical routine for the majority of diagnostic samples also in a non-academic setting.']",
        "Doc_id":"ASCO_96219-114",
        "Doc_title":" Regional screening network for characterization of the molecular epidemiology of non-small cell lung cancer (NSCLC) and implementation of personalized treatment.",
        "_version_":1606189040627875840},
      {
        "Meeting_name":" Randomized phase II study of erlotinib (E) alone or combined with fulvestrant (F) in previously treated patients with advanced non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' Estrogen receptors (ERs) and aromatase are expressed in most NSCLC specimens. Preclinical data shows that estrogens stimulate NSCLC growth, while the pure antiestrogen fulvestrant (F) blocks NSCLC progression, adding to the effects of EGFR inhibitors (Weinberg et al. Cancer Res, 2005; Siegfried et al. Semin Oncol, 2009). Increased risk of death from NSCLC occurs in patients randomly assigned to receive exogenous estrogens (Chlebowski et al. Lancet, 2009), and retrospective studies show a reduced risk of death from lung cancer in breast cancer patients who received antiestrogen therapy (Rapiti et al. SABCS Abstract 35, 2009). Methods', ' This phase II clinical study evaluates whether fulvestrant (F) adds to the antitumor efficacy of erlotinib (E). Patients are randomized in a 2', '1 ratio to receive E (150 mg PO qd)  F (500 mg IM q2wk x 3, then q4wk), as 500 mg F has demonstrated clinical benefit in other estrogen target organs compared to the standard 250 mg (Di Leo A. SABCS Abstract 25, 2009). Response rate at 2 months is the primary endpoint, and secondary endpoints include correlation between clinical response and expression of ER, ER, EGF/HER-1 receptor and HER-2/neu biomarkers. Targeted enrollment is 102 patients. Eligibility', ' Men and pre- and postmenopausal women with advanced NSCLC and at least one prior chemotherapy regimen (unless patient refuses) are eligible. Patients must have sufficient available tissue for study of biologic correlates, including EGFR mutation analysis and gene copy number. Current Enrollment', ' To date, 30 patients have been enrolled, with enrollment ongoing. The study was initially restricted to a single site pending a successful protocol-mandated safety evaluation, but the study will open in 16 TORI network sites throughout the United States by April 2010. Supported by NIH Lung Cancer SPORE P50-CA90388 and P50-CA90440, AstraZeneca, Genentech, Stiles Program.']",
        "Doc_id":"ASCO_41913-74",
        "Doc_title":" Randomized phase II study of erlotinib (E) alone or combined with fulvestrant (F) in previously treated patients with advanced non-small cell lung cancer (NSCLC).",
        "_version_":1606188988967682049},
      {
        "Meeting_name":" Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung",
        "Background":"['Background', 'As the comprehensive genomic analysis of small cell lung cancer (SCLC) progresses, novel treatments for this disease need to be explored. With attention to the direct connection between the receptor tyrosine kinases (RTKs) of tumor cells and the pharmacological effects of specific inhibitors, we systematically assessed the RTK expressions of high-grade neuroendocrine carcinomas of the lung (HGNEC), including SCLC and large cell neuroendocrine carcinoma (LCNEC).Patients and Methods', 'Fifty-one LCNEC and 61 SCLC patients who underwent surgical resection were enrolled in this research. As a control group, 202 patients with adenocarcinomas (ADCs) and 122 patients with squamous cell carcinomas (SQCCs) were also analyzed. Using immunohistochemical staining (IHC), we stained all tumors with antibodies for 10 RTKs; c-Kit, EGFR, IGF1R, KDR, ERBB2, FGFR1, c-Met, ALK, RET and ROS1. We scored the expression of these RTKs for all enrolled tumors, and compared them according to the histological types.Results', 'The LCNEC and SCLC patients exhibited similar clinicopathological characteristics. The IHC scores for each RTK were almost equivalent between the LCNEC and SCLC groups, but they were significantly different from those of the ADC or SQCC groups. Especially, c-Kit was the only RTK that was remarkably expressed in both LCNECs and SCLCs. On the other hand, about 20% of the HGNEC tumors exhibited strongly positive RTK expression, and this rate was similar to those for the ADC and SQCC tumors. Intriguingly, strongly positive RTKs were almost mutually exclusive in individual tumors.Conclusions', 'Compared with ADC or SQCC, LCNEC and SCLC had similar expression profiles for the major RTKs. The exclusive c-Kit positivity observed among HGNECs suggested that c-Kit might be a distinctive RTK in HGNEC. These HGNECs which have strongly positive RTKs could be the targets of personalized therapies.']",
        "Doc_id":"AACR_2015-5004",
        "Doc_title":" Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung",
        "_version_":1606188999424081920},
      {
        "Meeting_name":" Inhibition of HER2 mutant non-small cell lung cancer using 3rd generation EGFR/HER2 inhibitors",
        "Background":"['HER2 is modified in approximately 20% of lung cancers and is mutated in approximately 2-3% of non-small cell lung cancer (NSCLC). Several HER2 mutations within the tyrosine kinase domain are activating mutations, and irreversible EGFR TKIs such as afatinib are known to be effective at inhibiting HER2 phosphorylation in tumor cells expressing HER2 activating mutations. However, the clinical use of these second generation irreversible EGFR inhibitors, such as afatinib, has been limited by adverse toxicities such as skin rash and diarrhea. Our recent study in lung cancer showed that ibrutinib, a well-tolerated TKI currently FDA approved for B-cell lymphoma, is capable of inhibiting EGFR. Study by others also demonstrated that ibrutinib can inhibit HER2 phosphorylation in HER2 overexpressing breast cancer cell lines. In addition, recent studies in other cancers show that the effects of ibrutinib can be amplified in combination of with other small molecule inhibitors targeting AKT and mTOR. Therefore, we hypothesized that HER2 overexpression or activating mutations render NSCLC tumor cells sensitive to ibrutinib. To investigate this, we generated a panel of Ba/F3 cell lines expressing twelve individual clinically observed HER2 mutations and evaluated the transforming capability of the mutations as indicated by sustained cell viability following IL-3 deprivation. Common HER2 mutations such as A775insYVMA, G776del/insVV, and G776C V777insC as well as others were observed to be activating mutations. Mutant HER2 expressing Ba/F3 cells and the human HER2 mutant NSCLC cell line, H1781, were then screened against first, second, and third generation EGFR/HER2 inhibitors including ibrutinib, and cell viability was determined by the Cell Titer Glo assay. Drugs effective in growth inhibition were verified by Western blot analysis. The results showed that EGFR TKI erlotinib and the EGFR/HER2 TKI lapatinib failed to inhibit cell proliferation. However, ibrutinib and third generation EGFR/HER2 TKIs, EGF816 and AZD9291, inhibited cell proliferation and induced apoptosis at sub-micromolar concentrations. Western blotting analysis showed dose dependent decreases in phosphorylation of HER2 as well as HER2 downstream signaling molecules such as p-AKT, and p-MAPK. In order to determine if targeting downstream effectors of HER2 in combination with inhibition of the receptor would increase inhibition of cell proliferation and induction of apoptosis, we screened ibrutinib, EGF816 and AZD9291 in combination with both mTOR and AKT inhibitors. There was a modest additive effect when ibrutinib was used in combination with everolimus, an mTOR inhibitor, but there was no additive effect of EGF816 or AZD9291 was used in combination with everolimus. These results indicate that EGF816, AZD9291, or ibrutinib alone or in combination with mTOR inhibition may be effective therapeutic strategies for the treatment of HER2-driven NSCLC.']",
        "Doc_id":"AACR_2016-4799",
        "Doc_title":" Inhibition of HER2 mutant non-small cell lung cancer using 3rd generation EGFR/HER2 inhibitors",
        "_version_":1606189009250287616},
      {
        "Meeting_name":" Next-generation sequencing in metastatic lung cancer patients",
        "Background":"['Background', '  Several patients with lung cancer (LC) maintain good performance status even after disease progression following all standard therapies. More recently, targeted therapies have been improving prognosis of patients with advanced LC. We aim at exploring the role of a next-generation sequencing (NGS) assay in identifying therapeutic targets for refractory LC. Methods', '  Patients diagnosed with metastatic LC with available paraffin-embedded tissue evaluated by the method of NGS (Foundation Medicine, USA) were included. Hybridization capture of 3,769 exons from 236 cancer-related genes and 47 introns of 19 genes commonly rearranged in cancer was applied to  50 ng of DNA extracted from 12 LC specimens and sequenced to high, uniform coverage. Genomic alterations (GA) were reported for each patient sample. Actionable GA were defined as those identifying anti-cancer targeted therapies available on the market or in registered clinical trials.  Results', '    Twenty-nine patients were included (86.2% adenocarcinoma, 6.9% squamous cell carcinoma). Median age was 59 years (range 30-80); 65.5% were male and 55.2% were smokers or previously smokers. A total of 40 GA were identified', ' 29 patients (72.4%) harbored    1 GA, and 16 patients harbored    1 actionable GA (55.2%). The most frequent actionable GA were detected in EGFR (24.1%), AKT2 (10.3%), STK11 (10.3%), MET (6.8%), HER2 (3.4%), ROS1 (3.4%), and FGFR1 (3.4%). Non-actionable GA were mostly detected in TP53 (48.3%), MCL1 (17.2%), and CDKN2A (13.8%). The use of trastuzumab in a patient with mutated HER-2 yielded a time to progression (TTP) of 8 months. Five patients previously identified as wild-type EGFR were found to actually have EGFR mutation, with a median TTP of 11 months (1-16m) with tyrosine kinase inhibitors. Conclusions', '  Comprehensive NGS may identify novel mutations in LC patients with potential clinical utility and serve as genetic biomarkers for personalized therapeutics.']",
        "Doc_id":"ASCO_152355-156",
        "Doc_title":" Next-generation sequencing in metastatic lung cancer patients",
        "_version_":1606188975860482048},
      {
        "Meeting_name":" Mutation profile in non-small cell lung cancer",
        "Background":"['Background', '  Non-small cell lung cancer (NSCLC) is known to harbor molecular mutations or rearrangements predictive to a variety of targeted therapies, which have been increasing the overall survival (OS) in recent years. There is a lack of studies evaluating the prevalence of those molecular alterations in NSCLC patients in Brazil.  Methods', '  This was a retrospective analysis of patients diagnosed with lung adenocarcinoma who were treated at Antonio Ermirio de Moraes Oncology Center (Brazil) from January 2011 to December 2014. Status of EGFR (epidermal growth factor receptor) mutation, ALK (anaplastic lymphoma kinase) translocation, KRAS (kirsten rat sarcoma) mutation, HER2 (human epidermal receptor-2) ampification, and ROS1 (c-ros oncogene 1) rearrangement status was evaluated. Results', '  A total of 290 patients with lung adenocarcinoma were included in the analysis. Median age was 65 years (range 30-89), 51.7% were male and 67.9% were smokers or previously smokers. At diagnosis, 57.6% were metastatic and 4.8% were stage IIIB according to AJCC 2010. The analysis of EGFR status was performed in 162 patients (55.9%). The prevalence of EGFR mutation was 32.7%', ' 23 patients at exon 19, 21 at exon 21; 6 at exon 20; and 1 at exon 18. The prevalence of ALK translocation was 4.0% (3/75 patients). KRAS mutation was detected in 20% (3/15), BRAF mutation in 11.8% (2/17), HER2 amplification in 14.3% (2/14), and ROS1 mutation in 9% (1/11).   Conclusions', '  Despite being a retrospective analysis, a high prevalence of EGFR mutation (32.7%) and ALK translocation (4.0%) was detected in a brazilian population with NSCLC, which offers further clinical benefit.']",
        "Doc_id":"ASCO_152730-156",
        "Doc_title":" Mutation profile in non-small cell lung cancer",
        "_version_":1606189005181812737},
      {
        "Meeting_name":" Further molecular profiling of tumors harboring therapeutic targets within non-small cell lung cancer.",
        "Background":"['Background', '    Treatment of NSCLC has been revolutionized in recent years with the introduction of several targeted therapies for selected genetically altered subtypes of NSCLC. A better understanding of molecular characteristics of NSCLC, which features common drug targets, may identify new therapeutic options.  Methods', '    Over 6,700 non-small cell lung cancer cases referred to Caris Life Sciences between 2009 and 2014. Diagnoses and history were collected from referring physicians.  Specific testing was performed per physician request and included a combination of sequencing (Sanger, NGS or pyrosequencing), protein expression (IHC), gene amplification/rearrangement (CISH or FISH), and/or RNA fragment analysis.  Results', '    Tumors profiles from patients with hormone receptor positive disease (HER2, ER, PR, or AR positive by IHC) (n=629), HER2 mutations (n=8) ALK rearrangements (n=55), ROS1 rearrangement (n=17), cMET amplification or mutation (n=126), and cKIT mutation (n=11) were included in this analysis and compared to the whole cohort. Tumors with ALK rearrangement overexpressed AR in 18% of cases, and 7% presented with concomitant KRAS mutation. Lower rates of PTEN loss, as assessed by IHC, were observed in ALK positive (20%), ROS1 positive (9%) and cKIT mutated tumors (25%) compared to the overall NSCLC population (58%). cMET was overexpressed in 66% of ROS1 translocated and 57% of HER2 mutated tumors. cKIT mutations were found co-existing with APC (20%) and EGFR (20%) mutations. Pathway analysis revealed that hormone receptor positive disease carried more mutations in the ERK pathway (32%) compared to 9% in the mTOR pathway. 25% of patients with HER2 mutations harbored a co-existing mutation in the mTOR pathway.  Conclusions', '    Pathway profiling reveals that NSCLC tumors present more often than reported with several concomitant alterations affecting the ERK or AKT pathway. Additionally, they are also characterized by the expression of potential biological modifiers of the cell cycle like hormonal receptors, representing a rationale for dual inhibition strategies in selected patients. Further refining of the understanding of NSCLC biomarker profile will optimize research for new treatment strategies.']",
        "Doc_id":"ASCO_134054-144",
        "Doc_title":" Further molecular profiling of tumors harboring therapeutic targets within non-small cell lung cancer.",
        "_version_":1606188988404596737},
      {
        "Meeting_name":" The genomics of young lung cancer.",
        "Background":"['Background', ' Lung cancer is increasingly understood as a disease made up of genomically defined subtypes requiring distinct treatment strategies. We hypothesize that young age at diagnosis ( < 40 years) is a clinical characteristic associated with an increased chance for a targetable genomic alteration (GA). Our study will prospectively characterize the somatic and germline genomics of young lung cancer. Methods', ' Accrual opened in July 2014. Patients (pts) are eligible if diagnosed with bronchogenic lung cancer < age 40. The study website, https', '//www.openmednet.org/site/alcmi-goyl allows for virtual consenting and remote participation from anywhere in the world. We defined 7 GA of interest based on the Lung Cancer Mutation Consortium (LCMC) (EGFR, KRAS, HER2, BRAF, ALK, ROS1, RET). We aim to show the prevalence of targetable GA in our stage 4 adenocarcinoma (AC) pts will be greater in our population compared to the LCMC, with an increase from 35% to 50%; and an improvement in use of targeted therapy from 22% to 40%. Study subjects without a known genotype undergo genomic profiling with the FoundationOne test. Results', ' Preliminary results of 63 pts with stage 4 AC show that 83% have either an ALK re-arrangement n = 29 (46%), an EGFR activating mutation n = 16 (25%), a ROS1 fusion n = 4 (6%), a RET fusion n = 2 (3%) or a HER2 mutation n = 2 (3%). Other GA of interest in 22% with AC includes TP53, ATM and BRCA2 mutations. Though numbers are small, analysis of exposures show findings including', ' ROS1 fusion pts are never smokers, without exposure to secondhand smoke and compared to those with EGFR and ALK mutations, had a higher proportion of family history of lung cancer (60% vs. 25%). Conclusions', ' The trial is currently accruing (NCT02273336). Thus far in our prospective series our results have far exceeded our statistical expectations, with 83% of our stage 4 AC pts having an actionable mutation. We have defined a genomically enriched subtype of lung cancer and laid the groundwork for further studies of germline and environmental lung cancer risk factors and thus, are planning a large-scale Case Control study of the Epidemiology of YLC. (Final study results of 2 years of accrual will be presented at ASCO 2016 meeting). Clinical trial information', ' NCT02273336']",
        "Doc_id":"ASCO_163042-176",
        "Doc_title":" The genomics of young lung cancer.",
        "_version_":1606189029330518016},
      {
        "Meeting_name":" Managing metastatic breast cancer via serial monitoring with circulating cell-free tumor DNA next generation sequencing testing",
        "Background":"['Background', ' Metastatic breast cancer (MBC) is an incurable disease with complex molecular features including somatic mutations that evolve in relation to genomic instability and selective treatment pressure. Patients with treatment-refractory MBC may benefit from tumor genomic evaluation using next generation sequencing (NGS). Furthermore, analysis of circulating tumor DNA (ctDNA) in patients with advanced disease offers the possibility of non-invasive molecular monitoring.Methods', ' A patient with MBC was tested at each progression with a ctDNA NGS panel (Guardant360) that includes all NCCN-recommended somatic genomic variants for solid tumors and sequences complete exons of >50 genes to report single nucleotide variants (SNVs), fusions, amplifications, and indels with high sensitivity and ultra-high specificity (>99.9999%). The patient was diagnosed with invasive breast cancer at age 44 and treated with surgery and hormonal therapy. At age 61, she had axillary adenopathy and liver metastases. Treatment details are in Table 1.Results', ' ctDNA analysis was performed at the time of metastatic diagnosis and at 5 additional time points over the course of treatment. All samples revealed an ERBB2 exon 19 indel (p.Leu755_Glu757delinsSer), and multiple SNVs and gene amplifications. ERBB2 amplification was seen in 4 of 6 samples. Mutant allele fractions (Table 1) correlated with clinical response to treatment and progression.Conclusions', ' Analysis of ctDNA in this patient identified an ERBB2 exon 19 indel, which are present in 2-4% of non-small cell lung cancers but 1-2% in breast cancer. Treatment with anti-HER2 monoclonal antibody or dual anti-EGFR/ERBB2 tyrosine kinase inhibitor therapies may show clinical benefit. ctDNA analysis can detect emergence of actionable resistance mutations with the advantage of serial evaluation, allowing capture of inter- and intra-tumor heterogeneity and illustration of molecular progression and response.']",
        "Doc_id":"AACR_2016-172",
        "Doc_title":" Managing metastatic breast cancer via serial monitoring with circulating cell-free tumor DNA next generation sequencing testing",
        "_version_":1606189004621873152},
      {
        "Meeting_name":" Somatic mutation spectrum of non-small cell lung cancers (NSCLCs) from African Americans (AAs).",
        "Background":"['Background', '  In the AA population, previous studies have presented conflicting data on the frequency of EGFR mutations (Reinersman JTO 2011;Leidner JCO 2009), while frequencies of other gene mutations and translocations, including anaplastic lymphoma kinase (ALK), have not been described.   Methods', '  161 archival FFPE tumor specimens from self reported AA patients with any stage NSCLC from 1997-2010 were collected from 3 sites in Tennessee (132 samples) and one site in Michigan (29 samples).  Samples were evaluated for known recurrent driver mutations in EGFR, KRAS, BRAF, NRAS, AKT1, PI3KCA, PTEN, HER-2, MEK1 by standard SNaPshot/sizing assays, and translocations in ALK by FISH.  Clinical data was collected on 119 patients.  Chi-square was used to compare the frequency of mutations in subgroups and Kaplan-Meier and log rank were used to calculate and compare PFS between groups.  Results', '  5.0% of tumors had EGFR mutations, 14.9% had KRAS mutations, 0.6% had a BRAF, AKT1, PI3KCA, or HER2 mutation, and 0% had NRAS, PTEN, or MEK1 mutations.  Of 35 pan-negative non-squamous specimens, 0 had ALK translocations.  PFS was the same in those with and without KRAS mutation (p=0.74) and showed a trend towards improvement in those with EGFR mutation (p=0.08).  The frequency of EGFR mutations was higher in samples from Detroit versus those from Tennessee (17% vs 2.3%, p<0.01), as was the frequency of adenocarcinoma (62% vs 44%, p<0.05).  The frequency of EGFR mutations in never smokers was higher in the samples from Detroit versus Tennessee (83% vs 7.1%, p<0.01).  Conclusions', '  In the largest tumor mutational profiling study of NSCLC from AAs to date, EGFR mutations occurred less frequently than would be expected from a North American population.  We noted a regional difference, with fewer EGFR mutations in Tennessee than in Michigan, a finding that may have been the result of more adenocarcinoma samples from Michigan.  The rates of other mutations and translocations including ALK were low.  While lung cancer tumors should continue to undergo routine molecular testing to prioritize therapy, future comprehensive genotyping efforts should focus on identifying novel driver mutations in this population.  Funding', ' 5RC1CA162260 R01CA060691 R01CA87895.']",
        "Doc_id":"ASCO_96041-114",
        "Doc_title":" Somatic mutation spectrum of non-small cell lung cancers (NSCLCs) from African Americans (AAs).",
        "_version_":1606189038060961792},
      {
        "Meeting_name":" Survival following implementation of next-generation sequencing in routine diagnostics of advanced lung cancer",
        "Background":"['Background', ' The Network Genomic Medicine (NGM) Lung Cancer is a health care provider network offering comprehensive next generation sequencing (NGS)-based multiplex genotyping on a central diagnostics platform in Cologne for inoperable lung cancer patients (pts) in Germany. Methods', ' The NGS panel used consists of 14 genes and 102 amplicons to cover potentially targetable aberrations. Mutation analyses were run on an Illumina (MySeq) platform, FISH analyses were performed separately. In 2015, we have started the second outcome evaluation for all NGM pts who had received NGS-based molecular diagnostics. In particular, we have focused on pts with activating EGFR mutation (EGFR+), ALK translocation (ALK+), BRAF-V600E mutation (BRAF+), HER2 amplification (HER2+) and ROS1 translocation (ROS1+) and on the outcome of pts treated in clinical trials (ct). Results', ' From 2013-2015 6210 lung cancer pts (n = 4244 non-squamous NSCLC) were genotyped. Overall survival (OS) is shown for 934 NSCLC pts including 110 pts treated in ct. For 108 EGFR+ pts, the OS of pts treated in ct with different 3rd generation EGFR-TKIs was 55 months (n = 25) vs 22 months in the control group (n = 83) (p = 0,002; mean OS', ' 29 months; 95%CI', ' 36-83 months). For 85 ALK+ pts, the OS of pts treated in ct with next-generation ALK-inhibitor after crizotinib failure was 35 months (n = 19) compared to OS of 23 months for 45 pts treated with crizotinib only and 8 months for 19 pts treated with no ALK inhibitors (p < 0,0001; mean OS', ' 22 months; 95%CI', ' 22-33 months). For 32 BRAF+ pts and 11 HER2+ pts, the mean OS was 23 months (95%CI', ' 12-26 months) and 25 months (95%CI', ' 15-34 months) (p = 0,022). The mean OS of 13 ROS1+ pts was not reached (95%CI', ' 58-100 months). Conclusions', ' Here we show successful implementation of NGS-based molecular diagnostics in clinical routine use. Moreover, molecular diagnostics triggers personalized therapy in  and outside clinical trials and improves survival for EGFR+, ALK+, ROS1+, BRAF+ and HER2+ pts. In particular, the use of next-gen. inhibitors after failure of first gen. inhibitors in EGFR+ and ALK+ pts leads to a significant and substantial additional survival benefit.']",
        "Doc_id":"ASCO_170708-176",
        "Doc_title":" Survival following implementation of next-generation sequencing in routine diagnostics of advanced lung cancer",
        "_version_":1606189027889774593},
      {
        "Meeting_name":" Integrated genomic analysis for revealing broad remodeling of EGFR-targeted therapy resistant lung cancers.",
        "Background":"['Background', '  Patients with EGFR-mutant NSCLC often respond initially to EGFR kinase inhibitor therapy but ultimately relapse.  The spectrum of clinical resistance mechanisms and mechanistically appropriate therapeutic strategies to enhance EGFR inhibitor treatment responses remains incompletely defined. Methods', '  We used whole exome and transcriptome deep sequencing analysis of tumors obtained from 16 EGFR-mutant NSCLC patients both prior to EGFR inhibitor therapy and at clinical resistance to identify the spectrum and biological basis of molecular alterations that could drive therapy resistance and be targeted to enhance clinical responses.  Results', '  Tumors with acquired EGFR TKI resistance harbored individual and concurrent established resistance-conferring alterations, including EGFRT790M and upregulation of several receptor kinases, and other molecular alterations not previously associated with this resistance, including activating KRAS mutations.  Pathway analysis of the transcriptome data revealed upregulation of ERBB2 and FGFR signaling broadly in the therapy-resistant tumors and that the EGFRT790M positive resistant tumors exhibited therapy-induced upregulation of biological pathways underlying cell cycle progression and genome maintenance.  The evolution of EGFRT790M-positive resistance was also associated with increased genetic divergence and genomic instability.  Genomic amplification and increased levels of the NF-kB inhibitor NFKBIA correlated with improved EGFR TKI response.  Conclusions', '  This genome-scale characterization of the molecular landscape of EGFR inhibitor resistance uncovered biological programs and molecular events underlying the evolution of resistance, establishes the utility of whole exome and transcriptome deep sequencing in repeat biopsy specimens from NSCLC patients, and provides rationale for serial, comprehensive tumor molecular profiling in individual cancer patients to enhance therapeutic precision and response. Our findings also uncovered new molecular biomarkers of therapy response and provide new insight into the biological basis and complexity underlying the evolution of resistance.']",
        "Doc_id":"ASCO_130532-144",
        "Doc_title":" Integrated genomic analysis for revealing broad remodeling of EGFR-targeted therapy resistant lung cancers.",
        "_version_":1606189042068619264},
      {
        "Meeting_name":" Performance study of an amplification-based NGS test on clinical FFPE specimens in Chinas first multi-center study.",
        "Background":"['Background', ' Next Generation Sequencing (NGS) assays provide a comprehensive view of clinically actionable variations in patients. The increasing application of NGS holds new promise towards accurate diagnosis, personalized treatment and precision medicine. Formalin-fixed Paraffin-embedded (FFPE) treatment remains to be the most popular format of tissue preservation. To further standardize the whole process of the application of NGS assays on FFPE tissues, the Chinese Medical Association Pathology Division organized a multi-center performance study of a NGS assay on more than 1,000 clinical FFPE specimens by inviting top pathology departments in the country. Methods', ' OncoAim Tumor Mutation and PharmGx Detection Kit (Singlera Genomics, Shanghai) was used for this study. Reference samples with known mutations and allele frequencies together with 1045 clinical FFPE specimens from 11 participating hospitals were tested. Among them, 615 Colorectal Cancer (CRC) and 430 Non-Small Cell Lung Cancer (NSCLC) FFPE samples were processed and sequenced on Illumina Miseq platform and Thermo ion torrent PGM platform, respectively. Results', ' The results on reference materials show 100% (Confidence interval = 100%) analytical sensitivity for mutations with MAF  10% when median coverage is  500X.Positive predictive value of > 99% was observed for mutations with MAF at 5% (data not shown). The median depth for CRC and NSCLC samples were 977Xand 828X, respectively. Among all CRC samples, 564 (91.7%) samples were found containing at least 1 clinical hotspot alteration. The top mutated genes were TP53, KRAS, APC, PIK3CA, SMAD4, BRAF, FBXW7, NRAS, PTEN, and ERBB2. For all the NSCLC samples, 304 (70.69%) were detected containing at least 1 clinical hotspot mutation. The top 10 mutated genes were EGFR, TP53, KRAS, PIK3CA PTEN, VHL, ERBB2, SMAD4, NFE2L2 and CTNNB1. Conclusions', ' In this study, we showed that the amplification-based NGS assay can achieve very high sensitivity and specificity for samples with median depth over 500X. The samples containing at least 1 clinical hotspot mutation were about 83% on average, suggesting NGS could be of great use for further characterization of the tissues.']",
        "Doc_id":"ASCO_194442-199",
        "Doc_title":" Performance study of an amplification-based NGS test on clinical FFPE specimens in Chinas first multi-center study.",
        "_version_":1606189004077662208},
      {
        "Meeting_name":" Frequency and clinical characterization of NSCLC patients harboring PIK3CA mutations identified within a regional screening network.",
        "Background":"['Background', ' PIK3CA mutations are a rare oncogenic event of potential therapeutic relevance in NSCLC. Here we report frequency and characteristics of patients with PIK3CA mutated lung tumors. Methods', ' Patients with NSCLC and PIK3CA mutations were identified within our regional Network for Molecular Screening in Lung Cancer. We further analyzed the presence of BRAF, KRAS, EGFR mutations as well as ALK translocation, ERBB2 and FGFR1 amplifications in PIK3CA mutated samples. Clinical data on age, sex, TNM classification and tumor stage, histological type, grading, overall survival, smoking status, comorbidity, BMI and secondary malignancies were retrieved from clinical charts in accordance with the local ethics committee. Results', ' PIK3CA mutations were detected with a frequency of 3.7% (24% exon 20,76% exon 9) in 1000 patients. Histologically 32% were defined as squamous cell carcinoma, 48% as adenocarcinoma and 18% other histological subtypes or NSCLC-NOS. Exon 9 mutations were present in the acinar and lepidic subtype, whereas exon 20 mutations were seen in the papillary and solid subtype. Cooccuring genetic lesions were observed in 16%  (mutations in KRAS=2, EGFR=1, BRAF=1; FGFR1 amplification=2). 14 were female, 23 male with a mean age of 69 years.  21 of these patients were further clinically annotated. 11 patients presented with stage IIIb/IV eligible for palliative treatment and 10 stage I  IIIa eligible for surgical therapy +/- adjuvant therapy. All but 1 patient were smokers with an average BMI of  26,2kg/m2 with a typical high load of comorbidity mainly of cardiovascular diseases, 8 of 21 patients showed prior malignancies in their medical history. The median overall survival within this population has not been reached yet. Conclusions', ' Screening for PIK3CA mutations is feasible. A high proportion (38%) of patients with PIK3CA mutated lung cancer have prior malignancies and show a high load of comorbidity. Furthermore PIK3CA mutations are not exclusive to KRAS, EGFR or BRAF mutations or FGFR1 amplifications. Successful identification of patients with oncogenic lesions in lung cancer in a screening network might allow future personalized treatment of these patients.']",
        "Doc_id":"ASCO_96154-114",
        "Doc_title":" Frequency and clinical characterization of NSCLC patients harboring PIK3CA mutations identified within a regional screening network.",
        "_version_":1606189037508362240},
      {
        "Meeting_name":" Gene expression profiling of lung tumors and matched normal airways reveals common and disparate aberrant pathways in squamous cell carcinoma and adenocarcinoma development and potential markers for detection and targets for chemoprevention in early stage lung cancer",
        "Background":"['Detection and chemoprevention of non-small cell lung cancer (NSCLC) have been unsuccessful in part due to our limited knowledge of the pathogenesis of the disease. It has been suggested that normal airway epithelia share molecular abnormalities with tumors and may serve as progenitors for lung malignancies. We sought to analyze molecular profiles of lung adenocarcinomas and squamous cell carcinomas (SCCs), two major subtypes of NSCLC, and matched normal airways to elucidate aberrant expression patterns in early phases of lung tumorigenesis. All specimens were obtained from primary early stage NSCLC consented patients who did not receive neoadjuvant therapy (n=20). We profiled RNA isolated from tumors and normal lung as well as from brushings of multiple matched airways that were histologically confirmed to lack neoplastic or preneoplastic cells (n=194). Expression signatures signifying genes significantly and concurrently differentially expressed between both tumors and airways compared to normal lung tissue (tumor-airway-normal/TAN signatures) were then derived independently for SCC and smoker adenocarcinoma cases and were comprised of 1,803 and 1,938 genes, respectively. The TAN signatures effectively clustered tumor and airways from normal lung samples (p<0.001). Further analysis showed that a subset of the genes separated SCC- and adenocarcinoma-adjacent airways. Moreover, pathways and gene-network analysis using Ingenuity pathways software highlighted similarities and differences in pathway modulation between airway epithelial fields of SCCs and adenocarcinomas. Embryonic stem cell and eicosanoid signaling pathways were most significantly modulated among those common to both TAN signatures (p<0.001). Retinoic acid receptor and stem cell signaling pathways mediated by NANOG and lineage oncogene SOX2 were most significantly modulated in the SCC TAN signature, whereas NF-kB and PTEN signaling pathways were most prevalent in the adenocarcinoma TAN airway signature (all p<0.001). Gene networks mediated by lineage oncogene NKX2-1/TITF-1 down-regulation and TP63 up-regulation, and networks mediated by increased expression of the MET and ERBB2 oncogenes were predominantly functionally modulated in the SCC and adenocarcinoma TAN signatures, respectively. Quantitative PCR analysis confirmed up-regulation of MET in adenocarcinomas and normal airways compared to normal lung. These findings highlight expression patterns and pathways that are deregulated differentially in the pathogenesis of lung adenocarcinomas and SCCs and thus offer detection markers as well as therapeutic targets to guide personalized chemoprevention in early stage NSCLC patients. Supported by DoD grant W81XWH-10-1-1007.']",
        "Doc_id":"AACR_2012-1721",
        "Doc_title":" Gene expression profiling of lung tumors and matched normal airways reveals common and disparate aberrant pathways in squamous cell carcinoma and adenocarcinoma development and potential markers for detection and targets for chemoprevention in early stage lung cancer",
        "_version_":1606189015776624640},
      {
        "Meeting_name":" Evaluation of stored liquid biopsies for molecular profiling in patients with non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' Molecular profiling is often limited by access to sufficient tumour tissue for comprehensive analysis and due to tumour heterogeneity, the complete range of tumor DNA abnormalities may not be represented nor accurately reflect the clinical evolution of disease. Circulating tumour DNA (ctDNA) can be used as a liquid biopsy for molecular abnormalities detection, quantification and monitoring for personalised treatment strategies. Methods', ' Plasma was collected at baseline (BL) and during study therapy from advanced NSCLC patients (pts) enrolled in a placebo controlled phase III trial of a novel irrerversible EGFR inhibitor; all patients had received standard therapy with chemotherapy and gefitinib or erlotinib. Archival tissue was collected when available but biopsy was not required prior to enrolment. BL Plasma ( < 3ml), stored for ~8 years was used to extract DNA and analysed using InVision (enhanced tagged-amplicon sequencing). Results', ' BL plasma from 387 pts was tested; 289 pts had available tissue results (from archival tissue collected at diagnosis) for EGFR (174WT/115Mut) and 243 for KRAS (205WT/38Mut). Despite age of plasma samples, ctDNA analysis detected cancer mutations in 310 pts (82%)', ' TP53 (45%),KRAS (15%), and EGFR (43%; 56% were EGFR del19 and 29% L858R); T790M was detected in 80 patients. EGFR mutations were identified in 29 patients and KRAS in 10 patients with unknown tissue status. Also of note, STK11 (32 pts, 12 with KRAS), BRAF (5pts, 3 with V600E), MET(7 pts, 4 with METamp), ERBB2 (16pts, 10 with ERBB2amp) were identified in ctDNA analysis. Median time and median number of lines of systemic therapy between tissue biopsy and blood was 714 days and 3 lines respectively. Further analyses of ctDNA analyses in context of patient and trial outcomes are in progress. Conclusions', ' Liquid biopsies provide opportunity to evaluate molecular mutation profile in NSCLC patients. We demonstrate a highly sensitive method for ctDNA analysis which is complementary to tissue molecular analysis.']",
        "Doc_id":"ASCO_193212-199",
        "Doc_title":" Evaluation of stored liquid biopsies for molecular profiling in patients with non-small cell lung cancer (NSCLC).",
        "_version_":1606189008424009728},
      {
        "Meeting_name":" Do pan-negative never-smoker (NS) lung cancer patients (pts) represent a new distinct subgroup? Data from a single-institution experience.",
        "Background":"['Background', '  Identification of oncogenic drivers has dramatically changed current therapeutic strategies for lung cancer, initiating the era of personalized therapy. \"Pan-negative\" NS non-small cell lung cancers (NSCLC) represent an exciting challenge to discover rare gene fusions and to define the best treatment options.  Methods', '  From a 243 never-smoker NSCLC database, we identified 113 oncogene-addicted lung tumors, analyzed for a 5-genes panel', ' EGFR, K-RAS, ALK, ROS1, HER2. Out of  the 130 pan-negative pts, we were able to collect archived histological material of 29, to be analyzed for RETgene rearrangement, through the FISH test. Outcomes to first line chemotherapy and TKI treatment, were evaluated by Cox multivariate analysis.  Results', '  Patients characteristics', ' good clinical conditions (PS ECOG 0-1), predominance of female sex (21 pts, 64%), median age 55 (23-81), advanced moderately and poorly differentiated adenocarcinomas. In our cohort, 3 RET+ cases (10%) were identified, one compatible with KIF5B', 'RET and the other two with a non-KIF5Bfusion partner. There was no difference neither in progression free survival (PFS) (9 months, mo) for both groups nor in overall response rate (ORR) (66.7% vs 50%; p=0.24) for pts treated with a pemetrexed-based regimen (15 pts, 52%) as compared with the non-pemetrexed group (14 pts, 48%). Median overall survival (OS) of the pts who received pemetrexed was 17 mo compared to 25 mo of the non-pemetrexed subgroup (p=0.03). In our cohort 13 pts received an oral TKI. Median OS showed no significant differences between TKI and not-TKI treatment (22 vs 23 mo, p=0.94).  Conclusions', '  Our study in a highly selected population confirms the lack of benefit in any of the outcome measures in the absence of a genetic driver. Longer survival in pan-negative NS lung cancer pts compared to an unselected NSCLC population is probably a result of their distinct clinical features.']",
        "Doc_id":"ASCO_134872-144",
        "Doc_title":" Do pan-negative never-smoker (NS) lung cancer patients (pts) represent a new distinct subgroup? Data from a single-institution experience.",
        "_version_":1606188993377992704},
      {
        "Meeting_name":" Modulation of circulating biomarkers in NSCLC patients correlate with stage.",
        "Background":"['Background', ' NSCLC accounts for ~80% of all lung cancer cases. Five-year survival rates for stage IV disease are very poor compared with stage I (2% vs. 56%). Therefore, tools are needed to assist with early diagnosis for lung cancer patients and guide targeted therapies that might benefit them. We measured the modulation of specific biomarkers across lung cancer stages in NSCLC patients that are relevant to targeted therapies currently available or in development. Methods', ' 17 stage I, 24 stage II, 47 stage III, and 48 stage IV lung cancer patient serum samples were assayed for the following circulating biomarkers by ELISA', ' EphA2, HER-2/neu, VEGF165, and sVEGFR-2. We have developed a test for circulating EphA2 which may be useful for EphA2 targeted therapies. Results', ' We found significant differences between stages for the following biomarkers using the Kruskal-Wallis test', \" EphA2 (p < 0.0001), HER2/neu (p < 0.0001), VEGF165 (p < 0.0001), and sVEGFR-2 (p < 0.0001). Post-hoc analysis (Tukey's method) was performed to compare individual stages. VEGF165 levels were lowest in stage I and trended upwards at stage II, then downwards in later stages. Soluble-VEGFR-2 exhibited a similar pattern with lowest levels in stage I and highest levels in stage II (p = 0.001), while finally trending downwards in later stages. While not significant, soluble-EphA2 expression trended upwards from stage I to stage IV. In addition, soluble-HER2/neu expression was low in stages I-III and then significantly increased in stage IV (p < 0.0001). Conclusions\", ' Based upon the high levels of VEGF165 and sVEGFR-2 found in stage II, intervention with anti-angiogenesis therapies may benefit early stage NSCLC patients. The significant increase of soluble HER2/neu in stage IV indicates that intervention with ErbB therapies may benefit late stage NSCLC patients. A panel composed of these particular biomarkers may help to guide therapy decisions for NSCLC patients in whom these target therapies hold promise. This preliminary biomarker study in NSCLC highlights the need for further investigation of this panel correlated to survival outcomes and therapy prediction.']",
        "Doc_id":"ASCO_52575-74",
        "Doc_title":" Modulation of circulating biomarkers in NSCLC patients correlate with stage.",
        "_version_":1606188988078489600},
      {
        "Meeting_name":" The genomics of Young Lung Cancer Study.",
        "Background":"['Background', '  Primary lung cancer is increasingly understood as a heterogeneous disease made up of genomically defined subtypes requiring distinct treatment strategies. We hypothesize young age at diagnosis ( <  40 years) is a clinical characteristic associated with an increased chance for a targetable genomic alteration. This ALCMI study will prospectively characterize the somatic and germline genomics of young lung cancer. Our goals are to identify a genomically enriched subtype of lung cancer, facilitate delivery of targeted therapy and lay groundwork for further studies of heritable and environmental lung cancer risk factors. Methods', '   Accrual opened 07/2014. Patients are eligible if they were diagnosed with bronchogenic lung cancer less than age 40. A study specific website allows for virtual consenting so patients can participate remotely from anywhere in the country or the world; and use social media to share our trial. We have an integrated data and biorepository (Open Medicine Institute) that allows for seamless communication and completion of study activities like remote consenting, storage and routing of blood and tumor specimens. We have defined 7 genomic alterations of interest based on the Lung Cancer Mutational Consortium (LCMC) (EGFR, KRAS, HER2, BRAF, ALK, ROS1, RET). On study subjects without a known genotype will undergo comprehensive genomic profiling with the FoundationOne test to ensure that all of these genes have been tested. Subjects with advanced adenocarcinoma who are wild-type for all 7 genes will receive additional genomic profiling using the FoundationOne Heme test with the goal of identifying novel oncogenic drivers. Additional investigational genomics will include blood for germline analysis. All on study genomic analysis is at no cost to the participant. We aim to demonstrate that the prevalence of targetable genomic alterations will be greater in our population compared to the LCMC and have powered our study to show an increase from 35% to 50%; and an improvement in use of targeted therapy from 22% to 40%. The trial is currently accruing (NCT02273336) https', '//www.openmednet.org/site/alcmi-goyl. (Supported by grants from The Bonnie J. Addario Lung Cancer Foundation, Peter Barker Foundation, Genentech and Schmidt Legacy Foundation.) Clinical trial information', ' NCT02273336']",
        "Doc_id":"ASCO_146855-156",
        "Doc_title":" The genomics of Young Lung Cancer Study.",
        "_version_":1606188992069369856},
      {
        "Meeting_name":" Histologic and genotypic re-evaluation of non-small cell lung cancer (NSCLC)",
        "Background":"['Background', '    Mechanisms of resistance are responsible for the progression of the disease both in patients (pts) with lung cancer treated with cytotoxic drugs and in those receiving targeted therapies. Histological and genetic analyses on tissue samples performed after treatments could be relevant to define subsequent strategies. Methods', '    NSCLC pts with adequate archival tissue samples before and after at least one treatment have been evaluated from July 2006 to December 2013 in a single institution. All had ECOG Performance Status of 0 and IIA-IV stage at diagnosis, median age of 51 years. After histological examination, mutational analyses for EGFR, K-RAS, PIK3CA, B-RAF and HER2 genes were performed using pyrosequencing and Real time PCR was used to detect EGFR resistance mutation. ALK and MET genomic rearrangements were tested by FISH. Results', '   33 cases were analysed. Diagnoses were re-confirmed in all but one case (3%) in which morphological and immunophenotypical features of small cell lung cancer were detected. At the first biopsy, EGFR activating mutations were identified in 15/33 (45%) pts and 12/15 (80%) of them maintained activating mutations at the second biopsy with 5/12 (42%) having also a pT790M mutation (4/5 (80%) de novo and 1/5 (20%) already detected at baseline). ALK rearrangement was identified in 6/33 (18%) pts and it was mutually exclusive with EGFR mutations, both at the first and the second biopsy. MET amplification was evidenced at the first biopsy in 5/33 (15%) pts (3/5(60%) of these were also EGFR mutated) and in 11/33 (33%) pts at the second one. K-RAS mutations were found in 5/33 (15%) and in 6/33 pts (4 maintained and 2 de novo) at the first and second biopsy, respectively. PIK3CA mutations were present in 2/33 (6%) pts at the first and only one was maintained at the second biopsy. BRAF mutation was detected at the second biopsy in 2/33 (6%) pts. No HER2 mutations were found. Conclusions', '    This study confirms a relevant percentage of molecular profile changes (up to 61%) after therapy and underlines the value of repeated evaluations for molecular diagnostic purposes, in order to design appropriate tailored therapies, even after acquisition of various resistance mechanisms.']",
        "Doc_id":"ASCO_129646-144",
        "Doc_title":" Histologic and genotypic re-evaluation of non-small cell lung cancer (NSCLC)",
        "_version_":1606188996485971968},
      {
        "Meeting_name":" Whole-exome sequencing in tumor samples from sequenom-wild-type, ALK negative stage IV lung adenocarcinoma (ADC) patients (p).",
        "Background":"['Background', '  The majority of lung ADC tumors are characterized by specific genetic features with KRAS mutations (mut) seen in 20-30%, EGFR mut in 15%, EML4-ALK translocations in 5%, and ERBB2 mut in 2%, among others. Some of these genetic alterations are already being used for selecting targeted therapies. However, identification of additional genomic alterations is required.  Methods', '  In the present ongoing study we perform whole-exome sequencing in paraffin-embedded tumor samples from OncoCarta v1.0 panel wild-type (no mut in hotspots of KRAS, EGFR, ERBB2, AKT1, BRAF, PIK3CA genes) and ALK negative (by FISH) stage IV ADC lung cancer p, and in their matched normal tissue samples.  Results', '  To date, a total of 7 tumors and matched normal tissues have been successfully analyzed. We have detected mut in previously identified ADC genes, such as ERBB2, CTNNB1, TP53, SMAD4 or APC. Interestingly, mut were found in genes belonging to the proposed new cancer hallmark epigenetic and RNA regulation, such as BRD3, EPC1, PHF1 in almost every p included in our study.  Regarding alterations that could be considered relevant for lung tumor pathogenesis/growth or as potential targets for treatment therapies, we were able to identify candidates in 4 of the 7 p.  In one p, a case of a transmembrane domain ERBB2mut in exon 20 (p.E770delinsEAYVM) not previously detected by the OncoCarta v1.0 panel (that interrogates L755P, G776S/L/V/C, A775_G776insYVMA, P780_Y781insGSP, S779_P780insVGS mut) was found.  In another p, three somatic mut in the BRCA1/2 genes were detected. Additionally, one p had an ALK point mut (p.P336K), for which no functional information is available, together with an APC mutation. In the remaining p, a non-hotspot mutation (although previously detected in a colorectal tumor) was found in CTNNB1.  Conclusions', '  In this limited experience of whole-exome sequencing of a subgroup of stage IV lung ADC p, potentially targetable alterations not formerly detected by other techniques were found. We believe that genomic approaches to detecting alterations may be useful in clinical practice and will hopefully provide assistance in making treatment decisions.']",
        "Doc_id":"ASCO_113380-132",
        "Doc_title":" Whole-exome sequencing in tumor samples from sequenom-wild-type, ALK negative stage IV lung adenocarcinoma (ADC) patients (p).",
        "_version_":1606188981900279808},
      {
        "Meeting_name":" Genomic profiling of non-small cell lung cancer in the community setting.",
        "Background":"['Background', ' Genotyping in patients (pts) with advanced NSCLC may identify mutations (mut) amenable to targeted therapy (TT). We identified in a 2010-2014 community series a 60% testing rate for EGFR/ALK among stage IV pts (Gutierrez ASCO 2015; e19113). 2014 guidelines added 5 additional targets for testing. Methods', ' Retrospective review advanced non-squamous NSCLC treated by 89 community oncologists (16 sites) throughout NJ and MD (Jan 2013  Dec 2015). Results', ' 634 pts with NSCLC (566 stage IV and 68 stage IIIB) in the COTA database (89% adenocarcinoma, 7% NOS, 3% large cell, 1% sarcomatoid); median age 68 yrs; 52% female. 477 pts (75%) underwent any genotyping. Testing rates for EGFR were 67% in 2013, 80% 2014 and 69% 2015 (similar pattern with other mut). In never/passive smokers EGFR testing rate was 84% (47% pos for mut); 70% former smokers tested (13% pos); current 64% tested (5% pos) (p < 0.001 testing by smoking). KRAS testing performed in 32% with 31% pos, but did not triage genotyping (97% KRAS pos pts were tested for EGFR). Comprehensive NGS testing was performed in 15%, with additional 18% undergoing limited genotyping beyond EGFR/ALK. Rates of comprehensive NGS increased (2013', ' 10%, 2015', ' 23%; p < 0.001). Similar rates of NGS testing were observed among oncologists caring for > 10 pts or < 10 pts (15% vs 16%). 31 pts (5%) underwent second biopsy to obtain tissue for genotyping. Insufficient tissue was cited by 8%, with other documentation for non-testing lacking. Actionable EGFR/ALK findings were identified in 107 pts (22% tested); 73% of these received TT; 6% started chemo prior to test results (median 26 days vs 22 days who received TT; p = 0.36); 10% no treatment (7% early deaths). Genotyping identified actionable mut in 17 pts (2.6% overall population); (9 MET Amp/ 88 tested, 2 BRAF/98 tested, 2 ERBB2/ 52 tested, 2 RET/ 82 tested, 1 ROS1/ 85 tested, 1 MET Exon 14/ 46 tested). Among these 17 pts only 1 received TT (herceptin). Conclusions', ' Genotyping for EGFR/ALK remain below guidelines; most patients are undergenotyped for all 7 treatable mut. NGS testing rates are slowly increasing, which may reduce insufficient tissue exclusions. We plan to explore whether non-invasive comprehensive genotyping with cell-free DNA NGS may increase utilization of TT.']",
        "Doc_id":"ASCO_168560-176",
        "Doc_title":" Genomic profiling of non-small cell lung cancer in the community setting.",
        "_version_":1606189023327420417},
      {
        "Meeting_name":" Personalized treatment outcomes in never smokers with advanced non-small cell lung cancer (NSCLC) in the Princess Margaret Cancer Centre.",
        "Background":"['Background', '   Lung cancer in never smokers represents a distinct clinical and molecular entity characterized by frequent actionable driver mutations. Methods', '   Clinical and demographic data of 503 never smokers with advanced NSCLC were retrieved from patient records in order to characterize treatment outcome, survival, demographics, pathology and molecular profile. Results', '   There were 203 patients treated with targeted therapy (T-pts) and 300 patients without (NT-pts). Median age at diagnosis in T- and NT-pts was 59.7 & 61.6 yrs, respectively. Most patients in both groups were female (75%), with 49% & 37% Asians among T- and NT-pts, respectively. Most tumors in T-pts (193/203, 95%) had a single mutation (MUT)', ' EGFR 167/193 (87%), ALK 23/193 (12%), and HER-2 3/193 (1%). In T-pts, 10 had tumors with multiple MUTs', ' (EGFR 9, and ALK 1). NT-pts did not receive targeted therapy because of unknown mutation status (55%), absence of any MUT (29%), lack of druggable MUT (6%) or resected or asymptomatic stable disease in patients with tumors harboring targetable MUTs (10%). Median overall survival (mOS) in T-pts was 47 months (mo) compared with 23 mo in NT-pts (HR 0.56, 95% CI', ' 0.44-0.71, P < 0.001). Patients with EGFR- or ALK-mutant tumors who did not require systemic treatment because of clinically and radiologically stable disease had the longest survival (median > 47 mo). Caucasian vs. Asian ethnicity (p = 0.014) and ECOG PS 0 vs. 1 (p = 0.004) in T-pts and ECOG PS 0-1 vs 2-3 (p < 0.001) in NT-pts were associated with longer survival. EGFR Exon 21 MUT was associated with a trend towards shorter survival than Exon 19 (HR 1.48, 95% CI', ' 0.95-2.3, P = 0.083). Patients with EGFR MUTs and brain metastases at diagnosis had similar survival to those without (HR 1.16, 95% CI', ' 0.74-1.8, P = 0.514). However, in the 74 patients with CNS metastases at diagnosis EGFR Exon 21 compared to Exon 19 was associated with significantly shorter survival (med 21 vs 57 mo; HR 3.96, 95% CI', ' 1.73-9.05, P < 0.001). Conclusions', '   Never smokers with advanced NSCLC can achieve long survival when treated with targeted therapy. Our observation of poorer survival in patients with EGFR Exon 21 and brain metastases warrants further study.']",
        "Doc_id":"ASCO_144192-156",
        "Doc_title":" Personalized treatment outcomes in never smokers with advanced non-small cell lung cancer (NSCLC) in the Princess Margaret Cancer Centre.",
        "_version_":1606188997859606528},
      {
        "Meeting_name":" Clinical features and outcome in never-smoker (NS) non-small cell lung cancer (NSCLC) patients (pts)",
        "Background":"['Background', '  NSCLC in NS often harbors proto-oncogene aberrations, showing enrichment for targetable alterations compared to unselected populations. Objectives of this study were to define the proportions of the driver gene alterations and to examine survival in genotype-specific subsets of NS NSCLC.  Methods', '  We identified 243 NS NSCLC pts treated at our Institution from October 2003 to January 2014. Pts with tissue available for biological analysis were as follows', ' 207 pts (85.1%) assessable for EGFR/KRAS mutation, 77 (31.6%) for ALK rearrangement, 37 (15.2%) for ROS1 rearrangement, 33 (13.5%) and 32 (13.1%) for RET fusion and HER2 mutation. The cohort comprised 58% women, median age 62, 86% advanced adenocarcinomas (10% brain metastases at diagnosis).  Results', '  Out of 207 tumors, frequency of EGFR and KRAS mutation was 42.5% (88 pts) and 7.7% (16), respectively. Among pts screened for ALK, ROS1, RET, HER2, the proportion of individual testing, were 25.9% (20), 13.5% (5), 9% (3), 0%. 228 pts were evaluable for treatment and outcomes.158 pts (69%) received at least one line of an EGFR tyrosine kinase inhibitor (TKI), of which 42 (27%) as first line. 16 pts (7%) received an ALK/ROS1 inhibitor, and 8 pts (4%) had both treatments, 50 pts (21%) received exclusively chemotherapy. Median progression-free survival (PFS) after treatment with first line EGFR TKI was 13.2 months (mo) vs 5.3 mo for chemotherapy (p<0.001). Median PFS after a II line TKI (114 pts) was 14.1 mo. Median overall survival (OS) for EGFR mutans, ALK/ROS1 positive and chemotherapy-only treated pts was', ' 31.8 mo, not reached, and 14.1 mo, respectively (p<0.001). Median OS for KRAS mutated vs KRASwt pts was 32.2 mo vs 17.4 mo (p 0.363).  Conclusions', '  The study confirmed the clinical and outcome features which make lung cancer in NS a distinct disease. Of particular note is the marked increase in OS with EGFR TKI therapy when evaluating this subset in contrast to previous studies not specifically focusing on NS.']",
        "Doc_id":"ASCO_133979-144",
        "Doc_title":" Clinical features and outcome in never-smoker (NS) non-small cell lung cancer (NSCLC) patients (pts)",
        "_version_":1606189028269359104},
      {
        "Meeting_name":" Knockdown of EGFR to investigate its therapeutic potential for treatment of non-small cell lung cancers",
        "Background":"['Background', ' Epidermal growth factor receptor (EGFR) is a transmembrane protein consisting of an extracellular ligand-binding domain, and its activation leads to a multitude of effects including cell proliferation, cell differentiation, angiogenesis, metastasis, and antiapoptosis. EGFR can be a partner of heterodimer of other EGFR family such as HER2 and HER3. EGFR is often overexpressed in non-small cell lung cancer (NSCLC). Anti-EGFR agents including EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have considered to be effective for NSCLC when drug sensitive EGFR mutation is present. However, inherent and acquired resistances are major problems of EGFR targeting therapies. In this study, we knock-downed EGFR using small interfering RNAs (siRNAs) in NSCLC cell lines to examine the significance of targeting EGFR for NSCLC therapy. Materials and methods', ' We treated 14 NSCLC cell lines including nine EGFR mutant and five EGFR wild-type cell lines by geftinib or siRNAs for EGFR knock-down (siR-EGFR). Three cell line, PC-9-GR-N1, RPC-9, and HCC827-Met, were experimentally established as acquired resistant cells to gefitinib. The anti-tumor effect was determined by MTS or colony formation assay. The protein expression was evaluated using Western blotting. Results', ' All cell lines showed the expression of EGFR protein and siR-EGFR treatment down-regulated EGFR protein in all 14 cell lines. siR-EGFR suppressed cell viability in 7 of 9 EGFR mutant cells ranged from 8.0% to 73%. PC-9-GR-N1 and RPC-9 also showed inhibition. NCI-H1670 and HCC827-Met harboured EGFR mutation but were not inhibited. Of note, PTEN was deleted in NCI-H1670 and c-MET was amplified in HCC827-Met. Cell viability of all EGFR wild-type cells was not inhibited except NCI-H411. Conclusion', ' Our results indicated that EGFR can be the therapeutic target of NSCLC with EGFR activation. By contrast, targeting EGFR is not appropriate strategy for tumor of which EGFR is not activated even though EGFR is expressed.']",
        "Doc_id":"AACR_2012-7",
        "Doc_title":" Knockdown of EGFR to investigate its therapeutic potential for treatment of non-small cell lung cancers",
        "_version_":1606189004761333760},
      {
        "Meeting_name":" Effects of dual inhibition of EGFR and Aurora A kinase in a lung cancer model",
        "Background":"['Lung cancer is the leading cause of cancer related death in the US. Patients with advanced disease generally have a poor prognosis with a median survival of around 10 to 12 months with standard chemotherapy. Astsaturov and colleagues (2010) employed a synthetic lethal screening method and have reported that the combined inhibition of the EGFR and Aurora A kinase pathways had synergistic effect on cancer cell viability in head and neck and colon cancer cell lines suggesting a potential benefit of such combination therapy in patients. Our study aims to examine the effects of combination of erlotinib (E), an EGFR small-molecule inhibitor, and Alisertib (MLN8237, A), an inhibitor of Aurora A kinase, in lung cancer models. Treatment of two human NSCLC cell lines, A549 and H322M, with E+A showed synergistic activity in vitro. These cell lines were chosen for the xenografts studies in CB17 SCID mice. After tumors reached a volume of 100 mm3, mice were treated with E+A for three weeks. The xenografts were sensitive to growth inhibition by E (10 mg/kg/day) and A (20 mg/kg/twice daily) alone and the combination had an additive effect. In order to understand early cell signaling events in tumors treated with these agents we repeated the xenograft experiment by treating mice with a one time dosing of each drug alone and in combination. Three tumors per group were collected at 0 , 6 , 24 , or 48 hours after treatment and a panel of signaling molecules downstream of the EGFR and Aurora A kinase pathways were examined by Western blot. These included EGFR/pEGFR; HER2; HER3; MEK/pMEK; ERK/pERK; Src/pSrc and Akt/pAkt among others. Our results suggest that combined inhibition of both pathways in lung cancer cell lines and xenografts can lead to a reduced proliferative index as indicated by quantitative changes in these proteins and that this combination might be effective as a treatment strategy. A clinical trial with this combination is in progress at our center.']",
        "Doc_id":"AACR_2014-4242",
        "Doc_title":" Effects of dual inhibition of EGFR and Aurora A kinase in a lung cancer model",
        "_version_":1606188972718948352},
      {
        "Meeting_name":" Multiplexed molecular profiling of Japanese squamous cell lung cancers.",
        "Background":"['Background', ' Little advancement has been achieved in the development of efficacious molecular targeted therapies for squamous cell lung cancer, though great progress has been made in the treatment of lung adenocarcinoma in the past decade. However, results of comprehensive genome-wide characterization of squamous cell lung cancer have recently been reported and candidates for druggable targets were revealed. Thus it is becoming increasingly important to genotype squamous cell lung cancer as in the case of lung adenocarcinoma in which molecular profiles are incorporated into the lung cancer clinic. We conducted the Shizuoka lung cancer mutation study to analyze driver mutations in patients with thoracic malignancies and here we report the results of squamous cell lung cancer.Methods', ' Based on the biobanking system in conjunction with the clinic including the pathology lab, we have developed a multiplexed mutational panel designed to assess 23 mutations in 9 genes (EGFR, KRAS, BRAF, PIK3CA, NRAS, MEK1, AKT1, PTEN and HER2), EGFR, MET, PIK3CA, FGFR1 and FGFR2 amplifications, and EML4-ALK translocations using pyrosequensing plus capillary electrophoresis, qRT-PCR, and RT-PCR, respectively. These results are communicated to clinicians for assigning patients to appropriate therapy and/or clinical trials. A written informed consent was obtained upfront from all patients enrolled into this study.Results', ' Between July 2011 and July 2012, sixty-eight squamous cell lung cancer patients were included in this study. Patients characteristics were as follows', ' median age (range) 72 (38-92) years; male 85%; smoker 97%; stage I/II/III/IV 18/35/26/21 %; well/moderate/poor/undetermined differentiated 6/34/40/20 %; surgically resected snap-frozen samples 46% and formalin-fixed paraffin-embedded (FFPE) samples 54%. We detected driver mutations in 47% of all cases. Mutations found', ' EGFR 2 (3%), KRAS 3 (4%), PIK3CA 9 (13%), NRAS 1 (1%), EGFR amplification 2 (3%), PIK3CA amplification 5 (7%), FGFR1 amplification 3 (4%). The frequency of FGFR1 amplification was much lower in our study than that in previous reports in Caucasian population. Seven patients harbored simultaneous driver mutations (EGFR + other 5 (7%), PIK3CA amplification + other 2 (3%)). Driver mutations were more frequently detected in surgically resected snap-frozen samples than in FFPE samples (65% v.s. 32%). Tumor differentiation was not significantly correlated with the presence or absence of driver mutations.Conclusions', ' Driver mutations were detected in 47% of squamous cell lung cancer patients in this study. PIK3CA mutation seemed to be relatively frequent in squamous cell lung cancer as reported in other studies, while FGFR1 amplification seemed less frequent. This multiplexed mutational profiling should be incorporated into lung cancer clinic to facilitate personalized cancer medicine in patients with squamous cell lung cancer.']",
        "Doc_id":"AACR_2013-1194",
        "Doc_title":" Multiplexed molecular profiling of Japanese squamous cell lung cancers.",
        "_version_":1606189010114314240},
      {
        "Meeting_name":" Simultaneous detection of multiple key genes in Chinese non-small cell lung cancer was feasible in clinical practice.",
        "Background":"['Background', '    The identification of genetic mutational profiles is significant in personalized management of non-small cell lung cancer (NSCLC). Previous techniques are limited to analyzing only a single or a few mutations together. The study was to investigate the feasibility of simultaneously rapid detection of several key genes in a Chinese cohort. Methods', '    A multiplexed PCR-based assay (SnapShot) and GeneScan were integrated to genotype hotspots across over 9 key genes with pertinence to current or potential targeted therapy in NSCLC. Clinicalpathologic features, distribution frequency of individual gene and mutation overlap were reviewed.  Results', '    Totally 45 treatment-nave and 44 treated NSCLC patients with eligible tumor specimens were enrolled into the study. Eighty-four percent of the cohort was with adenocarcinoma, and 54% of patients were smokers. EGFR, KRAS, NRAS, PTEN, BRAF, PIK3CA, MEK1, HER2 and BIM were simultaneously analyzed in a platform. Forty-three percent of patients were classified as wild type in the analysis. Fifty-seven percent of the cohort harbored mutated genes. EGFR was the most prevalent mutated gene, and its rate reached 42% in the cohort; rare mutations were found in 9.0% of the enrolled patients. Four patients with BIM_DEL were male, adenocarcinoma, and no response to erlotinib treatment. None of patients were found to harbor BRAF, PTEN, or MEK1 mutation. Sixty-four percent of patients with adenocarcinoma were detected gene mutations. None mutated genes were detected in nine patients with squamous cell carcinoma. Three patients had overlap of mutations', ' EGFR_L858R/BIM_DEL, KRAS_G12R/EGFR_L858R, and NRAS_Q61R/EGFR_L858R.  Conclusions', '    Simultaneous detection of several targeted genes by multiplexed molecular testing was feasible in clinical practice. More studies are warranted to establish its utility as more targeted therapies are developed.']",
        "Doc_id":"ASCO_129709-144",
        "Doc_title":" Simultaneous detection of multiple key genes in Chinese non-small cell lung cancer was feasible in clinical practice.",
        "_version_":1606189038788673536},
      {
        "Meeting_name":" Novel role for MIG-6 in mediating TKI resistance in ALK-rearranged lung cancer",
        "Background":"['INTRODUCTION', ' Patients with ALK-rearranged non-small cell lung cancer (NSCLC) derive significant anti-tumor responses when treated with ALK tyrosine kinase inhibitors (TKIs), such as crizotinib, the first-in-class ALK TKI. However despite the high response rates to these agents, acquired resistance to ALK TKI therapy remains a significant barrier to overcome in order to maximize therapeutic responses in patients with ALK+ lung cancer. In crizotinib-resistant tumors, EGFR activation has been demonstrated to mediate acquired resistance in several independent studies. The tumor suppressor gene product MIG-6 (encoded by ERFFI1) acts as a natural inhibitor of signaling through EGFR (ErbB1) and other ErbB family members. However, a role for MIG-6 in ALK+ lung cancer has not yet been elucidated. Here, we investigated the regulation of human MIG-6 in ALK+ lung cancer cells.DESIGN', ' MIG-6 expression, protein interaction and phosphorylation status were evaluated in ALK+ lung cancer cell lines and human tumor samples. The impact of MIG-6 loss and gain of function on ErbB receptor activity and on cell proliferation/survival were determined in several models of TKI-sensitive and TKI-resistant ALK+ lung cancer.RESULTS', ' MIG-6 protein level is regulated by EML4-ALK fusion protein at both transcriptional and post-translational levels. Genetic or pharmacologic knock-down of ALK significantly reduced MIG-6 protein levels in ALK+/TKI sensitive cells. We established a novel interaction between MIG-6 and ALK fusion proteins (both EML4-ALK and other fusion partners), and this association was dependent on ALK kinase activity. MIG-6 can also be tyrosine-phosphorylated by EML4-ALK and be threonine-phosphorylated through EML4-ALK-dependent MAPK activation. The reduced MIG-6 protein level was accompanied by increased total and phosphorylated ErbB family members (EGFR, HER2, and HER3) in ALK+/TKI sensitive lung cancer cells. Consistent with this observation, MIG-6 protein level is also attenuated in ALK+/TKI resistant cells, following the decreased EML4-ALK activity, while EGFR signaling activity is remarkably up-regulated in these resistant cells. Crizotinib-resistant cells were re-sensitized upon exposure to EGFR/HER2 inhibitors in combination with crizotinib. In addition, MIG-6 reconstitution impeded the development of early adaptive resistance in crizotinib-sensitive cells and was also able to inhibit the proliferation of crizotinib-resistant cells.CONCLUSION', ' Our study presents an in-depth mechanistic understanding of how ErbB family members, such as EGFR, are up-regulated at the time of crizotinib resistance and provides insights into the early escape mechanisms tumor may have to evade ALK TKI therapy.']",
        "Doc_id":"AACR_2016-311",
        "Doc_title":" Novel role for MIG-6 in mediating TKI resistance in ALK-rearranged lung cancer",
        "_version_":1606188971015012352},
      {
        "Meeting_name":" Structural and biochemical analysis of ERBB4 mutations in cancer.",
        "Background":"['Genes encoding the ErbB receptor tyrosine kinases (EGFR/ERBB1, ERBB2, ERBB3, and ERBB4) are key regulators of cellular proliferation, survival, and differentiation, and thus represent potent proto-oncogenes. In particular, mutations or copy number variations of EGFR or ERBB2 are present in human malignancies and serve as biomarkers for targeted therapies. Recently, somatic mutations of the ERBB4 gene have been identified in various cancer types, such as non-small cell lung cancer and melanoma, indicating a role for mutated ERBB4 as a potential drug target. However, the structural and functional consequences of the ERBB4 mutations remain to be fully elucidated.We used both a structural as well as a biochemical approach to address the functional effects the ERBB4 mutations for ErbB4 signaling. The structural effects of the mutations were assessed in both active and inactive ErbB4 conformation in silico. The biochemical effects of the mutations on ErbB4 signaling were analyzed in vitro using assays measuring the kinase activity of ErbB4 as well as activation of downstream signaling pathways.Although all structural subdomains of ERBB4 have been reported to be affected by somatic mutations, our analyses indicated that the mutations cluster to regions important for activation of the receptor, such as the dimerization interface and the kinase domain active site. Some of the mutations were structurally non-hazardous and probably represent passenger mutations. Consistently, the biochemical analyses indicated for the presence of both activating and functionally non-significant mutations.These observations suggest for the presence of both driver as well as passenger mutations of ERBB4 in human cancer.']",
        "Doc_id":"AACR_2013-4407",
        "Doc_title":" Structural and biochemical analysis of ERBB4 mutations in cancer.",
        "_version_":1606189034395140096},
      {
        "Meeting_name":" Association between caring for a high proportion of older patients and adhering to standard care for younger patients.",
        "Background":"['Background', ' Multiple comorbidities and physiologic decline often prevent older patients from receiving the same standard care provided to younger patients. Therefore, providers who mainly treat older patients may become accustomed to not adhering to standards and thus might be less likely to provide standard care to younger patients. In this study, we compared the care provided to younger patients between facilities that care for a large number of elderly patients and those that treat relatively few older patients. Methods', ' We used a nationwide registry-linked claims database of 297 hospitals. Among the quality indicators (QIs) we formerly developed, we selected 2 and 3 QIs for lung cancer and gastric cancer, respectively, based on the variation in adherence across facilities. Facilities were divided into 2 groups based on the proportion of older patients (75) with each cancer type. We then compared the QI adherence in treating patients younger than 60 years old between the groups. The difference in adherence to standards of care (quality scores) between the 2 groups of facilities was assessed by using a logistic regression model adjusting for patient age and sex. Results', ' We analyzed data for 6,708 patients with lung cancer and 26,470 patients with gastric cancer. Respective quality scores for facilities with more older patients versus facilities with fewer older patients were 63.4% versus 66.1% (p=0.439) for the EGFR mutation test before the first chemotherapy among stage IV lung adenocarcinoma patients; 63.2% versus 52.5% (p=0.238) for concurrent chemoradiotherapy (CCRT) for localized small cell lung carcinoma patients; 51.6% versus 46.9% (p=0.229) for HER2 test before the first chemotherapy among patients with unresectable gastric cancer; 81.8% versus 79.7% (p=0.354) for Helicobacter pylori test on patients with gastric cancer who had ESD/EMR; and 60.9% versus 60.7% (p=0.948) for adjuvant chemotherapy within 6 weeks among pathological stage II/III gastric cancer patients. Conclusions', ' Caring for a high proportion of older patients is not associated with diminished provision of standard care to younger patients.']",
        "Doc_id":"ASCO_180036-198",
        "Doc_title":" Association between caring for a high proportion of older patients and adhering to standard care for younger patients.",
        "_version_":1606188993493336064},
      {
        "Meeting_name":" Clinico-pathologic features of lung cancer with EML4-ALK translocation.",
        "Background":"['Background', ' A small subset of human lung cancer harbors the fusion of the gene for echinoderm microtubule-associated protein-like 4 (EML4) and the gene for anaplastic lymphoma kinase (ALK), resulting from a small inversion within chromosome 2p. A phase I dose escalation trial for ALK tyrosine kinase inhibitor showed promising activity against these tumors. We examined our cohort of patients for EML4-ALK translocation and tried to concentrate this rare type of lung cancer according to the clinico-pathologic background of the patients. Methods', ' Methods We studied 345 patients with lung cancer who underwent pulmonary resection in our hospital (adenocarcinoma 314, large cell carcinoma 5, small cell carcinoma 1, squamous cell carcinoma 21, adenosquamous cell carcinoma 4) after obtaining appropriate informed consent from the patients. EML4-ALK translocation was detected by RT-PCR and direct sequencing. Results', ' We found 10 EML4-ALK translocations (3%). Seven were variant 1, two variant 2 and one variant 1. All were adenocarcinoma. Eight patients were female and 7 were never-smokers. None of the tumors harbored either of EGFR, KRAS, HER2 or TP53 mutation. The incidence of ALK fusion was 10 of 97 (10%) without any of four mutations. Median age of patients with ALK fusion was 56 that was significantly younger than that of entire cohort (63) or those with EGFR mutation (64) or KRAS mutation (65). Histopathologically, most of the tumors with ALK fusion were solid-acinar type with cribriform pattern. Conclusions', ' Lung caners with ALK fusion tended to occur in younger female patients with acinar type adencoarcinoma devoid of EGFR, KRAS, HER2 or TP53 mutations. Although this type of lung cancer is rare, we have to establish efficient screening method because genotype-based therapy would be possible in the near future.']",
        "Doc_id":"ASCO_48829-74",
        "Doc_title":" Clinico-pathologic features of lung cancer with EML4-ALK translocation.",
        "_version_":1606189006346780672},
      {
        "Meeting_name":" Liquid biopsies for molecular profiling of mutations in non-small cell lung cancer patients lacking tissue samples",
        "Background":"['Introduction', ' Approximately 30% of patients with an adenocarcinoma of the lung have an actionable driver mutation. Further understanding the molecular mechanisms of acquired resistance to targeted therapies provides key information for determining subsequent treatment options. Access to tumor tissue to perform either the initial molecular profile or at the point of acquired resistance, however, is often limited. Circulating tumor DNA (ctDNA) can be used as a minimally invasive method for the detection and quantification of molecular abnormalities. We performed a prospective study to assess molecular alterations in the ctDNA of NSCLC patients in whom the initial molecular profile or profile at acquired resistance was unknown due to lack of tumor tissue biopsy or insufficient cellularity in the biopsy.Methods', \" Plasma samples were collected from 52 pre-treated advanced NSCLC patients at the Gustave Roussy. DNA was extracted from < 5 ml of plasma and analysed using Inivata's enhanced TAm-SeqTM assay covering regions from 35 cancer-related genes. Sequences were generated using Illumina sequencing. We also analysed plasma taken following treatments prescribed after the original molecular profile detected using plasma ctDNA.Results\", ' From July 2015 to October 2015, 52 patients were included (63% female, 37% never-smoker, 95% diagnosed with an adenocarcinoma subtype, 95% with stage IV disease, and 54% had EGFR mutant tumors of which 68% had mutations in exon 19 and 32% had mutations in exon 21). ctDNA profiling was successfully performed for all patients, and mutations were detected in 38 of 52 patients. The median number of mutations detected in plasma samples was 1. Within the EGFR mutant subpopulation, T790M mutations were identified including 8 acquired cases (with a concomitant C797S mutation in 1 case) and 1 primary T790M mutation. Of these patients, 5 started personalised treatment with AZD9291 based on the results of ctDNA analysis. In the other 18 patients with EGFR mutant tumors, no acquired mutations associated with resistance were detected. Other results encompassed', ' 2 plasma samples with EGFR mutation exon 18 (G719A, G719C) leading to initiation of afatinib in one case, 1 case with EGFR mutation exon 21 (L861Q), 1 patients with ERBB2 exon 20 insertion, 3 KRAS mutant detected in plasma (G12C, G12S, G12F), 2 STK11 mutant samples, and 1 patient with a MET mutation (exon 14) who subsequently started crizotinib.Conclusions', \" ctDNA analysis with Inivata's enhanced TAm-Seq provides an alternative method of liquid biopsy for obtaining molecular profile of mutations present in NSCLC patients in the absence of an invasive tissue biopsy. Liquid biopsy identified cancer mutations in 73% of the study population, and 18% of those patients subsequently received treatment tailored to the plasma ctDNA detected mutations. An update on the analysis of 75 patients will be presented during the conference.\"]",
        "Doc_id":"AACR_2016-3192",
        "Doc_title":" Liquid biopsies for molecular profiling of mutations in non-small cell lung cancer patients lacking tissue samples",
        "_version_":1606189021611950080},
      {
        "Meeting_name":" An online tool for the validation of survival-predicting biomarkers in non small-cell lung cancer using microarray data of 1,329 patients.",
        "Background":"['To decipher the molecular basis of lung cancer and to improve treatment strategies we have to identify genes correlated to therapy response and to survival. Here, we present the development of a new, freely available online tool suitable for the real-time meta-analysis of published lung cancer microarray datasets to validate expression based survival related biomarker candidates.First we have searched the caBIG, GEO and TCGA repositories to identify datasets with published gene expression data and survival information. In this, three GEO platforms (GPL96, GPL570 and GPL3921) were considered as these possess 22,277 common probes, which were used for constructing the database. All together 1,329 NSCLC samples in 9 independent datasets were identified, 85% have overall survival and 45% progression free survival info, one-third adenocarcinomas and one-third squamous cell carcinomas, 57% male and the average overall survival is 45 months. Kaplan-Meier survival plot, and the hazard ratio with 95% confidence intervals and logrank P value are calculated and plotted in R using Bioconductor packages. To assess the prognostic value of a gene, each percentile (of expression) between the lower and upper quartiles are computed and the best performing threshold is used as the final cutoff in a Cox regression analysis. The complete meta-analysis tool can be accessed online at', ' www.kmplot.com/lung.We demonstrate the application of this integrative analysis pipeline by validating 22 previously published survival associated biomarkers including VEGF, ADAM28, ANXA3, CADM1, CD24, CD82, CDK1, CEA, cyclin E, ERCC1, EZH2, HER2, IFNAR2, MMP9, OPN, P16, p53R2, RAD51, S100A4, survivin, XAF1 and XIAP. Of these, high significances (p<1E-16) were achieved by ANXA3 (HR=0.63), CADM1 (HR=1.7), IFNAR2 (HR=0.54), RAD51 (HR=1.9) and XAF1 (HR=0.58). Five additional genes were significant', ' S100A4 (HR=1.46, p=3.6E-4), CD82 (HR=1.34, p=0.018), OPN (HR=1.33, p=0.02), HER2 (HR=1.3, p=0.02) and CD24 (HR=0.75, p=0.3). The remaining genes did not achieved statistical significance.In summary, we developed an online available meta-analysis tool for the validation of genes associated with survival in NSCLC.']",
        "Doc_id":"AACR_2013-2368",
        "Doc_title":" An online tool for the validation of survival-predicting biomarkers in non small-cell lung cancer using microarray data of 1,329 patients.",
        "_version_":1606188989844291584},
      {
        "Meeting_name":" Evaluation of liquid biopsies for molecular profiling in patients with advanced non-small cell lung cancer (NSCLC) in the relapse treatment setting.",
        "Background":"['Background', ' Molecular profiling is limited by access to sufficient tumor tissue for comprehensive analysis and due to tumor heterogeneity, the complete range of tumor DNA abnormalities may not be represented nor accurately reflect the clinical evolution of disease. Circulating tumor DNA (ctDNA) can be used as a minimally-invasive liquid biopsy for the detection, quantification and monitoring of molecular abnormalities for personalized treatment strategies. Methods', ' In a prospectively designed program, to date, we have recruited 227 advanced NSCLC patients having received prior therapy, with unknown molecular profile at time of blood collection. Blood collections (10ml K2-EDTA) were performed to assess molecular profile prior to or at time of relapse. Repeat samples were performed on patients initiated on treatment and followed for up to 18months. Patient samples were analyzed with InVision (enhanced tagged-amplicon sequencing) using a 34 gene panel. Interim analysis performed with full descriptive summary statistical analyses to be presented at conference. Results', ' ctDNA profiling detected somatic mutations in 182pts (80.2%), predominantly located in TP53 (46%), EGFR (28%), KRAS (11%) and STK11 (7%, half of which had concurrent KRAS). Of note, clinically actionable mutations were detected', ' T790M (25pts, median 1.4% AF), ERBB2 (8 pts), MET (8pts) and BRAF (4pts) providing eligibility for new therapy options. 20pts including 12 EGFR/T790M+ve were evaluated for ctDNA monitoring up to 18 months (median 10m); correlation between dynamic change in mutation allele fraction and clinical response was observed, especially predictive of relapse to treatment. 10 patients demonstrated SD/PR response to osimertinib treatment with T790M detection at low allele fraction (7/10 < 1% AF with 1pt at 0.08% AF). Conclusions', ' ctDNA can be used as a non-invasive liquid biopsy for molecular profiling of NSCLC patients to detect clinically relevant and actionable mutations when tissue biopsy is unavailable. Liquid biopsies can be repeated as needed where tissue is not feasible, providing real-time information to support personalised treatment.']",
        "Doc_id":"ASCO_194012-199",
        "Doc_title":" Evaluation of liquid biopsies for molecular profiling in patients with advanced non-small cell lung cancer (NSCLC) in the relapse treatment setting.",
        "_version_":1606188997841780736},
      {
        "Meeting_name":" DNA-based genomic profiling for classification of tissue of origin for patients with carcinoma of unknown primary site.",
        "Background":"['Background', ' Carcinoma of unknown primary (CUP) has a poor prognosis and accounts for diagnoses in > 30,000 patients annually in the United States. Current tissue of origin (TOO) methods use protein or RNA-based expression signatures, are costly, and often provide little clinically relevant information. We previously showed that use of comprehensive genomic profiling (CGP) identifies a clinically relevant genomic alteration in 96% of CUPs. We hypothesized that CGP could also potentially identify a TOO for some CUP patients, further refining potential targeted therapeutic options. Methods', ' DNA alterations from 44,065 samples that underwent CGP as part of standard clinical care were classified using logistic regression based on mutational profiles and select clinical features. Results', ' We first trained a logistic regression classifier to identify non-small cell lung cancers (NSCLC) with alterations in EGFR, ERBB2, BRAF, MET, KRAS, ALK, RET, or ROS1 (lung gene set). In cross-validation, the classifier correctly identified 79% of NSCLCs (92% of EGFR mutant samples) and 93% of non-NSCLCs. When applied to a set of 1352 CUPs with an alteration in the lung gene set, 425 (31%) were predicted to be NSCLC. We next trained a classifier to distinguish BRAF V600-mutant colorectal cancers (CRCs) from other BRAF V600-mutant cancers. The classifier correctly identified 90% of CRCs and 93% of non-CRC. Use of this classifier with a BRAF-mutant CUP data set predicted 32/87 (37%) of BRAF-mutant CUP tumors to be CRC. Conclusions', ' In a large series of CUP patients with alterations in the lung gene set, one-third were likely NSCLC, and could potentially benefit from approved targeted therapies in this disease. When applied to BRAF V600-mutant CUPs, 37% were predicted to be CRC, and therefore single agent vemurafenib therapy is unlikely to be effective and combination therapy indicated. This approach is useful for identifying targeted therapeutics likely to be effective based on molecular match and TOO. We plan to extend this DNA-based tool to 4 additional tumor types. Application of this classifier to CUPs may help identify therapeutic strategies from CGP without the need for additional material or testing.']",
        "Doc_id":"ASCO_168528-176",
        "Doc_title":" DNA-based genomic profiling for classification of tissue of origin for patients with carcinoma of unknown primary site.",
        "_version_":1606188993074954240},
      {
        "Meeting_name":" Incidence of inconsistent driver mutations between multiple lung ground-glass nodules in patients with non-small cell lung cancer.",
        "Background":"['Background', '  Intertumor heterogeneity had been observed in various kinds of malignant tumors including non-small cell lung cancer. Comparing with extra-pulmonary metastasis, patients with multiple pulmonary nodules have a significantly higher rate of heterogeneity. The aim of this study was to compare the known driver mutations distribution among non-small cell lung cancer(NSCLC) patients with multiple intrapulmonary ground-glass nodules(GGNs). Methods', '  35 consecutively resected lung cancer patients with multiple lung GGNs  at a single institution (Tongji University, Shanghai, China) were analyzed for mutations in EGFR, KRAS, HER2, BRAF and PIK3CA together with genes fusion in ALK, ROS1 and RET.  Results', '  The median age was 60 years old, male/female', '12/23, never smoker/smoker', ' 25/10, PS 0/1', ' 22/13. Totally, 72 lesions were included into this analysis, including 9 of adenocarcinoma in situ, 9 minimal invasive adenocarcinoma and 54 invasive adenocarcinoma. Among them, 33 (45.8 %) tumors harbored EGFR mutations, including 13 were deletions in exon 19, 18 were L858R missense changes, and two were 19 deletion together with L858R mutations. 5 (6.9 %) harbored EML4-ALK fusions, 4 (5.6%)had HER2 mutations, 3(4.2%)had KRAS mutations, 1 had ROS1 fusion and BRAF mutation respectively.  A majority of the mutations were mutually exclusive, except 1 both with EGFR mutation and ALK fusion. The discordant frequency rate of the driver mutation distribution was 68.6%(24/35) in the whole population, while it was 80%(24/30) in the patients harbored at least one of the detected driver mutations. In one of the 2 cases who had 3 resected lung lesions, exon21 L858R point mutation, exon 19 deletion, and L858R point mutation together with ALK fusion were found in the 3 tumor samples separately.  Conclusions', '  The high incidence of inconsistent driver mutations distribution between multiple intrapulmonary nodules in this study suggested that these GGNs might arise as independent events and contributed to the higher rate of heterogeneity in intrapulmonary nodules. Patients with multiple GGNs should be given a separate staging and treatment strategy.']",
        "Doc_id":"ASCO_133162-144",
        "Doc_title":" Incidence of inconsistent driver mutations between multiple lung ground-glass nodules in patients with non-small cell lung cancer.",
        "_version_":1606189008598073344},
      {
        "Meeting_name":" An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC).",
        "Background":"['Background', '  Ganetespib is a potent, next-generation Hsp90 inhibitor that is structurally unrelated to the first-generation ansamycin class of Hsp90 inhibitors and has shown superior activity to these agents in preclinical studies.  Ganetespib has been well tolerated and has shown promising antitumor activity in early trials in multiple cancers.   Methods', '  Patients (pts) with advanced NSCLC who failed prior treatments received 200 mg/m2 ganetespib as a 1-hr infusion once weekly for 3 of a 4-wk cycle in a Simon two-stage study design assessing primary endpoint of PFS rate at 16 wks.  Initial cohorts were defined by mutation status', ' A) EGFR B) KRAS C) EGFR and KRAS wild type (WT). If 2/14 pts in A, B or C were progression-free at 16 wks, enrollment increased to 23 pts for that cohort.  Tumor response was assessed every 8 wks. Cohort D was added to include 35 additional EGFR and KRAS WT pts with adenocarcinoma histology.  Additional mutational analysis of BRAF, PIK3CA, ERBB2 and MET, as well as FISH analysis for ALK translocation, were performed for Cohorts C and D.  Results', '  73 pts (31 M, 42 F; median age 62 yrs, range 28-82; ECOG 0-1; prior therapies range 1-10) received a median of 2 cycles (range 1-12) of ganetespib in cohorts A (14), B (17), and C+D (42).  AEs reported in 20% of pts included diarrhea, fatigue, nausea, anorexia, constipation, and dyspnea and were generally grade 1-2.  Expansion criteria were achieved for cohort C, including a durable partial response (PR) and seven pts with prolonged stable disease (16 wks).  Cohort D continues recruitment.  Mutational analyses of Cohort C and D samples will be presented.  Conclusions', '  Ganetespib administered as a single-agent is well-tolerated in pts with NSCLC at 200 mg/m2 once weekly without severe liver, ocular, cardiovascular or renal toxicity.  Clinical activity has been observed in pts with advanced NSCLC tumors harboring wild-type EGFR and KRAS.']",
        "Doc_id":"ASCO_82185-102",
        "Doc_title":" An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC).",
        "_version_":1606188971408228353},
      {
        "Meeting_name":" LUX-Lung 6",
        "Background":"['Background', '  A is an oral, irreversible, ErbB Family Blocker, blocking signaling from EGFR (ErbB1), HER2 (ErbB2) and ErbB4. A was superior to first-line pemetrexed/cisplatin in a global phase III trial (LUX-Lung 3) in EGFR M+ NSCLC. This study compared the safety and efficacy of first-line A with GC in EGFR M+ Asian pts.  Methods', '  The trial was conducted in Asian countries. Following central testing for EGFR mutations (TheraScreen EGFR RGQ PCR kit), 364 pts (stage IIIB/IV, PS 01, chemo-nave) were randomized 2', '1 (A', ' 242; GC', ' 122) to daily A 40 mg or IV GC (1,000 mg/m2 D1, 8 + 75 mg/m2q21 days up to 6 cycles). Primary endpoint was PFS by central independent review.  Results', '  Baseline characteristics were balanced in both arms', ' Female (64.0 vs 68.0%), non-smoker (74.8 vs 81.1%), exon 19 deletion (51.2 vs 50.8%), L858R (38.0 vs 37.7%) in A and GC arms, respectively. PFS was significantly prolonged with A compared with GC by independent review (median PFS 11.0 vs 5.6 months, HR=0.28, p<0.0001); this finding was consistent across all subgroups. Results from the investigator review were similar', ' HR=0.26, p<0.0001, median 13.7 (A) vs 5.6 months (GC). Objective response (66.9% vs 23.0%, p<0.0001) and disease control (92.6% vs 76.2%, p<0.0001) rates (ORR/DCR) were significantly higher with A. OS, based on 43% of events shows HR=0.95, p=0.7593. Drug-related AEs of G3 were reported in 36.0% (A) and 60.2% (GC) of pts, the most common of which were rash/acne (14.6%), diarrhea (5.4%) and stomatitis/mucositis (5.4%) with A and neutropenia (17.7%), vomiting (15.9%) and leukopenia (13.3%) with GC. Related AEs led to discontinuation in 5.9% (A) and 39.8% (GC) of pts. Patient reported-outcomes (PROs) showed significantly better control of cancer-related dyspnea, cough and pain with A.  Conclusions', '  In EGFR M+ Asian pts, A significantly prolonged PFS with significant improvements in ORR, DCR, PROs. AEs in both arms were as expected, with a more favorable safety profile with A. LUX-Lung 6 is the largest prospective trial in EGFR M+ lung cancer, providing further evidence of superiority of A over standard chemotherapy in this setting. Clinical trial information', ' NCT01121393.']",
        "Doc_id":"ASCO_112318-132",
        "Doc_title":" LUX-Lung 6",
        "_version_":1606189040758947840},
      {
        "Meeting_name":" Differential roles of trans-phophorylated EGFR, HER2, HER3 and RET as heterodimerization partenrs of MET in lung cancer with MET amplification",
        "Background":"['Background', ' MET is a receptor tyrosine kinase (RTK) whose gene is amplified in various tumor types. We investigated the roles and mechanisms of RTK heterodimerization in lung cancer with MET amplification. Methods', ' With the use of an RTK array, we identified several phosphorylated RTKs in lung cancer cells with MET amplification. We examined the roles and mechanisms of action of these RTKs with immunoprecipitation, annexin V binding, and cell migration assays. Results', ' We identified EGFR, HER2, HER3, and RET in addition to MET as highly phosphorylated RTKs in lung cancer cells with MET amplification. Immunoprecipitation revealed that EGFR, HER2, HER3, and RET each formed a heterodimer exclusively with MET and that these associations were markedly reduced in extent by treatment with a MET kinase inhibitor, but not by treatment with their spcific inhibitors. RNA interference-mediated depletion of EGFR, HER2, or HER3 induced apoptosis in association with inhibition of AKT and ERK signaling pathways, whereas depletion of HER2 or RET inhibited both cell migration and STAT3 signaling. Conclusion', ' Our data suggest that heterodimers of MET with EGFR, HER2, HER3, or RET play differential roles in tumor development, and they provide new insight into the function of trans-phosphorylated RTKs as heterodimerization partners of MET in lung cancer with MET amplification.']",
        "Doc_id":"AACR_2012-1231",
        "Doc_title":" Differential roles of trans-phophorylated EGFR, HER2, HER3 and RET as heterodimerization partenrs of MET in lung cancer with MET amplification",
        "_version_":1606189002438737920},
      {
        "Meeting_name":" Genomic profiling of lung adenocarcinoma patients reveals potential therapeutic targets when standard molecular testing is negative.",
        "Background":"['Background', ' Identification of oncogenic drivers is critical in selecting appropriate targeted therapy. Using next-generation sequencing (NGS), we performed comprehensive genomic profiling (CGP) of lung adenocarcinoma tumors. Methods', ' Formalin-fixed paraffin-embedded tumors from 51 lung adenocarcinoma patients whose tumors previously tested negative for EGFR/KRAS/ALK by conventional methods in an ongoing trial (NCT01964157) were collected, and CGP was performed via hybridization capture of 4,557 exons from 287 cancer-related genes and 47 introns from 19 genes frequently rearranged in cancer and next generation sequencing. Results', ' Genomic profiles of all 51 cases were obtained, with a median coverage of 564x and a total of 190 individual genomic alterations (GA). GA per specimen was a mean of 3.7 (range 0-10).Cancer genomes are characterized by 50% (80/190) non-synonymous base substitutions, 15% (29/190) insertions or deletion, and 3% (5/190) splice site mutation. TP53 was the most commonly mutated gene (30%, n = 24/80) among non-synonymous base substitutions, followed by KRAS (10%, n = 8/80) and EGFR (9%, 7/80). Insertions or deletions commonly occurred TP53 (17%, 5/29) and ERBB2 (14%, 4/29), and splice site mutations occurred in TP53, INPP4B, ATR, and MAP2K4. Gene amplification comprised 20% (39/190) of genomic alterations, and MDM2 amplification was the most frequent (13%, 5/39). Homozygous loss comprised 5% (10/190) of all GA which were CDKN2A/B. GA found with NCCN guidelines for NSCLC were identified in 16 patients (31%) (BRAF mutation [n = 1], EGFR mutation [n = 8], ERBB2 mutation [n = 4], MET amplification [n = 1], KIF5B-RET rearrangement [n = 2], CCDC6-RET rearrangement [n = 1], CD74-ROS1 rearrangement [n = 1], EZR-ROS1 rearrangement [n = 5], and SLC34A2-ROS1rearrangement [n = 1]). Other genes that conferred the possibility of benefit from targeted therapy were found in another 14 patients (27%). Conclusions', ' Fifty eight percent of patients wild type by standard testing for KRAS/EGFR/ALK have GA identifiable by CGP that suggest benefit from target therapy. CGP used when standard molecular testing for NSCLC is negative is able to reveal additional avenues of benefit from targeted therapy.']",
        "Doc_id":"ASCO_166704-176",
        "Doc_title":" Genomic profiling of lung adenocarcinoma patients reveals potential therapeutic targets when standard molecular testing is negative.",
        "_version_":1606189015779770368},
      {
        "Meeting_name":" Novel resistance mechanisms to first-generation EGFR tyrosine kinase inhibitors",
        "Background":"['Background', 'Patients with non-small-cell lung cancer (NSCLC) harboring sensitive epithelial growth factor receptor (EGFR) mutations invariably develop acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). Identification of actionable mutations conferring drug-resistance can be helpful for guiding the subsequent treatment decision. Currently, the known mechanisms of acquired resistance includes', ' the secondary gatekeeper EGFR-T790M mutation, activation of members of downstream signaling pathways such as PI3K/AKT/mTOR pathway, activation of bypass signaling such as MET, and changes in tumor histology. However, the mechanisms in the remaining patients are still unknown. Methods', 'In this prospective study, thirty-one advanced NSCLC patients initially carrying sensitive EGFR mutations and subsequently developing acquired resistance to the first-generation EGFR-TKIs were enrolled. Pre-treatment tumor samples as well as re-biopsies of tumor and plasma when the patients were diagnosed with EGFR-TKI resistance were acquired, followed by mutation profiling using targeted next generation sequencing (NGS) on 416 cancer-related genes. Results', ' In total, 55% of patients were identified to carry acquired secondary EGFR-T790M mutation. Three patients (~10%) harbor EGFR-T854A mutation, which has been reported as another TKI resistant mutation. 26% and 19% of cases accumulated TP53 and RB1 mutations, respectively. In T790M/T854A-negative cases, 30% of patients acquired MET amplification. Other potential acquired resistance mechanisms includes single nucleotide variants (SNVs) in genes such as SMAD4, DNMT3A, GNAS, ATM, KRAS, PIK3CA and TET2, and copy number variations (CNVs) in genes such as CDK4, MDM2, MYC, RICTOR and ERBB2. Conclusions', 'The study depicted the genetic landscapes comprehensively in matched pre- and post-EGFR-TKIs samples of NSCLC population resistant to first generation TKI treatments. Our analysis demonstrates new perspectives for further study of resistance and putting forward corresponding relevant tactics against the challenge of disease progression. Clinical trial information', ' NCT02804217']",
        "Doc_id":"ASCO_187490-199",
        "Doc_title":" Novel resistance mechanisms to first-generation EGFR tyrosine kinase inhibitors",
        "_version_":1606189038801256448},
      {
        "Meeting_name":" Phase I study of lapatinib, a dual-tyrosine kinase inhibitor, and pemetrexed in the second-line treatment of advanced or metastatic non-small cell lung cancer.",
        "Background":"['Background', ' Lapatinib is an oral, reversible small-molecule inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). EGFR overexpression is very common in non-small-cell lung cancer (NSCLC), ranging from 30% to 83%, whereas HER2 overexpression occurs in about 20%. Pemetrexed is currently given as second-line therapy and achieves a 9% response rate. The rationale for EGFR/HER2 inhibition in combination with pemetrexed is to demonstrate clinical synergy as previously shown with gemcitabine, another fluoropyrimidine pathway inhibitor. Methods', ' Eligible patients included those with stage IIIB or IV NSCLC and European Cooperative Oncology Group performance status of 0-2 following 1 previous chemotherapy treatment. Patients were treated in 3 escalating dose levels (DLs) of pemetrexed (given intravenously every 21 days) and daily lapatinib (DL 0', ' 400 mg/1,250 mg; DL 1', ' 500 mg/1,250 mg; DL 2', ' 500 mg/1,500 mg, respectively). A standard phase 1, 3+3 trial design was used. The primary objective was to determine the optimal treatment regimen. Results', ' Eighteen patients were treated (DL 0', ' n=4, DL 1', ' n=8; DL 2', ' n=6). The most common adverse events (any grade) were diarrhea (61%), rash (44%), fatigue (28%), nausea (28%), anemia (28%), anorexia (22%), vomiting (22%), dyspnea (17%), and neutropenia (17%). Grade 3/4 adverse events were lymphocytopenia (n=5) and neutropenia (n=5). Other related grade 3 events were diarrhea (n=2), nausea (n=1), decreased ejection fraction (n=1), and increased alkaline phosphatase (n=1). The optimal treatment regimen was determined as lapatinib 1250 mg given with 500 mg pemetrexed after occurrence of 3 dose-limiting toxicities during the first cycle in DL 2 (grade 3 diarrhea, grade 4 lymphocytopenia, and grade 3 mucositis). No further dose-limiting toxicities were observed in DL 0 or DL 1. Preliminary evidence of clinical activity was encouraging, with 3 patients showing partial response. Conclusions', ' The combination of lapatinib with pemetrexed is well tolerated; encouraging activity has been demonstrated in pretreated NSCLC patients and warrants further studies.']",
        "Doc_id":"ASCO_31020-65",
        "Doc_title":" Phase I study of lapatinib, a dual-tyrosine kinase inhibitor, and pemetrexed in the second-line treatment of advanced or metastatic non-small cell lung cancer.",
        "_version_":1606189019805253633},
      {
        "Meeting_name":" KEAP1-mutations in patients with non-small cell lung cancer (NSCLC).",
        "Background":"['Background', '    Mutations in genes of the KEAP1-NFE2L2 pathway of patients with NSCLC are associated with an increased tumor growth, resistence towards cytostatic drugs and reduced survival rates. KEAP1 suppresses NFE2L2 under physiological conditions. Oxidative stress or electrophiles cause NFE2L2 to stabilize and translocate to the nucleus, resulting in the transcription of various cytoprotective genes. Mutations in KEAP1 are described for diverse tumor entities with a relatively high frequency causing an increased level of NFE2L2. This leads to resistance of cancer cells against anti-cancer drugs and irradation. This study was performed to characterize KEAP1-mutated NSCLC clinically and genetically.  Methods', '    Tumor tissue collected from 446 patients within a regional screening network was analysed for KEAP1 mutations using next-generation sequencing (NGS). Clinical, pathological and genetic characteristics of these patients are described and compared with a control group of patients without KEAP1 mutation.  Results', '    So far, we identified 33 patients with KEAP1 mutations. Among these we found 34 different mutations, of which the majority was not previously described. KEAP1 mutations were not restricted to a special exon. In 30 patients (90.9%), additional driver aberrations in KRAS, EGFR,FGFR1, FGFR3, STK11, ALK, DDR2, HRAS, BRAF, PIK3CA, PTEN, NFE2L2, EP300, TSC1, CREBBP, NRAS, MET and Her2 could be detected, as well as mutations and polymorphisms in TP53. KEAP1 mutations occurred in both genders (male/female ratio 3/1), in squamous-cell carcinoma (36.4%) and adenocarcinoma (60.6%) and were significantly associated with smoking. The prognostic and predictive impact of KEAP1 mutations in a prospective cohort will be presented.  Conclusions', '    Our data suggest a role of KEAP1-mutations as a cofactor in addition to classical driver mutations underlying the malignant phenotype of lung cancer cells. So far, this is the largest cohort of patients with KEAP1-mutations analysed and described. Further survival and treatment analyses will reveal the role of these mutations for the outcome of these patients.']",
        "Doc_id":"ASCO_149401-156",
        "Doc_title":" KEAP1-mutations in patients with non-small cell lung cancer (NSCLC).",
        "_version_":1606189028646846464},
      {
        "Meeting_name":" Clinical, pathologic, and molecular characteristics of patients with non-small cell lung cancer harboring mutations in PIK3CA.",
        "Background":"['Background', '  PIK3CA encodes the p100a subunit of the mitogenic signaling protein phosphatidylinositol 3-kinase (PI3K).  PI3K is a RAS-activated tyrosine kinase that signals through downstream mediators including AKT and m-TOR.  PIK3CA mutations in the helical binding domain and catalytic subunit are implicated in tumorigenesis and treatment resistance in many cancers.  The clinical characteristics of patients with PIK3CA-mutant lung cancer have not been reported.  Methods', '   To identify patients with NSCLC harboring PIK3CA mutations, we examined results of routine assessment of histology and driver mutations in EGFR, KRAS, BRAF, HER2, PIK3CA, AKT1, NRAS, MEK1, and EML4-ALK (Kris, Proc ASCO, 2010).  Clinical data were extracted from the medical records of patients with PIK3CA mutant tumors.  Results', '  25 of 1325 (2%, 95% CI 1-3%) patients had a mutation in PIK3CA (11 E545K, 3 E542K, 3 H1047L, 8 H1047R).  The patients (64% women) had a median age of 66 (range 34-78).  9 patients (36%, 95% CI 20-56%) were never-smokers.  Tumor histologies included', ' 23 adenocarcinomas, 1 squamous, and 1 large cell neuroendocrine.  Stages at presentation were', '  10, IV; 2, IIIB; 6, IIIA; 2, IIA; 1, IB; and 4, IA.  The median survival of patients with stage IIIB and IV was 21 months.  16 of 25 (64%, 95% CI 44-80%) had co-existing mutations in other oncogenes', ' 10, KRAS; 1, MEK1; 1, BRAF; 1, EML4-ALK; and 3, EGFR exon 19 deletions.  Of the 3 patients with EGFR mutations, only 2 tumors responded to erlotinib, with acquired resistance developing at 5 and 15 months.  The tumor with BRAF responded to gefitinib.  Stable disease was the response in the patient with EML4-ALK given crizotinib.  Conclusions', '   We found PIK3CA mutations in all histologic types of non-small cell lung cancer. They are not mutually exclusive with mutations in EGFR, KRAS, BRAF, and EML4-ALK.  Data on the impact of PIK3CA mutations on the efficacy of targeted therapies (erlotinib, crizotinib) are scant. The testing of agents targeting PIK3CA requires complete genotyping of tumor specimens to assess the potentially confounding role of co-existing mutations to affect responses.  Support', '  NIH T32, P01 CA129243, RC2 CA148394.']",
        "Doc_id":"ASCO_84485-102",
        "Doc_title":" Clinical, pathologic, and molecular characteristics of patients with non-small cell lung cancer harboring mutations in PIK3CA.",
        "_version_":1606188982125723649},
      {
        "Meeting_name":" Systematic deconvolution of kinase inhibitor profiles identifies synthetic lethal targets in ERBB2-mutant and BRD4-NUT rearranged cancer",
        "Background":"['The development of targeted therapies that efficiently inhibit cancer signaling pathways is one of the main goals of modern precision cancer medicine. Consequently, genetic and biological phenotypic data of in vitro screens are increasingly utilized to develop compounds directed against distinct oncogenic alterations. However, current targeted therapies are often limited to small genetically defined patient cohorts due to the very finite number of proteins amenable to direct chemical inhibition. An alternative approach is the exploitation of synthetic lethality, i.e. inhibition of an unaltered protein required for cell viability in a certain genetic background. Systematic chemo-genomic analyses of cancer cell lines have been shown to be suitable tools for the identification of novel synthetic lethal dependencies in cancer (Chan et al. Sci Trans Med, 2011; Sos et al. PNAS, 2012; Kim et al. Cell 2013).To systematically extend this strategy to non-small cell lung cancer (NSCLC) we characterized the efficacy of 1505 chemical compounds based on a variety of kinase inhibitor motifs in a high-throughput screen against 80 NSCLC cell lines. We extracted patterns of biological activity based on chemical and genetic information and found that potency and selectivity of compounds are strongly related to their molecular scaffold, but independent of their overall chemical complexity. We thereby discovered a sunitinib derivative that exhibited exquisite activity against ERBB2-mutant cell lines but was devoid of ERBB2 kinase activity. Instead a kinome scan and an shRNA screen suggested a mechanism of synthetic lethality by activity against NTRK family members. Moreover a CDK9 inhibitor was identified as selective and potent against a midline carcinoma cell line - a tumor entity characterized by recurrent BRD4-NUT gene fusions. Using additional cell lines we validated the upregulation of c-Fos and selective induction of apoptosis in BRD4-NUT positive midline carcinoma compared to control cell lines following CDK9 inhibition. This can augment existing therapeutic approaches, which have primarily focused on directly targeting the fusion product with bromodomain inhibitors, and offers a novel target in this entity.In conclusion, by systematically screening a large number of compounds against a panel of genetically well characterized NSCLC cell lines and incorporating chemical information we were able to derive structure activity relationships and to identify potential synthetically lethal targets in two genetic entities in clinical need of advanced selective therapies.']",
        "Doc_id":"AACR_2016-1349",
        "Doc_title":" Systematic deconvolution of kinase inhibitor profiles identifies synthetic lethal targets in ERBB2-mutant and BRD4-NUT rearranged cancer",
        "_version_":1606189012725268480},
      {
        "Meeting_name":" Sample specific outlier kinase expression identified by RNA-Seq provide targets for precision therapy.",
        "Background":"['Protein kinases represent a most effective class of therapeutic targets in cancer cells, and potent inhibitors of oncogenic kinases including ABL, AKT, ALK, AURKs, BRAF, CDKs, EGFR, ERBB2, FGFRs, KIT, MAPKs, MET, PIK3CA, PLKs, RET, SRC, S6Ks, and VEGFR are in clinical use, trials, or development. Presence of activating mutations, gene fusions or copy number amplification of many of these kinases predict responsiveness to specific inhibitors, for example, imatinib for BCR-ABL-positive chronic myeloid leukemia, trastuzumab and lapatinib for ERBB2-amplified breast cancers, gefitinib for lung cancers with kinase domain mutations in EGFR, and crizotinib for lung cancers with ALK gene fusions. However, tumors with defined kinase aberrations represent a very small proportion of all cancers, and we hypothesize that potentially most, if not all, cancers are dependent on specific kinases, and that Outlier Expression of specific kinases in individual samples may be indicative of selection during clonal evolution, and thus may represent a therapeutic avenue. To explore this hypothesis, we analyzed RNA-sequencing data from a compendium of 482 cancer and benign samples belonging to 25 different tissue types to define sample-specific kinome expression profiles. Comparing the expression of kinases within a sample and across sample sets, we identified distinct outlier kinases in individual samples, defined as genes showing the highest statistically significant levels of absolute and differential expression. Frequently observed outlier kinases included known therapeutic targets like ERBB2 and FGFR4 in breast cancer, distinct from MET, AKT2, and PLK2 in pancreatic cancer. Outlier kinases imparted sample-specific dependencies in various cell lines as assessed by siRNA knockdown or pharmacologic inhibition in vitro and in vivo. Outlier expression of polo-like kinases (PLKs) observed in a subset of KRAS-dependent pancreatic cancer cell lines conferred increased sensitivity to the PLK inhibitor BI 6727. Together, our results suggest that outlier kinases represent effective personalized therapeutic targets that are readily identifiable through RNA-sequencing of tumors. Next, to help translate these observations into treatment options, we are attempting to establish 3D tumoroid cultures from tumor samples that can be used to optimize combinations of therapeutics including outlier kinase inhibitors.']",
        "Doc_id":"AACR_2013-3136",
        "Doc_title":" Sample specific outlier kinase expression identified by RNA-Seq provide targets for precision therapy.",
        "_version_":1606188996075978752},
      {
        "Meeting_name":" First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers.",
        "Background":"['Background', '  Dacomitinib irreversibly inhibits EGFR, HER2 and HER4, and showed superior activity vs. reversible EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer models, including resistant forms. This open-label Phase II study evaluates dacomitinib as 1st-line treatment (tx) for patients (pts) with lung cancers. Pts with sensitizing EGFR deletions/mutations in exons 19 or 21 are reported here.  Methods', '  Pts had stage IIIB/IV adenocarcinoma, no prior systemic tx, had smoked <10 pack years (none within 15 years of enrollment) or had known EGFR mutation. Pts received dacomitinib orally once daily continuously at 45 mg, or 30 mg with the option to escalate to 45 mg; evaluation was every 28 days.   Endpoints included progression-free survival rate at 4 months (PFS at 4M, primary); PFS, and partial response (PR) rate.  Results', '  92 pts enrolled; 47 had EGFR mutation in exons 19 (n=25) or 21 (n=22), 33 were female and 27 Asian. 34/46 evaluable pts with EGFR exon 19 or 21 mutations had a PR (PR rate = 74%; 95% CI', ' 5986; exon 19 = 72%; exon 21 = 76%). PR rates and preliminary PFS were not significantly different for exons 19 and 21. Preliminary PFS at 4M was 96% (95% CI', ' 8499), preliminary PFS rate at 1 year was 77% (95% CI', ' 6187) and preliminary median PFS was 17 months (95% CI', ' 1324). Median tx duration was 13.1 months. For pts with EGFR wild-type lung cancers, PR and PFS at 4M rates were 7% (n=14; 95% CI', ' 034) and 33% (n=14; 95% CI', ' 1158), respectively, and for pts with EGFR unknown lung cancers, 46% (n=22; 95% CI', ' 2468) and 68% (n=24; 95% CI', ' 45 83), respectively. 7 pts had lung cancers with non-sensitizing EGFR mutations; 2 had a PR and 3 SD. For all 92 pts, common side effects included dermatitis acneiform (grade 3/4 = 17%/0) and diarrhea (14%/0). 3/46 pts with EGFR exon 19 or 21 mutations discontinued tx due to drug-related toxicity.  Conclusions', '  74% of pts in this cohort with EGFR exon 19 or 21 mutant lung cancers experienced PRs with 1st-line dacomitinib; preliminary PFS rate was 77% at 1 year; preliminary median PFS was 17 months; further research is planned in this pt population. As dacomitinib is well tolerated, with preclinical activity against HER2, a cohort of pts with HER2 mutant lung cancers is recruiting.']",
        "Doc_id":"ASCO_99805-114",
        "Doc_title":" First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers.",
        "_version_":1606189031394115584},
      {
        "Meeting_name":" Features of prognosis, genetics and drug sensitivity of very elderly lung cancer patients.",
        "Background":"['Background', '  In anticipation of the increasing aging of the population, we need to clarify the characteristics of elderly patients and the survival benefit of treating elderly patients. We investigated the clinical and prognostic features of elderly lung cancer patients, and analyzed driver gene mutations and expression data related to anticancer drug sensitivity to validate the personalized therapy for elderly patients.  Methods', '  A total of 519 patients, who underwent surgical resection of primary lung cancer, were enrolled. Clinicopathological factors, status of driver mutations, survival differences including overall survival (OS), disease specific survival (DSS) were compared retrospectively stratified with aging. Of those, 60 tumor RNA sample available were assessed for mRNA levels related to anticancer drug sensitivity as follow; TYMS, DPYD, MFTHR, UMPS, ERCC1, ABCB1, GSTP1, TUBB3, BRCA1, RRM1.   Results', '  The numbers of the patients in each group were middle-aged (age 40-64)', ' 168, elderly (age 65-74)', ' 217, and very elderly (age  75)', ' 134. Pathological stages were IA', ' 219, IB', ' 97, II', ' 87, and III-IV', ' 116. Although adenocarcinoma histology was more frequent in young group (P = 0.001), significant differences of the frequency of driver gene mutation including EGFR, KRAS, HER2, BRAF were not observed. The OS of middle-aged group was significantly better than the other groups, but there were no difference between those of elderly and very elderly group. In terms of DSS, no significant survival differences among all three groups were observed. Multivariate analysis revealed that only elderly group was an independent unfavorable prognostic factor for OS, but very elderly group was not. For the mRNA expressional levels of anticancer drug sensitivity, lower expressions of ERCC1, GSTP1, DPYD, and ABCB1 in very elderly group than younger groups were observed.  Conclusions', '  The prognosis and the frequencies of driver mutations of very elderly lung cancer patients were comparable to those of younger patients. Expression levels of anticancer drug sensitivity genes in elderly suggest better response to the chemotherapy, especially to platinums. Cytotoxic chemotherapy could be beneficial to the elderly lung cancer patients.']",
        "Doc_id":"ASCO_149313-156",
        "Doc_title":" Features of prognosis, genetics and drug sensitivity of very elderly lung cancer patients.",
        "_version_":1606189021939105792},
      {
        "Meeting_name":" Cerebrospinal fluid pharmacokinetics and pharmacodynamics following high-dose erlotinib treatment in brain cancer patients",
        "Background":"['Patients with non-small cell lung cancer (NSCLC) who develop leptomeningeal metastases show significant clinical improvement following high-dose gefitinib therapy. Based on this data, we aimed to explore the effect of high-dose erlotinib on clinical response and CNS penetration in primary or metastatic CNS cancer.We selected patients who had received prior therapy for either primary glioma or for NSCLC with metastases to the brain and treated them with an alternate dosing regimen of erlotinib. Blood and cerebrospinal fluid (CSF) samples were collected at various time points to assess levels of erlotinib. We found that CSF concentrations of erlotinib were generally 2% that of plasma concentrations. Among the five patients examined, CSF concentrations of erlotinib reached up to 131 nM when high doses were administered at 600 to 1200 mg every four to six days. Additionally, drug clearance was decreased with an increased dosing regimen in one of the patients. In one patient, the area under the curve (AUC) estimations showed a 24% increase in the CSF versus only a 2% increase in the plasma following an increase from 150 mg to 600 mg of erlotinib. Moreover, longitudinal CSF samples were evaluated for expression and activation of EGFR as well as various other receptor tyrosine kinases, such as ErbB2, ErbB3, cMET and IGF1R, using the highly sensitive multiplexed immunoassay CEER platform. The latter provides insight into the molecular makeup of the CNS cancer throughout the therapeutic regimen.Our clinical data on patients receiving erlotinib therapy for primary and metastatic CNS disease suggests that increased dosing of erlotinib, administered as a pulse dose every four to six days leads to increased CSF drug concentrations. In spite of the variations seen among different patients, we conclude that higher erlotinib dosing regimens can provide enhanced CNS penetration that may prove to be more effective in primary and metastatic CNS cancers especially when coupled with real-time molecular monitoring of the disease to help guide the clinician during the course of treatment.']",
        "Doc_id":"AACR_2014-4652",
        "Doc_title":" Cerebrospinal fluid pharmacokinetics and pharmacodynamics following high-dose erlotinib treatment in brain cancer patients",
        "_version_":1606189026089369600},
      {
        "Meeting_name":" Afatinib monotherapy in patients with metastatic squamous cell carcinoma of the lung progressing after erlotinib/gefitinib (E/G) and chemotherapy",
        "Background":"['Background', '  Patients with squamous NSCLC have limited treatment options. For those deriving benefit from EGFR TKIs, it is unclear whether sustained ErbB family blockade offers benefit upon progression. We evaluated afatinib, an irreversible blocker of EGFR (ErbB1), HER2 (ErbB2) and ErbB4 receptor tyrosine kinases, in patients with metastatic NSCLC who had failed chemotherapy and E/G. Here we describe a pre-specified analysis of those with squamous histology in Part A.  Methods', '  This randomized Phase III, open-label, multi-center trial enrolled patients with pathologically confirmed metastatic NSCLC after failing 1 line of cytotoxic chemotherapy and E/G. In Part A, patients received oral afatinib 50 mg until disease progression. Those with clinical benefit (12 wks) who progressed were eligible to receive afatinib plus paclitaxel or investigators choice chemotherapy (Part B). Primary endpoint was PFS (RECIST 1.1). Following an amendment, an interim analysis of Part A was performed to assess afatinib monotherapy.  Results', '  Patient enrolment into Part A was from April 2010 to May 2011. Of 1154 afatinib-treated patients, 91 (8%) had squamous histology; 18/91 and 40/91 had CR/PR and SD on prior E/G, respectively (by investigator). Median age was 63 yrs, 71% were male, 76% were current/ex-smokers. Median PFS on afatinib was 3.7 mths in the squamous histology subset. Of 91 patients, 42 had PFS 3 mths; 13 had PFS of 6 mths. In evaluable patients (n=77), 1 CR and 3 PRs were confirmed; 51 and 22 patients had best overall response of SD and PD, respectively. Of the 31 patients with PD on prior E/G with no intervening chemotherapy, 10 achieved confirmed disease control (2 PR; 8 SD) on afatinib. Most commonly reported grade 3/4 adverse events (AEs) in Part A were diarrhea (13%) and rash/acne (12%). The safety profile in the squamous histology subset was similar to that observed for the whole trial.  Conclusions', '  Afatinib monotherapy demonstrated encouraging activity in treatment-refractory NSCLC patients with squamous histology that merits further evaluation.']",
        "Doc_id":"ASCO_91937-114",
        "Doc_title":" Afatinib monotherapy in patients with metastatic squamous cell carcinoma of the lung progressing after erlotinib/gefitinib (E/G) and chemotherapy",
        "_version_":1606189008183885824},
      {
        "Meeting_name":" Targeted therapy for non-small cell lung cancer (NSCLC) with HER2, BRAF, or hedgehog alterations",
        "Background":"['Background', ' Treatments targeting critical molecular alterations (EGFR, ALK, and ROS1) in NSCLC are highly effective. MyPathway (NCT02091141) is an ongoing, phase 2, multi-basket study evaluating the efficacy of targeted treatment in non-indicated tumor types harboring alterations in the HER2, BRAF, Hedgehog (Hh), or EGFR pathways. Interim results in NSCLC are presented. Methods', ' Patients with previously treated advanced NSCLC and alterations in the HER2 (amplification and/or mutation), BRAF (V600E or other mutations), Hh (SMO or PTCH-1 mutations), or EGFR (mutations other than known activating mutations) pathways received standard doses of pertuzumab + trastuzumab, vemurafenib, vismodegib, or erlotinib, respectively, until disease progression or unacceptable toxicity. The HER2, BRAF, and Hh cohorts are included in this analysis. The primary endpoint is investigator-assessed objective response rate (ORR, defined as complete response [CR] + partial response [PR]) by RECIST v1.1. Results', ' As of November 30, 2016, 61 patients with NSCLC and HER2 (n = 36), BRAF (n = 22), or Hh (n = 3) alterations have been treated (median age of 64 years, 49% male, 85% adenocarcinoma, and a median of 2 previous regimens). Median treatment duration was 1.8 (range, 021.4) months. Efficacy in the 55 patients with the minimum required follow-up for efficacy analysis is summarized in the table. Conclusions', ' Targeted therapy is active in patients with previously treated NSCLC harboring BRAF V600E mutations or HER2 alterations (amplifications and/or mutations). These cohorts have been expanded as MyPathway accrual continues. Additional efficacy data and details regarding molecular alterations will be presented. Clinical trial information', ' NCT02091141Patients, nORR, n (%)Clinical benefit ratea, n (%)Durations of objective responses, monthsHER2 alterationsb316 (19)10 (32)< 1+, 3+, 5+, 6, 8, 10BRAF V600E146 (43) (1 CR)8 (57)4, 4, 5, 5+, 10+, 14BRAF other701 (14)NAHh301 (33)NA+ indicates response is ongoing. aCR + PR + stable disease > 4 months. bHER2 amplified and/or mutated.']",
        "Doc_id":"ASCO_184706-199",
        "Doc_title":" Targeted therapy for non-small cell lung cancer (NSCLC) with HER2, BRAF, or hedgehog alterations",
        "_version_":1606188974337949696},
      {
        "Meeting_name":" Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigators choice chemotherapy following progression on afatinib monotherapy.",
        "Background":"['Background', '  The benefit of sustained ErbB family blockade in NSCLC patients with acquired resistance (AR) to EGFR TKIs is unknown. We investigated afatinib, an irreversible blocker of EGFR (ErbB1), HER2 (ErbB2) and ErbB4 receptor tyrosine kinases, in patients with metastatic NSCLC, who had failed chemotherapy and E/G.  Methods', '  This was a Phase III, randomized, open-label, multi-center trial. Patients with pathologically confirmed Stage IIIB/IV metastatic NSCLC after 1 line of chemotherapy who failed E/G received oral afatinib 50 mg until disease progression (Part A). After progression, patients with clinical benefit (12 wks) were eligible to continue afatinib 40 mg plus paclitaxel or receive investigators choice chemotherapy (Part B). Primary endpoint for Part A was PFS (RECIST 1.1; CT scan every 6 wks). Available tumor samples were collected for central EGFR mutation testing; local mutation data were also collected. An interim analysis of Part A, assessing afatinib monotherapy, is reported.  Results', '  Part A enrolled April 2010 through to May 2011; 1154 patients received afatinib monotherapy. The majority had adenocarcinoma (85%), 57% were female, 43% were Asian, 54% were never smokers. Best response to prior E/G was CR (2%), PR (31%), SD (42%) and PD (20%). Median PFS for afatinib was 3.3 mths; 88 patients (8%) achieved an objective tumor response, 648 (56%) had SD. For EGFR mutation positive patients (n=49, centrally confirmed), PFS was 4.2 vs. 2.6 mths for EGFR mutation negative patients (n=35). When applying clinical enrichment criteria for AR, PFS was 4.2 mths for those with enrichment (n=597) vs. 2.8 mths for those without (n= 557; logrank test p<0.0001). The most common grade 3/4 adverse events were diarrhea (17%) and rash/acne (11%). In Part A, 99 patients remain on treatment.  Conclusions', '  Afatinib monotherapy provided a clinically meaningful benefit in this large, treatment-refractory NSCLC trial, similar to LUX-Lung 1. Those clinically enriched for AR to EGFR TKIs achieved prolonged disease control upon continued ErbB blockade.']",
        "Doc_id":"ASCO_91872-114",
        "Doc_title":" Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigators choice chemotherapy following progression on afatinib monotherapy.",
        "_version_":1606188982896427008},
      {
        "Meeting_name":" Development and validation of a real-world clinicogenomic database.",
        "Background":"['Background', ' Genomic findings have diagnostic, prognostic, and predictive utility in clinical oncology. Population studies have been limited by reliance on trials, registries, or institutional chart review, which are costly and represent narrow populations. Integrating electronic health record (EHR) and genomic data collected as part of routine clinical practice may overcome these hurdles. Methods', ' Patients in the Flatiron Health Database with non-small cell lung cancer (NSCLC) who underwent comprehensive genomic profiling (CGP) by Foundation Medicine were included. EHR processing included structured data harmonization and abstraction of variables from unstructured documents. EHR and CGP data were de-identified and linked in a HIPAA-compliant process. Data included clinical characteristics, alterations across > 300 genes, tumor mutation burden (TMB), therapies and associated real-world responses, progression, and overall survival (OS). Results', ' The cohort (n = 1619) had expected clinical (mean age 66; 75% with smoking hx; 80% non-squamous) and genomic (18% EGFR; 4% ALK; 1% ROS1) properties of NSCLC. Presence of a driver mutation (EGFR, ALK, ROS1, MET, BRAF, RET, or ERBB2; n = 576) was associated with younger age, female gender, non-smoking, improved OS (35 vs 19 mo, LR p < 0.0001), and prolonged survival when treated with NCCN-recommended therapy (42 vs 28 mo, LR p = 0.001). CGP identified false negative results in up to 30% of single-biomarker tests for EGFR, ALK, and ROS1. CGP accuracy was supported by clinical outcomes. For example, 5 patients with prior negative ALK-fusion testing began ALK-directed therapy after positive CGP results. All 5 exhibited at least a partial response as recorded in the EHR by treating clinicians. Immunotherapy was used in 22% of patients (n = 353). TMB predicted response to nivolumab, including in PD-L1 negative populations. We recapitulated known associations with smoking, histology, and driver mutations. Conclusions', ' We present and validate a new paradigm for rapidly generating large, research-grade, longitudinal clinico-genomic databases by linking genomic data with EHR clinical annotation. This method offers a powerful tool for understanding cancer genomics and advancing precision medicine.']",
        "Doc_id":"ASCO_194753-199",
        "Doc_title":" Development and validation of a real-world clinicogenomic database.",
        "_version_":1606189018541719553},
      {
        "Meeting_name":" Molecular profiling in African American NSCLC patients to identify novel potential driver mutations",
        "Background":"['African Americans continue to have poorer 5 year survival after a lung cancer diagnosis than whites for reasons that remain to be fully characterized. This disparity remains even with advances in treatments targeting specific driver mutations that have improved outcomes for some patients. Although the relative frequency of these genetic alterations varies in subsets of individuals defined by sex, histologic subtype, smoking history and race, little is known about the occurrence of these mutations in African Americans. In this study, we characterize the spectrum of known driver mutations in 200 African American NSCLC patients and seek to identify novel somatic mutations in this population. Initially, the population was screened using the Sequenom LungCarta panel of 216 mutations in 24 genes known to contain alterations associated with lung cancer, RET and ROS1 fusion gene expression, and amplification of FGFR1. Whole-exome sequencing is being performed on tumors from those patients with no known somatic mutations. Paired normal and tumor DNA/RNA samples are being genotyped to distinguish germline from somatic mutations in both the screening and sequencing phases. Initial screening has been completed on 130 patients, with the remaining 70 underway. The mean age of the patients enrolled is 61.7 years, 58.5% are female, and 8.5% are never smokers. In profiling the first 130 African American patients, we find that only 28% of patients (N = 36) carry a known somatic mutation that is not present in the germline, far lower than the 41% reported in white patients in our previous studies. Of the identified mutations, approximately 23.8% are KRAS and 23.8% are PT53 alterations. The next most frequent somatic alterations are in EGFR (16.7%). The remaining alterations occurred in only 1 or 2 tumors and include EPHA3, ERBB2, FGFR1, MET, NOTCH1, NRAS, NTRK2, PIK3CA, PTEN, RET and STK11. Five percent of patients have tumors with two driver mutations. Half of the tumors carrying 2 driver mutations had concurrent alterations in KRAS and TP53. Patients with known genetic alterations were more likely to be female than patients with no known genetic alterations (p = 0.42), but did not differ in age, smoking status, pack-years, family history of lung cancer, history of COPD, stage at diagnosis or histology. Mutations in EGFR were responsible for the differences by sex. Exome sequencing is complete for the first 48 of the 92 patients with no known somatic mutations. Sequences are being aligned using Novoalign and GATK will be used for variant calling; results will be available soon. Genetic profiling of NSCLC in African Americans has the potential to both identify novel mutations, expanding the list of potential targets for tailored treatments, and aid clinical decision making in African American patients leading to improvements in outcomes.']",
        "Doc_id":"AACR_2016-5227",
        "Doc_title":" Molecular profiling in African American NSCLC patients to identify novel potential driver mutations",
        "_version_":1606188979986628608},
      {
        "Meeting_name":" Implications of specific T-cell responses by different novel and known immunogenic tumor-associated antigens (TAA) in patients with metastatic lung cancer.",
        "Background":"['Background', '  In the last years, new therapeutic strategies of lung cancer with encouraging results have been investigated including immunotherapeutic approaches, e.g. against MAGE-A3 and hTERT. Thus, tumor vaccination seems to be a promising strategy especially in situations of reduced tumor load, i.e. in maintenance therapy. Here we address the question, whether there are further interesting candidates besides the antigens MAGE-A3 and hTERT that induce intensive immune reactions in a high frequency in lung cancer and are therefore eligible for immunotherapeutic approaches.  Methods', '  Immune reactions of CD8+ T-cells were measured in ELISPOT assays for IFN-gamma and granzyme B. Moreover, tetramer assays and chromium release assays were performed. Epitopes were tested derived from the lung-cancer associated antigens MAGE-A3 and hTERT, and from the antigens RHAMM, Survivin, WT-1, PRAME, HER2 and G250 known from other tumor entities as well as novel antigens, like Aurorakinases A and B. For these novel antigens more than 10 HLA-A2-binding peptides were predicted and tested in 20 healthy volunteers and 15 lung cancer patients.  Results', '  Specific T-cell responses could be detected against at least one peptide in all patients. Most frequent responses were detected against PRAME (67%), hTERT (60%), G250 (60%) and RHAMM (40%). Lower frequency was measured for Survivin- (27%), WT-1- (27%), the two MAGE-A3- (27 and 20%) and Her2- (15%) derived peptides. Specific T-cell responses could be also detected against Aurorakinases A and B. The novel peptides AuraA01 and AuraB01 showed specific T-cell responses in 33% and 40% of patients respectively. Serological immune responses are under investigation.  Conclusions', '  Specific T-cell responses against several TAA could be detected for the antigens hTERT, PRAME, G250 and RHAMM in a high frequency of patients with lung cancer, but also in a lower frequency against several other antigen peptides. Moreover, novel immunogenic targets like Aurorakinases were identified. Therefore, further antigen structures are appropriate for immuno-targeted approaches in lung cancer.']",
        "Doc_id":"ASCO_81246-102",
        "Doc_title":" Implications of specific T-cell responses by different novel and known immunogenic tumor-associated antigens (TAA) in patients with metastatic lung cancer.",
        "_version_":1606189012852146176},
      {
        "Meeting_name":" LUX-Lung 6",
        "Background":"['Background', '  Afatinib (A) is an oral, irreversible, ErbB Family Blocker, blocking signaling from EGFR (ErbB1), human epidermal growth factor receptor 2 (HER2; ErbB2) and ErbB4. In LUX-Lung 6, A was significantly better than gemcitabine/cisplatin (GC) in terms of progression free survival (PFS) and tumor response, with a more favorable safety profile. Here, we report the PRO results.  Methods', '  364 pts were randomized (2', '1) to receive A or GC. PROs were measured using EORTC questionnaires QLQ-C30/LC13 at baseline and q3w until progression. Changes of 10 points (scale 0100) were considered clinically significant. Analyses of cough, dyspnea and pain were prespecified. Time to deterioration (1st 10-point worsening from baseline) was analyzed using a stratified log-rank test. Percentage improved/worsened by 10 points or stable was determined. Mean scores over time were estimated using longitudinal (mixed-effects growth curve) models.  Results', '  Compliance on treatment with questionnaires was >90%. Baseline symptom burden was low (cough', ' 35; dyspnea', ' 25; pain', ' 24). Compared with GC, therapy with A significantly delayed time to deterioration for cough (HR=0.45; p=0.0001), dyspnea (HR=0.54; p<0.0001) and pain (HR=0.70; p=0.03). A higher proportion of A-treated pts had 10-point improvements in cough (76% vs 55%; p=0.0003), dyspnea (71% vs 48%; p<0.0001) and pain (64% vs 47%; p=0.003) compared with GC, particularly among pts with baseline symptoms. Mean scores over time for cough, dyspnea and pain also significantly favored A. Consistent with their safety profiles, a significantly higher proportion of A-treated pts had worsening of diarrhea, sore mouth and dysphagia, while fatigue, nausea, and vomiting were significantly worse with GC. Overall, therapy with A significantly improved global health-related quality of life (HRQoL; p<0.0001), physical (p<0.0001), role (p=0.01) and social (p<0.001) functioning compared with GC.  Conclusions', '  In LUX-Lung 6, prolongation of PFS with A was associated with significantly better HRQoL and significantly longer control of lung cancer-related symptoms compared with GC. Clinical trial information', ' NCT01121393.']",
        "Doc_id":"ASCO_112338-132",
        "Doc_title":" LUX-Lung 6",
        "_version_":1606188974643085312},
      {
        "Meeting_name":" Molecular evaluation of primary tumor (PT) and synchronous liver metastasis in colorectal cancer (srLmCRC) patients after cetuximab-based chemotherapy.",
        "Background":"['Background', '   Molecular heterogeneity among PT and LmCRC is not yet defined. Next Generation Sequencing (NGS) in clinical practice could increase the change of identifying multiple molecular driver alterations calling for therapy. This study evaluates mutations in PT and sLmCRC exon2 KRAS wt patients who underwent chemotherapy (CT) containing cetuximab.  Methods', '    Genomic analysis was conducted in 7 sLmCRC pts', ' before CT on a PT biopsy, after CT on a PT surgical specimen and all srLmCRC. A total of 54 lesions were examined. DNA libraries were generated using the Ion AmpliSeq Colon and Lung Cancer Panel including 22 mutated genes (KRAS, EGFR, BRAF, PIK3CA, AKT1, ERBB2, PTEN, NRAS, STK11, MAP2K1, ALK, DDR2, CTNNB1, MET, TP53, SMAD4, FBXW7, FGFR3, NOTCH1, ERBB4 , FGFR1, FGFR2) and sequenced on a Ion PGM system Results', '    A partial response was achieved in all pts, with a median PFS of 11 months (4-15). Molecular analysis of genes correlated with target therapy is shown in the following table (K=KRAS; N=NRAS; P=PIK3AC; M=MET; m= -; wt= + ). Pt 1 showed heterogeneity in PT before and after CT with KRASm clonal selection and related expression of the mucinous pattern; in srLmCRC', ' 5/9 KRASm exon2, 1/9 PIK3CAm exon20, 2/9 KRASm exon2 and PIK3CA exon20. In pt 7 NRASm exon2 was identified in PT before and after CT; differences in srLmCRC', ' 3/5 no mutation, 1/5 NRASm exon2, 1/5 PIK3CAm exon20. The other cases showed rare mutations', ' SMAD4 (pt 2), TP53 (pts 2,5,6,7), FBXW7 (pt1).  Conclusions', '    Our preliminary data suggest a potential role for NGS in the evaluation of biological drug resistance affecting future sequential treatments strategy']",
        "Doc_id":"ASCO_133879-144",
        "Doc_title":" Molecular evaluation of primary tumor (PT) and synchronous liver metastasis in colorectal cancer (srLmCRC) patients after cetuximab-based chemotherapy.",
        "_version_":1606189035268603904},
      {
        "Meeting_name":" Somatic driver mutations among never smoking female lung cancer cases in China identify unique mutation pattern that may be associated with household coal burning",
        "Background":"[\"Globally, about 53% of lung cancer cases in women and 15% of lung cancer cases in men are not attributable to active tobacco use, making lung cancer in never smokers the seventh leading cause of cancer death. Experimental and epidemiological evidence suggest that lung cancer in never smokers has unique risk factors, clinical features, and histological distributions as compared to those lung cancer cases attributed to tobacco smoking. In general, lung cancer in never smokers presents predominately as adenocarcinoma and in females. The lung cancer rate among females in Xuanwei, China is among the highest in the world for nonsmoking females, and has been attributed to indoor air pollution from domestic fuel combustion, particularly from bituminous coal. To further explore the clinical and histological aspects of lung cancer in Xuanwei, we collected formalin-fixed paraffin embedded (FFPE) tissue samples from a series of 76 female lung cancer cases. The mean age of the patients was 47.7 years old (9.2 years). Expert consensus review found 54 (71%) of the female lung cancer cases were adenocarcinomas (ADCs), 11 (14.5%) were squamous cell carcinomas (SCCs), 1 (1.3%) was an adenosquamous carcinoma (ADSC), 8 (10.5%) were large cell carcinomas, and 2 (2.7%) were other subtypes. We then used two multiplexed assays to detect in DNA from FFPE tissue more than 40 recurrent mutations in nine genes relevant to existing and emerging targeted lung cancer therapies among subjects who were confirmed never smoking female lung cancer cases (32 ADCs, 7 SCCs, 1 ADSC). These assays include amplification of DNA through Applied Biosystem's SNaPshot technology to detect 38 different recurrent somatic point mutations in 8 driver genes (EGFR, KRAS, BRAF, NRAS, PIK3CA, MEK1, AKT1, and PTEN) and a PCR-based sizing assay that assesses for EGFR exon 19 deletions, EGFR exon 20 insertions, and HER2 exon 20 insertions. We detected 15 EGFR mutations [E20-6bp-ins. (n=1); EGFR_19-15bpDel (n=4); EGFR_G719A_2156G>C (n=2); EGFR_G719C_2155G>T (n=3); EGFR_G719S _2155G>T (n=1); EGFR_G719S_2155G>A (n=1); EGFR_L858R_2573T>G (n=2); EGFR L861Q_2582T>A (n=1)] in 12 ADCs and 2 SCCs. Six KRAS mutations, all of which were KRAS G12C_34G>T, were detected in 5 ADCs and 1 SCC. EGFR and KRAS mutations were mutually exclusive and no mutations were observed for BRAF, NRAS, PIK3CA, MEK1, HER2, AKT1, or PTEN. The high percentage of samples with KRAS mutations (15.0% overall; 15.6% ADCs; 14.3% SCCs) in our series is of interest, primarily because KRAS mutations are reportedly more rare in other populations from Asia (5%) and populations of never smokers from Asia (2%). Given that all subjects with KRAS mutations burned coal indoors for heating and cooking, our findings may provide new insights into the pathogenesis of lung cancer among never smoking females exposed to indoor air pollution from coal.\"]",
        "Doc_id":"AACR_2012-5479",
        "Doc_title":" Somatic driver mutations among never smoking female lung cancer cases in China identify unique mutation pattern that may be associated with household coal burning",
        "_version_":1606188997303861248},
      {
        "Meeting_name":" Lung cancer in never-smokers from the Princess Margaret Cancer Centre.",
        "Background":"['Background', '  Lung cancer in never smokers accounts for ~15-20% of cases, and globally is a growing clinical problem.   Methods', '  We identified 570 never-smokers with lung cancer diagnosed from 1988-2013 at the Princess Margaret Cancer Centre. Clinical and demographic data were retrieved from the electronic patient record with the aim of characterizing the epidemiology, demographics, pathology, molecular profile, treatment, and survival in these patients.  Results', '  There were 409 females (72%) and 161 males (28%), median age 62.1 years (18 94), 46% Caucasian, 34% Asian, 6% Black, 4% South Asian, 4 % Filipino, 6% Other/Unknown. Environmental tobacco exposure was identified in only 17%.  A history of prior malignancy was present in 89 (14.2%) patients (1 cancer 81; multiple cancers 8 patients).  Most patients (87.3%) had adenocarcinoma and most presented in stage IV - 54.9%, followed by I - 26%, III - 12.8% and II - 6.3%. In stage IV patients, 88% were ECOG PS 0-1. Among 310 patients with molecular results to date, the mutation rate was 71% (EGFR mutation [mut] 76%, ALK 10%, KRAS 4%, HER2 1.4% BRAF 0.5%, other 1.8%, multiple mut 6.3%.  Brain metastases at presentation occurred in 18.4% stage IV patients (77/419)', ' 67% (52/77) with EGFR mut vs 22% (17/77) with EGFR WT vs 10% (8/77) with other mut (P=0.0023).  Median overall survival (OS) of EGFR mut patients vs EGFR WT with brain metastases at presentation was 57 vs 16 mo (P=0.031). Stage IV patients with EGFR and ALK mut received targeted treatment in 88% (121/138) and 89% (16/18) cases, respectively, with 65% (92/138, 66% for EGFR and 14/18, 82% for ALK) staying on TKI >6 months. Overall, 68% (285/419) of patients received 1-3 lines of systemic therapy (range 0-8 lines). Median OS was 47 mos. Median OS for patients with known vs unknown mutation status was 59 mo vs 34 (P<0.001). Early stage (P<0.0001), PS 0-1 (P<0.0001), presence of EGFR (P=0.003) or ALK mut (P=0.035) were associated with longer survival, but not Asian ethnicity (P=0.6) or female sex (P=0.1).   Conclusions', '  Lung cancer in never-smokers represents a distinct clinical and molecular entity characterized by a high incidence of targetable mutations and long survival. Updated molecular profiling results will be presented for the entire cohort.']",
        "Doc_id":"ASCO_130542-144",
        "Doc_title":" Lung cancer in never-smokers from the Princess Margaret Cancer Centre.",
        "_version_":1606188992194150400},
      {
        "Meeting_name":" My Cancer Genome",
        "Background":"['Background', '  Lung cancer has traditionally been treated according to histologic subtype with a plateau in the efficacy of combination chemotherapy.  Recent advances have identified oncogenic driver mutations in lung cancer that predict response to targeted therapies. However, knowledge resources are limited regarding the clinical relevance of such mutations.   Methods', '  We performed a literature review regarding the prevalence and clinical significance of various treatments for ~40 mutations in 10 genes (EGFR, KRAS, BRAF, NRAS, PIK3CA, MEK1, AKT1, HER2, PTEN, and ALK) for non-small cell lung cancer (NSCLC). Data from prospective and retrospective trials as well as preclinical studies was collected.   Results', '  ~100 articles/abstracts were synthesized into the publicly available My Cancer Genome website (mycancergenome.org) which launched in Jan 2011. Content includes information about the oncogene pathway (e.g. What is EGFR-), the clinical significance of the gene for a specific type of cancer (e.g. EGFR in NSCLC), and a summary of clinically relevant data related to a particular gene mutation (e.g. EGFR Exon 19 deletion in NSCLC).  Information regarding mutation directed clinical trials open for accrual both at Vanderbilt Ingram Cancer Center and worldwide is provided using a direct query of clinicaltrials.gov. This decision support tool is integrated into Vanderbilts electronic medical record to provide actionable decision support for mutation directed treatment prioritization and clinical trial availability. Clinicians, patients, and researchers with access to the internet can also access the website freely and directly.   Conclusions', '  My Cancer Genome is an international resource to assist clinicians in prioritizing genome directed cancer therapies.  The first implementation includes content for NSCLC.  We are now expanding the content to include melanoma, breast cancer, colon cancer and other malignancies. New data will be incorporated on an ongoing basis.  We welcome public/private partnerships to expand content and make this a truly global resource.']",
        "Doc_id":"ASCO_82277-102",
        "Doc_title":" My Cancer Genome",
        "_version_":1606188981206122496},
      {
        "Meeting_name":" LUX-Lung 3",
        "Background":"['Background', ' Afatinib (A) is a selective, orally bioavailable, irreversible ErbB family blocker of EGFR (ErbB1), HER2 (ErbB2), and ErbB4. This global study investigated the efficacy and safety of A compared with pemetrexed/cisplatin (PC) in pts with EGFR mutation positive advanced lung adenocarcinoma.  Methods', ' Following central testing for EGFR mutations (companion diagnostic TheraScreen EGFR RGQ PCR kit), 345 pts (stage IIIB/IV, PS 01, chemo-naive) were randomized 2', '1 (A', ' 230; PC', ' 115) to daily A 40 mg or iv PC (500 mg/m2 + 75 mg/m2  q21 days up to 6 cycles). Primary endpoint was progression-free survival (PFS) by central independent review.  Results', ' Baseline characteristics were balanced in both arms', ' median age, 61 y; female, 65%; Asian, 72%; never-smoker, 68%; Del19, 49%; L858R, 40%; other mutations, 11%. Treatment with A led to a significantly prolonged PFS vs PC (median 11.1 vs 6.9 mos; HR 0.58 [0.430.78]; p=0.0004). In 308 pts with common mutations (Del19/L858R), median PFS was 13.6 vs 6.9 mos, respectively (HR=0.47 [0.340.65]; p<0.0001). Objective response rate was significantly higher with A (56% vs 23%; p<0.0001). Significant delay in time to deterioration of cancer-related symptoms of cough (HR=0.60, p=0.0072) and dyspnea (HR=0.68, p=0.0145) was seen with A vs PC. Most common drug-related adverse events (AEs) were diarrhea (95%), rash (62%) and paronychia (57%) with A, and nausea (66%), decreased appetite (53%) and vomiting (42%) with PC. Drug-related AEs led to discontinuation in 8% (A; 1% due to diarrhea) and 12% of pts (PC).  Conclusions', ' LUX-Lung 3 is the largest prospective trial in EGFR mutation positive lung cancer and the first study using pemetrexed/cisplatin as a comparator. Treatment with afatinib significantly prolonged PFS compared to PC, with significant improvements in secondary endpoints. AEs with afatinib were manageable, with a low discontinuation rate. With 4.2 mos PFS improvement in the overall population and 6.7 mos in pts with common mutations, afatinib is a clinically relevant first-line treatment option.']",
        "Doc_id":"ASCO_91942-114",
        "Doc_title":" LUX-Lung 3",
        "_version_":1606188976390012928},
      {
        "Meeting_name":" A survey on the clinical actionable somatic variations among 1,000 Chinese cancer patients to provide personalized global clinical decision roadmap.",
        "Background":"['Background', ' Precision medicine has become a major paradigm shifting effort in cancer care globally to improve the outcome of cancer patients. More and more patients receive individualized cancer treatments based on their tumor-specific characteristics at both gene and genomic level. Methods', ' We have sponsored a translational research project to sequence the whole exome of tumor specimen and case-matched normal samples among 1,000 Chinese cancer patients, to prospectively provide clinical decision roadmap recommendations based on globally available treatment options, and to follow up the treatment implementation and disease evolvement of each patient. These patients are from more than 70 hospitals across 18 provinces in China. The preliminary data yields rich tumor specific genomic variations and the potential precision clinical treatments among a few common tumor types in China, including Lung cancer, Gastric cancer, Colorectal cancer and Breast cancer. Results', ' Within this dataset, we demonstrated the use of tumor-normal matched whole exome sequencing to measure a wide spectrum of molecular abnormalities closely related to targeted therapy and immune therapy clinical decision for Chinese cancer patients. The information includes somatic mutations (such as EGFR and BRAF), somatic copy number changes (such as ERBB2 and cMET), genome wide mutation load measurement (for immune check-point inhibitors), and microsatellite instability status (in Gastric and Colorectal cancer). By working with the treating physicians, we have also demonstrated the clinical value of such roadmap recommendations for Chinese cancer patients, by providing the facilitation for the patients to access these drugs and clinical trials globally. Conclusions', ' This project laid the foundation for future implementation of genomic-based clinical trials in China.']",
        "Doc_id":"ASCO_169174-176",
        "Doc_title":" A survey on the clinical actionable somatic variations among 1,000 Chinese cancer patients to provide personalized global clinical decision roadmap.",
        "_version_":1606189015250239488},
      {
        "Meeting_name":" Circulating tumor DNA profiling to reveal heterogeneity of EGFR-TKI resistance mechanisms in lung adenocarcinoma patients.",
        "Background":"['Background', ' EGFR-TKI therapy has significantly improved prognosis of NSCLC patients with EGFR sensitive mutation. However, almost all patients ultimately develop PD while receiving TKI treatment. Circulating tumor DNA (ctDNA) is promising as a minimally-invasive liquid biopsy for comprehensive analysis of molecular abnormalities. Methods', ' A total of 254 advanced lung adenocarcinoma patients with signs of EGFR-TKI resistance were enrolled in the study. ctDNA was analyzed using next-generation sequencing based ER-Seq method, which enables simultaneously assess single-nucleotide variants, insertions/deletions, rearrangements, and somatic copy-number alterations across 59 genes. Results', ' ctDNA profiling was possible for all patients, 172 patients had  1 ctDNA alteration(s). Median number of plasma somatic mutations was 2, predominantly located in EGFR and TP53, with MET, ERBB2 and PIK3CA followed. Of that, 30.6% of mutations detected in ctDNA were at a frequency below 1%. In exploring the mechanisms of TKI-resistance, we found TKI-sensitizing mutations were not detected in plasma of 138 patients (54.3%). Known mechanisms such as EGFR T790M/C797S mutation, activating mutations of PI3K-AKT-mTOR signaling, amplification of MET, activating mutation / amplification of ERBB2, activating mutation of KRAS, BRAF or mutations in EGFR EX20 other than T790M/C797S were identified in 59, 16, 8, 7, 3, 2, and 2 patients respectively. T790M/C797S was detected in 50.8% of patients with plasma positive for TKI-sensitizing mutations. Of note, C797S was only detected in patients treated with AZD9291. EGFR amplification were identified in 15 patients, though whether it would result in TKI-resistance was still controversial. Co-occurrence of resistance mechanisms were observed in 22 patients including 13 patients without TKI-sensitizing mutations. Conclusions', ' There was a high frequency of inter and intra-patient heterogeneity of resistance mechanisms after EGFR TKI therapy. ctDNA can be used as a liquid biopsy to facilitate the broad exploration of potential resistance mechanisms.']",
        "Doc_id":"ASCO_192168-199",
        "Doc_title":" Circulating tumor DNA profiling to reveal heterogeneity of EGFR-TKI resistance mechanisms in lung adenocarcinoma patients.",
        "_version_":1606189025312374784},
      {
        "Meeting_name":" The introduction of systematic genomic testing for patients with non-small cell lung cancer (NSCLC) at Dana-Farber Cancer Institute (DFCI).",
        "Background":"['Background', '  Systematic genomic testing to identify potential predictive biomarkers to select targeted therapy is emerging for NSCLC.  DFCI introduced systematic testing for mutations in BRAF, HER2, PIK3CA and EML4-ALK translocations in addition to routine characterization of EGFR and KRAS in July 2009 as part of a prospective study.  One and a half years have passed, thus we report our initial experience.  Methods', '  Providers consented patients with advanced non-squamous NSCLC.   Pathology specimens were dissected and analyzed by PCR-Sanger sequencing for mutations in selected exons of EGFR, KRAS, BRAF, PIK3CA and HER2.  ALK rearrangements were detected with fluorescence in-situ hybridization.  Results', '  Between 7/1/2009 and 4/12/2010, 226 consecutive patients were tested.  The median age was 62 years.  134 (59%) were female, 195 (86%) had adenocarcinoma, 174 (77%) were former/current smokers and 182 (81%) had stage IIIB/IV disease.  Five patients had two different specimens tested; three of these had repeat analyses due to test failure, one patient had two sites tested and another had two synchronous tumors tested.  Of the 231 specimens, 25 (11%) either failed analysis or were inconclusive.  The most frequent reason for inconclusive results was less than 50% tumor in the specimen (15/25).  Of the remaining 206 specimens (204 pts), all underwent mutation testing for BRAF, HER2 and PIK3CA; 197/204 for EGFR, 187/204 for KRAS and 116/204 for ALK rearrangements.  Mutations were identified in 110/204 (54%) patients (EGFR', ' 30; KRAS', ' 52; BRAF', ' 9; HER2', ' 9; ALK', ' 8; PIK3CA', ' 5) of whom three had concurrent mutations, all involving PIK3CA.  The median time to complete testing for this initial phase was 30 days. From 7/1/2009 to 6/15/2010, 31 of 61 (51%) patients with EGFR, HER2, BRAF or EML4-ALK alterations were treated with molecularly targeted therapy based on their genetic alteration.  Compared to 67% of patients with EGFR mutations, 9.6% patients with KRAS mutations received erlotinib.  Conclusions', '  Large scale testing for alterations in EGFR, KRAS, BRAF, PIK3CA, HER2 and EML4-ALK is feasible and has an impact on treatment at our center.  Updated results will be presented in June 2011.']",
        "Doc_id":"ASCO_80210-102",
        "Doc_title":" The introduction of systematic genomic testing for patients with non-small cell lung cancer (NSCLC) at Dana-Farber Cancer Institute (DFCI).",
        "_version_":1606189006254505984},
      {
        "Meeting_name":" In vivo and in vitro generation and characterisation of EGFR-TKI resistance in patient-derived xenograft (PDX) and cell line-derived xenograft (CDX) models of NSCLC with activating EGFR mutations",
        "Background":"['Background', ' Non-small cell lung cancer (NSCLC) patients that have activating mutations in the epidermal growth factor receptor (EGFR) gene are treated with EGFR tyrosine kinase inhibitors (TKIs) e.g. Erlotinib (Tarceva) and Gefitinib (Iressa). Most NSCLC patients with activating EGFR mutations will respond to EGFR-TKIs; however, in about 50% of these cases a secondary mutation in EGFR (T790M) subsequently occurs which results in resistance to treatment. Other mechanisms of clinical resistance can also occur such as amplification of c-MET kinase, Her-2 and EMT conversion; however, additional routes of resistance are poorly defined. Using a novel NSCLC patient-derived xenograft (PDX) model, driven by the L858R EGFR mutation, we set out to recapitulate the reported clinical routes of resistance to EGFR inhibitors and to evaluate if additional mechanism could also be identified.Methods', ' LU6422 is a Caucasian NSCLC adenocarcinoma PDX model with an activating EGFR mutation (L858R) which is maintained subcutaneously in vivo admixed with a human stromal cell component. HCC827 is NSCLC adenocarcinoma cell line with an activating EGFR mutation (exon 19 del E746-A750).Resistant models of LU6422 and HCC827 were generated in vivo and in vitro (respectively) through repeated dosing or exposure to EGFR-TKIs. Resistant tumour material was characterised for further mutations in the EGFR gene by direct sequencing and for c-MET, Axl and Her2 over-expression and genomic amplification by quantitative PCR. Combination efficacy treatment (in vitro and in vivo) was carried out to verify documented resistance mechanisms.Results', ' Nave LU6422 and HCC827 tissue exhibited exquisite sensitivity to EGFR-TKIs (100% reduction in pre-treatment tumour volume, p<0.0001). Following successive cycles of EGFR-TKI treatment several resistant subtypes were generated, cloned and characterized. Combination treatment of resistant HCC827 variants restored efficacy to nave treatment levels.Conclusions', ' EGFR-TKI resistant subtypes were generated in vivo and in vitro from a proprietary patient-derived xenograft model (LU6422) and the HCC827 cell line and were characterised for their resistance mechanisms.Pre-clinical modes of acquired resistance will be invaluable in assessing novel agents targeting the EGFR pathway and the development of new combination strategies which seek to prevent or overcome resistance to EGFR-TKIs.']",
        "Doc_id":"AACR_2014-4875",
        "Doc_title":" In vivo and in vitro generation and characterisation of EGFR-TKI resistance in patient-derived xenograft (PDX) and cell line-derived xenograft (CDX) models of NSCLC with activating EGFR mutations",
        "_version_":1606189006496727041},
      {
        "Meeting_name":" Detection of actionable genome alterations using hybrid capture based next generation sequencing technology",
        "Background":"['Background', ' Advances in the area of molecular cancer genomics has led to the identification of an increasing number of tumor-driven genetic alterations, with many being already candidates for tailor-made targeted therapies. NEO is a comprehensive molecular diagnostics platform capable of detecting genomic alterations including mutations, copy number alterations and translocations in both liquid biopsy (NEOliquid) and tumor tissue (NEOplus) samples to support cancer treatment decisions. Methods', ' We have developed a hybrid capture based next generation sequencing assay capable of detecting clinically relevant genomic alterations, such as point mutations, small insertions and deletions, gene fusions and copy number alterations. The NEOliquid assay is specifically designed for liquid biopsies and covers a panel of more than 30 genes. The NEOplus panel is specifically designed for FFPE tumor tissue covering more than 90 clinically relevant cancer genes. Results', ' Following signed patient consent, a series of lung cancer patient samples were examined using NEOliquid or NEOplus analysis. The spectrum of actionable genomic alterations that were detected, included oncogenic alterations (e.g. ARAF p.S214F, MET exon 14 skipping, BRAF p.N486_A489 deletion, microsatellite instability detection), resistance mutations (e.g. EGFR p.T790M), gene fusions (e.g. ALK-CARS, EML4-ALK, EGFR-KDD), and copy number alterations (e.g. ERBB2 amplifications) These cases are presented in their clinical context and treatment recommendations and outcome are discussed. Conclusions', ' Using the NEOplus and NEOliquid assays, we have identified a broad spectrum of therapeutically relevant genomic alterations with high sensitivity and specificity that resulted in concrete therapeutic recommendations. In comparison to standard diagnostics that require several methodologies for different types of genomic alterations, such as sequencing and FISH the NEO assays efficiently detect all relevant alterations in a single assay, thereby conserving both tissue and processing time.']",
        "Doc_id":"ASCO_168220-176",
        "Doc_title":" Detection of actionable genome alterations using hybrid capture based next generation sequencing technology",
        "_version_":1606188975757721600},
      {
        "Meeting_name":" Activation of HER Family signaling as a mechanism of acquired resistance to ALK Inhibitors in EML4-ALK-positive Non-Small Cell Lung Cancer.",
        "Background":"['Purpose', ' Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) such as crizotinib show marked efficacy in patients with non-small cell lung cancer positive for the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein. However, acquired resistance to these agents has already been described in treated patients, and the mechanisms of such resistance remain largely unknown.Experimental Design', ' We established lines of EML4-ALK-positive H3122 lung cancer cells that are resistant to the ALK inhibitor TAE684 (H3122/TR cells) and investigated their resistance mechanism with the use of immunoblot analysis, ELISA, reverse transcription and real-time PCR analysis, and an annexin V binding assay. We isolated EML4-ALK-positive lung cancer cells (K-3) from a patient who developed resistance to crizotinib and investigated their characteristic.Results', ' The expression of EML4-ALK was reduced at the transcriptional level, whereas phosphorylation of the epidermal growth factor receptor (EGFR), HER2, and HER3 was up-regulated, in H3122/TR cells compared with those in H3122 cells. This activation of HER family proteins was accompanied by increased secretion of EGF. Treatment with an EGFR-TKI induced apoptosis in H3122/TR cells, but not in H3122 cells. The TAE684-induced inhibition of extracellular signal-regulated kinase (ERK) and STAT3 phosphorylation observed in parental cells was prevented by exposure of these cells to exogenous EGF, resulting in a reduced sensitivity of cell growth to TAE684. K-3 cells also manifested HER family activation accompanied by increased EGF secretion.Conclusions', ' EGF-mediated activation of HER family signaling is associated with ALK-TKI resistance in lung cancer positive for EML4-ALK.']",
        "Doc_id":"AACR_2013-4446",
        "Doc_title":" Activation of HER Family signaling as a mechanism of acquired resistance to ALK Inhibitors in EML4-ALK-positive Non-Small Cell Lung Cancer.",
        "_version_":1606188981883502592},
      {
        "Meeting_name":" Cell-free DNA sequencing-guided therapy in a prospective clinical trial",
        "Background":"['Background', ' Analysis of cell-free circulating tumor DNA (ctDNA) by next-generation sequencing (NGS) is a promising method to identify druggable genomic alterations, especially when tumor specimen is inadequate for genomic sequencing or targeted sequencing. In our previous study, we have demonstrated an extremely high concordance rate between conventional sequencing and ctDNA sequencing. Based on this result, we designed a prospective trial to test the feasibility of the ctDNA genomics and to test the matched therapy rate in metastatic cancer patients focusing on lung cancer, gastric cancer and melanoma. Methods', ' The trial was a prospective, master protocol, trial with ctDNA genomic profiling and several matched trials were aligned to this protocol as independent trials. Guardant360 is the first comprehensive NGS-based liquid biopsy for cancer which is a 70-gene blood test interrogating all four major types of genomic alterations. Results', ' From Aug 2014 to Feb 2016, 210 metastatic cancer patients participated in the trial. Of 210 patients, 200 patients had analyzable ctDNA sequencing data (10 patients excluded due to follow-up loss, withdrawal of consent, etc). 73 patients were lung cancer patients, 78 patients were gastric cancer patients, 36 were melanoma patients and the remaining were rare cancer. The major alterations that were found in ctDNA were EGFR amplification, ERBB2 amplification, MET amplification, PIK3CA H1047R/E545K, TP 53 mutations, KRAS Q12, RET fusion, ALK fusion, EGFR mutation, and KIT mutation. Based on the ctDNA sequencing data, patients were directed to the matched therapy in the context of clinical trials or in clinical practice. The median turnaround time from blood draw to the sequencing report was 14 days. Conclusions', ' In conclusion, we have shown that the feasibility of ctDNA genomics was very high with extremely low failure rate and rapid turnaround time for sequencing report. The matched therapy rate based on ctDNA genomics will be available at the meeting for presentation. Clinical trial information', ' NCT02140463']",
        "Doc_id":"ASCO_169832-176",
        "Doc_title":" Cell-free DNA sequencing-guided therapy in a prospective clinical trial",
        "_version_":1606188991074271233},
      {
        "Meeting_name":" Secondary nonbreast malignancies (SNBM) after primary breast cancer (BC).",
        "Background":"['Background', '  BC survivors are at higher risk of developing SNBM due to treatment effects and shared behavioral and genetic factors. Associations between histologic subtypes of primary BC and secondary endometrial or ovarian cancer have been reported. Less is known about subtype-specific associations with other secondary solid tumors. We aimed to determine the prevalence of SNBM across US Oncology practices and what subtype-specific associations, if any, exist between primary BC and SNBM.   Methods', '  We conducted a retrospective database analysis identifying BC patients (pts) diagnosed between 01/2007 and 05/2013. SNBM were ascertained from codified fields in pts electronic records. Age at BC diagnosis, BC stage, estrogen receptor (ER), progesterone receptor (PR), HER2 status, BMI and smoking history were collected. Chi-square tests were used to compare categorical variables. Logistic regression was used to predict likelihood of secondary malignancies in separate multivariate models.  Results', '  105,795 pts with stage 0-IV BC were identified. 2,237 (2.1%) were diagnosed with  1 SNBM. Mean age at diagnosis and follow-up were 59.5 and 2.6 years respectively. Pts with SNBM were more likely to have', ' older age,  stage I, HER-2 negative disease, BMI 25 and past/current smoking history. SNBM were most commonly', ' Non-small cell lung cancer (NSCLC) (n=346), colorectal (CRC) (n=250), uterine (n=192), ovarian (n=130), thyroid (n=106) and kidney cancer (n=73). No associations were found between BC subtypes and ovarian, uterine, thyroid or NSCLC. Significant positive and negative associations between triple-negative breast cancer (TNBC) and secondary CRC and kidney cancer, respectively, were noted. In multivariate analysis, TNBC was predictive of secondary kidney cancer (OR 2.00, p=0.019). TNBC (OR 0.47, p=0.009), age 55 (OR 0.27, p<0.0001) and BMI 30 (OR 0.64 for BMI 25-30, p=0.019) were negative predictors of secondary CRC.  Conclusions', '  Our study is the first to report direct and inverse associations between primary TNBC and secondary kidney and CRC, respectively. The short follow-up precludes treatment-related effects. Results may potentially be attributed to genetic, environmental or lifestyle factors and warrant further research.']",
        "Doc_id":"ASCO_136942-151",
        "Doc_title":" Secondary nonbreast malignancies (SNBM) after primary breast cancer (BC).",
        "_version_":1606189024270090240},
      {
        "Meeting_name":" Detection of soluble protein biomarkers in NSCLC serum samples by meso scale discovery electrochemiluminescence platform",
        "Background":"['Identification of soluble biomarkers has become a critical non-invasive approach for disease diagnosis and monitoring in the treatment of solid tumors. Non-Small Cell Lung Cancer (NSCLC) is the most common form of lung cancer, accounting for approximately 85% of all lung cancers worldwide. The EGFR family of genes is known to be highly expressed in NSCLC tumors and play a critical role in the progression of the disease. Although patients initially respond well to EGFR TKI therapy, acquired resistance occurs through several mechanisms, including compensatory cMET pathway activation (Robinson et al. 2013). Previous reports have demonstrated that soluble forms of EGFR, Her2 and cMET are generated through either alternate splicing of mRNA or proteolytic cleavage of the full length receptors (Wilken et al. 2013). Serum concentrations of these receptors can be correlated with prognosis as well as treatment response (Gregorc, 2004, Kasahara, 2010 Heinmoller, 2003). Soluble receptor ligands, including Hepatocyte growth factor (HGF), have also been evaluated in NSCLC and a strong correlation has also been observed between the levels of serum HGF and disease outcome in patients treated with EGFR-TKIs (Kasahara et al. 2010).In this study, we evaluated concentrations of sEGFR, sMET, sHER2,, and HGF in NSCLC versus healthy normal serum samples via meso scale discovery (MSD) platform. Inventoried and custom MSD assays were optimized to measure these proteins in a training set consisting of 19 NSCLC and 16 normal healthy serum samples. Significantly lower concentrations of sEGFR and sHER2 were observed in the NSCLC serum samples compared to normal (p value = 0.0092 for both receptors), whereas, in contrast, the levels of HGF were significantly higher in the NSCLC patient samples (p value <0.0001). No significant difference in sMET concentration was observed between NSCLC and normal serum. Based on this data, it was determined that a ratio of protein concentration of each soluble receptor (EGFR, Her2 and cMET) to HGF yielded a greater differentiation between NSCLC and normal samples (p value <0.0001, = 0.0041,and 0.0327 respectively). Cut-off values to define NSCLC versus normal patients were established for each ratio and validated in a blinded independent cohort, consisting of 50 NSCLC and 12 healthy normal serum samples. PPV and NPV were then calculated to determine sensitivity and specificity for each protein ratio. Results from the validation study show an almost complete separation between healthy and NSCLC patient samples (p value <0.0001, AUC = 1)for all three ratios tested (sEGFR/HGF, sHER2/HGF and sMET/HGF), with a PPV = 100%, 98%, 100% and NPV = 100%, 100%, 85.7%, respectively. Overall, these findings indicate potential clinical applications for these protein pairs as non-invasive biomarkers of NSCLC diagnosis, prognosis and treatment monitoring to support emerging TKI therapies']",
        "Doc_id":"AACR_2016-5027",
        "Doc_title":" Detection of soluble protein biomarkers in NSCLC serum samples by meso scale discovery electrochemiluminescence platform",
        "_version_":1606188994218950657},
      {
        "Meeting_name":" Pilot trial of molecular profiling and targeted therapies in advanced thoracic malignancies",
        "Background":"['Background', '  For decades, clinical trial design strategies have relied upon the broad classification of tumors into tumor site and histopathology. Several lines of evidence have shown that a molecular approach to patient selection may be better in its capacity to improve patient outcomes. CUSTOM is an innovative clinical trial that allows for the parallel evaluation of multiple targeted therapies in molecularly selected patients with multiple cancer histological subtypes and the prospective evaluation of multiple molecular biomarkers.  Methods', '  All patients with advanced lung cancer and thymic malignancies and a good performance status are eligible independently of previous lines of treatment. The trial begins with tumor biopsy and molecular profiling using a multi-platform approach to identify oncogenic alterations in more than 34 genes for treatment allocation (12 genes) and exploratory purposes. Depending upon the specific biomarker identified, patients are then triaged into 5 experimental arms. Erlotinib for sensitizing EGFR mutations; AZD6244 for KRAS, NRAS, HRAS and BRAF mutations; MK2206 for PIK3CA, AKT and PTEN mutations and PIK3CA amplification; Lapatinib for ERBB2 mutations or amplification; Sunitnib for KIT mutations and PDGFRA mutations and amplification. Patients not eligible for the experimental treatment arms are enrolled into a standard treatment arm. Upon disease progression patients are eligible for repeat biopsy and molecular profiling in order to identify molecular changes and mechanisms of resistance. All patients are followed until death. The primary endpoint is response rate and secondary endpoints include progression-free survival, duration of response and overall survival. With three disease types and five experimental drugs, there are 15 possible treatment arms which will be under active consideration. For each of these, the study will be conducted as an optimal two-stage phase II trial in order to rule out an unacceptably low 10% clinical response rate in favor of a modestly high response rate of 40%.  As of January 11, 2012, two hundred and sixteen patients have been enrolled.']",
        "Doc_id":"ASCO_91531-114",
        "Doc_title":" Pilot trial of molecular profiling and targeted therapies in advanced thoracic malignancies",
        "_version_":1606189031101562880},
      {
        "Meeting_name":" MEKK1 regulates DMP1 transcriptional activity via phosphorylation and predicts breast cancer patient outcome",
        "Background":"['Breast cancer remains a significant public health issue in the industrialized countries. Physicians depend on surgery, cytotoxic adjuvant chemotherapy, or radiation for treatment of breast cancer patients. Few novel therapies are approved for clinical use. Although existing therapies are effective in controling the disease in many patients, the cytotoxic side-effects make them limited. This is especially the case in the patients with early stage breast cancer whose prognosis with surgery alone is good and avoiding adjuvant chemotherapy would spare them toxic side effects. On the other hand, significant fraction of patients relapses and develops metastasis. Therefore, it is critical to identify markers for better breast cancer patient stratification based on their prognosis that would guide physicians in selection and aggressiveness of therapies. Recently, we linked transcription factor DMP1 (cyclin D binding protein 1, Dmtf1) as a critical tumor suppressor that blocks proliferative signals from ErbB2 and oncogenic Ras by activating p14Arf-p53 pathway. hDMP1 is hemizygously deleted in 50% of human breast tumors that retain wild-type ARF and p53. In this study we identified an upstream kinase, MEKK1, which cooperates with Dmp1 to activate Arf transcription. In constitutively active form (C-terminal kinase domain or CA-MEKK1), MEKK1 increased transcriptional activity of Dmp1 via direct phosphorylation, while the full length (regulatory and kinase domain) form behaved as a feedback inhibitor by increasing Dmp1 ubiquitination. Phosphorylation sites on DMP1 that increase its transcriptional activity were mapped to the C-terminal transactivation domain. Expression of CA-MEKK1 in breast cancer cell lines activated endogenous Arf-p53 pathway. hMEKK1 is located on human 5q11 chromosome, a locus frequently deleted in breast and lung cancer. Since MEKK1 appeared to be an activator of p53 tumor suppressor pathway, we wondered if MEKK1 is involved in human cancer. Using DNA from breast cancer patient tumors and matched normal tissue, we analyzed hMEKK1 gene deletion using specific loss of heterozygosity (LOH) primers. MEKK1 was found hemizygously deleted in 20% of patients. Immunohistochemistry confirmed reduction of MEKK1 protein intensity to LOH(+) compared to LOH (-) patients. In the independent cohort of breast cancer patients, we show that low MEKK1 mRNA expression is associated with adverse outcome. Here we show that constitutively active MEKK1 is a novel activator of Dmp1-Arf-p53 pathway via Dmp1 phosphorylation. The MEKK1 gene was frequently deleted in breast tumor tissue and its expression was correlated with disease outcome. Overall, MEKK1 is a potential prognostic/predictive indicator for breast cancer and could be used by physicians to better stratify patients.']",
        "Doc_id":"AACR_2012-4158",
        "Doc_title":" MEKK1 regulates DMP1 transcriptional activity via phosphorylation and predicts breast cancer patient outcome",
        "_version_":1606189013247459328},
      {
        "Meeting_name":" An unbiased survey of cancer-related rearrangements in 5,917 solid tumors identifies therapeutically actionable fusions across multiple disease subtypes",
        "Background":"[\"The growing trend to make cancer treatment more precise depends on the accurate identification of clinically actionable genomic alterations within a patient's tumor. Fusion proteins that result from genomic rearrangements are attractive therapeutic targets because they are tumor-specific and cancer cells depend on their expression for survival. The goal of this study was to investigate the breadth of genomic rearrangements in 19 genes shown to be fused in at least one solid cancer across a collection of 5,917 tumors from a diverse variety of subtypes. All tumor samples were submitted to a CLIA-certified CAP-accredited laboratory (Foundation Medicine, Cambridge MA) for next-generation sequencing-based genomic profiling of 3,769 exons from 236 cancer related genes and 47 introns of 19 genes frequently rearranged in cancer. We observed 350 genomic rearrangements in 338 samples from 82 different solid tumor pathologies. Rearrangements involving kinases were observed in 176 samples (3% of total samples). We identified potentially druggable rearrangements of BRAF (n=13 unique partners; 9 pathologies), ALK (n=11 unique partners; 11 pathologies), FGFR2 (n=9 unique partners; 6 pathologies), ROS1 (n=7 unique partners ; 3 pathologies), RET (n=7 unique partners; 5 pathologies), FGFR3 (n=5 unique partners; 6 pathologies), NTRK1 (n=3 unique partners; 3 pathologies), ERBB2 (n=2 unique partners; 2 pathologies), and ERBB3 (n=2 unique partners; 2 pathologies). ALK, ROS1, RET, and NTRK1 fusions in lung cancer have all shown sensitivity to targeted agents in patients. The largest number of genomic rearrangements (n=87) was found in lung adenocarcinoma (12% of cases). Interestingly, we identified a KIAA1549-BRAF fusion in a triple negative breast cancer sample, a FIP1L1-PDGFRA fusion in glioblastoma, a KIF5B-RET fusion in ovarian cancer, and an NCOA4-RET fusion in colon adenocarcinoma. These fusions have been identified previously in pilocytic astrocytoma, myeloid malignancies, lung cancer and thyroid cancer, respectively, but have rarely been reported outside of these diseases; importantly, hypereosinophilic syndromes harboring FIP1L1-PDGFRA are sensitive to imatinib, and lung cancers with KIF5B-RET are sensitive to cabozantinib. Collectively, these data demonstrate that gene fusions exist across a multitude of tumor types and that known fusions are not always confined to the disease in which they appear most often. These rearrangements include clinically actionable fusions which may identify tumors that are sensitive to selective FDA-approved targeted agents.\"]",
        "Doc_id":"AACR_2014-4268",
        "Doc_title":" An unbiased survey of cancer-related rearrangements in 5,917 solid tumors identifies therapeutically actionable fusions across multiple disease subtypes",
        "_version_":1606188991790448640},
      {
        "Meeting_name":" Concurrent driver mutations in non-small cell lung cancer (NSCLC) patients (p) on targeted therapy uncovered by comprehensive molecular profiling.",
        "Background":"['Background', '  NSCLC p with EGFR mutations respond initially to EGFR tyrosine kinase inhibitors (TKIs) but invariably develop acquired EGFR TKI resistance.  Prior studies identified the EGFR T790M mutation and activation of MET, PI3K, AXL, HER2 and the MAPK pathway as drivers of acquired EGFR TKI resistance. To date, comprehensive molecular profiling to identify actionable modifiers of EGFR TKI response has not been conducted in NSCLC p on therapy.    Methods', '  We performed next generation sequencing (NGS) using a 263-gene Nimblegen custom cancer panel on DNA isolated from primary patient lung adenocarcinoma FFPE specimens prior to initiating standard erlotinib treatment and upon the development of acquired erlotinib resistance after only 3 months of therapy.   Results', '  In the pretreatment sample, we confirmed the presence of the EGFRL858R mutation in 95% of the sequencing reads and discovered a concurrent BRAF V600E mutation with a frequency of ~ 6%. NGS performed on the acquired erlotinib resistance sample revealed acquisition of the EGFR T790M mutation with a frequency of ~ 14%. Notably, the frequency of the BRAF V600E mutation increased 10-fold upon acquired erlotinib resistance from ~ 6% in the pretreatment tumor to ~ 60% in the recurrent tumor.  We found that overexpression of BRAF V600E in H3255 human NSCLC, which harbor EGFR L858R (but not BRAF V600E) and are erlotinib sensitive, caused resistance to erlotinib treatment (10-fold increase in erlotinib IC50).  BRAF V600E-mediated erlotinib resistance was reversed by treatment with the BRAF inhibitor vemurafenib. Additional functional studies are ongoing and the complete dataset will be presented.  Conclusions', '  These results indicate that EGFR-mutant NSCLC can harbor additional oncogenic driver mutations in BRAF at low frequencies prior to therapy.  EGFR TKI treatment can lead to expansion of BRAF V600E expressing tumor cells, resulting in acquired EGFR TKI resistance that can be reversed by BRAF inhibitor treatment. The data demonstrate the utility of routine molecular profiling of NSCLC p on targeted therapy and offer unprecedented insight into the genetic basis of therapeutic resistance.']",
        "Doc_id":"ASCO_118069-132",
        "Doc_title":" Concurrent driver mutations in non-small cell lung cancer (NSCLC) patients (p) on targeted therapy uncovered by comprehensive molecular profiling.",
        "_version_":1606189024149504000},
      {
        "Meeting_name":" Variations in inpatient stays for non-metastatic HER2- breast cancer (BC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC) in a real world setting.",
        "Background":"['Background', ' We aim to compareprevalence and duration of inpatient stays during the most commonly used chemotherapy regimens for BC, NSCLC, and CRC in a commercially insured population. Methods', ' This analysis used clinical data obtained from a prior authorization program for chemotherapy linked with administrative claims data from 6/1/2015 to 5/31/2016. Clinical data included cancer type, stage at diagnosis, relevant biomarkers, and evidence of progression/relapse. Eligible patients included commercially insured members with a prior authorization request for one of the most commonly used NCCN recommended regimens for BC, NSCLC and CRC. Outcomes, including percent of patients experiencing an inpatient stay and number of inpatient days were tracked from the first claim for chemotherapy until end of treatment due to discontinuation, death or change in treatment, with remaining patients censored at 5/31/2016 or end of enrollment. Results', ' There were 1612 HER2- BC, 237 NSCLC, and 386 CRC patients who completed therapy during the study period. Incidence and inpatient stay days per 100 patient months for the most common regimens for each cancer are summarized in the table. Conclusions', ' The rates and duration of inpatient stays varied substantially across the most commonly used therapies for BC, NSCLC and CRC. These data show the importance of systematically incorporating the impact of hospitalizations alongside other clinical outcomes in treatment choice in routine clinical practice. As the database grows over time, these data will help clinicians and patients better evaluate regimen choices for various cancers. Inpatient stayN (%)Inpatient stay days per 100 patient monthsMean (SD)HER2- BCDocetaxel/Cyclophosphamide (N=462)51 (11)88 (813)Doxorubicin/CyclophosphamidePaclitaxel (N=423)38 (9)11 (47)Doxorubicin/Cyclophosphamide (N=241)17 (7)23 (134)NSCLCPaclitaxel/C (N=96)18 (19)202 (745)Pemetrexed/C (N=59)9 (15)49 (173)Etoposide/C (N=32)8 (25)119 (307)CRCFOLFOX* (N=224)23 (10)28 (177)CapOx (N=31)2 (6)8 (37)*with either leucovorin or levoleucovorin C=carboplatin or cisplatin']",
        "Doc_id":"ASCO_194519-199",
        "Doc_title":" Variations in inpatient stays for non-metastatic HER2- breast cancer (BC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC) in a real world setting.",
        "_version_":1606189021414817792},
      {
        "Meeting_name":" Two-dimensional phase I study of neratinib (NER) combined with temsirolimus (TEM) in patients (Pts) with solid tumors.",
        "Background":"['Background', ' NER (HKI-272) is an irreversible pan-ErbB tyrosine kinase inhibitor with antitumor activity in pts with HER2-amplified tumors.  TEM inhibits mTOR (TORC1).  Hyperactivation of the PI3K-Akt-mTOR axis mediates resistance to anti-HER2 therapies. Preclinical data in mouse models of HER2-driven cancers suggest that the combination of both mTOR and HER2 inhibitors improves anti-tumor efficacy compared with HER2 inhibition alone. Methods', ' This open-label trial evaluated the safety, pharmacokinetics (PK), and preliminary efficacy of NER plus TEM in pts with advanced solid tumors.  A novel bi-directional ascending/descending trial design involved 4 dose levels of each drug (NER', ' 120, 160, 200 and 240 mg/d orally; TEM', ' 15, 25, 50 and 75 mg/wk iv) to determine the maximum tolerated dose (MTD) contour.  Initial cohorts of 2 pts were enrolled to each tested dose level and observed for 28 days; the MTD(s) identified will enroll 6 pts for confirmation.  For determination of NER and TEM plasma concentrations, blood samples were collected at pre-dose and at selected time points following treatments on Week 4. Results', ' 53 pts have been treated, including 10 with non-small cell lung cancer (NSCLC), 14 with breast cancer (BC) and 29 with other tumors.  The most common dose-limiting toxicities were grade 3 mucositis, grade 3 diarrhea and grade 3 neutropenia.  12 of 16 possible dose combinations have been explored; MTDs to be confirmed are (NER/TEM) 200/25 and 160/50.  PK of NER and TEM are evaluated.  Of 6 pts with NSCLC HER2 exon 20 insertion mutation', ' 2 PR (17, 8 wks) and 2 SD (24, 13 wks).  Among 9 HER2+ BC', ' 1 CR (32 wks), 1 PR (49 wks) and 3 SD (43, 23 and 16).  Additional efficacy seen in pts with thymoma (CR), endometrial (PR) and urothelial (PR) cancers, and SD 24 wks in 1 pt each with NSCLC (genotype unk) and vulvar cancer. Conclusions', ' The combination of NER and TEM has demonstrated preliminary antitumor activity in pts with HER2-dependent NSCLC and BC, as well as other solid tumors, with an expected and manageable AE profile.  HER2-mutant NSCLC, like other molecular subgroups, may be uniquely sensitive to the appropriate targeted therapy.  An expansion cohort of 12 pts with NSCLC harboring HER2 mutation is planned at the 200/25 dose.']",
        "Doc_id":"ASCO_84228-102",
        "Doc_title":" Two-dimensional phase I study of neratinib (NER) combined with temsirolimus (TEM) in patients (Pts) with solid tumors.",
        "_version_":1606189037433913345},
      {
        "Meeting_name":" Discovery of recurrent KIF5B-RET fusions and other targetable alterations from clinical NSCLC specimens.",
        "Background":"['Background', '  Many NSCLCs have driving oncogenic alterations including in EGFR, KRAS, ERBB2, BRAF, ALK and ROS1. Clinically effective drugs are approved for EGFR and ALK and clinical trials are underway for other genomic targets. Thus having a means of identifying genomic alterations in routine formalin fixed paraffin embedded (FFPE) clinical specimens is critical.  Methods', '  We sequenced 24 FFPE NSCLC specimens with a next generation sequencing (NGS) assay that captures and sequences 2574 coding exons of 145 cancer relevant genes plus 37 introns from 14 genes often rearranged in cancer. Tumors from 643 additional patients were genotyped for KIF5B-RET.  Results', '  We identified 50 alterations in 21 genes with at least one in 83% (20/24) of tumors (range 1-7). In 72% (36/50) of NSCLCs, at least one alteration was associated with a current clinical treatment or targeted therapy trial, including mutations in KRAS, BRAF, EGFR, MDM2, CDKN2A, CCNE1, CDK4, NF1 and PIK3CA. We also found an 11,294,741 bp pericentric inversion on chromosome 10 generating a novel gene fusion joining exons 1-15 of KIF5B to exons 12-20 of RET (K15', 'R12) in a Caucasian never smoker. This fusion gene contains the kinesin motor and coiled-coil domains of KIF5B and the entire RET tyrosine kinase domain. In 643 additional tumors we identified 11 fusion positive patients who were all wild type for known oncogenes (frequency of 6.3% (10/159)). Four unique KIF5B-RET variants were found', ' 8 K15', 'R12, 3 K16', 'R12, 1 K22', 'R12 and 1 K15', 'R11. We introduced K15', 'R12 into Ba/F3 cells and observed IL-3 independent growth consistent with oncogenic transformation. KIF5B-RET Ba/F3 cells were sensitive to sunitinib, sorafenib and vandetinib, multi-targeted kinase inhibitors that inhibit RET, but not gefitinib, an EGFR kinase inhibitor. Sunitinib, but not gefitinib, inhibited RET phosphorylation in these cells.  Conclusions', '  We identified both known and novel genomic alterations from NSCLC FFPE specimens using a single test. Our findings suggest that RET inhibitors should be tested in prospective clinical trials in NSCLC patients bearing KIF5B-RET rearrangements and that NGS is a feasible approach to stratifying patients for treatment based on their genomic profiles.']",
        "Doc_id":"ASCO_96931-114",
        "Doc_title":" Discovery of recurrent KIF5B-RET fusions and other targetable alterations from clinical NSCLC specimens.",
        "_version_":1606189014782574592},
      {
        "Meeting_name":" Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS).",
        "Background":"['Background', '  IMPACT is an institution-wide screening program to identify patients (pts) treated at PMCC with somatic alterations that can be matched to targeted therapies.  Methods', '  Pts with advanced breast, colorectal (CRC), non-small cell lung (NSCLC), ovarian cancers and selected other solid tumors treated at PMCC were eligible. Tumor DNA was isolated from a FFPE archived sample and genotyped using a customized Sequenom panel (23 genes, 280 mutations) in a CLIA-certified laboratory. Verified mutations were reported in pts electronic health records. Selected FFPE samples were further characterized by NGS with the Illumina MiSeq TruSeq Amplicon Cancer Panel (48 genes, 212 amplicons, 500x coverage) for platform validation.  Results', '  From Mar 1/12-Jan 10/13, 485 pts were enrolled with median 1 prior treatment for advanced disease (range 0-6). Of 33 (7%) screen failures, 5% were for insufficient tissue and 2% for clinical deterioration. Median DNA quantity from FFPE = 4250ng (range 15-32550ng). The median time from tissue receipt to reporting was 5 weeks (range 1-23).  Mutations were identified by Sequenom in 137/349 (39%) pts, including 24/79 (30%) breast, 40/80 (50%) CRC, 54/88 (61%) NSCLC, 17/78 (22%) ovarian, and 2/24 (8%) other cancers. Mutations detected were', ' 76 KRAS, 35 PIK3CA, 22 EGFR, 5 NRAS, 5 ERBB2, 5 CTNNB1, 4 BRAF, and 1 AKT1. MiSeq was concordant with Sequenom in 112/113 (99%) pts, with mutations identified in 94/114 (82%). The average number of mutations detected by MiSeq was 1.72/pt (range 0-7) compared with 0.49/pt by Sequenom (range 0-2). After a median follow up of 5.0 months, 31/137 (23%) pts with mutations have been matched to targeted therapies, including 14 pts enrolled in clinical trials (15 trials) matched to their genotype. Of the 10 trial pts with at least one response assessment, 3 PR (1 confirmed) and 2 SD  24 weeks have been observed.  Conclusions', '  Molecular profiling can be integrated into the routine care of advanced cancer pts. Genotyping and targeted NGS are feasible in a clinical laboratory using stored archival FFPE tumor samples. NGS identifies additional actionable mutations to inform clinical-decision making. Clinical trial information', ' NCT01505400.']",
        "Doc_id":"ASCO_110989-132",
        "Doc_title":" Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS).",
        "_version_":1606189004227608576},
      {
        "Meeting_name":" Intratumoral heterogeneity of cancer driver genomic alterations across several tumor types.",
        "Background":"['Background', '    Intratumoral heterogeneity (ITH) or variations in genomic alterations (GA) between different areas of primary tumors or in their metastases has been an area of intense investigation and is often cited as a reason for failure of targeted therapies. We used an NGS-based comprehensive genomic profiling assay (CGP) to examine 5 tumor types across 10 tissue sections in 5 patients each to determine the impact of ITH on GA relevant to cancer biology (cancer drivers).  Methods', '    250 FFPE 40u sections from 25 patients were obtained from 2 separate non-adjacent blocks at levels throughout the entire block thickness. CGP was performed at Foundation Medicine, as previously described (PMID', ' 24142049). 245/250 sections were processed successfully, obtaining coverage depth > 700x, with all classes of GA (substitutions, indels, copy number alterations - CNA) assessed. Heterogeneity in cancer driver GA was evaluated including raw data review, and associated with clonal architecture.  Results', '    837 total substitutions or indels (short variants  SV) were observed in 245 sections, with 217 assessed to be subclonal based on mutant frequency (MAF) and tumor content. Only 20 SV were not detected in paired sections from same PT, for a discordance rate of 2.3% (20/857). All discordances were in subclonal variants, with avg MAF < 6%.  CNA concordance was 90.2%, with half of discordances associated with low tumor purity or coverage bias. Findings were similar across tumor types (Table), with key targetable GA including EGFR mutation in lung cancer and ERBB2 amplification in breast cancer concordant across all sections.  Conclusions', '    Our analysis reveals that intratumoral heterogeneity of cancer driver GA is limited. The data supports CGP of a single biopsy section as appropriate in most patients with advanced solid tumors, provided sufficient sensitivity is attained for sub-clonal events in impure clinical tissue. ConcordanceBreast Invasive Duct CarcinomasColorectalAdenocarcinomasHead and NeckSquamous Cell CarcinomasRenal(1 oncocytoma + 1 chromophobe, 1 urothelial and 2 unclassified carcinomasLung(3 adenocarcinomas + 2 squamous cell carcinomas)Short Variant GA95.0%98.5%99.4%96.0%98.1%CNA96.3%86.4%88.2%80.0%90.0%']",
        "Doc_id":"ASCO_149174-156",
        "Doc_title":" Intratumoral heterogeneity of cancer driver genomic alterations across several tumor types.",
        "_version_":1606188992033718272},
      {
        "Meeting_name":" Genetic variability and clinical presentation of patients with non-small cell lung cancer (NSCLC) harboring MET-amplifications.",
        "Background":"['Background', '    Amplification of cMET has been described as mechanism underlying resistance to EGFR-targeted therapy in EGFR-mutated NSCLC. Nevertheless, few is known about cMET amplification beside the EGFR-resistance setting. This study was performed in order to characterize patients with low-level, intermediate-level and high-level cMET amplification focusing on frequency, co-occuring driver mutations and clinical outcome.  Methods', '    Within a regional molecular screening network cMET amplification status was analyzed by fluorescence in-situ hybridization (FISH) in 588 patients with NSCLC regardless of histology. Next-generation parallel sequencing (NGS) using 102 amplicons and 14 genes was performed in all analyzed samples. Clinical parameters (age, sex, UICC tumor stage, smoking status and medical and therapeutical history) of all patients were assessed.  Results', '    171 patients (29.1%) with cMET amplification were identified, whereof 17 (9.9%) had high-level amplification. cMET amplifications co-occured in 98 patients (57.3%) with a large spectrum of other driver mutations (EGFR, KRAS, HER2, STK11, NRAS, BRAF) or amplifications (FGFR1) in both adenocarcinoma (60.2%) and squamous cell carcinoma (21.1%). 9 patients of the high-level-amplified patients did not have an additional driver mutation, while the remaining 8 patients had mutations within EGFR, KRAS, PIK3CA, BRAF and STK11. cMET amplification was associated with a history of smoking and detected in all UICC tumor stages.  Conclusions', '    Our data suggest a high prevalence of cMET amplification in NSCLC patients with many oncogenic driver mutations. Most patients with an additional mutations had KRAS mutations. These data show that screening for MET-amplified patients in order to identify patients for  MET-targeted treatment should not be performed on the basis of sequencing results.']",
        "Doc_id":"ASCO_149488-156",
        "Doc_title":" Genetic variability and clinical presentation of patients with non-small cell lung cancer (NSCLC) harboring MET-amplifications.",
        "_version_":1606189021305765889},
      {
        "Meeting_name":" Radiogenomics in 332 metastatic non-small cell lung cancer (NSCLC) patients.",
        "Background":"['Background', ' Radiogenomics is focused on defining the relationship between image and molecular phenotypes. Therefore, we assess the association between metastatic sites at baseline CT and molecular abnormalities (MA) in NSCLC patients (pts). Methods', ' One senior radiologist reviewed retrospective basal CT scans of metastatic NSCLC pts from Gustave Roussy included in the MSN cohort. Tissue biopsy samples of these pts were collected for detecting the molecular profile by NGS platform (Ion-torrent) and/or Sanger sequencing molecular test as daily clinical practice. Radiological characteristics regarding metastatic sites were correlated with the molecular profile. Results', ' From 06/2009 to 06/2015, 332 metastatic NSCLC pts treated with first-line platinum-based chemotherapy were included (median age 59 years, 63% males, 14% never smokers, 76% adenocarcinoma, 11% with squamous cell carcinoma). Number of metastatic sites by patient was', ' one for 49%, 2 for 28%, 3 for 14%, > 4 for 9%. After 32.4 months of median follow-up, the median overall survival was of 15.3 months (95%CI', ' 12.9-17.8). Overall, 60% of NSCLC pts had a MA', ' 28% KRAS mutation, 14% EGFR mutation, 6% ALK rearrangement, 5% MET amplification or mutation, and 7% other mutations (BRAF and PI3K mutation, and HER2 mutation or amplification). Among pts with KRAS (n = 93), EGFR (n = 47), ALK (n = 21) and MET(n = 16) abnormalities, the respective percentages of brain, adrenal, metastatic pleural effusion, bone and lung metastases were', ' 39%/28%/18%/40%/33%; 45%/6%/36%/47%/49%; 52%14%/19%/43%/48%; and 44%/25%/0%/44%/25%. Among the 12 pts with peritoneal carcinomatosis, 5 had a mutation (3 with KRAS, 1 NRAS and 1 BRAF). Conclusions', ' Bone is the most common site of metastases in NSCLC pts. Baseline metastatic sites in molecular selected NSCLC pts are different according to the molecular abnormality. Among KRAS mutant tumours there are a higher percentage of adrenal metastases and a trend toward association with peritoneal carcinomatosis, whereas among ALK tumors exists higher percentage of brain metastases than pleural effusion. MET tumors have a tropism for the brain similar to the other molecular abnormalities, whereas lung metastases are especially frequent in EGFR and ALK tumours.']",
        "Doc_id":"ASCO_169610-176",
        "Doc_title":" Radiogenomics in 332 metastatic non-small cell lung cancer (NSCLC) patients.",
        "_version_":1606189022723440640},
      {
        "Meeting_name":" High-throughput parallel amplicon sequencing of common driver mutations from FFPE lung cancer samples in molecular pathologic routine diagnostics for a regional health care provider network.",
        "Background":"['Background', '  Treatment paradigms for nonsmall-cell lung cancer have shifted from histology based towards incorporation of molecular subtypes involving particular genetic alterations such as mutations in EGFR or translocations of ALK. The list of  targetable lesions is rapidly increasing including mutations in genes such as EGFR, HER2, KRAS, ALK, BRAF, PIK3CA, AKT1, ROS1, NRAS, FGFR1 and MAP2K1. Analysis of these potential targets is becoming a challenge in terms of work load, tissue availability as well as cost.  Within the Network Genomic Medicine Lung Cancer (NGM), a regional molecular screening network of the Center for Integrated Oncology Kln Bonn, we aimed to improve the sequential analysis of a set of 9 target amplicons by Sanger sequencing using bench top ultra-deep parallel sequencing platforms. We aimed to reduce 1) the time requirement for comprehensive molecular diagnostics, 2) the minimal amount of formalin fixed paraffin embedded (FFPE) derived input DNA, 3) while at the same time increasing the number of target regions analysed.  Methods', '   We established a multiplex PCR to amplify up to 640 lung cancer relevant target regions from at least 20ng of FFPE derived tumor DNA. The amplicon libraries were ligated to adapters encompassing medical identifier sequences that allowed multiplexing of up to 48 patients. The resulting libraries were sequenced on a benchtop Illumina platform (MiSeq). Mutations identified by parallel sequencing were confirmed by Sanger sequencing.  Results', '  330 patients were analyzed by traditional Sanger sequencing of 9 amplicons and the newly established parallel sequencing protocol. The time needed to complete the mutation screening was significantly reduced to 7 working days from previously 21 days. A total of at least 300ng of DNA was needed to complete the analysis of 9 amplicons by Sanger sequencing compared to 20 to 100ng of DNA needed for up to 640 amplicons analyzed by parallel sequencing.  Conclusions', '  Newly multiplex PCR based parallel sequencing allows rapid comprehensive mutation testing in routine molecular pathological diagnostics even on small transbronchial biopsies.']",
        "Doc_id":"ASCO_115519-132",
        "Doc_title":" High-throughput parallel amplicon sequencing of common driver mutations from FFPE lung cancer samples in molecular pathologic routine diagnostics for a regional health care provider network.",
        "_version_":1606189023664013312},
      {
        "Meeting_name":" TRY",
        "Background":"['Background', '  HER2 amplifications and/or mutations are rare genetic alterations in NSCLC accounting for approximately 4%. Preliminary clinical data suggested efficacy of trastuzumab (Herceptin) in patients with HER2 immunochemistry 3+ (IHC3+) status or positive fluorescence in situ hybridization (FISH). The heat shock protein HSP90 is a molecular chaperone modulating stability and/or transport of intracellular client proteins including HER2. In breast cancer HSP90 inhibition showed anticancer activity in HER2-positive patients after trastuzumab failure. Here we are investigating the efficacy of the combination of trastuzumab and the HSP90 inhibitor AUY922 in lung cancer patients with aberrant HER2.  Methods', '  This phase II study recruits metastatic NSCLC patients with HER2 overexpression (IHC DAKO-score 3+) or amplification (FISH positive) or activating mutation after failure of at least one previous standard treatment. In the first part of the study, patients are treated with trastuzumab only (initially 4mg/kg, followed by 2 mg/kg weekly). CT scan is scheduled every 6 weeks during treatment. In case of disease progression, AUY922 (70 mg/m2) is given additionally. Patients are recruited in two German centers', ' in Cologne and Essen.  Results', '  Within the Network of Genomic Medicine in Cologne, 3,863 NSCLC patients of all stages were screened. Patients with overexpression were tested for amplification and mutation. HER2 amplification was seen in 4% and HER2 mutations in 1.6% of all adenocarcinomas. Patients in Essen are screened separately. The study is ongoing. Five patients with HER2 amplifications were treated in the study. Two patients progressed after 6 and 12 weeks on the combination. One patient showed clinical progression within first 6 weeks on trastuzumab. Two patients are still ongoing on trastuzumab monotherapy. The best CT response was -29.3% in patient on trastuzumab and AUY922 at week 6.   Conclusions', '  HER2 overexpression, amplification or mutation is a rare genetic alteration in NSCLC patients. Data on treatment with HER2 antibody trastuzumab and HSP90 inhibitor AUY922 will be presented Clinical trial information', ' DRKS00003301.']",
        "Doc_id":"ASCO_134046-144",
        "Doc_title":" TRY",
        "_version_":1606189026142846976},
      {
        "Meeting_name":" NT113, a potent and selective pan-ErbB inhibitor, is efficacious in vivo and has high brain penetrance.",
        "Background":"['Background', ' The ErbB family of receptor tyrosine kinases EGFR (ErbB1), Her2 (ErbB2) and ErbB4 (Her4) function to transduce signals across the cell membrane in a wide variety of epithelial cells. ErbB dimerization results in the phosphorylation of intracellular tyrosine residues, activating diverse signaling pathways. These downstream pathways culminate in a variety of cellular responses, including cell growth, proliferation, differentiation and migration. In addition, interactions between ErbB receptors provide a mechanism for signal differentiation and amplification. Dysregulation of ErbB mediated signaling confers a growth advantage, and can result in cellular transformation and/or increased tumor metastatic potential. ErbB family members have been well validated cancer targets. Both antibodies and small molecule kinase inhibitors targeting individual ErbB receptors or both ErbB1/ErbB2 together have been approved for the treatment of human cancers. In addition, some ErbB targeting agents are in late stages of clinical testing.A large fraction of glioblastoma multiforme (GBM, the most common and malignant primary brain tumor) harbors EGFRvIII activating mutation, and may represent an especially appropriate subgroup of this cancer for treatment with ErbB inhibitors.Results', ' NT113 is a potent and selective pan-ErbB family kinase inhibitor. It also inhibits known mutant EGFRs resistant to first generation EGFR inhibitors, including the T790M gate keeper mutant. NT113 inhibited proliferation of ErbB kinase driven cell lines, and GBM cell lines harboring EGFRvIII mutations.NT113 showed excellent oral PK in mouse and rat. rat, iv CL = 6.3 L/h/Kg, oral t1/2 = 15 h, F = 70%; mouse iv CL = 1.4 L/h/Kg, oral t1/2 = 16h, F = 100%. Importantly, NT113 showed significant brain exposure in rat oral PK studies, with brain/plasma ratio > 4 at 2, 4 and 24 hr time points, while afatinib brain level was not detectable at all 3 time points. If these PK results are maintained in human patients, it may lead to significant clinical activity. Longer half life would allow the drug to better permeate into tumor, while the brain penetrance is favorable for insuring the clinical activity of NT113 for CNS cancer, as well as for brain metastasis of NSCLC and breast cancers.In vivo, NT113 displayed excellent activities in NT87 gastric cancer xenograft models, and in NCI-H1975 (T790M gate keeper mutation) NSCLC xenograft models. In an intracrania GBM xenograft model with EGFRvIII mutation, NT113 completely suppressed the growth of tumor, and significantly prolonged the life span of the mice after two weeks of oral dosing.Conclusion', ' NT113 appears to be a promising best-in-class agent for treating cancers whose growth is driven by both wild type and mutant ErbB. It is currently undergoing IND enabling studies.']",
        "Doc_id":"AACR_2013-2089",
        "Doc_title":" NT113, a potent and selective pan-ErbB inhibitor, is efficacious in vivo and has high brain penetrance.",
        "_version_":1606189009323687937},
      {
        "Meeting_name":" Efficacy of EGFR/HER2 duel-kinase inhibitors in PDX models harboring known and novel HER2-mutations",
        "Background":"['Background', ' Neratinib and afatinib are small molecule therapies that irreversibly bind to the kinase domain of the epidermal growth factor receptors 1 (HER1/EGFR) and 2 (HER2/ERBB2). Afatinib is currently approved for non-small-cell lung cancers harboring acquired EGFR mutations; however both agents have recently reported clinical activity in HER2-mutated breast cancer. HER2 mutations have also been reported in melanoma and colorectal cancer and at least two mutations (S310F/V777L) have been shown to affect EGFR/HER2 signaling. Whether other reported or novel mutations are important in EGFR/HER2 signaling in colorectal and other cancer types is unclear. To better understand effects of HER2 mutations we characterized a panel of patient-derived xenograft tumor models representing colorectal, ovary, pancreas and endometrial cancers using RNA- and DNA-based sequencing. EGFR and HER2 expression was also quantitated using immunohistochemistry (IHC). Models identified positive for HER2 mutation by sequencing were evaluated in vivo, testing antitumor activity of neratinib, afatinib and other targeted therapies.Methods', ' START-PDX models were established from tissue or fluid samples as previously described. DNA or RNA were extracted and subjected to NGS and HER2 and other cancer-related mutations reported; growth factor receptor densities were interrogated using standard IHC. Drug studies were performed evaluating sensitivity of models to single agent neratinib, afatinib, lapatinib, trastuzumab and T-DM1 administered on standard treatment regimens. Study endpoints included tumor volume and time from treatment initiation with T/C values and tumor regression reported at study completion.Results', ' DNA and RNA sequence analysis of 300 models identified eleven HER2 mutations including six previously reported in COSMIC (S310F, A386D, H473R, D582N, V777L, R678Q) and five novel variants (R330Q, G366R, Q398K, I628T, A1216D) in thirteen total models. High EGFR staining was reported in two colorectal models', ' ST427 (HER2V777L) and ST428 (HER2A1216D) while high EGFR and HER2 staining was reported in a lung model designated ST1243 (HER2S310F). In vivo treatment with neratinib or afatinib resulted in tumor growth inhibition in some tested models including ST022 (HER2G366R/R678Q) ovary and ST204 (HER2A386D) pancreas and tumor regressions were reported with either agent in the ST427 (HER2V777L) colorectal line. Neratinib or afatinib were also found active in one each of four tested endometrial models. Lapatinib, trastuzumab and T-DM1 were inactive in all tested HER2-mutant models.Conclusion', ' We have sequenced a panel of PDX models and identified six previously reported and five novel HER-2 mutations in thirteen models which we screened in vivo for sensitivity to EGFR/HER2 duel kinase inhibitors and HER2-targeting therapies with the colorectal model ST427 (HER2V777L) identified as most sensitive to neratinib and afatinib.']",
        "Doc_id":"AACR_2016-4760",
        "Doc_title":" Efficacy of EGFR/HER2 duel-kinase inhibitors in PDX models harboring known and novel HER2-mutations",
        "_version_":1606188972582633472},
      {
        "Meeting_name":" Brain metastases (BM) in breast (BC) and lung cancer (LC) patients.",
        "Background":"['Background', ' Most BM arise from BC or LC. Few studies compare their attributes and distribution, though BC BM have been reported to more often involve the cerebellum. Methods', ' Brain scanning was for clinical evidence of BM. Contrast-enhanced computer-automated tomograms (CT) or magnetic resonance images (MRI) of brains of all BC and LC patients irradiated for BM between 1996 and 2008 were reviewed. BC epidermoid growth factor receptor2 (HER-2) expression was determined. Results', ' Data was from 63 BC and 59 LC patients; 58% of the BC and 55% of the LC patients had MRIs. MRIs showed more cerebellar BM (p = 0.047). Primary to BM diagnosis intervals were shorter for LC than for BC patients (p = 0.001), but LC BM were more edematous (0.019). BC patients had more cerebellar BM (p = 0.004) than LC patients, and more BM in the cerebellum only (p = 0.017). LC patient gender and small cell histology did not correlate with cerebellar BM. Both cerebrums and cerebellums of BC patients had more BM than those with LC (p = 0.020; 0.013). Cerebellar BMs were more frequent in brains with more cerebral BM (p = 0.0020). Amongst BC over-expressing HER-2 was a trend to more cerebellar BM (p = 0.072). Conclusions', \" LC BM, which elicit more edema, produce symptoms earlier than BC BM. There are larger numbers of BC BM, perhaps due to BC's longer disease course and responsiveness to therapy. BC causes more cerebellar mets than LC, often without cerebral BM. This may be due both to the larger number of BC BM, and a predilection for the cerebellum. Periodic brain MRI, more sensitive than CT to posterior fossa lesions, may be indicated in some BC patients, and early radiation may control multiple small BM.\"]",
        "Doc_id":"ASCO_30249-65",
        "Doc_title":" Brain metastases (BM) in breast (BC) and lung cancer (LC) patients.",
        "_version_":1606189032617803776},
      {
        "Meeting_name":" One year experience of MET gene exon 14 skipping analysis in lung cancer",
        "Background":"['Background', ' Lung adenocarcinoma (LAC) is the most common histological type of non-small-cell lung cancer and is one of the malignancies with the most evolved personalized treatments based on molecular characteristics of the tumor. Mutations in EGFR, HER2 and BRAF, specific translocations of ALK, ROS1, RET and amplification of MET all have standard diagnostic importance and lead to specific treatment options for the individual LAC patients. Recently, in 2-4% of LAC MET gene mutations leading to skipping of exon 14 were found. These mutations were described to occur more frequently in tumors with sarcomatoid histology. LAC with MET exon 14 skipping mutations showed impressive, although temporary, responses to MET tyrosine kinase inhibitors (TKI) crizotinib, cabozantinib and capmatinib. We will present our experience with routine molecular diagnostic detection of the most common MET exon 14 skipping mutations. Methods', ' In January 2016 we included in our standard, DNA based, molecular diagnostics custom-made NGS analyses 4 amplicons for detection of MET skipping mutations. The analyses were performed on microdissected FFPE tissue sections or routine histology or cytology stained preparations. Nine different mutations were validated for their effect on splicing by RT-PCR on RNA isolated from the same tissue samples. Results', ' Between January 2016 and January 2017 676 routine molecular diagnostic analyses on LAC were performed. In 18 (2.7%) cases MET mutations were detected possibly resulting in exon 14 skipping. Nine out of 16 different mutations were tested by RT-PCR and all 9 were demonstrated to result in MET exon 14 skipping. Conclusions', 'MET exon 14 skipping mutations can reliably be detected in routine pathology tissue samples. These analyses can easily be included in routine molecular diagnostic NGS. When necessary, confirmation of the mutational effect on RNA splicing can be implemented as well. Routine identification of MET skipping mutations (2.7% of cases) adds substantially to the personalized targeted treatment strategies for LAC patients.']",
        "Doc_id":"ASCO_190636-199",
        "Doc_title":" One year experience of MET gene exon 14 skipping analysis in lung cancer",
        "_version_":1606189008800448512},
      {
        "Meeting_name":" SNaPshot genotyping of non-small cell lung cancers (NSCLC) in clinical practice.",
        "Background":"['Background', '   Cancer diagnostic and treatment strategies are shifting from organ-of-origin and histology-based paradigms to genotype-based approaches, especially in NSCLC. Responding to the clinical need for real-time, effective tumor genotyping, we implemented SNaPshot (SS), a clinical genotyping panel that uses formalin-fixed paraffin-embedded tissue.   Methods', '   This was a retrospective chart review of all NSCLC patients (pts) undergoing SS genotyping at Massachusetts General Hospital Cancer Center from March 2009 to May 2010. Tumors were tested for common hot-spot mutations or translocations in 14 cancer-related genes including EGFR, KRAS, ALK, BRAF, PIK3CA, NRAS, TP53, beta-catenin and others.   Results', '   During the study period, 552 of 589 samples (94%) sent for SS were successfully genotyped. Pt median age was 62, with 58% female and 92% white. 81% of cases were adenocarcinoma; smoking status was 24% never, 51% former and 11% current; and 64% had stage III or IV disease. Median turn around time for SS results was 20 days. 48% of samples were positive for a mutation or translocation, including 25% KRAS, 13% EGFR, 5% ALK, 5% TP53, 4% PIK3CA, 2% beta-catenin, 1% BRAF, 1% NRAS, and 1 pt each with HER2 and IDH1. Beta-catenin tended to co-exist with other mutations, including EGFR and PIK3CA. EGFR, ALK and BRAF mutations were associated with low smoking; KRAS and NRAS with heavy smoking. EGFR and KRAS were more common in adenocarcinoma; PIK3CA was associated with squamous cell histology. ALK was associated with younger age and KRAS with earlier stage. Overall, 15% of pts with advanced or recurrent NSCLC during the trial period enrolled on a clinical study of a targeted agent as a result of their genotype and an additional 4% went on an EGFR TKI off-protocol due to SS results. Tumor staging dilemmas were clarified via SS analysis of multiple biopsies in 6 cases.   Conclusions', '   Broad cancer genotyping is increasingly important in NSCLC. In our cohort, about half of pts had an identifiable mutation or translocation. We demonstrated that SS testing is feasible in a clinical setting, and can influence treatment options.']",
        "Doc_id":"ASCO_81145-102",
        "Doc_title":" SNaPshot genotyping of non-small cell lung cancers (NSCLC) in clinical practice.",
        "_version_":1606188980273938432},
      {
        "Meeting_name":" Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) with acquired resistance to erlotinib.",
        "Background":"['Background', ' NSCLC p with EGFR mutations initially respond to EGFR tyrosine kinase inhibitors (TKIs) but ultimately relapse. Sub-genomic molecular studies indicate that the EGFR T790M mutation and the activation of MET, PI3K, AXL, HER2 and MAPK can lead to acquired resistance to EGFR TKIs. To date, no integrated comprehensive genomic investigation of EGFR TKI resistance has been performed. Methods', ' FFPE biopsies of erlotinib-sensitive and erlotinib-resistant tumors were obtained from 11 EGFR mutant NSCLC p. DNA was extracted from all tumor and corresponding normal tissue samples and underwent whole exome sequencing using the Illumina HiSeq2500. RNA was extracted from all tumor samples and analyzed by whole transcriptome sequencing, also using the Illumina HiSeq2500. Results', ' Erlotinib resistant NSCLC specimens harbored upregulation of known resistance drivers including MET and AXL and novel alterations including upregulation of genes that are', ' 1) recurrently mutated in NSCLC, including ALK, STK11; 2) components of established embryonic stem cell signatures, including targets of Nanog, Oct4, Sox2, c-Myc, 3) neuronal lineage specific regulators, including NTRK3, NRCAM, ALK, LRP4. The analysis also revealed downregulation of several genes that are', ' 1) components of innate and acquired immunity, including HLA-A, -B, DQ, CD40; 2) phosphatases regulating survival signaling pathways, including PTEN, PTPRD, 3) proapoptotic components, including BNIP3L, IKIP. Conclusions', ' This study demonstrated the feasibility and utility of comprehensive genomic analysis in the clinical management of NSCLC p receiving targeted therapy. We identified known and novel molecular biomarkers of erlotinib acquired resistance in NSCLC p, and uncovered a previously unappreciated role for genetic events governing stem cell and neuronal phenotypes as well as immune evasion in erlotinib acquired resistance in NSCLC p. Together, our data provide unprecedented insight into the molecular pathogenesis of escape from EGFR oncogene inhibition in NSCLC. We are now conducting a prospective observational study in additional NSCLC p.']",
        "Doc_id":"ASCO_117711-132",
        "Doc_title":" Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) with acquired resistance to erlotinib.",
        "_version_":1606188995734142976},
      {
        "Meeting_name":" LungMATCH",
        "Background":"['Background', ' For metastatic non-small cell lung cancer (NSCLC), guidelines include molecular testing for actionable biomarkers and recommend broad profile testing. Yet previous studies indicate that not all patients with NSCLC receive testing, even for actionable mutations in EGFR, ALK, and ROS. We hypothesized low testing rates for patients calling a community HelpLine and that we could increase rates with one-on-one caller education and free precision medicine services. Methods', ' Caller statistics were collected on the toll-free Lung Cancer Alliance (LCA) HelpLine from Sept 1, 2016  Jan 31, 2017. Recruitment to the LungMATCH molecular testing program began Nov 10, 2017. Patients are recruited through conversations on the LCA HelpLine, then consented into Perthera Cancer Analysis (PCA) through an IRB-approved registry protocol. PCA includes tissue acquisition, multi-omic molecular profiling, and medical review of testing results and clinical and treatment history. PCA reports are returned to both treating physicians and patients. Data is being collected longitudinally on treatment decisions, patient outcomes including progression-free and overall survival, and patient experience. Results', ' Data from the LCA Helpline identified a gap in molecular testing. 50% (57/115) of patients asked if they received any kind of molecular testing replied \"No\". Of 32 patients who were tested and knew the results, patients indicated potentially actionable changes in EGFR(15), ALK(8), PD-L1(3), RET, MET, BRAF, and HER2, along with KRAS (4). Since LungMATCH launch, 23 interested patients were referred for PCA. Six patients consented and are undergoing PCA with seven more in the consent process. Reasons for non-consent include', ' doctor refusal, initiation of testing at the treating institution, concern about financial implications, and one death. Updated results will be presented. Conclusions', ' Our data indicate that patients with lung cancer are not receiving molecular testing in accordance to guidelines. To address this, we created a program through nonprofit-corporate partnership that navigates patients and their physicians through comprehensive precision therapy. This type of program is feasible and there is patient interest.']",
        "Doc_id":"ASCO_186095-199",
        "Doc_title":" LungMATCH",
        "_version_":1606188991565004801},
      {
        "Meeting_name":" Development and characterisation of AZD-8931-resistant HER-2 positive breast cancer cells.",
        "Background":"['The introduction of HER-2 directed therapies has revolutionised the management of both early and advanced HER-2 positive breast cancer. However, despite significant improvements in treatment outcomes, both inherent and acquired resistance are frequently encountered problems. Emerging evidence from early phase neo-adjuvant clinical trials, such as Neo-sphere and Neo-ALTTO, suggests that targeting multiple members of the Human epidermal growth factor receptor (HER) family is more efficacious than single target inhibition. AZD 8931 is a novel equipotent reversible tyrosine kinase inhibitor of EGFR, HER-2 and HER-3 signalling with proven pre-clinical efficacy in breast, head and neck and non-small cell lung cancers {1}.To investigate potential mechanisms of acquired resistance to AZD-8931, HER-2 amplified SKBR-3 breast cancer cells were rendered resistant by culture with escalating doses of drug. Resistant and parental cell lines were phenotypically distinct with resistance being associated with greater cell spreading and increased cell density. Cross resistance to lapatinib, a reversible dual EGFR/HER 2 tyrosine kinase inhibitor, was demonstrated with an over 50 fold increase in IC50. Signalling changes associated with a resistant phenotype were explored with a combination of Reverse Phase Protein Array (RPPA) and western blotting. Following drug treatment, resistant cells still displayed a dose-dependent reduction in phospho HER-2 (Tyr 1248)/EGFR (Tyr 1173). However, constitutive activation of the HER 3 pathway resulted in persistent downstream signalling via the PI3K/AKT pathway and increased cell survival.Tumorigenesis in the MMTV-Nic model is driven by mammary-specific expression of a constitutively active HER 2 transgene {2}. This model has been crossed with a strain with a floxed PTEN allele {2} and studies are currently under way to explore the role of PTEN in AZD-8931 resistance.']",
        "Doc_id":"AACR_2013-4453",
        "Doc_title":" Development and characterisation of AZD-8931-resistant HER-2 positive breast cancer cells.",
        "_version_":1606189028712906753},
      {
        "Meeting_name":" Molecular profiling of neuroendocrine tumors (NETs)",
        "Background":"['Background', '  The rarity of NETs can limit clinical trial accrual to develop new therapies. Given fewer approved treatments, a better understanding of underlying biology is critical to development of and assignment of patients (pts) to clinical trials.  Methods', ' Pts with NETs (excluding small/large cell lung cancer) of all grades at FCCC were enrolled onto a prospective IRB approved protocol that utilized an NGS platform to detect somatic mutations (SM) in 50 cancer-related genes (Cancer Code) on archived tissue from primary or metastatic sites. Genes tested included ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO,SRC, STK11, TP53 and VHL. Review of pathology specimens for grade and Ki -67 was also performed.  Results', '  Thirty-nine pts (median age 59 y, males 46%) were enrolled from October 2013 to July 2014. Gene profiling results are available on thirty-five pts. Ki-67 score was reviewed for 31/35 tumors. 6 (20%) pts had high grade (HG) tumors (Ki-67 > 20%) and 25 (80%) had low/intermediate grade (LIG) tumors (Ki-67 20%). Thirteen (37%) pts were found to have SMs and 22 (63%) did not, with 4 (12%) pts tumors having >1 SMs (2 HG and 2 LIG tumors). Incidence of SM was 41% (12/29) in Caucasians, 16% (1/6) in other races, 46% (6/13) in smokers and 30% (6/20) in non-smokers. Incidence of SM was 24% (6/25) in LIG NETs and 84% (5/6) in the HG NETs. Among HG tumors, 66% (4/6) harbored TP53 gene mutation and 33% (2/6) were BRAF mutation positive.  Conclusions', ' Tumor-specific mutations are seen in a minority of low grade NETs but are common in high grade tumors. Interestingly, no mutations were identified in pts with unknown primary.  Analysis of clinical outcomes based on treatment received is ongoing to assess for possible prognostic/therapeutic implications of these mutations.   Mutations according to primary site.Primary siten (total)n (with mutations)Type of mutationStomach/bowel164BRAF, PIK3CA, TP53, KRAS, CTNNB1Pancreas115KRAS (2), RB1, ATM, TP53Unknown40Other22TP53, KRAS']",
        "Doc_id":"ASCO_139139-158",
        "Doc_title":" Molecular profiling of neuroendocrine tumors (NETs)",
        "_version_":1606189000943468544},
      {
        "Meeting_name":" Identification of putative molecular targets in Merkel cell carcinoma.",
        "Background":"['Background', '  Merkel cell carcinoma (MCC) is a rare and aggressive cutaneous neuroendocrine tumor.  MCC is attributed to Merkel Cell Polyoma virus infection in up to 80% of patients, but is of unknown molecular pathogenesis in the remainder.  Advanced disease has been managed by analogy, using regimens for small-cell lung cancer (SCLC).  No targeted agents have been identified for treatment.  We profiled molecular changes in MCC to provide insight into new therapeutic strategies.   Methods', '  64 MCC cases referred to Caris Life Sciences between 2009 and 2013 were evaluated.  Diagnoses were collected from referring physicians and classified at intake based on pathology and clinical history.  Specific testing was performed per physician request and included a combination of sequencing (Sanger, NGS), protein expression (IHC), and gene amplification (CISH or FISH).   Results', '  Positive expression of biomarkers occurring in more than half of specimens included MRP1 and TOP2A (94%), TUBB3 (90%), RRM1 (79%), PTEN (66%), and TS (63%).  Low expression of biomarkers occurring in more than half of specimens included PGP and SPARC (84%), ERCC1 and TLE3 (80%), PDGFRA (75%), and BCRP, cKIT, and MGMT (~60%).  TOPO1 and PR were overexpressed in approximately 40% of patients.  Gene amplification was not observed in cMET, EGFR, HER2, or TOP2A.  Sanger sequencing did not reveal mutations in BRAF, cKIT, EGFR, KRAS, NRAS, or PIK3CA.  NGS detected variant genes in 6 of 11 (55%) patients', ' alterations occurred in APC (n=1), ERBB4 (n=1), HRAS (n=1), RB1 (n=1), and TP53 (n=5).  Two patients exhibited multiple mutations.   Conclusions', '  Our data support the utility of cytotoxic therapies for MCC by analogy to SCLC, including platinum agents, anthracyclines, and topotecan.  MRP1 was however expressed in 94%, suggesting etoposide resistance.  A novel finding was overexpression of PR in 37% (22/60) of patients; anti-hormonal therapies merit further investigation in light of the diseases male predominance.  Sporadic mutations of cancer-related genes were identified by NGS.  The only mutational pattern observed was the presence of TP53 mutations in 5/11 (45%), potentially targeted by Wee1 and ChK1 inhibitors. Further evaluation is necessary to identify key changes in MCC that might be exploited.']",
        "Doc_id":"ASCO_134802-144",
        "Doc_title":" Identification of putative molecular targets in Merkel cell carcinoma.",
        "_version_":1606188987250114560},
      {
        "Meeting_name":" Biomarker analyses from a phase l study of pertuzumab combined with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' Pertuzumab (P) is a fully humanised, murine monoclonal antibody that targets the dimerisation epitope of human epidermal growth factor receptor (HER) 2, preventing dimerisation between HER2 and other HER receptors and inducing antibody-dependent cell-mediated cytotoxicity. P as a single agent is not associated with meaningful activity against NSCLC, though stable disease (SD) has been observed in a phase II study (Herbst et al. Clin Cancer Res 2007;13', '6175). Erlotinib (E) inhibits HER1 tyrosine kinase signalling and is widely registered for treatment of relapsed NSCLC. By inhibiting extracellular receptor dimerisation, as well as internal signal transduction through HER1, the combination of E and P would be expected to result in extensive blockade of HER signalling. Preclinical and initial response data seem to confirm this (Felip et al. ESMO 2008, abs 269P). Methods', ' 15 pts in 2 cohorts were treated in this Phase I, dose-escalating study. There was no evidence of pharmacokinetic interaction and the majority of treatment-related adverse events were CTC grade 1 or 2; full doses of each drug were recommended for further phase II evaluation. Potential biomarkers possibly associated with antitumour activity of P and E were measured in tumour tissue and evaluated against clinical disease status. Proteins of potential significance were measured by immunohistochemistry (IHC) and mRNA by reverse transcriptase real-time quantitative polymerase chain reaction (RT qPCR). The panel of biomarkers measured included HER1 (epidermal growth factor receptor [EGFR]), HER2 and HER3. Results', ' Progression-free survival and tumour response were evaluated in all 15 pts. There were 3 partial responses (20%), with 1 further pt experiencing SD of  6 months. 13 pts had tumour samples that were suitable for full quantification of EGFR, HER2 and HER3 by RT qPCR as well as other markers by IHC. Interestingly, higher levels of mRNA for some HER receptors, as well as IHC markers, may correlate with treatment response. Conclusions', ' The biomarker analyses may provide some initial insight into markers of efficacy, although the data are limited by small numbers. Full data will be presented.']",
        "Doc_id":"ASCO_52735-74",
        "Doc_title":" Biomarker analyses from a phase l study of pertuzumab combined with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC).",
        "_version_":1606189034293428225},
      {
        "Meeting_name":" Overcoming acquired EGFRi resistance in NSCLC with targeted beam irradiation in combination with targeted agents",
        "Background":"['BACKGROUND', ' Non-small cell lung cancer (NSCLC) patients undergo primary, adjuvant or neoadjuvant radiotherapy treatment with image-guided radiotherapy (IGRT) being widely used to provide more accurate treatment plans and reduced side effects.Patients who have activating mutations in the epidermal growth factor receptor (EGFR) gene are treated with EGFR tyrosine kinase inhibitors (EGFRi). However, resistance to EGFRi occurs in the majority of patients with the main clinical drivers being secondary gatekeeper mutations (T790M) or amplification of genes such as c-MET and Her2.The small animal radiation research platform (SARRP), which allows the treatment of rodent models of cancer more accurately with planned protocols similar to those utilised in the clinic, was used in combination with EGFRi, to assess the efficacy of combination treatment strategies of irradiation (IR) in EGFRi resistant NSCLC xenografts.METHODS', ' Resistance to EGFRi in the NSCLC cell line HCC827, which harbours an activating EGFR mutation, was generated through repeated exposure to Gefitinib or Erlotinib. Resistant models were characterised for further mutations in the EGFR gene by direct sequencing and for c-MET, Axl and Her2 over-expression/genomic amplification by quantitative PCR.EGFRi resistant or parental HCC827 cells were implanted subcutaneously into nude mice, xenograft growth was monitored by calliper measurements and treatment initiated when the mean tumour volume reached 200mm3. An image guided IR dose of 3Gy/mouse/day (30Gy total) was targeted directly to the xenografts whilst sparing the surrounding normal tissue. Mice were treated with IR either alone or in combination with Erlotinib or Crizotinib; response to treatment was evaluated by tumour volume measurement.RESULTS', ' EGFR-TKI resistant HCC827 cell lines were generated following successive cycles of treatment. Amplification of c-MET was identified in a number of clones, but no Her2 amplification or gatekeeper mutations; therefore Crizotinib, a c-MET inhibitor, was selected for evaluation in these models.When assessed in vivo, treatment of parental HCC827 xenografts with targeted IR or Erlotinib treatment resulted in tumour regression. However, in the c-MET driven resistant model, both the IR and Erlotinib response was significantly attenuated, resulting in tumour re-growth. Combination testing with Crizotinib restored the efficacy of both IR and Erlotinib to nave treatment levels confirming the role of c-MET in resistance.CONCLUSIONS', ' Resistance to EGFRi and IR in a HCC827 model is driven by c-MET amplification. Treatment with Crizotinib restored sensitivity to both EGFRi and IR demonstrating that pre-clinical models of resistance are invaluable in assessing novel agents targeting the EGFR pathway and the development of new combination strategies which seek to prevent/overcome resistance to EGFRi.']",
        "Doc_id":"AACR_2015-765",
        "Doc_title":" Overcoming acquired EGFRi resistance in NSCLC with targeted beam irradiation in combination with targeted agents",
        "_version_":1606188970613407744},
      {
        "Meeting_name":" Genomic landscape of small cell carcinoma of the breast (SCCB) contrasted to small cell carcinoma of the lung (SCLC).",
        "Background":"['Background', ' SCCBis a rare, aggressive form of breast cancer that is associated with extremely poor outcomes (Hare 2015). In an effort to identify new treatment options, we utilized comprehensive genomic profiling to assess the potential for novel therapies in SCCB. Methods', ' Under an IRB approved protocol, we identified patients (pts) with SCCB and SCLC profiled by Caris Life Sciences between 2007-2015. Tumors were assessed with up to 21 IHC stains, in situ hybridization (ISH) of cMET, EGFR, HER2 and TOP2A, and next generation sequencing (NGS) as well as Sanger sequencing of 47 genes. Results', ' 19 patients with SCCB were identified, median age was 58 years (range 37-79) and 42% had metastatic disease at presentation; for comparison 58 pts with SCLC were identified (66 [36-86], 65% metastatic). By IHC 30% SCCB pts expressed ER, 15% expressed PR and 18% expressed androgen receptor; SCLC pts expressed ER 0%, PR 2%, AR 6%. SCCB and SCLC pts had similar patterns of other IHC expression (0% v 0% PDL1, 50% v 42% PD1, 80% v 95% TOP2A, respectively). All SCCB and SCLC pts were negative for HER2 and cMET amplification by ISH. NGS revealed TP53 mutations in 75% of patients both with SCCB and SCLC and PIK3CA mutations in 38% of SCCB pts but no SCLC pts (Fishers exact test p = 0.005, OR 0.02 [0.00-0.52]). No other mutations were found in SCCB pts and no other mutation occurred in over 10% of SCLC pts except RB1 in 20% (p = 0.31). Conclusions', ' SCCB is an aggressive tumor with few therapeutic options. Molecular profiling suggests many similarities between SCCB and SCLC with the exception an increased incidence of PIK3CA mutations in SCCB, which may have therapeutic implications.']",
        "Doc_id":"ASCO_161712-176",
        "Doc_title":" Genomic landscape of small cell carcinoma of the breast (SCCB) contrasted to small cell carcinoma of the lung (SCLC).",
        "_version_":1606188977238310912},
      {
        "Meeting_name":" Phase I study of the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with docetaxel, cisplatin, and dacomitinib.",
        "Background":"['Background', ' Inhibition of phosphatidylinositol-3-kinase (PI3K)-mediated signaling may overcome resistance to chemotherapy or human epidermal growth factor receptor (EGFR) inhibitors. Gedatolisib (G) is a dual inhibitor of PI3K/mammalian target of rapamycin (mTOR) in development for solid tumors. Methods', ' This is an ongoing study to determine the maximum tolerated dose (MTD) and safety of G in combination with', ' 1) docetaxel', ' Arm A, in castrate resistant prostate cancer, advanced breast cancer (BC), or non-small cell lung cancer (NSCLC) patients (pts); 2) cisplatin', ' Arm B, in urothelial transitional cell cancer (TCC), triple negative BC (TNBC), NSCLC or ovarian cancer pts; 3) the pan-EGFR TKI dacomitinib', ' Arm C, in refractory HER2+BC, HER2+esophagogastric cancer, head and neck cancer, or EGFR-mutated NSCLC pts. Pts received a G lead-in dose 7 days (A, B) or 14 days (C) prior to day 1, followed by weekly intravenous (IV) G plus', ' docetaxel or cisplatin (75 mg IV every 3 weeks); or oral dacomitinib (3045 mg/d). Secondary objectives included pharmacokinetics (PK), clinical efficacy (partial or complete response [PR or CR]), and associated biomarkers. Results', ' 74 pts (median prior therapies', ' 2; range', ' 06) received 90260 mg/week of G in', ' A, 21; B, 21; and C, 32. The top drug related adverse events', ' A', ' neutropenia, mucositis, alopecia; B', ' nausea, fatigue, vomiting; and C', ' mucositis, diarrhea, nausea, fatigue. Cycle 1 dose limiting toxicities (DLTs) were', ' A', ' grade 3 mucositis (n = 1); B', ' no DLT; C', ' grade 3 mucositis (n = 1), pneumonitis (n = 1), rash (n = 1), and grade 2 fatigue (n = 1). PK parameters for G were similar regardless of combination agent. Best overall response was A', ' 4/21 PRs; B', ' 8/21 PRs (5 TNBC, 2 NSCLC, 1 TCC), and C', ' 6/32, (1 CR, 5 PRs). In Arm B, 3 of the 8 PRs (2 NSCLC, 1 TCC) had prior platinum exposure. Next generation sequencing involving PI3K data from a subset of patients is under evaluation. Conclusions', ' G can be combined with docetaxel, cisplatin, or dacomitinib, with manageable toxicity profiles and preliminary antitumor activity, even when heavily pre-treated. Due to portfolio prioritization, dose escalation and expansion continues in Arm B, with closure of Arms A and C (MTD not reached). Clinical trial information', ' NCT01920061']",
        "Doc_id":"ASCO_166280-176",
        "Doc_title":" Phase I study of the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with docetaxel, cisplatin, and dacomitinib.",
        "_version_":1606189018765066240},
      {
        "Meeting_name":" Biomarkers (BM) France",
        "Background":"['Background', '  Personalized medicine is now a reality for advanced NSCLC pts on the basis of routine screening for EGFR mutation and ALK gene fusion assessment. The French NCI (INCa) also decided to additionally fund the routine assessment of 4 additional BM (HER2, KRAS, BRAF, PI3KCA).  Methods', '  Starting on April 2012, these BM analyses were prospectively collected into a database head by the IFCT (www.ifct.fr) with 15-20,000 analyses awaited after one year. The physicians prescribing each of these BM analyses were then connected to this database and were asked to regularly complete epidemiological, clinical and therapeutic data for each corresponding patient.  Results', '  10,000 BM analyses were collected and entered into the BM France database at the time of this first analysis (January 2013). On the basis of available data, the patients were mainly male (63.8%), (ex)smokers (83.3%) and stage IV pts (64%). The tumors were mainly adenocarcinomas (76.1%). The samples for BM analysis were collected under bronchoscopy, surgery or transthoracic biopsy in 27.4, 28.1 and 24.2%, respectively. The 10,000 molecular profiles were characterized by 9.4% EGFR (including 0.8% EGFR resistant), 0.9% HER2, 26.9% KRAS, 1.6% BRAF, and 2.6% PI3KCA mutated and 4.0% EML4-ALK fusion genes. Double mutations were seen in 0.9% of the tumors. On January 2013, data on treatment were available for 18.6% of patients among whom 56.9% of patients received a treatment according to their molecular profile (labeled drugs or bio-guided trials). Updated data will be presented during the meeting.  Conclusions', '  Biomarkers France is the largest ever conducted biomolecular study on advanced NSCLC patients and provides solid data on the value of a nationwide BM screening policy for NSCLC patients.']",
        "Doc_id":"ASCO_114562-132",
        "Doc_title":" Biomarkers (BM) France",
        "_version_":1606189008801497089},
      {
        "Meeting_name":" Identification of a novel binding protein playing a critical role in HER2 activation in lung cancer cells",
        "Background":"['Human epidermal growth factor receptor 2 (HER2) is a member of epidermal growth factor receptor (EGFR) family. Previous studies have revealed that many kinds of malignant tumors have genetic mutations or amplification of HER2, indicating that HER2 alterations are oncogenic. Many kinds of HER2 targeted therapies are effective to HER2 positive tumors, but those treated tumors often get resistance to drugs. Thus, to elucidate HER2 related pathway in cancer biology is important to develop new therapeutic strategy for cancers.Recently, we newly identified a protein X (a temporary name) as a novel binding protein to HER2 with immunoprecipitation and following LC-Ms/Ms analysis. The protein generally expressed in lung and breast cancers at remarkable level.We constructed plasmid vectors carrying wild type HER2 and gene X. These vectors were simultaneously introduced to HEK293T cells to examine the binding ability of protein X and HER2 as well as the effect of gene X on HER2-mediated signal-transduction pathway. The approach clearly showed that the expression of gene X, resulted in phosphorylation of HER2 and subsequent activation of oncogenic effector molecules.We next constructed several kinds of gene X-truncated variants and subjected to the binding assay to look for the binding domain of gene X to HER2. The analysis showed that N-terminal head domain of gene X was essential for the HER2 binding. This domain has an ability to induce HER2 phosphorylation and subsequent activation of the effector kinase, ERK.In conclusion, we found that gene X is a novel binding protein to HER2 and has a role in HER2 activation.']",
        "Doc_id":"AACR_2015-48",
        "Doc_title":" Identification of a novel binding protein playing a critical role in HER2 activation in lung cancer cells",
        "_version_":1606188996090658817},
      {
        "Meeting_name":" The Drug Rediscovery Protocol (DRUP).",
        "Background":"['Background', ' Bringing precision medicine to cancer patients remains a challenge. For many cancers, the relative contribution of tumor type, mutations or CNV to drug sensitivity remains unknown. In addition, drug access is generally limited to the labeled indication, bypassing rarer disease subgroups for which large trials are not feasible. An innovative trial that facilitates drug access, whilst systematically analyzing treatment outcomes and biomarkers, could help overcome these challenges. Methods', ' We designed a prospective, non randomized clinical trial in which patients with advanced cancer are treated with targeted or immunotherapy matched to their tumor profile, defined by genetic aberration, microsatellite instability (MSI) or high mutational load (HML). Upon a mandatory pre-treatment tumor biopsy for biomarker research, patients are enrolled in multiple parallel cohorts, each defined by study drug, histologic tumor type and molecular tumor profile. Efficacy is analyzed per cohort, enrolling 8 patients in stage I and 16 more in stage II if 1 response is observed in stage I. Study endpoints include objective tumor response (CR or PR), stable disease (SD) at 16 weeks and grade3 adverse events. The DRUP is registered at ClinicalTrials.gov (NCT02925234). Results', ' Since start of recruitment in Sep 2016, 76 patients have been submitted for review (mean per month 15, range 8-17) and 16 (21%) have started treatment in 10 different cohorts, directed at either ATM (n = 1; breast cancer), BRAF (n = 2; salivary duct carcinoma and ACUP), BRCA (n = 1; breast cancer), ERBB2 (n = 2; CRC), HML (n = 2; prostate and CRC), MSI (n = 5; CRC, GBM and urothelial carcinoma), RET (n = 1; NSCLC) or RAS-RAFwt (n = 2; SCC and sarcoma). Out of the 7 patients for whom response evaluation is available, PR (n = 2) or SD at 16 weeks (n = 1) was observed in 3 (43%). Thirteen study drugs (supplied by 6 pharmaceutical companies) are currently available, 6 more are expected soon. Conclusions', ' Execution of a nationwide multidrug precision oncology trial is feasible. It contributes to oncologists education on molecularly targeted therapies and to identification of early signs of activity in rare cancer subsets. Data sharing with similar studies such as TAPUR and CAPTUR will help to enlarge cohorts and affirm conclusions. Clinical trial information', ' NCT02925234']",
        "Doc_id":"ASCO_181452-199",
        "Doc_title":" The Drug Rediscovery Protocol (DRUP).",
        "_version_":1606189018707394560},
      {
        "Meeting_name":" Use of 18F-HX4 PET/CT to estimate tumor hypoxia enrolled subjects from ongoing Phase 2 trials using tarloxotinib bromide in advanced NSCLC and SCCHN.",
        "Background":"['Background', ' Tumor hypoxia is associated with resistance to chemotherapy and radiotherapy. Recurrent/metastatic squamous cell carcinomas of the head and neck & skin (SCCHN/SCCS) and non-small cell lung cancer (NSCLC) tumors can be hypoxic leading to EGFR-TKI resistance. Tarloxotinib bromide (TRLX) is a hypoxia-activated prodrug that releases an irreversible pan-ErbB TKI targeting WT EGFR, mutant EGFR and HER2. Hypoxic tumor targeting with TRLX may lead to greater TKI tumor exposure with less toxicity than current EGFR TKIs. 18F-flortanidazole (18F-HX4) is a new hypoxia PET imaging agent that has the potential to identify and quantify tumor hypoxia with better tumor hypoxia targeting than earlier PET hypoxia agents. However, cross-institutional comparison of PET results without a standardization program can be challenging leading to insufficient or inappropriate conclusions based on PET results. Methods', ' Two concurrent multicenter Phase 2 trials are investigating the safety and activity of single-agent TRLX in recurrent or recurrent/metastatic SCCHN and SCCS (NCT02449681) or NSCLC (NCT02454842). Subjects have a whole-body18F-HX4 PET/CT scan prior to treatment. PET scanners are prequalified using a phantom harmonization program to ensure consistent image quality and robust 18F-HX4 quantitation for cross-institutional comparison. 18F-HX4 uptake will be quantitated to help correlate tumor 18F-HX4 uptake with measurement-based tumor treatment responses. Results', ' Up to 4 sites have been qualified with anthropomorphic phantoms to standardize PET scans and avoid poor quantitation of 18F-HX4. Excellent image quality scans in 3 of 4 patients have shown 18F-HX4 tumor uptake with preliminary estimates of tumor hypoxia ranging from 0-21% for hypoxic fractions (% of tumor hypoxia relative to reference tissue) and volumes (volume of hypoxia relative to reference tissue) permitting feasibility of signal detection to be correlated with responses. Conclusions', ' Multicenter PET studies of 18F-HX4 uptake and tumor response to TRLX is ongoing. Our PET harmonization strategy has shown promising early results in tumor hypoxia visualization. Recruitment is ongoing. Clinical trial information', ' NCT02449681']",
        "Doc_id":"ASCO_171670-176",
        "Doc_title":" Use of 18F-HX4 PET/CT to estimate tumor hypoxia enrolled subjects from ongoing Phase 2 trials using tarloxotinib bromide in advanced NSCLC and SCCHN.",
        "_version_":1606189006430666752},
      {
        "Meeting_name":" Deciphering antitumour response and resistance with intratumour heterogeneity (DARWIN II).",
        "Background":"['Background', ' The importance of intratumour heterogeneity (ITH) is increasingly recognised as a driver of cancer progression and survival outcome. However understanding how tumour clonal heterogeneity impacts upon therapeutic outcome is still an area of unmet clinical and scientific need. The TRACERx trial (NCT01888601), a prospective study of patients with radically resected primary non-small cell lung cancer (NSCLC), aims to define the evolutionary trajectories of lung cancer in both space and time through genetic analysis of multi-region and longitudinal tumour sampling. DARWIN II is an investigator initiated study for patients who are enrolled within the TRACERx trial, or who have multi-region sequencing of their primary disease, but subsequently relapse with metastatic disease. This study will examine the role of intra-tumour heterogeneity and predicted neo-antigens on the anti-tumour activity of anti-PDL1 immunotherapy. Methods', ' This multicentre non-randomised phase II molecularly stratified umbrella study will examine how clonal dominance and ITH influence outcomes after treatment, offering a unique opportunity to decipher mechanisms of resistance to immunotherapy with anti-PDL1. These data will help improve future study design by developing greater understanding of patient selection for immunotherapies in patients with NSCLC. The relationship between ITH and cfDNA/CTCs will also be explored in DARWIN II. The study arms', ' Arm 1', ' Patients either -1) without an actionable mutation and PDL1 positive or 2) without an actionable mutation and PDL1 negative following first line cytotoxic chemotherapy - Atezolizumab. Arm 2', ' BRAFV600 - Vemurafenib. Arm 3', ' ALK/RET gene rearrangement - Alectinib. Arm 4', ' Her2 Amplification - Trastuzumab Emtansine. Primary Outcome Measures', ' Progression free survival (PFS), defined as the period between the date of registration to the date of subsequent progression or death will be assessed according to', ' Neo-antigen burden, mutational burden, ITH as assessed using an ITH ratio index and genomic instability as assessed using a weighted genome instability index (wGII). Trial Sponsor', ' University College London. Clinical trial information', ' NCT02314481']",
        "Doc_id":"ASCO_183717-199",
        "Doc_title":" Deciphering antitumour response and resistance with intratumour heterogeneity (DARWIN II).",
        "_version_":1606189007157329920},
      {
        "Meeting_name":" Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines",
        "Background":"['Robust prediction of in vivo chemotherapeutic response, using baseline gene expression and drug sensitivity data gathered on cancer cell lines, has been a profoundly important, long standing and controversial problem in pharmacogenomics. Here, we present for the first time, a solution to this problem.Currently, personalizing cancer chemotherapy relies on pathology and more recently molecular biomarker-based approaches (e.g. ERBB2 amplification in breast cancer). However, as the driving biology are normally not fully understood, the majority of existing biomarkers do not capture a substantial proportion of variability in drug response. This partly explains the commonly observed lack of reproducibility of findings (e.g. from many conventional gene expression signatures) when these markers are applied to new datasets.In this study, we developed an approach to predict in vivo drug sensitivity that leverages whole-genome gene expression microarray data and allows the expression of every gene to influence the prediction by a small amount. The method works by fitting a ridge regression model of baseline genome-wide gene expression levels against in vitro drug sensitivity in a very large panel of approximately 700 cancer cell lines. Then, after a (crucial) data homogenization step, these models are applied to baseline expression levels from primary tumor biopsies. Our method successfully predicted patient response to different chemotherapeutic agents in three (of four total suitable) independent, publicly available clinical trials, each investigating different drugs and different types of cancer. In each of these cases, we predicted drug response at least as accurately as previously published models that had been derived from the clinical data itself. Interestingly, our approach could also predict clinical response in the absence of any known drug sensitivity biomarker. We effectively enriched for drug responders in breast, myeloma and lung cancers, treated with docetaxel, bortezomib and erlotinib respectively, thus identifying responders to both cytotoxic and targeted agents.Many previous clinical trials and in vitro assays have attempted to discover biomarkers of drug sensitivity, but found that the genes/aberrations which they had identified, performed poorly as predictors, once applied to out-of-batch sets of samples. Our models, on the other hand, are trained on an independent set of cancer cell lines and performed well on three completely separate and independent clinical trial datasets (all assessed using different microarray platforms). These results have far-reaching implications for personalized medicine and drug development (e.g. for the development of companion diagnostics). All datasets and bioinformatics tools to reproduce our results are publicly available.']",
        "Doc_id":"AACR_2014-5561",
        "Doc_title":" Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines",
        "_version_":1606189028276699137},
      {
        "Meeting_name":" Comprehensive molecular characterization of 412 muscle-invasive urothelial bladder carcinomas",
        "Background":"['Introduction', \" In 2014, TCGA's Bladder Cancer Working Group presented a preliminary integrated molecular analysis of 131 muscle-invasive urothelial carcinomas (Nature 507\", '315, 2014). We now report on the entire cohort of 412 fresh-frozen, chemotherapy-nave tumors. Included in the analysis were paired blood and/or tumor-adjacent tissue samples. This is the largest sequencing project on bladder cancer to date. After strict clinical and pathologic quality control, tumors were analyzed for DNA copy number variants, somatic mutations, DNA methylation, mRNA, microRNA and (phospho-) protein expression, transcript splicing, gene fusions, viral integration, APOBEC mutagenesis, pathway perturbation, clinical correlates, and histopathology.Results', ' There was a high overall somatic mutation rate (8.0/Mb), with a median of 245 and mean of 348 coding-region mutations per sample. That is the third highest mutation rate among the cancer types profiled by TCGA (after cutaneous melanoma and non-small cell lung cancers). We identified 54 genes as significantly mutated, compared with 32 in the original report on 131 tumors. TP53 mutations were the most common (49%), and also quite common were mutations in a number of chromatin-modifying genes, including MLL2 (29%), KDM6A (26%), ARID1A (25%), MLL3 (19%), EP300 (15%), CREBBP (12%), and MLL (11%). Other cancer-related genes showing frequent mutations included PIK3CA (22%), RB1 (17%), FGFR3 (14%), STAG2 (14%), ATM (14%), ELF3 (12%), FAT1 (12%), SPTAN1 (12%), ERBB2 (12%), ERBB3 (11%), ASXL2 (10%), ERCC2 (9%), CDKN1A (9%), TSC1 (8%), CDKN2A (7%), RHOB (6%), NFE2L2 (6%), PARD3 (6%), FAM47C (5%), RBM10 (5%),HRAS (5%), KRAS (4%), and PTEN (3%). High mutation burden was associated with improved outcome (p = 0.0004). APOBEC mutagenesis explained 70% of the mutation burden and was associated with survival. Gene silencing by promoter hypermethylation was identified in 167 genes with at least 5% frequency in the cohort. The previously identified four mRNA expression subtypes were again found in the complete set of 412 tumors, and the proportions of samples in each subtype were similar to the previous proportions. Reverse-phase proteomic array analysis of 344 of the samples revealed clusters associated with diagnostic subtype, pathological stage, and grade but not with smoking history or non-muscle invasive status.Conclusions', ' This integrated molecular analysis of 412 TCGA tumor samples largely validates and considerably extends observations from the initial cohort of 131 patients. The larger cohort significantly increased our power to detect lower-frequency aberrations that were not identified in the original cohort. The results provide a robust basis for further functional studies of bladder cancer biology and also provide additional incisive information for the identification of molecular targets for therapy.']",
        "Doc_id":"AACR_2016-128",
        "Doc_title":" Comprehensive molecular characterization of 412 muscle-invasive urothelial bladder carcinomas",
        "_version_":1606188971698683904},
      {
        "Meeting_name":" A next generation sequencing assay to detect the fusion products of ALK, ROS1 and RET with any fusion partner genes and hotspot mutations in FFPE samples",
        "Background":"['Targeted drugs have been widely used in the treatment of lung cancer, especially for non small cell lung cancer (NSCLC) patients. NCCN guideline lists multiple drugs which are particularly effective in the subgroup of patients with specific gene mutation variants, including the fusion transcripts of ALK, ROS1 and RET, and the mutations of EGFR, KRAS, BRAF and HER2. Multiple techniques have been developed to detect fusion transcripts in tumor samples, such as FISH, IHC and PCR assays. FISH is the most accurate method for fusion detection currently. The split probe FISH assay, which does not require the pre-knowledge of what is the fusion partner with ALK for example, can detect unknown ALK fusion products as well. However, it fails to identify which gene is fused with ALK (or other oncogene) in the chimera products, therefore is not informative for the mechanism or drug resistance study. In addition, due to the limitation on the fluoresce dye, it is quite difficult to multiplex fusion FISH probes for different genes into one assay.We describe here a next generation sequencing assay to detect a panel of fusion transcripts and mutations in one single assay. Our single assay can detect the fusion products of ALK, ROS1 and RET with any known or unknown fusion partners, together with the hotspot mutations in EGFR, KRAS, BRAF and HER2. Our assay can identify not only the exact sequence of the unknown fusion partners, but also any mutations within the full coding regions of ALK, ROS1 and RET. This information is critical for the resistance mechanism study and the next generation inhibitor drug development, since about half of the ALK inhibitor resistance was caused by the mutations in ALK gene itself. We have identified a novel ALK fusion gene with a never-reported fusion partner in a lung cancer patient. The xenograft model derived from this patient responds to crizotinib well in the in vivo study (published on Journal of Thoracic Oncology). We have demonstrated that our assay can reliably detect both the novel fusion and the well known EML4-ALK fusion from only 1-2 5um FFPE slides of the lung tumor tissues, together with other possible fusions and mutations as well.Note', ' This abstract was not presented at the meeting.']",
        "Doc_id":"AACR_2014-4668",
        "Doc_title":" A next generation sequencing assay to detect the fusion products of ALK, ROS1 and RET with any fusion partner genes and hotspot mutations in FFPE samples",
        "_version_":1606189005233192960},
      {
        "Meeting_name":" Tumor biomarker evaluation of 6,785 patients for combination treatment strategies in NSCLC.",
        "Background":"['Background', '  Non-small cell lung cancer (NSCLC) exhibits activation of multiple tumor pathways.  Presence of multiple aberrations may account for drug resistance as well as strategies for combination therapies. We examined concurrent aberrations of biomarkers in NSCLC to present an overview of potential patient cohorts who may benefit from such combinations.   Methods', '  6,785 NSCLC cases were evaluated.  Specific testing was performed and included a multiplatform approach', ' sequencing (Sanger, NGS), protein expression (IHC) and gene amplification (CISH/FISH).   Results', '  The EGFR mutation (MT) rate in this population was 12.7% (135/1059), of which 57% (55/96) overexpressed EGFR (IHC) and 61% (169/277) had EGFR gene amplification (FISH).  This demonstrates the dependence on the EGFR pathway and potential importance of dual inhibition with cetuximab and EGFR TKIs.  66% (63/96) and 7% (6/90) of EGFR MT patients were MET high (IHC) and amplified (CISH), respectively, suggesting potential benefit from dual targeting of EGFR and MET.  Interestingly, TP53 mutations were observed in 54% (70/129) of EGFR MT which has important implications for resistance to EGFR TKIs and possible cross-resistance to radiotherapy.  ALK translocations were observed in 101 of 3611 (2.8%) patients, among which 19% (7/36), 3% (1/29) and 2% (1/48) carried concurrent EGFR, MET and HER2 amplification (ISH), respectively, suggesting the potential for combining crizotinib with agents such as cetuximab, onartuzumab or trastuzumab.  A BRAF mutation was observed in 3.3% (34/1061), among which EGFR and MET expression was high by IHC (both have been implicated in resistance to BRAFi in other tumor types) in 58% (15/26) and 48% (12/25), respectively, indicating benefit from combination of newly approved dabrafenib with cetuximab or onartuzumab.   Conclusions', '  This is one of the largest analyses in the United States of biomarkers in NSCLC.Our study shows the non-exclusive activation of multiple pathways.  These results also show the importance of multiplatform testing as both protein, gene copy number and genetic alterations were detected.']",
        "Doc_id":"ASCO_133696-144",
        "Doc_title":" Tumor biomarker evaluation of 6,785 patients for combination treatment strategies in NSCLC.",
        "_version_":1606189008883286017},
      {
        "Meeting_name":" Detecting low abundant mutations in circulating cell free DNA and FFPE samples",
        "Background":"['Detection of low abundant alterations in oncogenes from circulating cell free DNA (cfDNA) samples or formaldehyde fixed-paraffin embedded samples (FFPE) has been a challenge for the community. Additionally, cfDNA and FFPE samples are typically limited in the amount of material that can be obtained, and often the FFPE samples are highly degraded, compounding the ability to sequence them and to perform accurate variant calling. To overcome these challenges, we have developed a single tube, multiplexed amplicon sequencing technology that employ hundreds of primer pairs for amplification of targeted loci, producing ready-to-run libraries for Illumina sequencing platforms. The resulting amplicons are less than 150 bp in length, enabling amplification and sensitive detection of mutations from cfDNA-sized DNA fragments or highly damaged DNA. A 200+ amplicon panel across 55 genes was developed to target known clinically relevant oncological mutations. The panel design encompasses single exons (e.g. BRAF) as well as comprehensive exon coverage of entire genes (e.g. TP53).DNA was extracted from FFPE, and cfDNA was extracted from fresh plasma. DNA was quantified by qPCR using 2 primer pairs targeting ALU repeat regions. 10ng of DNA input was used to perform the multiplexed PCR. Libraries were quantified by qPCR and sequenced with MiSEQ V2 reagents, paired end reads. Alignment was performed using Burrows-wheeler Aligner (BWA) and variant calling was performed with at least two validated publicly available tools and confirmed manually by IGV. A variety of tools were used to validate allele technology was used to validate the sequencing data.We interrogated 80 FFPE samples using our amplicon technology.The percent of on-target bases was over 95% and the coverage uniformity was over 98%, where uniformity is the percent based covered over 20% of the mean coverage. Out of the 40 colorectal cancer samples tested, 17 showed mutations in KRAS. Out of the 20 melanoma samples (Cure line) also analyzed, 9 were positive for BRAF V600E. The presence of those mutations was confirmed using myTprimerTM KRAS and BRAF qPCR assay. The limit of detection of the assay was set at 3% due to the inherent noise caused by the damage from the FFPE samples. For cell lines with known mutations, the sensitivity was 0.5%. No false positive or false negative were reported. 20 FFPE samples from different cancer types were also assessed. Mutations were identified in ERBB2 (cervical cancer), ALK (lung cancer) and TP53 (colon cancer) genes, as well as MET amplification (lung cancer).Cell free DNA provides a non-invasive tool to monitor cancer progression and treatment efficacy. Tumor DNA, matching blood DNA and cfDNA from 10 cancer patients will be subjected to our multiplex PCR oncology panel. Data of this study will be presented.Our results show that this unique multiplex PCR panel is an excellent tool to assess multiple oncogenes in limiting clinical samples, enabling high throughput, cost effective NGS analysis.']",
        "Doc_id":"AACR_2015-4902",
        "Doc_title":" Detecting low abundant mutations in circulating cell free DNA and FFPE samples",
        "_version_":1606188971681906688},
      {
        "Meeting_name":" Evaluation of genomic alterations in primary small cell carcinoma of the ovary (SCCO).",
        "Background":"['Background', ' As we have previously reported, SCCOis a rare, aggressive form of ovarian cancer associated with poor outcomes (Jamy 2015). In an effort to identify new treatment options, we utilized comprehensive genomic profiling to assess the potential for novel therapies in SCCO. Methods', ' Under an IRB approved protocol, we identified patients (pts) with SCCO, SCCO-HT (hypercalcemic type), neuroendocrine tumors of the ovary (NET-O) and small cell carcinoma of the lung (SCLC) profiled by Caris (company info) between 2007-2015. Tumors were assessed with up to 21 IHC stains, in situ hybridization of cMET, EGFR, HER2 and PIK3CA, and next generation sequencing (NGS) as well as Sanger sequencing of selected genes. Results', ' 46 pts with SCCO (10 SCCO, 18 SCCO-HT, 18 NET-O) were identified as well as 58 pts with SCLC. While small numbers prohibited comparisons SCCO patients were numerically younger (median 42 [range 12-75], SCCO-HT pts 26 [8-40] and NET-O pts 62 [13-76]) than SCLC pts 66 [36-86]. SCCO pts were numerically more likely to be metastatic (70%) than SCCO-HT (50%) or NET-O (33%) pts but at a similar rate to SCLC pts (65%). PD1 expression varied across tumor type with SCCO (100%), SCCO-HT (50%), NET-O (33%) vs SCLC (42%). PDL1 expression also varied with SCCO (50%), SCCO-HT (20%), NET-O (33%) and SCLC (0%). No amplifications were identified in cMET, EGFR, or HER2 and only 1 was found in PIK3CA (NET-O). Actionable mutations were rare with 50% of SCCO pts having a BRCA2 mutation and 29% of pts with NET-O having PIK3CA mutations. No other actionable mutations were identified. Conclusions', ' SCCO/NET-O represent rare and difficult to treat malignancies. While randomized trials will be difficult these tumors may respond to biomarker guided checkpoint or PARP inhibitors.']",
        "Doc_id":"ASCO_161369-176",
        "Doc_title":" Evaluation of genomic alterations in primary small cell carcinoma of the ovary (SCCO).",
        "_version_":1606188993501724672},
      {
        "Meeting_name":" Selective isolation of epithelial to mesenchymal transitioned circulating tumor cells in NSCLC using novel magnetic nanocubes.",
        "Background":"['The 5-year survival rate for early to advanced NSCLC patients is 10-5%. Once the tumor metastasizes, the survival rate often drops below 1%. One of the major challenges is to select the patient for appropriate therapy, and the selection process involves invasive biopsy that is difficult to recurrently perform during treatment. Recent studies have shown that liquid biopsy is an attractive alternative. Liquid biopsy involves analysis of either CTCs or ctDNA to understand the tumor therapy. Isolating entire tumor cells provide an opportunity to perform whole genome sequencing for in depth understanding of the tumor. However, frequent changes in cancer signaling and acquired mutations during treatment lead to drug resistance that cannot be diagnosed using current CTC techniques. These oncogenic biochemical modifications that are often associated with metastasis involve upregulation of epithelial to mesenchymal transition (EMT) pathway that change the elasticity of tumor cells for easy shedding into the blood stream. Consequently, EMT transition leads to depletion in epithelial markers such as EpCAM and cytokeratin that are to be targeted. This effect largely limits the use of present technologies utilizing EpCAM as a marker to isolate the CTCs. We hypothesized that these cells can be captured by targeting surface markers that are overexpressed in EM transitioned CTCs. For example, markers such as EGFR and HER2 have been shown to be overexpressed pre and post EMT tumors and therefore can present as a new strategy for non-invasive diagnosis before and during treatment. In this study we have shown that EGFR and HER2 receptors are overexpressed in EGFR and KRAS mutated NSCLC cells. We artificially activated EMT in NSCLC cells and compared the surface biomarker concentrations. Furthermore, we used protein analysis data using western blotting to identify our targets after EMT. Based on the biomarker concentrations, we designed and developed magnetic nanocubes (MNC) surface attached with antibodies to target the selected biomarkers to capture EMT CTCs. The capture efficiency of these magnetic nanocubes was compared in multiple cell lines (HCC827 and A549). Overall we could achieve capture as low as 10 spiked cells in our study. In conclusion, cancer markers such as EGFR and HER-2 that are highly expressed in tumors, once shed as CTCs can be targeted for diagnosis. Therefore, we have developed a novel method to capture EMT CTCs with high selectivity and this method presents a minimally-invasive method for real-time monitoring of patients during drug treatment.']",
        "Doc_id":"AACR_2017-3794",
        "Doc_title":" Selective isolation of epithelial to mesenchymal transitioned circulating tumor cells in NSCLC using novel magnetic nanocubes.",
        "_version_":1606189034229465088},
      {
        "Meeting_name":" HER2 mutations in lung adenocarcinoma",
        "Background":"['Background', '  A variety of somatic mutations and gene rearrangements have been described in patients with lung adenocarcinoma. The Lung Cancer Mutation Consortium (LCMC) tested for the presence of 10 driver mutations in over 1,000 patients with metastatic adenocarcinoma of the lung.  Methods', '  Tumor specimens were assessed for diagnosis and adequacy; multiplexed genotyping utilizing SNaPshot or Sequenom was performed, and mutations were recorded in GeneInsight database. We reviewed the LCMC database for patients tested for HER2 mutations and accessed clinical characteristics, including age and stage at diagnosis, sex, smoking status, treatment history, sites of metastatic disease, and vital status. We conducted an exploratory analysis to compare survival of HER2 mutated patients treated with HER2 targeted therapies to those who did not receive targeted therapies.  Results', '  Of the 920 patients tested for human epidermal growth factor receptor-2 (HER2) mutation, 24 patients (2.6%) had exon 20 insertion mutations. The mutation was located at exon 20 insertion at codon 775 in all patients; 1 patient also had concurrent MET amplification. The median age was 62 (37-84) and the majority were never smokers (71%). Nearly 70% had advanced stage disease at the time of diagnosis. There was a slight predominance of females (n=14) over males (n=10). The median survival for patients that received HER2 targeted therapies (n=12) or not (n=12) was 18.3 months and 16.4 months respectively. HER2- targeted therapies included dacomitinib (n=5), dacomitinib and crizotinib (n=1), neratinib (n=2), trastuzumab (n=1), lapatanib and trastuzumab (n=1), and STA-9090 (n=1). At last assessment of vital status, 50% (6/12) of the patients treated with targeted therapy were alive as compared to only 33% (4/12) of the remainder. The overall survival for HER2 mutated patients was worse than that for overall LCMC cohort in which median survival with genotype directed therapies was 3.5 years versus 2.4 years without targeted therapy.  Conclusions', '  HER2 mutations were detected in 2.6% of patients with lung adenocarcinoma. There was a favorable survival trend among patients that received HER2 targeted therapies.']",
        "Doc_id":"ASCO_133889-144",
        "Doc_title":" HER2 mutations in lung adenocarcinoma",
        "_version_":1606188981360263168},
      {
        "Meeting_name":" RG7116, a novel humanized anti-HER3 antibody with superior preclinical in vitro and in vivo efficacy in combination with, everolimus and other anti-cancer agents",
        "Background":"['HER3 is a member of the Human Epidermal Growth Factor Receptor (HER) family. HER3 is a kinase dead receptor, but by forming heterodimers with other HER family receptors, HER3 works as amplifier for PI3 kinase driven tumorigenesis. It has been reported that tumors treated with EGFR-, HER2-, cMET-or mTOR targeted therapies can escape via HER3 activation or upregulation. HER3 is expressed in a large variety of tumors for example in non-small cell lung cancer (NSCLC), head and neck, colorectal, gastric, pancreatic, breast, ovarian, thyroid and prostate cancer. Anti-HER3 antibodies can work via various mechanisms including', ' (1) blocking ligand (HRGs) binding to the receptor, (2) blocking heterodimerization with other HER family members (HER1, 2 and 4), (3) downregulation of the receptor from the cell surface, and (4) engaging immune effector functions such as antibody-dependent cellular cytotoxicity (ADCC). The first three mechanisms lead to inhibition of HER3 phosphorylation and downstream signaling thereby resulting in tumor cell growth inhibition, while ADCC is a mechanism of direct target cell killing triggered by cross-linking of Fc receptors on immune effector cells (e.g. NK cells, macrophages).RG7116 is a novel humanized and glycoengineered IgG1 antibody currently in clinical development, that binds to HER3 with high affinity. This antibody prevents ligand binding and receptor heterodimerization, thereby blocking receptor phosphorylation. In various tumor xenograft models monotherapy treatment with this antibody leads to substantial tumor growth inhibition. Only in a few cases monotherapy treatment resulted in complete tumor remission. Most of the models initially show convincing efficacy, but tumors regrow after a while. Combination therapy with other HER targeted therapies such as pertuzumab, cetuximab or erlotinib, lead to complete remission in preclinical models. The combination of RG7116 with downstream signaling inhibitors like', ' everolimus (mTOR) andand other anti-cancer agents leads to increased efficacy.']",
        "Doc_id":"AACR_2014-2668",
        "Doc_title":" RG7116, a novel humanized anti-HER3 antibody with superior preclinical in vitro and in vivo efficacy in combination with, everolimus and other anti-cancer agents",
        "_version_":1606189031471710208},
      {
        "Meeting_name":" Phase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with other antitumor agents.",
        "Background":"['Background', '  Inhibition of phosphatidylinositol-3-kinase (PI3K)-mediated signaling may overcome resistance to different classes of chemotherapies as well as epidermal growth factor receptor (EGFR) inhibitors. PF-05212384 (PF384) is an intravenous (IV) inhibitor of PI3K/mammalian target of rapamycin (mTOR) in development for metastatic colorectal cancer and other solid tumors in combination with other agents.  Methods', '  An ongoing phase I dose escalation study is enrolling cohorts of 36 patients (pts) to determine maximum tolerated dose (MTD) and safety of PF384 plus docetaxel (arm A), cisplatin (arm B), or the EGFR tyrosine kinase inhibitor dacomitinib (arm C). Eligible pts have castrate resistant prostate cancer, advanced breast cancer, or non-small cell lung cancer (NSCLC; arm A); urothelial transitional cell cancer, triple negative breast cancer, or NSCLC (arm B); or refractory Her2+ breast cancer, Her2+ esophagogastric cancer, head and neck squamous cell cancer, or EGFR-mutated NSCLC (arm C). Dose assignment is guided by a modified toxicity probability interval method (arms A,B) or zone-based design (arm C). Pts receive a lead-in PF384dose 7 (arms A,B) or 14 days (arm C) prior to cycle 1 day 1. Then, pts receive weekly PF384plus standard chemotherapy (docetaxel or cisplatin 75 mg IV every 3 wk) or dacomitinib (3045 mg/d orally; started 7 days prior to cycle 1 day 1). Primary endpoint is cycle 1 dose-limiting toxicities (DLTs), including lead-in dose. Secondary endpoints include pharmacokinetics, tumor response, and PI3K pathway protein biomarkers.  Results', '  52 pts received escalating doses (90150 mg) of PF384', ' 14, 12, and 26 pts in arms A, B, and C. Drug-related adverse events in > 30% pts were neutropenia, mucositis, and nausea in arm A; nausea, decreased appetite, fatigue, vomiting, anemia, and hypomagnesaemia in arm B; and mucositis, diarrhea, nausea, dermatitis acneiform, and decreased appetite in arm C. There were no DLTs in arms A or B; in arm C, DLTs were grade 3 mucositis, pneumonitis, and rash, and grade 2 fatigue ( < 75% of planned dose received).  Conclusions', '  PF384can be combined with docetaxel, cisplatin, or dacomitinib with a manageable toxicity profile. Dose escalation to determine MTD is ongoing. Clinical trial information', ' NCT01920061']",
        "Doc_id":"ASCO_147210-156",
        "Doc_title":" Phase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with other antitumor agents.",
        "_version_":1606188997693931520},
      {
        "Meeting_name":" Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut)",
        "Background":"['Background', '    Afatinib (A) is an oral, irreversible ErbB family blocker of EGFR, HER2, ErbB3 and ErbB4 signalling. LL3 compared A with cisplatin/pemetrexed in 345 pts recruited globally and LL6 compared A with gemcitabine/cisplatin in 364 Asian pts. The primary analysis (2012) showed improved progression-free survival (PFS) with A versus CT in the overall EGFR mut positive population (HR=0.58 [LL3], HR=0.28 [LL6]) and pts with common (Del19/L858R) EGFR mut (HR=0.47 [LL3], HR=0.25 [LL6]). The FDA has approved A for the first-line treatment of pts with advanced NSCLC harboring common EGFR mut. Here we present a pooled analysis of mature OS data among such pts.  Methods', '    Treatment-nave pts with EGFR mut stage IIIB/IV NSCLC were randomized 2', '1 to 40 mg A or up to 6 cycles of standard CT and stratified by EGFR mut and race (LL3). The primary endpoint was PFS, with OS as a key secondary endpoint. Adverse events were also recorded.  Results', '    The pooled analysis included 631/709 pts randomized into LL3 and LL6 with common EGFR mut (Del19=355, L858R=276); 419 pts received A and 212 received CT. At the time of analysis (January 2014), 404 (64%) pts had died. Median follow-up for OS was 36.5 months. Following progression, 78% of pts received subsequent systemic therapies (median of 3 regimens); 68% in the CT group received EGFR TKIs and 70% in the A group received CT. OS was significantly improved with A versus CT (median 27.3 vs 24.3 months, HR=0.81 [CI 0.66, 0.99; p=0.037]). Individual HRs for OS in LL3 and LL6 were consistent with the pooled analysis. Among Del19 pts the HR=0.59 (CI 0.45, 0.77; p<0.001) and in L858R pts the HR=1.25 (CI 0.92, 1.71; p=0.160). Updated PFS and safety findings were consistent with earlier primary reports.   Conclusions', '    This pooled analysis reveals that first-line A significantly improves OS in pts with advanced NSCLC harboring common EGFR mut (Del19/L858R) compared with CT. This is the first analysis to show that genotype-directed therapy for EGFR mut pts can improve survival. Clinical trial information', ' NCT00949650.']",
        "Doc_id":"ASCO_129081-144",
        "Doc_title":" Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut)",
        "_version_":1606188994984411136},
      {
        "Meeting_name":" Targetable genetic alterations screen by broad, hybrid capture-based next generation sequencing in driver-negative advanced malignant tumor facilitated personalized therapy.",
        "Background":"['Background', '    There were few effective regimens in treating advanced malignant tumor, especially for those which previous routine genetic assay had not yielded a targetable alteration. In this study, a broad, hybrid capture-based next generation sequencing (NGS) assay was used to identify additionally targetable genetic alterations from cancer tissue. Consequently, approved molecular target drugs or available agents on clinical trials could be selected for these driver-negative patients.  Methods', '    114 cases of advanced tumor (19 lung cancers, 46 breast cancers, 21 gastric cancers, and 28 colorectal cancers) were tested. The 114 tumor biopsies were all previously tested negative of specific alterations by multiple non-NGS methods (including EGFR, k-ras mutation, and ALK rearrangement in lung cancer, HER2 gene copy number amplification in breast or gastric cancer, RAS and RAF mutation in colorectal cancer). 7708 exons of 508 tumor related genes and 78 introns of 19 frequently rearranged genes were assessed for base substitutions, indels, copy number alterations, and gene fusions. The average median sequencing depth was 460.  Results', '    The targetable genetic alterations were detected in 13 of 19 (68.4%) lung cancers and 16 of 28 (57.1%) colorectal cancers. Its worth noting that these alterations were only found in 18 of 46 (39.1%) breast cancers and as low as 6 of 21(28.6%) gastric cancers. More specifically, the common actionable alterations were in PTEN (n = 8), EGFR (n = 7), PIK3CA (n = 6), HER2 (n = 5), BRCA1/2 (n = 4), andFBXW7 (n = 4). Partial patients had received targeted therapy including TKI inhibitor, mTOR inhibitor and anti-HER2 agents.  Conclusions', '    46.5 % (53/114) of driver-negative advanced malignant tumor harbored at least one actionable genetic alteration identified by NGS testing. The detected genetic alterations frequency in lung cancer and colorectal cancer was much higher than that of breast cancer and gastric cancer. These findings suggest that high throughput NGS testing in cancer tissue might help identify available targeted drugs especially for the driver-negative advanced malignances.']",
        "Doc_id":"ASCO_148702-156",
        "Doc_title":" Targetable genetic alterations screen by broad, hybrid capture-based next generation sequencing in driver-negative advanced malignant tumor facilitated personalized therapy.",
        "_version_":1606189028438179840},
      {
        "Meeting_name":" A real-time PCR assay for detecting EGFR mutations in formalin-fixed paraffin-embedded tissue (FFPET) specimens of non-small cell lung cancer (NSCLC)",
        "Background":"['EGFR mutations identify patients with NSCLC who have a high likelihood of benefiting from first-line treatment with anti-EGFR tyrosine kinase inhibitors. Sanger sequencing is widely used for mutation detection but can be time-consuming, and has limited sensitivity for low levels of mutations. We describe the analytic performance of the cobas EGFR Mutation Test, a multiplex, 3-reaction real-time PCR assay designed to detect 41 mutations in exons 18, 19, 20 and 21. The mutations detected and the mutation report calls are listed below', ' The amount of DNA required for the assay (150 ng) can typically be isolated from a single 5-micron FFPET section, and the test can be performed in < 8 hours. Analytic sensitivity was assessed using DNA blends from NSCLC FFPET tumor sections. A >95% hit rate was obtained in blends with >5% mutant alleles for L858R and exon 19 deletions as determined by 454 sequencing (quantitative massively parallel pyrosequencing) at a total DNA input of 150ng, or 50 ng per PCR amplification. The cobas test was compared to 2x bidirectional Sanger sequencing using a set of 152 NSCLC FFPET specimens. The overall percent agreement (OPA) between the 2 methods was 96.7% (negative agreement - NPA 97.5%; positive agreement - PPA 95.8%). Specimens with discordant cobas EGFR Test and Sanger results were analyzed by 454 and a revised agreement analysis was performed based on the composite results of the 3 assays. The revised OPA was 98.7% (NPA 98.8%; PPA 98.6%). The call repeatability of a panel of NSCLC FFPET specimens was 98% when tested with two operators, instruments, and reagent lots. Necrotic tissue, hemoglobin, triglycerides, and common respiratory organisms did not interfere with the assay. The test showed no cross reactivity with the corresponding exon sequences from the HER2, HER3, and HER4 genes. These analytic studies demonstrate that the cobas EGFR Mutation Test is a sensitive, accurate and reproducible assay.']",
        "Doc_id":"AACR_2012-1707",
        "Doc_title":" A real-time PCR assay for detecting EGFR mutations in formalin-fixed paraffin-embedded tissue (FFPET) specimens of non-small cell lung cancer (NSCLC)",
        "_version_":1606189012442152960},
      {
        "Meeting_name":" Analysis of MET-amplified solid tumors using chromogenic in situ hybridization (CISH)",
        "Background":"['MET amplification has been implicated in signaling pathways that promote cell proliferation, invasion, and survival. It has been identified as an oncogenic driver in various malignancies and is currently being investigated as a potential therapeutic target. To date, MET exon 14 skipping by sequencing and MET amplification by FISH have been found to have potential clinical utility in predicting those patients who may derive benefit from MET-targeted therapy. However, little research has been conducted on alternative technologies to FISH such as CISH, which does not require a dark room and can be interpreted by a board-certified pathologist. The purpose of this study is to report our experience with MET amplification across solid tumors using CISH.A retrospective analysis was done on 26,619 specimens analyzed for MET amplification by CISH at a CLIA-certified lab (Caris Life Sciences). The validated CISH assay, previously validated against a FISH assay, utilized a gene copy number > 5 to assess amplification. Concordance and correlative studies were done in MET-amplified, non-small cell lung cancer (NSCLC) specimens analyzed using a cMET IHC (SP44, 2+ or 3+ staining intensity in 50% or more tumor cell membrane) analyzing protein expression. Correlative studies involving co-existing aberrations, including PD-L1 (SP142, any intensity in at least 50% of tumor cells), in this MET-amplified, NSCLC cohort were also performed.MET amplification utilizing CISH was 0.7% (188/26,619) overall. MET-amplified solid tumors included carcinomas such as NSCLC (3.1%, 87/2767), gastric adenocarcinoma (3.8%, 11/293), esophageal and esophagogastric junction adenocarcinoma (3.3%, 11/338), and endometrial carcinoma (0.4%, 9/2020) along with non-carcinomas, including glioblastoma multiforme (1.0%, 5/510), uterine sarcoma (1.3%, 5/400), melanoma (0.4%, 2/538), and rare tumors such as placental-site trophoblastic tumor (100%, 1/1) and prostatic neuroendocrine tumor (100%, 1/1). A sub-analysis of MET-amplified, NSCLC specimens demonstrated co-occurring protein overexpression in 92.6% (75/81) of cases. These same MET-amplified, NSCLC specimens were found to have EGFR pathogenic/presumed pathogenic mutations (19.7%, 15/76), ALK rearrangements (2.5%, 2/80), and PD-L1 overexpression (27.5%, 14/51). ROS1 rearrangements were not detected in this NSCLC cohort (0%, 0/76).Our data suggest MET amplification detection utilizing CISH is a viable option for identifying MET-driven cancers. The presence of MET across various solid tumors contrasts with biomarkers like HER2, which are exclusive to carcinomas. A sub-analysis of our NSCLC population shows MET-amplified tumors contains a similar molecular distribution to the general NSCLC population. Future studies should incorporate MET CISH in clinical trials utilizing MET-targeted agents to determine its potential as a predictive test for evaluating who may derive the most benefit.']",
        "Doc_id":"AACR_2016-396",
        "Doc_title":" Analysis of MET-amplified solid tumors using chromogenic in situ hybridization (CISH)",
        "_version_":1606188983115579392},
      {
        "Meeting_name":" Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514.",
        "Background":"['Background', ' BMS-690514 is an oral selective inhibitor of EGFR, HER2, and VEGFR1-3. Previous results from the phase I portion of this phase I/II study established 200 mg/day as safe and tolerable (ASCO 2008; abstr 2564). Methods', ' Erlotinib-nave and erlotinib-resistant adult patients with advanced/metastatic, measurable NSCLC received BMS-690514 200 mg/d. Eligible patients had an ECOG PS 1 and adequate organ function. Objectives were to assess disease control rate (DCR; CR, PR, SD >4 months), safety, PK and potential predictive and PD biomarkers of BMS-690514. Response was assessed every 8 weeks (modified WHO criteria). Predictive biomarkers included EGFR copy number, and EGFR and KRAS mutations. PD biomarkers included immunohistochemistry of EGFR signaling proteins in skin biopsies, circulating sVEGFR2, blood pressure, skin rash and diarrhea. Results', ' For 60 patients treated, DCR were 11/28 (39%) and 7/32 (22%) for erlotinib-naive and -resistant patients, respectively. DCR was significantly higher among patients harboring an EGFR mutation (6/8) than those with WT EGFR (5/18). One erlotinib-naive patient had PR (57 wks) and subsequent surgical removal of remaining tumor. Regression (48%) was seen in one erlotinib-naive patient harboring a KRAS G13D mutation. One erlotinib-resistant patient had PR (66%, 31 wks). Two erlotinib-resistant patients with EGFR T790M mutations had SD with 6% and 31% decrease in tumor burden. Most frequent treatment-related AES were diarrhea (90%), skin rash (31%), asthenia (29%), anorexia (27%), hypertension (26%), and reversible acute renal insufficiency (11%). sVEGFR2 (14% decrease from baseline, n=14) and decreased pMAPK levels from skin biopsies (14 of 18 pts) were consistent with EGFR and VEGFR2 inhibition. Conclusions', ' BMS-690514 200 mg/d showed evidence of anti-tumor activity and disease control in patients with NSCLC, including erlotinib-resistant and those with WT EGFR, EGFR T790M or KRAS mutations. Predictive and PD clinical biomarkers confirmed inhibition of both EGFR and VEGFR signaling pathways by BMS-690514. A randomized phase II trial versus erlotinib in NSCLC is underway.']",
        "Doc_id":"ASCO_34621-65",
        "Doc_title":" Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514.",
        "_version_":1606188989964877825},
      {
        "Meeting_name":" Non-covalent EGFR T790M targeting TKIs inhibit AZD9291 resistant EGFR C797S mutants.",
        "Background":"['Approximately 10-15% of non-small-cell lung cancers (NSCLC) have epidermal growth factor receptor (EGFR) mutations resulting in increased sensitivity to 1st generation tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib. For common mutations in EGFR, treatment with 1st generation TKIs results in approximately 70% overall response rate, increased progression free survival, and increased quality of life compared to chemotherapy alone. However, resistance to 1st generation TKIs typically develops within ~12 months, and approximately 55% of patients acquire a secondary mutation in EGFR Exon 20, T790M. To overcome resistance, 2nd and 3rd generation covalently binding TKIs targeting T790M mutations have been developed. Recent studies show that approximately 40% of acquired resistance to 2nd and 3rd generation TKIs can also occur via a third acquired EGFR mutation at the site of covalent binding, C797S. To date, there are no standard approved targeted therapies for treating EGFR C797S mutant NSCLC. Moreover, with proposed increased use of covalent inhibitors in the first line setting, C797S mutations are expected to become more prevalent and new strategies to overcome therapeutic resistance will be required. To this end, we have generated stable Ba/F3 and HCC827 NSCLC cell lines expressing C797S mutant EGF receptors with common mutations in EGFR including, L858R/T790M/C797S, and Ex19del/T790M/C797S. EGFR mutant cell lines expressing C797S were screened against 1st, 2nd, and 3rd generation EGFR TKIs and cell viability was determined using Cell Titer Glo. Triple mutant cell lines containing T790M and C797S mutations were not sensitive to any 1st, 2nd, or 3rd generation inhibitors with IC50 values of >10M, 7.0M, and 7.6M, respectively. However Ba/F3 and HCC827 cell lines transfected with EGFR triple mutants were inhibited by non-covalent inhibitors', ' CUDC-101, an EGFR, HER2 and HDAC inhibitor, and PKC412, a FLT3 inhibitor. In triple mutant Ba/F3 cells, CUDC-101 and PKC412 had IC50 values of 470nM and 250nM in Ex19del/T790M/C797S EGFR mutants, respectively, and IC50 values of 690nM and 270nM in L858R/T790M/C797S EGFR mutants. In HCC827 cells, PKC412 had IC50 values of 610nM and 520nM in L858R/T790M/C797S and Ex19del/T790M/C797S triple mutants, respectively. In addition, western blot analysis of triple mutant Ba/F3 cells showed decreased phosphorylation of EGFR in presence of 50nM PKC412 and 500nM of CUDC-101. Moreover, PKC412 partially decreased p-EGFR expression at 50nM in HCC827 triple mutant cell lines. In conclusion, unlike other EGFR TKIs, the non-covalent EGFR inhibitors CUDC-101 and PKC412 inhibit both T790M and C797S EGFR mutants at low concentrations. Currently, we are establishing additional osimertinib resistant HCC827, H1975, PC9 and H4006 cell lines for further in vitro and in vivo studies.']",
        "Doc_id":"AACR_2017-2061",
        "Doc_title":" Non-covalent EGFR T790M targeting TKIs inhibit AZD9291 resistant EGFR C797S mutants.",
        "_version_":1606188990307762176},
      {
        "Meeting_name":" Alterations in two oncogenic drivers",
        "Background":"['Background', '  Little is known of prognosis and the efficacy of targeted therapies in patients whose lung adenocarcinomas harbor two oncogenic drivers.  Methods', '  We identified patients treated at MSKCC from 2009-2013 whose lung adenocarcinomas harbored two oncogenic drivers. Molecular diagnostic testing was performed via an institutional algorithm involving 1 of the following', ' mutational hotspot testing (91 mutations in EGFR, HER2, KRAS, NRAS, BRAF, MAP2K1, PIK3CA and AKT1), multiplex sizing assays (insertions/deletions in EGFR and HER2), and break apart FISH tests (fusions involving ALK, ROS1 and RET). Overall survival (OS) and duration of response to EGFR tyrosine kinase inhibitor (TKI) therapy (EGFR-mutant subgroup) were assessed using Kaplan-Meier estimates. Outcomes were compared between double-driver and single-driver stage-matched control groups from the Lung Cancer Mutation Consortium study (log-rank test).  Results', '  49 patients (55% KRAS-mutant, 39% EGFR-mutant, 2% BRAF-mutant, 2% MAP2K1-mutant, 2% ALK fusion-positive) were found to have a driver in a second gene (PIK3CA 94% or AKT1 6%). In patients with advanced disease (stage IIIB/IV), the median OS was worse if their tumors harbored a concurrent PIK3CA or AKT1 mutation (n=31, 11 mo, 95%CI 8.9-23.1) vs a single-driver (n=87, 24 mo, 95%CI 16.2-31.1, p=0.017). Median OS in subgroups (concurrent PIK3CA or AKT1 vs not) were as follows', ' KRAS-mutant (8 vs 12 mo, p=0.032), EGFR-mutant (18 vs 34 mo, p=0.066), and PIK3CA-mutant (concurrent driver vs not; 14 vs 21 mo, p=0.840). In patients with EGFR-mutant lung cancers who received single-agent EGFR TKIs, while the median duration of therapy was similar between groups (15 vs 15 mo, single vs double, p=0.157), 33% (95% CI 19-59%) of patients with EGFR-mutant-only tumors versus 0% with concurrent PIK3CA or AKT1-mutated tumors remained on therapy at 2 and 3 years.  Conclusions', '  In patients with metastatic oncogene-driven lung adenocarcinomas, the presence of a concurrent PI3KCA or AKT1 mutation is a negative prognostic factor for OS. In EGFR-mutant lung cancers, continued EGFR TKI benefit at 2 yrs was observed only in patients without concurrent PIK3CA or AKT1 mutations.']",
        "Doc_id":"ASCO_129982-144",
        "Doc_title":" Alterations in two oncogenic drivers",
        "_version_":1606188993017282561},
      {
        "Meeting_name":" Novel targets mediating resistance to EGFR/c-Met tyrosine kinase inhibitors in NSCLC.",
        "Background":"['Combination therapy of c-Met/EGFR TKIs against c-Met/EGFR, while initially effective, has been shown to be susceptible to acquired resistance. To establish a mechanism of TKI resistance, the NSCLC model cell lines H2170 and H358 were made resistant to the c-Met/EGFR TKIs SU11274, erlotinib, or a combination by exposing the cells to progressively increasing concentrations of inhibitors. Phospho-Met (Tyr1003) was found to be downregulated 4- and 1.5- fold in H2170 and H358 cells, respectively. Phospho-EGFR was found to be upregulated in H2170 cells and downregulated in H358 cells. Interestingly, no significant differences were observed in c-Met/EGFR downstream signaling proteins, indicating that alternative signaling pathways such as the canonical Wnt pathway may confer TKI resistance. To determine differences in Wnt signaling between parental and resistant cell lines, immunoblotting was performed. In the H2170 erlotinib resistant (H2170-ER) cell line, a 5- and 6-fold increase in phospho-LRP5/6 as well as a 2- and 3-fold increase in total-LRP5/6 was observed in the presence or absence of erlotinib, respectively. Furthermore, H2170-ER cells exhibited a 3- and 16-fold increase in NKD2 as well as a 2.5- and 6-fold increase in Wnt3A in the presence or absence of EGF, respectively. A 2- to 2.5-fold increase was also observed in DVL2/3 in the absence of EGF. However, the Wnt pathway did not seem to have a significant role in H358 cells. Since EGFR and Wnt signaling are known to exhibit crosstalk, activation of the Wnt pathway may stimulate activation of EGFR causing resistance. This is suggested as upregulation of proteins involved in the Wnt pathway was seen only in the H2170 cell line. These results were confirmed by treating H2170 cells with the Wnt inhibitor XAV939. MTT analysis indicated that parental cells showed no significant response to XAV939, however, resistant cell lines showed a 2-fold decrease in viability when compared to a c-Met/EGFR TKI combination treatment. We propose a new treatment modality with Wnt inhibitors which have not yet entered clinical testing.To identify new targets for NSCLC, stable isotope labeling by heavy/light amino acids in cell culture (SILAC) coupled with mass spectroscopy was used. Analysis revealed more than 200 proteins modulated greater than 1.5-fold, six of which have significant potential to influence cell growth and survival based on their biological roles in NSCLC. These proteins include total--catenin, TPR, syntenin, HMGB2, TOM34 and AIF. We are currently using tandem mass tagging (TMT) to further investigate additional modulated proteins. Proteins of interest identified by this method include TPD52, erbB2, MESDC2, PIN1, PEA15 and NRAS. Proteins confirmed to be upregulated/activated in resistant cell lines will be further investigated as targets which induce drug resistance in NSCLC.Citation Format', ' Ryan Jacobs, Jason Fong, David Moravec, Greg Botting, Ryan Bomgarden, John Rogers, Rosa Viner, Michael Blank, Neelu Puri. Novel targets mediating resistance to EGFR/c-Met tyrosine kinase inhibitors in NSCLC. [abstract]. In', ' Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA)', ' AACR; Cancer Res 2013;73(8 Suppl)', 'Abstract nr 5653. doi', '10.1158/1538-7445.AM2013-5653']",
        "Doc_id":"AACR_2013-5653",
        "Doc_title":" Novel targets mediating resistance to EGFR/c-Met tyrosine kinase inhibitors in NSCLC.",
        "_version_":1606188971417665536},
      {
        "Meeting_name":" In vivo generation of EGFR-TKI resistance in a patient-derived xenograft (PDX) with an activating EGFR mutation (L858R), and molecular characterisation of resistance mechanisms..",
        "Background":"['BACKGROUND', ' Non-small cell lung cancer (NSCLC) patients that have activating mutations in the EGFR gene are treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) e.g. Erlotinib (Tarceva) and Gefitinib (Iressa). Most NSCLC patients with activating EGFR mutations will respond to EGFR-TKIs; however, in about 50% of these cases a secondary mutation in EGFR (T790M) subsequently occurs which results in resistance to treatment. Other mechanisms of clinical resistance can also occur such as amplification of MET kinase and EMT conversion; however, additional routes of resistance are poorly defined. Using a novel patient-derived NSCLC xenograft model, driven by the L858R EGFR mutation, we set out to recapitulate the reported clinical routes of resistance to EGFR inhibitors and to evaluate if additional mechanism could also be identified.METHODS', ' LION102 is a NSCLC adenocarcinoma patient-derived xenograft (PDX) model with an activating EGFR mutation (L858R) which is maintained subcutaneously in vivo admixed with a human stromal cell component. Resistant models were generated in vivo through repeated cycling of treatment for up to 10 weeks with EGFR-TKI alone or in combination with a MET inhibitor. Resistant tumour material was characterised for further mutations in the EGFR gene by direct sequencing as well as for MET, AXL and HER2 over-expression and genomic amplification by quantitative PCR; Epithelial-to-Mesenchymal transition (EMT) was assessed by immunohistochemistry (IHC).RESULTS', ' Nave LION102 PDX tumours exhibited exquisite sensitivity to EGFR-TKIs (100% reduction in pre-treatment tumour volume, p<0.0001). Following successive cycles of EGFR-TKI treatment in vivo several resistant subtypes were generated and characterized.CONCLUSIONS', ' EGFR-TKI resistant subtypes were generated in vivo from a proprietary patient-derived xenograft model (LION102) bearing an activating EGFR mutation (L858R) and characterised for their resistance mechanism. PDX models of resistance will be invaluable in assessing novel agents targeting the EGFR pathway and the development of new combination strategies which seek to prevent or overcome resistance to EGFR-TKIs.']",
        "Doc_id":"AACR_2013-5651",
        "Doc_title":" In vivo generation of EGFR-TKI resistance in a patient-derived xenograft (PDX) with an activating EGFR mutation (L858R), and molecular characterisation of resistance mechanisms..",
        "_version_":1606188998858899456},
      {
        "Meeting_name":" Studying cancer drug resistance in patient derived xenograft tumor models",
        "Background":"['Anti-cancer drugs, either targeted therapies or cytotoxic chemotherapies, have proven to be effective in treating certain cancer patients. However, in most cases, tumors recur and become resistant to the treatment after a period of time. There are urgent needs to understand the underlying drug resistance mechanisms, to discover drug resistance targets and drug resistance biomarkers and to develop new therapies or combination therapies to tackle this widely occurring clinical problem. Currently the main approaches to study cancer drug resistance include analyzing clinical samples and developing drug resistance models in vitro. Numerous potential resistance mechanisms have been revealed. However, validation of these findings in a clinical-like setting and to test therapies in preclinical studies requires in vivo tumor models of drug resistance.At GenenDesign, we have developed cancer drug resistance PDX tumor models through short term drug testing or long term treatment of xenograft tumor mice. Cancer drugs investigated in our studies include major classes of targeted therapeutic modalities such as Her2 inhibitors, EGFR inhibitors, FGFR inhibitors and cMet/ALK inhibitors, as well as several standard of care (SoC) chemotherapies. From these studies, we have identified de novo resistance models, acquired resistance models and reversible resistance models in multiple cancer types including lung cancer and gastric cancer.In analyzing more than a dozen of Her2 positive but Herceptin resistance PDX models, we have uncovered molecular abnormalities such as Pten deletion, PI3K mutation, amplification of EGFR, cMet and cyclin E, which have been reported previously to be associated with Herceptin resistance in early studies. Studies are on-going to test whether combination therapies will be effective in overcoming Herceptin resistance.In drug response profiling of our PDX models, we also found wide spread phenotypical and functional heterogeneity in individual tumors. The heterogeneity within each tumor, in some cases, contributed to evolving of drug resistance from initially responsive tumors.']",
        "Doc_id":"AACR_2014-1212",
        "Doc_title":" Studying cancer drug resistance in patient derived xenograft tumor models",
        "_version_":1606189027761848321},
      {
        "Meeting_name":" Broad, hybrid capture-based next generation sequencing of circulating tumor DNA identified actionable genetic alterations in advanced cancer with treatment resistance.",
        "Background":"['Background', '    Circulating tumor DNA (ctDNA) is an optional specimen used to identify potentially targetable genetic alterations in solid tumors, particularly for those that developed treatment resistance and cancer tissue sample cannot be obtained. There are still few sensitive and clinically applicable ctDNA detection methods. In this study, we used a broad, hybrid capture-based next generation sequencing (NGS) assay to screen actionable genetic alterations in plasma ctDNA with diverse cancer patients.   Methods', '    147 cases of advanced tumor were enrolled, including 65 lung cancers, 39 breast cancers, 23 gastric cancers, and 20 colorectal cancers. 7708 exons of 508 tumor related genes and 78 introns of 19 frequently rearranged genes were assessed for base substitutions, indels, copy number alterations, and gene fusions. The average median sequencing depth was 940.  Results', '    Targetable genetic alterations were detected in 19 of 65 (29.2%) lung cancers, 15 of 39 (38.5%) breast cancers, and 6 of 20 (30%) colorectal cancers. Remarkably, these alterations were only found in 3 of 23 (13.0%) gastric cancers. Specifically, EGFR mutation was found in 8 of 65 (12.3%) lung cancers. HER2 gene amplification was detected in 8 of 39 (20.5%) breast cancers, and in 1 of 23 (4.3%) gastric cancers. Additionally, K-ras mutation was found in 4 of 20 (20.0%) colorectal cancers. The common actionable alterations found in various cancer types were in HER2 (n = 12), EGFR (n = 9), K-ras (n = 6), and PTEN (n = 4).   Conclusions', '    29.3% (43/147) of all ctDNA samples harbored at least one actionable genetic alteration identified by NGS testing. Noninvasive actionable genetic alterations detection in ctDNA by NGS assay might be an efficient strategy to guide personalized therapy for advanced cancer patients.']",
        "Doc_id":"ASCO_148642-156",
        "Doc_title":" Broad, hybrid capture-based next generation sequencing of circulating tumor DNA identified actionable genetic alterations in advanced cancer with treatment resistance.",
        "_version_":1606189035110268928},
      {
        "Meeting_name":" KL-ON113, a novel orally available dual EGFR kinase inhibitor targeting EGFR-activating and T790M mutants",
        "Background":"['Introduction', ' First generation reversible, ATP competitive inhibitors, gefitinib and erlotinib are effective treatments for a subset of non-small cell lung cancers, in particular specific EGFR-activating mutations. However their initial efficacy is limited by the development of drug resistance mutations, including the gatekeeper T790M mutation. Second-generation irreversible EGFR inhibitors that were designed to overcome the drug resistance by T790M mutation have thus far had limited success. Our goal was then to develop a dual kinase EGFR inhibitor effective against gefitinib sensitive and resistant (T790M) mutations. Herein, we describe the biological and pharmacokinetic properties of a representative molecule, KL-ON113 from a series of novel and small molecule EGFR inhibitors as a clinical development for non-small cell lung cancer (NSCLC).Experimental Procedures', ' Based on structure activity relationship (SAR) studies, we identified a novel dual kinase EGFR inhibitor, KL-ON113 effective against gefitinib sensitive and resistant (T790M) mutations. EGFR tyrosine kinase activity of KL-ON113 was determined using HTRF KinEASE assay kit (CisBio, Bedford, MA) with modifications. EGF induced cell proliferation assay (XTT) was conducted to determine the growth inhibitory effect of KL-ON113 in EGFR expressing WT and mutant cell lines. Inhibition of EGF induced EGFR phosphorylation (Y1173) in A431 cells was measured by PathScan Phospho-EGF Receptor (Tyr1173) Sandwich ELISA Kit (Cell Signaling Technology, Beverly, MA). Metabolic stability of the KL-ON113 was evaluated in microsomes obtained from mouse, rat, monkey, and human. Pharmacokinetic behavior of KL-ON113 in plasma after single dose oral administration or IV injection was determined in female Balb/c mice.Results', ' KL-ON113 demonstrated remarkable potency against the purified EGFR/HER2 including EGFR (wt), EGFR (L858R), EGFR (delE746_A750), EGFR (T790M), EGFR (L858R/T790M) and HER2 with IC50 of 12nM, 1.3nM, 0.9nM, 49nM, 325nM and 14nM, respectively with 100-fold more active against gefitinib/erlotinib resistant L858R/T790M EGFR mutant. Additionally, KL-ON113 caused a significant reduction in viability & EGFR phosphorylation (Y1173) in A431 cells, while no effect observed in normal WI-38 lung fibroblast cells confirming its selectivity. Pharmacokinetic studies in female Balb/c mice indicated good oral bioavailability of 80% for KL-ON113. Further, KL-ON113 was metabolically stable across the species studied.Conclusions', ' Our findings demonstrate that KL-ON113 as a potent dual kinase EGFR inhibitor effective against gefitinib sensitive and resistant (T790M) mutations with a favorable pharmacokinetic profile. KL-ON113 is also being tested for its in-vivo efficacy in NSCLC xenograft models harboring EGFR WT and EGFR L858R/T790M besides selectivity against other receptor tyrosine kinases.']",
        "Doc_id":"AACR_2014-1729",
        "Doc_title":" KL-ON113, a novel orally available dual EGFR kinase inhibitor targeting EGFR-activating and T790M mutants",
        "_version_":1606188997407670272},
      {
        "Meeting_name":" GE-huMab-HER3, a novel humanized, glycoengineered HER3 antibody with enhanced ADCC and superior preclinical in vitro and in vivo efficacy",
        "Background":"['HER3 is a member of the Human Epidermal Growth Factor Receptor (HER) family. HER3 is a kinase dead receptor, but by forming heterodimers with other HER family receptors, HER3 works as amplifier for PI3 kinase driven tumorigenesis. It has been reported that tumors treated with EGFR-, HER2- or cMET-targeted therapies can escape via HER3 activation or upregulation. HER3 is expressed in a large variety of tumors for example in non-small cell lung cancer (NSCLC), head and neck, colorectal, gastric, pancreatic, breast, ovarian and prostate cancer. Anti-HER3 antibodies can work via various mechanisms including', \" (1) blocking ligand (HRGs) binding to the receptor, (2) blocking heterodimerization with other HER family members (HER1, 2 and 4), (3) downregulation of the receptor from the cell surface, and (4) engaging immune effector functions such as antibody-dependent cellular cytotoxicity (ADCC). The first three mechanisms lead to inhibition of HER3 phosphorylation and downstream signaling thereby resulting in tumor cell growth inhibition, while ADCC is a mechanism of direct target cell killing triggered by cross-linking of Fc receptors on immune effector cells (e.g. NK cells, macrophages). GE-huMab-HER3 is a novel humanized and glycoengineered IgG1 antibody that binds to HER3 with high affinity. This antibody prevents ligand binding and receptor heterodimerization thereby blocking receptor phosphorylation. In various tumor xenograft models treatment with this antibody leads to substantial tumor growth inhibition. E.g. GE-huMab-HER3 treatment achieved >50% tumor growth inhibition in 10 out of 17 NSCLC models and in some cases even resulted in complete tumor remission. However, these xenograft experiments only reveal part of this antibody's therapeutic potential. A unique feature of GE-huMab-HER3 that differentiates it from other anti-HER3 antibodies, including AMG 888 and MM-121, is its ability to bind to human FcgRIIIa on immune effector cells with a 50-fold higher affinity than standard IgG1 antibodies, a property conferred by the engineered glycosylation of the antibody Fc region. Consequently, GE-huMab-HER3 exhibits superior potency and efficacy in ADCC, as shown in vitro using recombinant A549 cells and in vivo by its Fc mediated greater anti-tumor effect in A549 orthotopic mouse models compared to a non-glyco-engineered variant of the antibody, WT-huMab-HER3. The combination of strong signaling inhibition and enhanced ADCC capability renders GE-huMabHER3 a highly potent HER3-targeting agent. Phase I clinical testing of this promising novel compound is ongoing.\"]",
        "Doc_id":"AACR_2012-2508",
        "Doc_title":" GE-huMab-HER3, a novel humanized, glycoengineered HER3 antibody with enhanced ADCC and superior preclinical in vitro and in vivo efficacy",
        "_version_":1606189034280845313},
      {
        "Meeting_name":" Expression of EGFR and HER2/neu and absence of activating mutations in patients with castration-resistant prostate cancer.",
        "Background":"['Background', ' Immunohistochemical expression (IHC) and activating mutations of EGFR and HER2 have been used as predictive markers for response to targeted therapies in various cancer types. The aim of our study was to analyze the expression of EGFR and HER2 and presence of activating mutations in castration-resistant prostate cancer (CRPC) tumor tissue for the use as predictive markers. Methods', ' IHC of EGFR and HER2 using paraffin-embedded samples of tumor tissue from 51 patients with CRPC was analyzed according to the percentage of positively stained tumor cells and the intensity of staining. Genomic DNA was extracted from 18 tissue samples containing 60% tumor tissue. Nested PCR using specific primers for exons 18, 19 and 21 of EGFR and exons 18-24 of the HER2 followed by direct DNA sequencing was performed. Internet based BLAST-search was used to identify mutations of the amplified exons and neighbouring introns. Results', ' According to the different cut-off values of 10%, 30%, 50% or 70% for the percentage of positively stained cells, expression rates ranged from 30.6%-61.2% for EGFR and 9.6%-28.8% for HER2. Defining positive expression as 30% positively stained tumor cells, with an intensity of staining of 2+, resulted in positive expression of EGFR in 38.8% and HER2 in 13.5% of the patients. None of the 180 examined exons and neighbouring introns of EGFR and HER2 contained activating mutations that are known to influence response to targeted therapies. Conclusions', ' Our results demonstrate different rates of expression according to the definition of positive expression for EGFR and HER2 which may have a major impact on the results of clinical targeted trials. In our series no activating mutations of EGFR and HER2 were found. Since activating mutations for EGFR have only been found in about 10% of patients with non-small cell lung cancer, the number of analyzed samples seems to be too small to detect a relevant number of mutations in CRPC. Nevertheless, our series adds information to already published data about mutations of EGFR and HER2 in 33 patients with CRPC and 89 patients with hormone-sensitive prostate cancer that revealed activating mutations in 8/122 (6.6%) altogether.']",
        "Doc_id":"ASCO_42925-74",
        "Doc_title":" Expression of EGFR and HER2/neu and absence of activating mutations in patients with castration-resistant prostate cancer.",
        "_version_":1606189030162038784},
      {
        "Meeting_name":" Targeting HER3 and EGFR in NRG1 positive and HER3 mutated lung squamous cell carcinoma",
        "Background":"['HER3 is a member of the ErbB family of receptor tyrosine kinases. Aberrant activation of HER3 as a result of HER2 amplification or neuregulin 1 (NRG1) over-expression has been demonstrated to mediate constitutive activation of downstream oncogenic signals. LJM716 is a fully human IgG1 anti-HER3 monoclonal antibody. It locks HER3 in an inactive conformation and prevents HER3 dimerization with other ErbB family members. This unique mode of action enables LJM716 to block both ligand dependent and ligand independent HER3 activation. In search of new indications that may benefit from anti-HER3 therapies, we noted that squamous cell carcinomas (SCC) tend to have relatively higher NRG1 expression as compared to their adenocarcinoma counterparts. Highest NRG1 expression was observed in the lung SCC cell lines in cell line encyclopedia (CLE). A subset of the lung SCC cell lines with high NRG1 expression are moderately sensitive to LJM716, with HER3 activation detected in all of the sensitive lines. Additionally, EGFR activation is consistently observed in our panel of squamous lung carcinoma models. In some cases, activation of HER2 and/or HER3 is also noted. We hypothesize that squamous lung carcinomas may be dependent on signaling through EGFR, HER2 and HER3. To completely block EGFR, HER2-HER3 signaling, we set to test the treatment of LJM716 and Cetixumab in a number of NGR 1 positive squamous lung carcinomas tumor models. Enhanced anti tumor activity of LJM716 and Cetixumab is observed in four out nine tumor models. Analysis of broad activation status of receptor tyrosine kinases (RTK) reveals that a subset of responsive models have activated pEGFR, pHER2 and pHER3. These data suggest that activated HER3 signaling may be important in a subset of lung squamous cell carcinoma. Combination of anti-HER3 and anti EGFR treatment is effective at inhibiting growth in these tumors.Note', ' This abstract was not presented at the meeting.']",
        "Doc_id":"AACR_2015-5320",
        "Doc_title":" Targeting HER3 and EGFR in NRG1 positive and HER3 mutated lung squamous cell carcinoma",
        "_version_":1606189020383019009},
      {
        "Meeting_name":" Multiplexed mutational profiling of Japanese lung adenocarcinoma patients for personalized cancer therapy.",
        "Background":"['Background', ' Integration of genotype-based stratification into the lung cancer clinic is essential to implement the personalized medicine for patients with lung adenocarcinoma. Thus we have developed a multiplexed tumor genotyping panel for detecting somatic mutations relevant to molecular targeted therapies for lung cancer. The mutation profile data are communicated to clinicians to assign patients to appropriate therapy and/or clinical trials.Methods', ' Multiplexed tumor genotyping panel was developed to assess 23 mutations in 9 genes (EGFR, KRAS, BRAF, PIK3CA, NRAS, MEK1, AKT1, PTEN and HER2), 5 genes amplifications (EGFR, MET, PIK3CA, FGFR1 and FGFR2), and 5 fusion genes (EML4-ALK, CD74-ROS1, SLC34A2-ROS1, KIF5B-RET and CCDC6-RET) using pyrosequencing plus capillary electrophoresis, qRT-PCR, and multiplex RT-PCR, respectively. A written informed consent was obtained upfront from all patients enrolled into this study. Surgically resected tissues, tumor biopsies, pleural effusions and/or pericardial effusions from 280 patients were collected between July 2011 and July 2012 and used for tumor genotyping.Results', ' Somatic mutations were detected in 52.9% (148/280) of all patients. The most common mutation detected in this study was EGFR mutation (35.4%, 99) followed by KRAS mutation (10.4%, 29). EGFR L858R (52.5%) and KRAS G12C (44.8%) was the most frequent among EGFR and KRAS mutations, respectively. Other detected mutations were PIK3CA mutation (2.5%), PIK3CA amplification (2.5%), EGFR amplification (2.5%), MET amplification (2.1%), EML4-ALK fusion gene (1.4%), BRAF mutation (1.1%), NRAS mutation (1.1%), HER2 mutation (1.1%), MEK1 mutation (0.7%), AKT1 mutation (0.7%), KIF5B-RET fusion gene (0.4%), CD74-ROS1 fusion gene (0.4%) and FGFR1 amplification (0.4%). EGFR tyrosine kinase inhibitor (EGFR-TKI) was administered to 71.9% (41/57) of previously untreated patients who harbor EGFR activating mutations. Among those treated with EGFR-TKIs, simultaneous mutations in other genes with EGFR mutations were detected in 21.9% (9/41). Response rate of EGFR-TKIs in patients with simultaneous mutations (44.4%) was lower than that in patients with EGFR mutation alone (68.8%), suggesting that additional mutations may play some role in evading oncogenic signaling blockade. EGFR mutations were detected less frequently in smokers than in never-smokers (25.1% vs 60.5%, p<0.0001). Meanwhile, KRAS mutations were detected more frequently in smokers than in never-smokers (13.6% vs 2.5%, p=0.0043), which is consistent with previous reports. The majority of patients with never-smoking history harbored targetable somatic mutations compared to those with smoking history (71.6% vs 45.2%, p<0.0001).Conclusions', ' We have established the multiplexed tumor genotyping panel and this should be incorporated into lung cancer clinical practice to facilitate personalized cancer medicine.']",
        "Doc_id":"AACR_2013-37",
        "Doc_title":" Multiplexed mutational profiling of Japanese lung adenocarcinoma patients for personalized cancer therapy.",
        "_version_":1606188971989139456},
      {
        "Meeting_name":" A phase Ib trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in combination with docetaxel.",
        "Background":"['Background', ' IPI-504 is a water-soluble heat shock protein 90 (Hsp90) inhibitor. IPI-504 causes the degradation of a variety of mutated or amplified oncoproteins, including epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). The combination of IPI-504 and docetaxel demonstrates additive efficacy in murine xenograft models. This Phase 1b trial was undertaken to identify the maximum tolerated dose (MTD) of IPI-504 in combination with docetaxel. Methods', ' Eligible patients (pts) had advanced solid tumors that were either refractory to available therapies or for which docetaxel alone was an appropriate therapy. Intravenous (IV) 75 mg/m2 docetaxel was given once every three weeks (q 3- weekly). IPI-504 was administered IV q 3-weekly, with 3 pts per cohort and inter-cohort dose escalation. All pts were evaluated for safety, pharmacokinetics (PK), and tumor response. Results', ' 16 pts have been enrolled at 3 dose levels of IPI-504 (7 at 300 mg/m2, 6 at 450 mg/m2, and 3 at 550 mg/m2). 6 pts had non-small cell lung cancer (NSCLC). Median age was 59 yrs (range 33-77). Median number of cycles received was 3 (1-11), with 5 pts currently on study. There have been 4 dose-limiting toxicities (DLTs)', ' 1 at 300 mg/m2 (Grade 3 febrile neutropenia); 1 at 450 mg/m2 (Grade 3 fatigue); and 2 at 550 mg/m2 (Grade 1 asymptomatic sinus bradycardia requiring hospitalization for observation, and Grade 3 elevated AST with Grade 3 acute respiratory distress syndrome). All DLTs resolved on trial. No PK interactions between docetaxel and IPI-504 have been observed. The regimen of IPI-504 450 mg/m2 with docetaxel 75 mg/m2 has been identified as the recommended phase 2 dose on a q 3-weekly schedule. Conclusions', ' In this Phase 1b trial, the MTD of IPI-504 plus docetaxel q 3-weekly was identified. Toxicities were reversible and similar to those seen with docetaxel or IPI-504 alone in this patient population. Given the activity of single-agent IPI-504 against NSCLC and the standard use of docetaxel in that disease, an expanded evaluation of this regimen in pts with previously treated NSCLC is on-going. The combination of IPI-504 and docetaxel on a weekly schedule is also being explored.']",
        "Doc_id":"ASCO_33356-65",
        "Doc_title":" A phase Ib trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in combination with docetaxel.",
        "_version_":1606188990225973248},
      {
        "Meeting_name":" A patient derived xenograft tumor model platform for mouse trials",
        "Background":"['From Chinese cancer patients, close to 600 patient derived xenograft (PDX) tumor models have been established (> P3, three passages in mice) at GenenDesign through serial passages in the immune-compromised nude mice. The major collection of GenenDesign PDX tumor model platform represents cancer types that are prevalent in Asian patients, including gastric cancer (> 200 models), esophageal cancer (>100 models), liver cancer (50 models), pancreatic cancer (>60 models) and lung cancer (> 80 models). Establishment of variant PDX models from the same patient tumor is on-going to support translational studies of tumor heterogeneity.Initial characterization indicates that the mouse PDX models have captured the major histopathological characteristics of the original human tumors. Reproducible growth curves for PDX models (>P3) support their usage in efficacy analysis of anti-cancer therapeutic agents. Response curves to SoC (standard of care) chemotherapies such as Paclitaxel for lung cancer, FOLFOX for gastric cancer and Sorafenib for liver cancer have been established in the PDX tumor models, providing a baseline for further investigation of novel therapies in a combination setting.On-going molecular characterization including oncogene mutational analysis and target specific IHC and FISH analysis has identified panels of PDX tumor models with aberrations in key oncogenic signaling pathways, including lung panels with EGFR overexpression or KRAS mutations, gastric panels with FGFR2 amplification or being HER2 positive, lung and gastric panels with cMET overexpression. Testing of Herceptin in the gastric HER2 positive tumor panel resulted in observations similar to that from the ToGA trial. At the same time, Herceptin resistant PDX tumor variants (de novo or acquired) were identified or established. The PDX tumor model panels facilitate translational studies in a mouse trial format in a setting similar to clinical trials to test patient stratification strategies and drug response predictive biomarkers for emerging therapeutic modalities.']",
        "Doc_id":"AACR_2014-1210",
        "Doc_title":" A patient derived xenograft tumor model platform for mouse trials",
        "_version_":1606189037509410816},
      {
        "Meeting_name":" Imaging and treatment of brain metastatic tumors using nanopolymers.",
        "Background":"[\"A significant clinical problem with brain metastatic (BM) tumors is drug delivery and diagnostic imaging to verify MRI enhancement(s) for planning treatment. MRI enhancement in cancer patient's brain may result from infection after chemotherapy that impairs immune system; metastasis from primary lung/breast cancer; or a new primary brain tumor. Unlike lung/breast, brain biopsies are often technically impossible. Most drugs or monoclonal antibodies (mAb) are effective for primary tumors but cannot penetrate blood brain barrier (BBB) failing to treat brain metastasis.We used a natural nanobiopolymer, polymalic acid (PMLA), as a platform for the tumor-targeted PolycefinTM drugs for differential brain tumor imaging and treatment.Three xenogeneic orthotropic human brain metastatic tumors, MDA-MB-474, HER2+ breast cancer; A549 lung cancer, and MDA-MB-468, triple negative breast cancer (TNBC), both EGFR+, were injected into the brain of mice.For imaging, PolycefinTM had a covalently attached MRI tracer Gadolinium (Gd-DOTA). Antisense oligonucleotides (AON) were conjugated to PolycefinTM to inhibit gene/protein expression to block tumor growth. The combination of cell surface targeting mAbs, including anti-transferrin receptor (TfR) mAb for drug BBB transcytosis, and AONs to multiple tumor markers on the same delivery polymer was used for tumor treatment.MRI 1H imaging was performed on a 9.4-Tesla MRI system. Treatment groups of animals included (1) HER2+ MDA-MB-474 breast cancer metastases targeted with PMLA-Gd-DOTA/Trastuzumab/TfR mAb; (2) EGFR+ MDA-MB-468 TNBC metastases targeted with PMLA-Gd-DOTA/Cetuximab/TfR mAb; and (3) Controls inoculated with PMLA-IgG mAb and clinical Gd.Imaging\", ' Specific tumor imaging was shown for brain-implanted lung and breast tumors', ' the inverse of T1-1 relaxation time proportional to Gd concentration was measured in healthy brain and in the tumor. T1-1 time dependence for Gd-DOTA-Polycefin (T1-1 ratio tumor/normal brain) was compared with clinical Gd, MultiHance. After reaching a maximum, high T1-1 relative values prevailed for several hours for Gd-DOTA-mAb-Polycefin, but declined rapidly for Gd. High contrast for Gd was seen in 20 min, whereas that for Gd-DOTA-Polycefin peaked in 45-60 min, and remained for up to 3 hrs. By differential MRI with anti-HER2 (Trastuzumab) or anti-EFGR (Cetuximab) mAb attached to the nanoplatform, we were able to differentiate HER2+ from EGFR+ metastatic brain tumors.Treatment', ' Animal survival after Polycefin treatment was significantly higher than in untreated or mAb (Herceptin or Cetuximab) treated animals. Survival increases were as follows', ' 66% for lung cancer, 47% for HER2+ breast cancer, and 81% for TNBC.We developed a system for differential imaging and successful systemic treatment of various metastatic brain tumors based on specific metastasis targeting, and inhibition of expression of tumor-specific genes/proteins.']",
        "Doc_id":"AACR_2013-3911",
        "Doc_title":" Imaging and treatment of brain metastatic tumors using nanopolymers.",
        "_version_":1606188980442759168},
      {
        "Meeting_name":" Prognostic factors and survival of patients with brain metastasis (BM) from breast cancer (BC) who underwent craniotomy.",
        "Background":"['Background', '  BC is the second most frequent cause of BM after lung cancer, with metastases occurring in 10% - 16% of all patients. BM in patients with BC is a catastrophic event that results in poor prognosis. Identification of prognostic factors associated with breast cancer brain metastases (BCBM) could help to identify patients at risk. The aim of this study was to assess clinical characteristics, prognostic factors and survival of patients with BCBM who had craniotomy and resection in a series of patients treated with modern multimodality therapy.  Methods', '  We analyzed 42 patients with BCBM who underwent resection. Patients were diagnosed with BC between April 1994 and May 2010. Cox proportional hazards regression was selected to describe factors associated with time to BM, survival from the date of first recurrence, and overall survival (OS).  Results', '  Median age was 51 years (range 24-74). Median follow-up was 4.2 years (range 0.6-18.5). The mean time to BM from primary diagnosis was 49 months (range 0-206.22). Patients had a median of 2 BM with a median size of 3.25 cm. The proportion of the biological subtypes of BC was ER+/HER2- 25%, ER+/HER2+ 15%, ER-/HER2+ 30% and ER-/HER2- 30%. Brain radiotherapy was given to 28 patients, of which 10 had stereotactic radiosurgery, 7 whole brain radiation, and 11 both. Median OS from the date of primary diagnosis was 5.74 years. Median survival after diagnosis of BM was 1.33 years. In multivariate Cox regression analyses, stage was the only factor associated with shorter time to the development of BM (P=0.059), whereas age was the only factor associated with survival from the date of recurrence (P=0.027) and with OS (P=0.037). Controlling for age and stage, neither the biological subtype of cancer, the radiation modality nor the site of first recurrence showed any impact on survival.  Conclusions', '  Stage at primary diagnosis correlated with shorter time to the development of BM, while age at diagnosis was associated with shorter survival in BCBM. None of the other clinical factors had influence on survival.']",
        "Doc_id":"ASCO_119347-135",
        "Doc_title":" Prognostic factors and survival of patients with brain metastasis (BM) from breast cancer (BC) who underwent craniotomy.",
        "_version_":1606189005982924800},
      {
        "Meeting_name":" Prognostic factors and survival of patients with brain metastasis (BM) from breast cancer (BC) who underwent craniotomy.",
        "Background":"['Background', '  BC is the second most frequent cause of BM after lung cancer, with metastases occurring in 10-16% of all patients. BM in patients with BC is a catastrophic event that results in poor prognosis. Identification of prognostic factors associated with breast cancer brain metastases (BCBM) could help to identify patients at risk. The aim of this study was to assess clinical characteristics, prognostic factors and survival of patients with BCBM who had craniotomy and resection in a series of patients treated with modern multimodality therapy.  Methods', '  We analyzed 42 patients with BCBM who underwent resection. Patients were diagnosed with BC between April 1994 and May 2010. Cox proportional hazards regression was selected to describe factors associated with time to BM, survival from the date of first recurrence, and overall survival (OS).  Results', '  Median age was 51 years (range 24-74). Median follow-up was 4.2 years (range 0.6-18.5). The mean time to BM from primary diagnosis was 49 months (range 0-206.22). Patients had a median of 2 BM with a median size of 3.25 cm. The proportion of the biological subtypes of BC was ER+/HER2- 25%, ER+/HER2+ 15%, ER-/HER2+ 30% and ER-/HER2- 30%. Brain radiotherapy was given to 28 patients, of which 10 had stereotactic radiosurgery, 7 whole brain radiation, and 11 both. Median OS from the date of primary diagnosis was 5.74 years. Median survival after diagnosis of BM was 1.33 years. In multivariate Cox regression analyses, stage was the only factor associated with shorter time to the development of BM (P=0.059), whereas age was the only factor associated with survival from the date of recurrence (P=0.027) and with OS (P=0.037). Controlling for age and stage, neither the biological subtype of cancer, the radiation modality nor the site of first recurrence showed any impact on survival.  Conclusions', '  Stage at primary diagnosis correlated with shorter time to the development of BM, while age at diagnosis was associated with shorter survival in BCBM. None of the other clinical factors had influence on survival.']",
        "Doc_id":"ASCO_111545-132",
        "Doc_title":" Prognostic factors and survival of patients with brain metastasis (BM) from breast cancer (BC) who underwent craniotomy.",
        "_version_":1606189031179157504},
      {
        "Meeting_name":" Different receptor tyrosine kinases mediate EMT and erlotinib-resistance in NSCLC cell lines through bypass signalling",
        "Background":"['Introduction', ' Erlotinib is a potent drug in the treatment of EGFR-driven lung cancer. Many patients initially benefit from erlotinib treatment, but nearly all acquires resistance and die of the disease. Several mechanisms related to erlotinib-resistance have been described including epithelial to mesenchymal transition (EMT). Signalling by TGF, Wnt or through receptor tyrosine kinases can initiate EMT, but not much is known about the trigger in relation to erlotinib-resistance. In this study, we investigate how EMT is initiated in two erlotinib-sensitive NSCLC cell lines developing erlotinib-resistance.Methods', ' HCC827 (EGFR mutated) and Calu-3 (HER2 amplified) were treated with erlotinib in escalating concentrations (0.01 M - 5 M) over approximately 3 months, and erlotinib resistant (ER) sublines were established and investigated.Results', ' Both HCC827ER and Calu-3ER gained EMT features including upregulation of SLUG, SNAIL and ZEB1. These changes were accompanied by increased IGF1R signalling in Calu-3ER and HCC827ER gained a MET amplification. To detect the relevance of MET and IGF1R signalling in accordance to EMT, we treated the cells with the tyrosine kinase inhibitors crizotinib (MET) and linsitinib (IGF1R). In both cases, we saw a decrease in EMT-marker transcription after the treatment. In addition, HCC827ER showed growth inhibition when treated with the MET-inhibitor crizotinib, but linsitinib did not inhibit the growth of Calu-3ER. Conclusion', ' Our study demonstrates how different receptor tyrosine kinase signalling pathways can induce EMT during the development of erlotinib-resistance. Furthermore, we show that EMT can accompany well-know resistance mechanisms such as MET-amplification and hereby contribute to the phenotype of the resistant cells.']",
        "Doc_id":"AACR_2015-339",
        "Doc_title":" Different receptor tyrosine kinases mediate EMT and erlotinib-resistance in NSCLC cell lines through bypass signalling",
        "_version_":1606188997797740545},
      {
        "Meeting_name":" A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas",
        "Background":"['Background', '  The detection of driver mutations in the EGFR and ALK genes and targeted therapy has transformed treatment of lung cancer. The LCMC was established in 2009 to assay lung adenocarcinomas for driver genomic alterations in 10 genes and to study and treat patients by their molecular subtypes.  Methods', '  The 14-member LCMC enrolled patients with metastatic adenocarcinoma of the lung and tested their tumors in CLIA laboratories for KRAS, EGFR, HER2, BRAF, PIK3CA, AKT1, MEK1, and NRAS mutations using multiplexed assays, and for ALK rearrangements and MET amplifications using fluorescence in situ hybridization (FISH).    Results', '  1,102 eligible patients were enrolled; 1,007 underwent testing for at least one genomic alteration with 733 undergoing testing for all 10 genes.  600 patients were women (60%) with a median age of 63; 341 were never smokers (34%) and 589 former smokers (58%).  A driver alteration was detected in 622 (62%) of the 1,007 with any genotyping, and in 465 (63%) of the 733 fully genotyped cases.  Among the tumors with full genotyping, drivers were found as follows', ' KRAS 182 (25%), sensitizing EGFR 107 (15%), ALK rearrangements 56 (8%), other EGFR 43 (6%), two genes 29 (4%), BRAF 16 (2%), HER2 15 (2%), PIK3CA 6 (1%), MET amplification 5 (1%), NRAS 5 (1%), MEK1 1 (<1%), and AKT1 0 (0%). Results were used to select targeted therapy or targeted trials in 279 patients with a driver alteration (28% of 1,007 total).  Among 938 patients with clinical follow-up and treatment information, 264 with a driver alteration treated with a targeted agent had a median survival of 3.5 years; 313 with a driver who did not receive targeted therapy had a median survival of 2.4 years; while 361 without an identified driver had a median survival of 2.1 years (p<0.0001).   Conclusions', '  An actionable driver alteration was detected in 62% of tumors from patients with lung adenocarcinomas, leading to use of a targeted therapy in 28%. The patients with an identified driver treated with a targeted agent lived longer than those patients who did not receive targeted therapy.  Multiplexed genomic testing can aid physicians in matching patients with targeted treatments and appropriate clinical trials.']",
        "Doc_id":"ASCO_111918-132",
        "Doc_title":" A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas",
        "_version_":1606188985951977472},
      {
        "Meeting_name":" Trastuzumab and paclitaxel in patients (pts) with EGFR mutated non-small-cell lung cancer (NSCLC) that express HER2 after progression on EGFR TKI treatment.",
        "Background":"['Background', ' HER2 expression as well as amplification has been well recognized in tumor biopsies of pts with an EGFR mutation who developed EGFR TKI resistance. It is unknown whether HER2 targeting in this setting can result in tumor responses. Methods', ' Single arm open label phase II study to study the safety and efficacy of paclitaxel-trastuzumab treatment in pts with a sensitizing EGFR mutation who show tumor membrane HER2 expression in a tumor biopsy (immunohistochemistry (IHC) 1) after progression on EGFR TKI treatment. Paclitaxel (60 mg/m2) and trastuzumab (first dose 4 mg/kg, thereafter 2 mg/kg) were dosed weekly until disease progression or unacceptable toxicity. Primary end-point was tumor response according to RECIST. Sample size of 20 pts was calculated to evaluate the primary objective of 30% objective response rate. The study was deemed positive when 7 pts would show a partial or complete response. Results', ' 21 pts were enrolled from 08-2012 to 02-2017. 7 pts were exon 21 L858R positive and 14 exon 19 del. Last TKI was erlotinib (n = 6), gefitinib (n = 4), rociletinib (n = 3) or osimertinib (n = 8). Median HER2 IHC was 2+ (range 1-3). 17 pts were evaluable for response assessment, while 4 pts are awaiting their first response scan. The primary end-point was met with 7/17 pts (41%) showing a partial response. 2 pts showed stable disease, 7 progressive disease and 1 pt had clinical progression before CT response evaluation. Median duration of response was 9 (range 6-18) months with one ongoing responder. 3 pts experienced grade 3 toxicity, including fatigue, neuropathy and neutropenia. Upon progression on study treatment, all responding pts were rebiopsied. 4/6 samples were negative for HER2 (IHC), suggesting that the combination effectively targeted HER2 positive tumor cells. Conclusions', ' The study met its primary end-point. Paclitaxel-trastuzumab induces durable objective tumor responses in EGFR TKI pretreated pts with an activating EGFR mutation and HER2 bypass track activation. The treatment was well tolerated. Post-progression tumor biopsies showed absence of HER2 staining in the majority of pts, suggesting effective HER2 targeting. Clinical trial information', ' NCT02226757']",
        "Doc_id":"ASCO_191981-199",
        "Doc_title":" Trastuzumab and paclitaxel in patients (pts) with EGFR mutated non-small-cell lung cancer (NSCLC) that express HER2 after progression on EGFR TKI treatment.",
        "_version_":1606189018803863552},
      {
        "Meeting_name":" The EGFR gatekeeper mutation T790M is present in selected patients with early breast cancer",
        "Background":"['Introduction. The epidermal growth factor receptor (EGFR) is one of the major oncogenes in a variety of human cancers including breast cancer (BC). While EGFR overexpression and/or amplification has been shown to occur frequently in human breast cancer, EGFR-activating mutations are suggested to be rare if not absent. Thus, the aim of our study was to examine the presence of somatic EGFR gene mutations in a group of norwegian patients diagnosed with early breast cancer. Patients. We investigated tumor biopsies obtained from 132 patients with early breast cancer treated at the Akershus University Hospital (University of Oslo) in 2007/2008. The majority of patients (n = 82) belonged to the luminal- A/B subtypes of BC. In addition, 33 patients were classified as HER-2 positive patients (IHC 3+ or amplification verified by FISH) and 17 as triple-negative breast cancer (TNBC) patients. Methods. Briefly, DNA was extracted from formalin-fixed, paraffin-embedded (FFPE) tumor tissue using QIAsymphony DSP DNA Mini Kit (Qiagen Inc.). The extraction of DNA was performed by fully automated purification using the QIAsymphony SP/AS system. EGFR-mutations were detected using a Therascreen EGFR RGQ PCR kit according to the manufacturers protocol. We tested for point mutations in exon 18 (G719A/C/S), in-frame deletions in exon 19 (E746-A750), in-frame insertions as well as point mutations in exon 20 (S768I, T790M) and a point mutation in exon 21 (L858R). Results. In the present study we detected three individuals with an EGFR-T790M mutation. Two of the patients were diagnosed with TNBC, while the disease of the third patient was classified as a luminal-A type breast cancer. Interestingly, the T790M-mutation was present in the biopsies obtained during surgery before adjuvant therapy was initiated. No anti-cancer therapy has been given prior to surgery. According to our best knowledge, the T790M-TKI-resistance-mutation has not been detected in early breast cancer previously. This finding contrasts the observations made in lung cancer patients where the T790M mutation in general is a classical second mutation causing drug resistance during ongoing TKI-therapy. No other EGFR-mutations were detected in our patients. Conclusion', ' To our best knowledge we provide first evidence for the presence of the EGFR-T790M-mutation in human early breast cancer. Thus, treatment with novel EGFR-targeting cancer drugs (like pan-HER-inhibitors) affecting also T790M-mutated-EGFR may be worthwhile to be tested in highly selected breast cancer patients.']",
        "Doc_id":"AACR_2015-121",
        "Doc_title":" The EGFR gatekeeper mutation T790M is present in selected patients with early breast cancer",
        "_version_":1606189030558400513},
      {
        "Meeting_name":" Integrating molecular profiling into cancer treatment decision making",
        "Background":"['Background', '  Molecular profiling of both common and rare cancer types provides for the identification of actionable targets for chemotherapy with many unexpected associations.  Methods', '  Caris Life Sciences database of >35,000 profiled cancers was reviewed for well-established driver gene mutations and copy number alterations, and protein expression patterns that are relevant for selection of targeted therapy.  Based on the published literature, these tumor characteristics were then associated with potential benefit or no benefit to the specific therapeutic agents.  All relevant published studies were evaluated using the USPSTF grading scheme for study design and validity. Assay methodologies included sequencing (Sanger, pyrosequencing), PCR, FISH, CISH, and immunohistochemistry.  Results', '  All common malignancies (10 most common cancer types in men and women) and 10 rare cancer types were well represented (minimum of 100 cases in each individual cancer type). Well established driver mutations and protein expression in common cancers were all identified with expected frequencies (e.g. HER2 amplification in breast, PIK3CA mutations in ER+ breast cancer, EGFR mutations in NSCLC, etc.). Importantly, unexpected new and potentially actionable targets were identified in common (e.g., 6.7% HER2 amplification in NSCLC, 1.6% KRAS mutation in prostatic adenocarcinoma) and rare cancers (e.g., 8.3% ALK alteration in soft tissue sarcomas, 10.5% c-MET and 26.4% EGFR gene amplification in melanomas, 16.3% KRAS mutation in cholangiocarcinomas, 10% AR expression in STS), as well in cancers of unknown primary site (approximately 4% of all tested cases).  Conclusions', '  This review of the large referral cancer profiling database provided an unparalleled insight in the distribution of common and rare genetic and protein alterations with direct and potential treatment implications. Numerous targets were discovered that had a potential to be treated by the conventional chemotherapy as well as targeted therapy not usually considered for the cancer type. Comparison between an individual patient tumor profile and database for the matched cancer type provides additional level of support for targeted treatment choices.']",
        "Doc_id":"ASCO_110052-132",
        "Doc_title":" Integrating molecular profiling into cancer treatment decision making",
        "_version_":1606189019414134784},
      {
        "Meeting_name":" Differential expression of Notch1 in lung, ovarian and breast cancers",
        "Background":"['Targeting the Notch signaling pathway for cancer treatment is currently the subject of early clinical trials. However, treatment-related toxicities, particularly gastrointestinal adverse events, have limited clinical development of this class of agents. The development of efficacy biomarkers to gamma-secretase inhibitors and antibodies to Notch ligands and receptors could speed clinical testing. Mutations in Notch1, a dominant Notch receptor, are rare in human solid tumors, and clinical activity has not been observed in patients with tumors bearing Notch1 activating mutations, including T-cell acute lymphoblastic leukemia from available clinical data. Identification of tumors with abundant target expression and/or active Notch signaling status characteristic of Notch intracellular domain (NICD) expression by immunohistochemistry may have clinical utility. All levels of tumor Notch1 expression comprised of low, moderate and high detected by immunohistochemistry and quantitated by digital imaging technology were observed in 52% (34/66) of lung cancers, 51% (35/68) of ovarian cancers, and 11% (7/63) of breast cancers (lung or ovary vs. breast, P<0.0001 by 2-sided Fisher Exact Test). Notch1 was expressed at high levels in 20% of lung cancers including sarcoma, neuroendocrine, small cell and undifferentiated carcinomas, as well as adenocarcinoma and squamous cell carcinomas. High expression of Notch1 was observed in 9% of ovarian tumors including undifferentiated carcinoma, serous adenocarcinoma, and endometrioid adenocarcinoma. In breast cancer, it was noted in one case of infiltrating ductal carcinoma with triple-negative phenotype. Expression of high-level Notch1 varies in lung cancer vs. ovarian cancer vs. breast cancer (P=0.002 by Chi-square statistic), and was frequently associated with NICD expression. Notch1 was not significantly associated with estrogen receptor, progesterone receptor or HER2 status in breast cancer. These data suggest that the frequency of all levels of Notch1 expression is significantly higher in lung cancer and ovarian cancer than breast cancer; and high-level Notch1 is more frequent in lung cancer than in ovarian cancer, and, likewise, more frequent in ovarian cancer than in breast cancer. For the first time, expression of Notch1/NICD has been identified in undifferentiated carcinomas. The findings may provide useful information for the rational design of Notch inhibitor clinical trials.']",
        "Doc_id":"AACR_2014-3838",
        "Doc_title":" Differential expression of Notch1 in lung, ovarian and breast cancers",
        "_version_":1606188985937297408},
      {
        "Meeting_name":" Uptake of BRAF and ALK mutation screening versus HER2 overexpression testing.",
        "Background":"['Background', '  Genetic mutation testing in cancer has become standard practice with the advent of targeted therapies such as vemurafenib, crizotinib, and trastuzumab and their associated companion diagnostics. We observed a rapid uptake in BRAF mutation screening in melanoma compared to ALK mutation in NSCLC and HER2 overexpression in breast cancer. Hypothesizing this discrepancy may be related to the overall impact the drugs had on standard of care within their respective indications, we evaluated the relationship between mutation screening frequency and hazard ratios (HRs) from pivotal clinical trials (Shaw Lancet Oncol 2011; Gerber Cancer Cell 2010; Slamon NEJM2001). As a historical control, we also assessed HER2 screening trends.  Methods', '  BRAF, ALK, and HER2 screening data were collected via Ipsos Tandem Oncology Monitor, a commercial system in which oncologists in US (500) and EU (783) enter de-identified data on actual prescriptions and mutation screening orders by indication for cancer patients from their practice.  Results', '  Our results show an increase in mutation testing from 42 to 83% for BRAF and from 13 to 34% for ALK from Q1 2011 to Q4 2011. HER2 testing has increased from 56%, Q1 2001, to 95%, Q4 2011. Correlation in uptake in testing vs. PFS/TTP HR endpoints in the US was -0.866. This implies a relationship between outcomes and the propensity for mutation testing. Conclusions', '  While it is likely that the potential for benefit drives mutation testing, clinicians may also be less likely to screen for an uncommon mutation (~5% of NSCLC patients), or may choose to test only those patients with known predisposing factors. Additionally, oncologists may go through a testing algorithm for NSCLC patients where mutations that are more common are screened first (i.e., EGFR  KRAS  ALK).  BRAF testing reached nearly 90% in one year compared to nearly 10 years for HER2 and emphasizes the impact vemurafenib has had on standard of care. ALK mutation screening increased, but not to the same extent as BRAF.  These results are encouraging, but also demonstrate that mutation testing in all patients is not yet a reality.']",
        "Doc_id":"ASCO_103353-127",
        "Doc_title":" Uptake of BRAF and ALK mutation screening versus HER2 overexpression testing.",
        "_version_":1606188998825345024},
      {
        "Meeting_name":" Ultra-deep sequencing of circulating free DNA to identify predictive, mutated HSP90 clients in the GALAXY TrialTM (NCT01348126)",
        "Background":"['Background', ' Non-small cell lung cancer is a mosaic, comprising several distinct molecular subtypes driven by somatic mutations in so-called cancer genes. Several of these oncogenic mutations confer dependence on HSP90 e.g. EML4-ALK, BRAF, KRAS, KIT. Inhibition of Hsp90 induces apoptosis and can exploit this dependence. Ganetespib (G) is an Hsp90 inhibitor with single agent activity in molecularly defined disease, including EML4-ALK rearrangement, KRAS mutations, HER2 amplification and BRAF mutations. Circulating free DNA (cfDNA) is present at low levels in plasma of healthy individuals allowing detection of somatic mutations by deep sequencing. The aim of this work was to determine the mutational spectrum of patients enrolled into the GALAXY trial using this liquid biopsy strategy.Methods', ' We performed a prospective exploratory analysis to identify plasma-borne somatic mutations as predictors of clinical outcome with G in GALAXY, a randomized trial, comparing G + docetaxel (D), to D alone in 2nd line advanced NSCLC patients. Plasma samples were collected from approximately 200 patients with adenocarcinoma at baseline prior to initiation of treatment, and during cycles 1 and 2. cfDNA samples were evaluated using the Ion AmpliSeq Cancer Panel on the Ion Torrent |PGM platform to survey 739 amplicons in 46 cancer genes at up to 6000x depth.Results', ' CfDNA targeted sequence analysis of the first 38 patients revealed multiple concurrent mutations in client proteins including the HSP90 client proteins BRAF, PDGFR and KIT, demonstrating the feasibility of this method. Sequencing of a larger cohort is underway. Longitudinal sampling of plasma has been conducted to monitor temporal evolution of the penetrance of mutations.Summary', ' Ultra-deep re-sequencing of multiple somatic mutations in circulating cfDNA is feasible, and can potentially enable identification of G sensitive subgroups. This represents a new approach to biomarker discovery in the context of phase II trials.']",
        "Doc_id":"AACR_2013-2012",
        "Doc_title":" Ultra-deep sequencing of circulating free DNA to identify predictive, mutated HSP90 clients in the GALAXY TrialTM (NCT01348126)",
        "_version_":1606188972665470976},
      {
        "Meeting_name":" The use of long-read sequencing to determine the structure of the Her2 amplicon in breast cancer.",
        "Background":"['HER2 amplification is present in ~15% of breast cancers, and is present in small subsets of other cancer types including gastric and lung cancers. Therapy targeting HER2 is now routinely used in treatment of HER2-amplificed breast cancer and has changed the natural history of this disease. The region of chromosome 17q12 containing Her2 contains many genes, and little is known about the actual genomic alterations that underlie the amplification event. While it is known that parts of the amplicon exist in multiple copies in a tumor, the exact structure of the duplicated region is not known and their relative orientation and positions in the genome is not clear. There is the potential for rearrangements between the genes and for different segments of the amplicon to exist and varied copy numbers. There is no clear way to assemble the complete structure of this region using short reads, as they cannot resolve repetitive regions and identify junction reads. Long read sequencing has the potential to overcome these limitations, however the sequencing depth is limited and difficult to apply to large genomes. To apply long read sequencing to a limited part of the cancer genome, we have used Nimblegen target enrichment coupled with Oxford Nanopore and Pacific Bioscience sequencing in an attempt to sequence and assemble the Her2 amplicon. The error rate of the sequencers are not of concern since we are not looking at base-pair level variation. Instead, our need is for long reads that can span the gene boundaries and repetitive elements to give complete structure of the amplicon. Nimblegen custom capture probes were designed for the 2mb chromosomal region containing Her2. DNA was extracted from 3 breast cancer cell lines and enriched using the Nimblegen kit. This DNA was then sequenced with long reads on the MinIon and the PacBio to allow for complete assembly of the region. The DNA was assembled to determine the structure of the HER2 amplicon in each cell line. These results may give new insight into the molecular events that led to formation of the HER2 amplicon.']",
        "Doc_id":"AACR_2017-3373",
        "Doc_title":" The use of long-read sequencing to determine the structure of the Her2 amplicon in breast cancer.",
        "_version_":1606189032567472128},
      {
        "Meeting_name":" Circulating sEGFR arises through a fibronectin/integrin-regulated proteolytic cleavage event",
        "Background":"['A circulating isoform of EGFR has been identified as an emerging serum biomarker in cancer patients. Serum concentrations of EGFR have been evaluated as screening, diagnostic, prognostic, and theragnostic markers for diverse human malignancies, including breast, ovarian, endometrial, colorectal, and lung cancer. Yet full-length EGFR is rarely shed from normal or malignant cells. Here we demonstrate that an alternately spliced EGFR isoform, termed sEGFR, gives rise to the circulating sEGFR protein through proteolytic cleavage of a cell surface precursor. This cleavage event is inhibited by fibronectin and stimulated by both an anti-5/1 integrin antibody and the metalloprotease activator 4-aminophenylmercuric acetate. Preliminary results identify ADAM17/TACE as at least one mediator of sEGFR shedding. Shed sEGFR binds to EGF with high affinity. Two FDA-approved therapeutic anti-EGFR antibodies, cetuximab (Erbitux) and panitumumab (Vectibix), inhibit shedding of sEGFR, implicating sEGFR as a potential alternative target for these antibodies, consistent with previous studies indicating that baseline serum sEGFR concentrations may predict responsiveness to anti-EGFR-targeted therapy. These observations bear striking similarity to aspects of trastuzumab regulation of HER2, shedding, and, by analogy, may have implications for the design of future clinical trials using EGFR-directed therapeutics, including cetuximab and panitumimab.']",
        "Doc_id":"AACR_2012-3624",
        "Doc_title":" Circulating sEGFR arises through a fibronectin/integrin-regulated proteolytic cleavage event",
        "_version_":1606189035015897089},
      {
        "Meeting_name":" Screening for RET and ROS1 fusions in an enriched cohort of pan-negative never-smokers with advanced lung adenocarcinomas to identify patients for treatment in targeted therapy trials.",
        "Background":"['Background', '  RET and ROS1 fusions have been identified pre-clinically as drivers of tumor growth in lung adenocarcinomas. In addition, based on response to crizotinib in ROS1-positive tumors and emerging data on RET inhibition in some tumors, these fusions represent druggable targets. While each occurs in 1-2% of unselected patients, a screening paradigm based on testing never-smokers whose tumors have no known oncogenic mutations or fusions may enrich identification for ongoing clinical trials.  Methods', '  Patients with a never-smoking history (<100 lifetime cigarettes) and advanced pan-negative lung adenocarcinomas (absence of mutations in EGFR, KRAS, NRAS, BRAF, HER2, PIK3CA, MEK1, and AKT, and ALK fusions) were selected for testing. Screening for RET and ROS1 fusions was performed in real-time via dual-probe FISH breakapart assays, RT-PCR, and next-generation sequencing in selected cases. We enrolled patients onto a phase II trial of cabozantinib for RET fusion-positive lung cancers (NCT01639508) and, as part of the Lung Cancer Mutation Consortium (LCMC), a phase I trial of crizotinib for ROS1-positive lung cancers (NCT00585195).  Results', '  Thirty five (n=35) never-smokers with advanced pan-negative lung adenocarcinomas were identified. A RET or ROS1 fusion was found in 31% [n=10/32, 95% CI, 15-47%] of patients. RET and ROS1 fusions were found in 15% [n=5/34, 95% CI, 3% - 27%] and 15% [n=5/33, 95% CI, 2%-27%] of patients, respectively. 1 patient had a novel TRIM33-RET fusion. 3 of 5 patients with RET fusion-positive tumors were eligible for treatment with cabozantinib, 2 of which had partial responses to therapy.  1 of 5 patients with ROS1 fusion-positive tumors was treated on-protocol with crizotinib and achieved a partial response.  Conclusions', '  31% of never-smokers with pan-negative advanced lung adenocarcinomas harbor a gene fusion involving either RET or ROS1. Until multiplexed mutation and fusion testing is routinely available, targeting this population for screening represents an interim enrichment strategy for patient identification and enrollment on clinical trials where responses are already being documented.']",
        "Doc_id":"ASCO_113149-132",
        "Doc_title":" Screening for RET and ROS1 fusions in an enriched cohort of pan-negative never-smokers with advanced lung adenocarcinomas to identify patients for treatment in targeted therapy trials.",
        "_version_":1606188995037888512},
      {
        "Meeting_name":" Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC).",
        "Background":"['Background', ' T-DM1 is an antibody-drug conjugate approved for HER2-positive metastatic breast cancer. We report primary results from a fully enrolled, ongoing phase 2 study (NCT02289833) of pts with previously treated HER2-overexpressing mNSCLC who received single-agent T-DM1. Methods', ' Eligible pts had HER2-overexpressing mNSCLC and were previously treated with platinum-based therapy. Pts received T-DM1 3.6 mg/kg every 3 weeks and were analyzed in 2 cohorts based on centrally determined HER2 status (immunohistochemistry [IHC]2+ vs IHC3+ [10% cells stained with 2+ or 3+ intensity, respectively]). HER2 amplification was assessed via ISH (HER2 gene ratio 2.0). The primary endpoint is objective response rate (ORR; proportion of pts with confirmed [4 weeks] complete or partial response per RECIST v1.1). Results', ' The clinical cutoff date for this analysis was Oct 26, 2016.Of 393 screened pts, 102 (27%) were IHC2+ and 29 (7%) were IHC3+. In total, 49 pts (IHC2+, n = 29; IHC3+, n = 20) received T-DM1. At cutoff, median follow-up was 16.3 (range 0.9*22.4; * = censored observation) months. No IHC2+ pt had a response (0%, 95% CI 011.9); 4 IHC3+ pts had partial responses (20%, 95% CI 5.743.7) with a median duration of response of 7.3 (range 2.98.3) months. Median progression-free survival (PFS) in IHC2+ and IHC3+ pts was 2.6 (95% CI 1.42.8) and 2.7 (95% CI 1.48.3) months, respectively. At 6 months after start of study treatment, 9 pts (IHC2+, n = 4; IHC3+, n = 5) were still at risk for a PFS event. Median overall survival was 12.2 (95% CI 3.8not estimable [NE]) months in IHC2+ pts and 12.1 (95% CI 9.3NE) months in IHC3+ pts. Of 16 pts with HER2 amplification (IHC2+, n = 5; IHC3+, n = 11), 3 responded, all in the IHC3+ cohort (27.3%, 95% CI 6.061.0). Eleven pts (22%) experienced a grade 34 adverse event, with fatigue and dyspnea being the only events reported in > 1 pt (n = 2 each). Conclusions', ' This is the first study to report on the clinical activity of T-DM1 in HER2-overexpressing mNSCLC. Objective responses were observed in IHC3+ pts. Additional molecular analyses are underway to refine markers for optimal pt selection. Clinical trial information', ' NCT02289833']",
        "Doc_id":"ASCO_186300-199",
        "Doc_title":" Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC).",
        "_version_":1606189011674595328},
      {
        "Meeting_name":" Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in heavily pretreated HER2 expressing solid tumors.",
        "Background":"['Background', ' Human epidermal growth factor 2 (HER2) is a potential strong tumor driver for breast (BC) and gastric cancer (GC) as well as other HER2 expressing tumors. Antibody-drug conjugates (ADC) provide wider therapeutic window by more efficient and specific drug delivery. DS-8201a is a HER2 targeting ADC of high drug to antibody ratio (7 to 8) with a novel topoisomerase I inhibitor. In preclinical studies, DS-8201a showed a broader antitumor spectrum than T-DM1, including efficacy against low HER2 expressing tumors. Current trial includes dose escalation (Part 1) and expansion (Part 2) focusing on HER2 expressing solid tumors (NCT02564900). Methods', ' Part 1 used a modified continuous reassessment method to identify the expansion dose in patients (pts) with BC or GC. Part 2 was designed to evaluate the safety and efficacy in 4 expansion cohorts', ' T-DM1 treated HER2+ BC, trastuzumab treated HER2+ GC, BC with low HER2 expressing and other HER2 expressing solid tumors. Adverse events (AEs), objective response rate (ORR) and durability of responses were assessed. Results', ' 89 pts were administered in total', ' 24 pts in Part 1 and 65 pts (BC, GC, colorectal, salivary and non-small cell lung cancer) in Part 2 with median prior therapies of 4. DS-8201a was administered up to 8.0 mg/kg in Part 1, and dose levels of 6.4 and 5.4 mg/kg IV every 3 weeks were chosen for Part 2. There was no dose limiting toxicity, and maximum tolerated dose was not reached in Part 1. The most common AEs in Part 1 and Part 2 were nausea (62%), anorexia (56%) and platelet count decreased (28%). 29% pts experienced  Gr3 AEs (Gr3', ' 25% Gr4', ' 4%). The ORR and disease control rate (DCR', ' CR + PR + SD) are shown in the table. ORR and DCR were 40% and 90%, respectively in evaluable 73 pts including 14 low HER2 expression. One T-DM1 treated BC pt achieved CR. 4 PRs were achieved in pts with low HER2 expression. 63 pts in total are currently being treated. Median duration of treatment was 27 weeks in Part 1 and not reached in Part 2. Conclusions', ' DS-8201a was well tolerated and is remarkably active in heavily pretreated HER2 expressing cancers. Clinical trial information', ' NCT02564900ORRDCRTotal40% (29/73)90% (66/73)Part 143% (10/23)91% (21/23)Part 238% (19/50)90% (45/50)Low HER229% (4/14)93% (13/14)']",
        "Doc_id":"ASCO_191619-199",
        "Doc_title":" Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in heavily pretreated HER2 expressing solid tumors.",
        "_version_":1606189024644431872},
      {
        "Meeting_name":" Distribution analysis of S-222611 in brain metastases of HER2-positive breast cancer by quantitative imaging mass spectrometry",
        "Background":"['S-222611 is a potent and selective reversible tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), human EGFR2 (HER2), and human EGFR4 developed in Shionogi. Greater potency of anti-tumor activity than lapatinib was demonstrated in vitro and in animal models. In the intracranial implantation mice model implanted the HER2-positive cell line (MDA-MB-361-luc-2), S-222611 showed more potent anti-tumor activity than lapatinib. On the basis of higher penetration in brain of S-222611 than lapatinib indicated by the preclinical pharmacokinetic studies, we demonstrated the application of S-222611 to brain metastases with breast cancer. In order to enhance the clinical predictability of S-222611 to the treatment of brain metastases, we have developed the experimental brain metastases models in mice of HER2-positive breast cancer (MDA-MB-361-luc-2-BR2/BR3) or T790M-EGFR expressing lung cancer (NCI-H1975-luc). After a single oral administration of S-222611 or lapatinib, the concentrations of S-222611 and lapatinib in the brain metastatic regions of these mice models were analyzed by quantitative imaging mass spectrometry (IMS). In the NCI-H1975 lung cancer model (intraventricular injection model), the concentrations of S-222611 in brain metastases quantified by IMS were comparable to those of lapatinib. In contrast, in the MDA-MB-361 breast cancer model (intraventricular injection model), the concentrations of S-222611 in brain metastases were over 10 times higher than those of lapatinib, and the tumor-to-normal brain ratio of S-222611 was approximately 4 times higher than that of lapatinib. IMS revealed that the concentrations in brain metastases and tumor-to-normal brain ratio of S-222611 were significantly higher than those of lapatinib in the breast cancer mice model. In addition, the blood-tumor barrier (BTB) permeability in each brain metastatic region using these mice models was assessed simultaneously. In the lung cancer model, fluorescently labeled dextran was highly detected in the brain metastatic regions than brain parenchyma. However, in the breast cancer models, fluorescence intensities for dextran in the brain metastatic regions and brain parenchyma were comparable, indicating that the BTB was remained to be largely intact in brain metastases of the breast cancer model but disrupted in the lung cancer model. These results show that S-222611 is expected to be useful for the prevention and the prompt treatment of patients with HER2-positive breast cancer having brain metastases.']",
        "Doc_id":"AACR_2017-4085",
        "Doc_title":" Distribution analysis of S-222611 in brain metastases of HER2-positive breast cancer by quantitative imaging mass spectrometry",
        "_version_":1606188996035084288},
      {
        "Meeting_name":" The role of nuclear HER3 in breast cancer resistance",
        "Background":"['HER3 is reported to be overexpressed in 18-29% of human breast cancers and suggested to be a marker of reduced disease-specific survival in 4,406 patients with invasive breast carcinoma. Overexpression and subcellular localization of HER3 may be a negative predictive marker for targeted therapies, and HER3 status may play a role in the development of drug resistance and metastasis. Translocation of ERBB family members EGFR, HER2 and HER4 into nucleus for regulating gene transcription have been reported, but only a few studies about nuclear HER3 have been reported and the biological role of nuclear HER3 is still unknown. HER3 was detected in the nucleus of 57% in Japanese lung cancers, and has also been detected in the nuclei of prostate cancers and other cancer cell lines. A study suggested that nuclear HER3 by IHC is associated with favorable overall survival in 128 uveal melanoma patients. The potential mechanism of HER3 translocation and its role on drug resistance was intensively studied in the work. According to our observation, nuclear HER3 was found to be significantly increased in HER2-positive breast cancer cells SKBr3 during an EGFR-targeted therapy Iressa, and increased sub-band of HER3 was detected by Western blot in the Iressa-resistant SKBr3 cells. The Iressa-induced HER3 nuclear localization in SKBr3 and BT474 cells can be inhibited by the application of ADAM17 and gamma-secretase inhibitors or siRNA, the additional inhibitors can sensitize the cells to Iressa treatment which may be a new target for preventing HER3-mediated drug resistance. If the HER3 subcellular localization is important for cancer development and drug resistance, inhibitor for this pathway will enhance the efficiency of recent therapies on breast cancer.']",
        "Doc_id":"AACR_2014-3334",
        "Doc_title":" The role of nuclear HER3 in breast cancer resistance",
        "_version_":1606189037550305280},
      {
        "Meeting_name":" Antitumor activity of multikinase inhibitors in HER2-positive gastric cancer cells.",
        "Background":"['Background', ' The developments of novel anti-HER2 drugs including multikinase inhibitors have achieved advancing evolution for past several years, and the options in the treatment of HER2-positive malignant tumors have been increasing, especially in breast and lung cancers. On the other hand, regarding HER2-positive gastric cancer, trastuzumab is still the only anti-HER2 drug with the established clinical evidences. Afatinib, an irreversible human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, binds to the kinase domain of HER2, and is one of the hopeful candidates as novel molecularly targeted drugs for HER2-positive gastric cancer. In this study, we investigated the antitumor effect of multikinase inhibitors including afatinib in gastric cancer cell lines.']",
        "Doc_id":"AACR_2017-4194",
        "Doc_title":" Antitumor activity of multikinase inhibitors in HER2-positive gastric cancer cells.",
        "_version_":1606189027150528512},
      {
        "Meeting_name":" HER2 amplification in EGFR mutant NSCLC after acquired resistance (AR) to EGFR-directed therapies.",
        "Background":"['Background', ' Both first generation EGFR tyrosine kinase inhibitors (TKIs) and second generation agents with dual EGFR/HER2 inhibition have robust activity in EGFR-mutant NSCLC. HER2 amplification (amp) has been proposed as a potential mechanism of AR to first-generation EGFR TKIs. To further understand HER2 alterations as resistance mechanisms to EGFR TKIs, we evaluated HER2 amp in patients (pts) with EGFR-mutant NSCLC before and after AR. Methods', ' Tissue biopsies from pts with metastatic or recurrent EGFR-mutant lung adenocarcinomas with AR to EGFR TKIs were obtained before initiation of treatment and at the time of AR. HER2/CEP17 ratio and average HER2 copy number were assessed by FISH. HER2 protein expression was determined using IHC. Results were interpreted based on the 2013 ASCO/CAP guidelines. Results', ' 83 pts with AR to EGFR TKIs have been enrolled. HER2 status was evaluated in 55 samples collected from 49 pts (33 female, 16 male, 27 never-or light smokers). 44 samples were obtained after AR to erlotinib, 9 after resistance to afatinib + cetuximab (AFAT + CET), and 2 after AR to afatinib (AFAT). At AR to erlotinib, 3 cases (6.8%) were found to have HER2 amp. In all 3, low-level HER2 amp was detected pre-treatment and increased in 2 cases at AR. Of the 9 pts treated with AFAT + CET, 2 pts (22.2%) were found to have HER2 amp at time of resistance, in one case exhibiting a 4-fold increase in copy number post-treatment. Neither of the 2 pts treated with AFAT alone had HER2 amp. Results are summarized in the table. Conclusions', ' We demonstrate that HER2 amp may be a mechanism of resistance to erlotinib and AFAT + CET, as it was detected in 6.8% and 22.2% of cases respectively after AR to these agents. These findings support further investigation into HER2-directed therapies in EGFR mutant tumors that harbor HER2 alterations. CaseTreatmentWks on treatmentHER2 Copy #HER2', 'CEP17 ratioHER2 IHCT790MMET1Baseline6.72.82+-NAPost Erlotinib28.712.88.03+--2Baseline4.22.62+-NAPost Erlotinib118.313.6; 3.6*6.0; 1.4*3+--3Baseline12.63.33+-NAPost Erlotinib25.79.52.63++-4Baseline4.41.60-NAPost AFAT + CET8.017.56.63+--5BaselineNANANANANAPost AFAT + CET33.45.32.1NA+-*Two cell populations observed']",
        "Doc_id":"ASCO_163599-176",
        "Doc_title":" HER2 amplification in EGFR mutant NSCLC after acquired resistance (AR) to EGFR-directed therapies.",
        "_version_":1606189027964223489},
      {
        "Meeting_name":" A phase Ib, first-in-human, dose escalation and expansion study of XMT-1522, a novel antibody-drug conjugate (ADC) directed against HER2, in patients with advanced breast cancer and other advanced tumors expressing HER2.",
        "Background":"['Background', ' XMT-1522 is an ADC consisting of a novel human IgG1 anti-HER2 monoclonal antibody conjugated to an auristatin-based cytotoxic payload (AF-HPA). An average of 12 AF-HPA molecules is conjugated to each antibody via a biodegradable polymer. In pre-clinical xenograft experiments XMT-1522 achieved complete, durable tumor regressions in models of HER2-positive and HER2 1+/2+ breast cancer, HER2 2+/3+ NSCLC, and HER2-positive and HER2 1+ gastric cancer. Methods', ' This study (NCT02952729) is comprised of two parts', ' a dose escalation segment (DES) and an expansion segment (EXP). The primary objectives of the DES are determination of the maximum tolerated dose and recommended Phase 2 dose (RP2D) and assessment of safety and tolerability. The DES will enroll patients with advanced or metastatic breast cancer who have progressed following standard therapies and have HER2 protein at least 1+ by IHC. XMT-1522 will be administered intravenously every 3 weeks. DES uses a 3+3 design. Post-dose assessments include LVEF measurement at the end of cycles 1, 3, then every 3 cycles, ophthalmologic exams at the end of cycles 1, 2, then every 2 cycles, and re-staging CT scans every 2 cycles. Pharmacokinetics of antibody, AF-HPA payload and an AF-HPA metabolite will be measured. Two patients have completed dose level 1 without DLT. The EXP segment will open at the RP2D and will further assess safety and tolerability of XMT-1522 and assess efficacy in selected patient populations. EXP will enroll 4 cohorts (N = 20 each). Cohort 1', ' HER2 1+/2+ advanced breast cancer with 2-3 prior chemotherapy regimensCohort 2', ' HER2-positive advanced breast cancer with prior pertuzumab and ado-trastuzumab emtansine (T-DM1)Cohort 3', ' HER2-positive advanced gastric cancer with prior trastuzumabCohort 4', ' HER2 2+/3+ NSCLC with at least 1 prior platinum regimen The protocol requires archival tumor tissue for central confirmation of HER2 status, alternative HER2 measurements, and targeted gene expression and sequencing studies. Tumor biopsies will be requested at the time of progression from patients who responded to XMT-1522. Clinical trial information', ' NCT02952729']",
        "Doc_id":"ASCO_192086-199",
        "Doc_title":" A phase Ib, first-in-human, dose escalation and expansion study of XMT-1522, a novel antibody-drug conjugate (ADC) directed against HER2, in patients with advanced breast cancer and other advanced tumors expressing HER2.",
        "_version_":1606189030619217920},
      {
        "Meeting_name":" AV-203, a fully humanized ERBB3 inhibitory antibody, reverses ERBB3-induced resistance to targeted therapies.",
        "Background":"['Targeted therapies have changed the treatment paradigm of cancer. Specifically, the use of tyrosine kinase inhibitors (TKIs) has improved therapeutic responses in a number of tumor types. However, initial response to TKIs is often followed by rapid relapse due to the acquisition of molecular features that lead to resistance. ERBB3, a receptor of the epidermal growth factor receptor (EGFR/ERBB1) family, has been linked to the development of resistance to multiple ERBB targeting TKIs. A proposed potential mechanism is the recruitment and activation of ERBB3 as a bypass mechanism to activate PI3K dependent pro-survival pathways. We investigated whether the inhibition of ERBB3 could reverse TKI resistance linked to ERBB3 activation. AV-203 is a humanized IgG1 antibody directed against ERBB3. AV-203 potently inhibits both ligand dependent and ligand independent activation of ERBB3. AV-203 was shown to inhibit the binding of NRG1 to ERBB3 and promote ERBB3 degradation. The tumor growth inhibitory activity of AV-203 was demonstrated in numerous xenograft models representing major human carcinomas (breast, lung, ovarian, kidney and pancreas). Here, we investigated the ability of AV-203 to restore TKI sensitivity in models with activated ERBB3. First, we demonstrated that ligand mediated (NRG1) activation of ERBB3 leads to acquired resistance to the EGFR TKI erlotinib in a lung cancer model bearing EGFR TKI sensitizing mutation, to the ERBB2/HER2 inhibitor lapatinib in a HER2 amplified breast cancer model, and to the EGFR inhibitory antibody cetuximab in head and neck cancer models. AV-203 was able to restore sensitivity to these RTK inhibitors. This data suggest that the combination of AV-203, with EGFR/HER2 targeted therapies could potentially extend the efficacy of these agents by preventing the emergence of ERBB3 mediated resistance. This hypothesis will be tested in future clinical trials. AV-203 is currently in Phase I development for the treatment of solid tumors.']",
        "Doc_id":"AACR_2013-1228",
        "Doc_title":" AV-203, a fully humanized ERBB3 inhibitory antibody, reverses ERBB3-induced resistance to targeted therapies.",
        "_version_":1606188989808640000},
      {
        "Meeting_name":" Clinical Survey of 19 actionable proteins in multiple indications using multiplex mass spectrometry",
        "Background":"['Many available oncology therapies are targeted to specific proteins, the most notable examples being therapies targeted to EGFR and Her2. For targeted therapies to have maximal efficacy, it is necessary to identify patients whose tumors express the target protein. As more pathways and proteins are identified as tumor drivers and therapies are developed that target those proteins, and more patient screening tools are needed to efficiently direct patients to correct therapeutic regimens.While chemotherapy regimens are not often considered targeted therapies, protein biomarkers for chemotherapy efficacy have been identified; for example amplification of TOPO2A is known to improve response to anthracycline-based therapy combinations. Though many chemotherapy biomarkers have been identified, screening is not routine, and chemotherapy regimens are not being adjusted for individual tumor biology.To address the growing need for efficient patient screening using minimal tissue, OncoPlex Diagnostics has built a comprehensive protein quantification panel that allows for the simultaneous quantitation of multiple actionable proteins from formalin-fixed, paraffin-embedded patient biopsies using multiplex mass spectrometry. This panel currently quantifies nine proteins that are markers of targeted therapy (including ALK, AR, EGFR, HER2, HER3, MET, MSLN, and PD-L1) and includes the ChemoPlex panel, which quantifies chemotherapy biomarkers (ERCC1, FRalpha, hENT1, RRM1, SPARC, TOPO1, TOPO2A). Since 2013, over 270 biopsies from multiple indications have been analyzed for protein expression in the OncoPlex Diagnostics CAP-qualified, CLIA-certified laboratory, revealing large ranges of expression for many drug targets that are not routinely assayed.Because of the importance of TOPO2A in anthracycline-based therapies, which are commonly prescribed in breast cancer patients, sixty-two breast cancer biopsies were retrospectively reviewed. Of the 62 samples, 41 were positive for TOPO2A expression; ranging from 233-1750amol/ug. Of the primary biopsies, 80% of them expressed TOPO2A; however only two of seven liver metastases were positive for TOPO2A. These data suggest that anthracycline-based therapy might not be as efficacious in metastatic sites due to the lack of TOPO2A.Also of interest, quantification of FRalpha, a biomarker for folate-targeted therapies, showed a 50-fold range of expression in NSCLC cases, and TOPO1, the target of irinotecan and topotecan, showed a 10-fold range of expression in various indications, with 4% of biopsies having no detectable TOPO1.These wide expression ranges of known biomarkers suggest that certain therapies might have vastly different response rates based on biomarker expression. To derive the best therapeutic response to both targeted and chemotherapy regimens, it is necessary to understand each patient tumor biology individually.']",
        "Doc_id":"AACR_2015-3395",
        "Doc_title":" Clinical Survey of 19 actionable proteins in multiple indications using multiplex mass spectrometry",
        "_version_":1606188975941222400},
      {
        "Meeting_name":" Initial results of LC-MAP",
        "Background":"['Background', ' Mutated oncogenes underlie the behavior of lung adenocarcinomas and can serve as targets for therapy. Determining the presence of these molecular abnormalities can direct the care of individual patients, qualify them for clinical trials, and aid research. To acquire this information on as many patients as feasible, in JAN 2009 our multidisciplinary Disease Management Team began a program (the Lung Cancer Mutation Analysis Project - LC-MAP), to prospectively detect all recurrent mutations in EGFR, KRAS, BRAF, HER2, PIK3CA, MEK1 and AKT1 and the EML4-ALK fusion gene in all patients diagnosed with lung adenocarcinoma with sufficient tissue. Methods', ' Patients sign an institutional consent to permit the use of previously obtained (\"leftover\") tissue for mutation profiling after standard morphologic and molecular diagnostic studies are complete. After PCR-based testing for EGFR exon 19 deletions and L858R, KRAS mutations are determined by direct sequencing, then remaining DNA is studied in a multiplexed mass-spectrometry-based system (Sequenom) to study 40 additional mutations in 7 genes. The EML4-ALK translocation is assayed by ALK FISH. Results', ' In the first six months, 301 patients entered the program. We completed all proposed testing in 92%. Mutations detected include 72 KRAS, 63 EGFR, 22 EML4-ALK, 1 BRAF, 4 PIK3CA, 0 HER2, 0 AKT1, and 0 MEK1. Based on this information, 27 patients with EGFR mutations received an EGFR tyrosine kinase inhibitor. No patient with wild type EGFR or a KRAS mutation received an EGFR TKI. 24 patients were entered on clinical trials testing agents targeting the specific molecular abnormality detected. Conclusions', ' (1) The presence of relevant mutations can be routinely determined in patients with adenocarcinoma of the lung. (2) The mutational data obtained can be used to select erlotinib or gefitinib for individuals with EGFR mutations and to identify patients appropriate for clinical trials of targeted therapies. (3) This effort supports making upfront genotyping of lung adenocarcinomas part of routine care. Support', ' P01 CA129243, Chandler Fund.']",
        "Doc_id":"ASCO_51376-74",
        "Doc_title":" Initial results of LC-MAP",
        "_version_":1606188996148330496},
      {
        "Meeting_name":" Humanized mouse models for evaluation of cancer therapies",
        "Background":"['Mice with a humanized immune system, so called humanized mouse models, have been established to study the complex interaction of the human immune system during human disorders. In case of cancer research, the in vivo model ideally should recapitulate the biological characteristics of the human tumor and of the related tumor microenvironment in patient such as immune system.Human immune system is reconstituted in immunodeficient mice using either human PBMCs or hematopoietic stem cells (HSCs). Humanized mice bearing human target tumor cells constitute relevant models for evaluation of cancer therapeutics such as bispecific antibodies, immune cell targeting antibodies.In vivo proof of concept studies were performed with humanized mice xenografted with either human disseminated lymphoma or with human solid tumors (tumor cell line and Patient Derived Xenograft model, Her2 positive breast, colon, ovarian and lung cancers) and treated with therapeutic antibodies.Biomarkers of response to immune cell targeting therapies were evaluated by flow cytometry as well as immunohistochemistry analyses. In case of disseminated B-cell lymphoma grafted into mice reconstituted with human PBMC, efficacy of antibody was evidenced by an increased survival and a high decrease of human B cells in mouse bone marrow. Lung and ovarian PDX developed in HSC reconstituted BRGS mice induced an increase in Tregs and a change in T/B ratio in blood and spleen samples. Furthermore, we evidenced the presence of Tregs within human PDX tumor by immunohistochemistry.']",
        "Doc_id":"AACR_2016-624",
        "Doc_title":" Humanized mouse models for evaluation of cancer therapies",
        "_version_":1606189008382066688},
      {
        "Meeting_name":" Dual inhibition of EGFR and HER2 in sublethally irradiated Lewis lung carcinoma cells suppresses MMP-9 production and cell invasiveness",
        "Background":"['Background', ' Radiotherapy (RT) is an essential component in multi-modality cancer management. While RT yields effective local disease control, distant failures remain great challenges that hinder cancer cure. Tumor cells that survive sublethal irradiation become invasive and metastasize, through up-regulation of matrix metalloproteinase-9 (MMP-9) and remodeling of extracellular matrix. Studies have shown that RT induces MMP-9 production in tumor cells by activating NF-B through PI3K/Akt and MAPK/ERK pathways. However, clinical applications of inhibitors targeting these pathways are lacking due to toxicity and low efficacy. EGFR and HER2 are canonical upstream signaling molecules that activate these pathways. Additionally, EGFR and HER2, when stimulated with ligands, have been found to induce MMP-9 expression. In this study, we aim to determine the roles of EGFR and HER2 in RT-induced MMP-9 expression, tumor cell invasiveness and metastasis using EGFR inhibitor, erlotinib and EGFR/HER2 inhibitor, afatinib.Methods and Materials', ' We used western blot analysis to determine EGFR, HER2, and Akt phosphorylations in irradiated Lewis lung carcinoma (LLC) cells (7.5 Gy) pretreated with erlotinib or afatinib. We then used RT-PCR, western blot assay, ELISA, and gelatin zymography to evaluate MMP-9 expression in irradiated LLC cells pretreated with erlotinib or afatinib. Clonogenic assays estimated irradiated LLC cell survival treated with erlotinib or afatinib. Matrigel-coated Boyden chamber assay was used to evaluate invasion capability of irradiated LLC cells. Lastly, tissue western blot analyses of EGFR/HER2/Akt phosphorylations and MMP-9 were performed in LLC tumor grown on the thigh of C57BL/6 mice treated with combined RT and either drug.Results', ' RT induced EGFR, HER2, and Akt phosphorylations as well as increased MMP-9 expression in LLC cells. Pretreatment with afatinib suppressed RT-induced MMP-9 mRNA and protein expression more significantly than erlotinib. Afatinib inhibited RT-induced invasiveness of LLC cells more than erlotinib did. Tissue western blot analysis of irradiated LLC ectopic xenografts showed more inhibition of RT-induced in vivo MMP-9 expression by afatinib than erlotinib. Afatinib was a stronger inhibitor than erlotinib for RT-induced MMP-9 up-regulation and cell invasiveness in LLC cells and ectopic xenografts. However, clonogenic assay of LLC cells showed that neither erlotinib nor afatanib sensitized LLC cells to RT in survival.Conclusion', ' Our results suggest that sublethal irradiation induces MMP-9 expression through EGFR and HER2 activation. Dual inhibition of EGFR and HER2 kinase better suppress RT-induced MMP-9 expression and abolish tumor cell invasiveness. Afatinib may serve as an orally bioavailable agent that ameliorates distant metastasis from inadequately irradiated primary lung tumor.']",
        "Doc_id":"AACR_2014-1731",
        "Doc_title":" Dual inhibition of EGFR and HER2 in sublethally irradiated Lewis lung carcinoma cells suppresses MMP-9 production and cell invasiveness",
        "_version_":1606188973425688576},
      {
        "Meeting_name":" HER2-targeted thorium-227 conjugate (HER2-TTC)",
        "Background":"['The human epidermal growth factor receptor 2 (HER2) is encoded by the proto-oncogene c-erbB-2 and initiates downstream signaling pathways leading to cell proliferation and tumorigenesis. HER2 is overexpressed in several cancer (Ca) types and is one of the most strongly validated targets for the treatment of breast and gastric cancer serving as both a prognostic and predictive biomarker. Several HER2-targeting antibodies as well as antibody-drug conjugates are either approved or are in clinical development. Prolonged treatment with monoclonal antibodies and antibody drug conjugates have resulted in development of resistance and so there is still an unmet medical need for drugs of new mechanism of action targeting this important receptor system. We describe herein the generation of a high energy, alpha-particle emitting HER2 targeted thorium-227 antibody-chelator conjugate. HER2-TTC consists of the humanized HER2 targeting IgG1 antibody (trastuzumab) covalently linked via an amide bond to a 3,2-hydroxypyridino-based chelator moiety, enabling efficient radiolabeling with the alpha particle emitting radionuclide thorium-227 (Th-227). HER2-TTC was prepared at high radiochemical yield and purity. When tested for binding to recombinant HER2, HER2-TTC was shown to retain comparable binding affinity to trastuzumab. In vitro cytotoxicity experiments were performed on 8 cell lines with different HER2 expression levels (from 7 000 - 500 000 mAbs bound/ cell as determined by FACS) of breast, ovarian, gastric and lung cancer origin. HER2-TTC demonstrated target mediated in vitro cytotoxicity in the pM-range. In vivo biodistribution and anti-tumor efficacy of HER2-TTC was evaluated in the dose range 100-500 kBq/kg at a protein dose of 0.14 mg/kg and i.v. injection in the s.c. KPL-4 breast and Calu-3 lung model previously described to be resistant to trastuzumab. The biodistribution study demonstrated specific tumor accumulation of HER2-TTC in both models with a maximum of 77 and 50 %ID/g 227Th at t = 168 h post dose (decay corrected to T0), respectively. Significant antitumor efficacy was shown for HER2-TTC in the JIMT-1 s.c. breast Ca xenograft model resistant to trastuzumab and T-DM1. The promising preclinical anti-tumor activity supports the development of the targeted alpha therapeutic HER2-TTC for the treatment of trastuzumab and T-DM1 resistant patients.']",
        "Doc_id":"AACR_2017-5859",
        "Doc_title":" HER2-targeted thorium-227 conjugate (HER2-TTC)",
        "_version_":1606189016230658048},
      {
        "Meeting_name":" Biomarker discovery through bioinformatic analysis of genomic profiles of PDX models with different responses to cancer therapies",
        "Background":"['Patient derived xenograft (PDX) tumor models have been proved to recapitulate the complexity and heterogeneity of their corresponding human tumors by phenotypic and genomic characterization, and thus become to be widely used in recent years in preclinical setting to facilitate drug discovery, translational studies and clinical trials support. Results from increasing number of preclinical studies, especially mouse trials, with PDX models in the past several years, have also demonstrated close correlation between drug response profiles with PDX models and clinical outcomes.GenenDesign has established over 800 PDX tumor models and derived around 100 resistance models to drugs of interest. Genomic profiling data of PDX models are acquired at hot-spot mutation, gene expression, gene copy number and RNA/Exome sequence levels. Through our in-house efforts, PDX models of different tumor types were tested with related SOCs and clinical candidates in biomarker-driven multi-drug multi-arm clinical trial settings. So far, more than 1200 data sets have been generated, including responses to targeted inhibitors against HER2, EGFR, FGFRs, c-Met/ALK, cell cycle regulators, Ras/Raf pathway, PI3K/Akt pathway, epigenetic targets, as well as chemotherapy drugs.In this study, we use bioinformatic tools to compare the genomic profiles of NSCLC PDX models based on their response profiles to multiple chemotherapy drugs. Biomarker signatures associated with SOC treatment sensitivity or resistance are revealed from bioinformatic analysis and being tested with both new NSCLC PDX models and clinical cohorts.The combination of genomic profiles and drug response information to multiple chemo/targeted therapies of over 800 PDX models at GenenDesign would help biomarker discovery for companion diagnosis to meet the increasing needs for precision medicine.']",
        "Doc_id":"AACR_2015-3222",
        "Doc_title":" Biomarker discovery through bioinformatic analysis of genomic profiles of PDX models with different responses to cancer therapies",
        "_version_":1606188988957196288},
      {
        "Meeting_name":" Pharmacokinetics and pharmacodynamics of AV-203, a humanized anti-ERBB3 antibody",
        "Background":"['ERBB3 is widely expressed in human carcinomas, and its over expression is associated with poor prognosis in patients with various carcinomas, (i.e., breast, ovarian, prostate, colorectal, pancreatic, gastric, and head and neck cancers). The presence of ERBB3 correlates with local to distal metastasis in lung, gastric, and colorectal cancers as well as bone invasion in prostate cancer. Activation of ERBB3 is also implicated in the development of resistance to current cancer treatments. Due to its lack of kinase activity, the activation of the ERBB3 receptor is dependent on heterodimerization with active receptor tyrosine kinases (RTKs). The recruitment of ERBB3 into active, heterodimer complexes is mediated by its ligand Neuregulin-1 (NRG-1) or by amplified, over expressed RTKs in a ligand independent manner. Therefore, ERBB3 can crosstalk with most major receptors involved in cancer development and maintenance such as epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and c-MET. AV-203 is a potent, humanized anti-ERBB3 antibody that inhibits both ligand-dependent and independent activation of ERBB3 both in vitro and in vivo. Pharmacokinetics and pharmacodynamics of AV-203 were characterized in mice using the A549 non-small cell lung cancer xenograft model. AV-203 administered IV in mice exhibits acceptable pharmacokinetics supporting preclinical efficacy studies. AV-203 administered IV in A549 NSCLC xenograft tumor bearing mice had lower serum AUC than nave mice, demonstrating that the presence of human ErbB3 may alter the PK parameters of AV-203. In evaluating pharmacodynamics in vivo, AV-203 was able to down regulate total ERBB3 and ERBB3 signaling in A549 tumors in a time-dependent manner. Inhibition of ERBB3 signaling correlated with significant dose-dependent tumor growth inhibition in the A549 xenograft model. Dose scheduling studies with the constant AV-203 dose of 2.5 mg/kg revealed that the most efficacious schedule is the more frequent dosing at Q3D. In comparing the total dose of 10 mg/kg per 14 day cycle, at varying dose per injection and frequency, AV-203 resulted in significant tumor growth inhibition at all dose schedules. These data conclude that the efficacy of AV-203 is driven by total drug exposure and that AV-203 is not dependent on Cmax for its antitumor activity.']",
        "Doc_id":"AACR_2012-3787",
        "Doc_title":" Pharmacokinetics and pharmacodynamics of AV-203, a humanized anti-ERBB3 antibody",
        "_version_":1606189012806008832},
      {
        "Meeting_name":" Genomic profiling of patients with multiple primary cancers reveals different cancer gene mutation pathways.",
        "Background":"['Background', '   Multiple primary cancers in a single individual are rare and usually challenging for effective treatments. Identification common cancer gene driver mutations and targets for patients with multiple primary malignant cancers will offer potential opportunities for effective personalized treatment.  Methods', '   We have collected and analyzed tumor tissue samples from patients diagnosed with multiple primary cancers including lung cancer, kidney caner, prostate cancer, and bone caner from the Affiliated Zhongshan Hospital of Dalian University. Deep sequencing of the tumor samples was done using TruSeq Amplicon - Cancer Panel (TSACP) which covers 48 cancer genes with more than 400 mutation hotspots.   Results', '   We have found that TP53 (75%), PIK3CA (50%), KDR(50%), VHL(50%), KRAS (25%), , FGFR(30%), EGFR(25%), HER2(25%) and ATM (25%) mutations are among the most common gene alterations across different types of primary cancers, they share some common cancer gene pathways. Missense exon variation(4.13%) , non-coding exone variation(2.8%), and frameshift variation (0.41%) are among the most frequent alterations for functional effects. Personalized treatments according to the individual cancer gene mutation profiles have been recommended.  Conclusions', '   Cancer hot-spot gene mutations in patients with multiple primary cancers have been investigated using next generation sequencing technologies. Common driver mutations and pathways among the different cancers have been identified, and targeted and chemotherapies have been suggested for personalized cancer treatments.']",
        "Doc_id":"ASCO_153619-156",
        "Doc_title":" Genomic profiling of patients with multiple primary cancers reveals different cancer gene mutation pathways.",
        "_version_":1606188974502576128},
      {
        "Meeting_name":" PLATFORM",
        "Background":"['Background', '    Outcomes for patients with advanced OG cancer remain poor, median overall survival for fit patients treated with platinum and fluoropyrimidine based chemotherapy is less than one year, with second line chemotherapy resulting in a modest (approximately 6 weeks) survival benefit for selected patients. Evidence from NSCLC trials suggests a survival benefit from maintenance treatment following first line chemotherapy. Emerging data also supports the use of immunotherapy in previously treated OG cancer. The PLATFORM study aims to evaluate maintenance therapy in patients with advanced OG cancer.   Methods', '    This is a prospective, open label, multicentre, randomised phase II clinical trial which will recruit at multiple UK cancer centres. Eligible patients are those who have measurable stable disease or better following completion of first line chemotherapy (at least 6 cycles) for locally advanced unresectable or metastatic disease. First line chemotherapy regime should contain a platinum and 5-fluoropyridimine (with trastuzumab if HER2 +), doublet or triplet drug combinations are permitted. Maintenance strategies are split by HER 2 status. For HER2 negative patients these are', '  Arm A1', ' surveillance, Arm A2', ' capecitabine, Arm A3', ' MEDI 4736 (anti PDL1 inhibitor) and for HER2 positive patients; Arm B1', ' trastuzumab, Arm B2', '  in development. Target recruitment is six hundred and sixteen patients, 154 patients will be recruited to each arm, with an interim analysis following recruitment of 61 patients to each arm. An adaptive trial design enables ineffective treatments to be discontinued early, with the opportunity to add novel treatment arms as the trial progresses. Primary endpoint is progression free survival. Secondary endpoints are progression free rate at 3, 6 & 12 months, overall survival, objective response rate by RECIST 1.1, toxicity and analysis of efficacy endpoints according to biomarker status for selected arms. Thirty two patients have been registered for the study with 3 patients randomised, recruitment is ongoing. Clinical trial information', ' EUDRACT', ' 2014-002169-30.']",
        "Doc_id":"ASCO_160052-173",
        "Doc_title":" PLATFORM",
        "_version_":1606189023854854144},
      {
        "Meeting_name":" Overcoming tumor antigen anergy in human malignancies using the novel indeolamine 2,3-dioxygenase (IDO) enzyme inhibitor, 1-methyl-D-tryptophan (1MT).",
        "Background":"['Background', \" The limited effect of cancer immunotherapy is due to the tumor's ability to induce host anergy towards its antigens. The enzyme indoleamine 2,3-dioxygenase (IDO) is thought to play a key role in anergy induction. IDO metabolizes tryptophan (trp) into immunosuppressive metabolites such as kynurenine (kyn). The oral IDO inhibitor, 1-methyl-D-tryptophan (1MT), was studied in preclinical models. The preclinical data support the activity of 1-MT in preventing T-cell anergy in TDLN, slowing growth of LLC mouse xenografts, and synergizing with chemotherapy in regression of autochthonous breast tumors in MMTV-Neu mice. This led to a phase I first-in-man trial using 1-MT in solid tumors. Methods\", ' This is a phase I study treating adults with refractory solid malignancies. Patients are treated with up to 6 consecutive 28-day cycles starting at 200mg once daily. A 3+3 dose escalation to MTD is used. PK analysis, weekly labs, and CT scans every 2 cycles were done. Correlative studies include serum kyn/trp levels, T-reg cell quantification by flow, tumor IDO expression by IHC, and humoral immune response using a proprietary tumor antigen microarray. Results', ' Ten pts have recieved 1-MT at 200mg daily. Tumors treated included 1 esophageal, 1 peritoneal, 3 melanomas, 2 sarcomas, and 3 NSCLC. PK results show good bioavailability and a t1/2 of 2-4 hrs. Of the 7 evaluable pts, 4 had SD and 3 had PD. Attributable toxicities were 1 case of grade 1 fatigue and 2 cases of grade 2 hypophysitis. Both cases occurred in pts who received prior immunotherapies. Six new pts without prior immunotherapy were enrolled at the 200mg dose level. Five pts remain on treatment currently. Three pts had decreased T-reg cells after treatment with 1MT and 4 pts showed marked CRP increases. One pt had increased autoantibody titers against 3 tumor antigens compared to baseline. Conclusions', ' 1-MT appears to be an active, orally bioavailable, and reasonably well tolerated immunomodulator at 200mg daily. Development of hypophysitis in 2 patients indicates the drug can break tolerance resulting in autoimmunity. Enrollment to the trial continues. Future trials will combine 1-MT with other immunotherapies and chemotherapies for solid tumors.']",
        "Doc_id":"ASCO_30295-65",
        "Doc_title":" Overcoming tumor antigen anergy in human malignancies using the novel indeolamine 2,3-dioxygenase (IDO) enzyme inhibitor, 1-methyl-D-tryptophan (1MT).",
        "_version_":1606188981804859392},
      {
        "Meeting_name":" Patient-derived xenograft (PDX) models expressing HER2 reflect clinical responses to targeted HER2 inhibition.",
        "Background":"['Background While HER2-directed agents are most often used for treating breast cancer, there is increasing evidence that these therapies may be of value in other solid tumors. Sequencing efforts and immunohistochemistry (IHC) have identified mutations, amplifications, and overexpression of HER2 in ovarian, HNSCC, NSCLC, and GI cancers. PDX models could permit evaluation of HER2 response/resistance mechanisms to optimize therapeutic strategies. In this pilot study, we evaluated the response of PDX models to HER2-targeted therapies and correlated responses to clinical outcomes.']",
        "Doc_id":"AACR_2017-1836",
        "Doc_title":" Patient-derived xenograft (PDX) models expressing HER2 reflect clinical responses to targeted HER2 inhibition.",
        "_version_":1606189040535601152},
      {
        "Meeting_name":" Molecular screening for cancer treatment optimization (MOSCATO 01)",
        "Background":"['Background', '  Characterization of the genomic alterations (GA) that could drive tumor growth of an individual patient (pt) is now critical to better select targeted therapies in phase I trials.  Methods', '  Pts with advanced solid tumors, who failed at least one line of standard therapy, were offered an on-purpose tumor biopsy for molecular characterization. Biopsies were mainly obtained using 18G needles under CT or ultra-sound control, from metastatic or primary tumor sites. DNA extracted from fresh tumor biopsies was analyzed by CGH (Agilent platform) (if  50% tumor cells in the sample) and by sequencing for 30 target genes (if  30% tumor cells in the sample). An expert panel of scientists and clinicians reviewed results to determine the biological signification of the GA and match such pts to the most relevant targeted therapy available (mainly in early clinical trials). PFS using therapy based on GA was compared to the PFS for the most recent therapy on which the pt had just experienced progression (PFS ratio).  Results', '  From December 2011 to august 2012, 129 heavily pretreated pts (median of 3 previous lines) were consented. Among them, 111 (86%) had a dedicated tumor biopsy. An actionable target was identified in 52 patients (40%). Among them, 25 pts (23% of biopsied pts) have been treated with a targeted therapy. The median time between biopsy and molecular results was 21 days [17  28]. GA of interest encompassed FGF ligand or receptor amplification (n=9), cyclin amplification or deletion (n=4), KRAS/BRAF/NRAS mutation (n=3), PI3K amplification or PTEN deletion (n=3), EGFR amplification or mutation (n=3) (outside lung cancer), HER2 amplification (n=2) (outside breast cancer), EML4/ALK translocation (n=1). Among the 25 pts treated according to their GA, we observed 5 PR (20%), 14 SD (56%) and 3 PD (12%). Three pts (12%) were not evaluable because of early discontinuation of the therapy. PFS ratio was >1.3 among 9 out of 19 evaluable pt (47%).  Conclusions', '  High throughput molecular analysis is feasible in daily practice. It allows enrichment of phase I trials with specific GA, and leads to promising anti-tumor activity (20% PR as compared to the classical 7-10% PR obtained in all comers phase I trials). Clinical trial information', ' NCT01566019.']",
        "Doc_id":"ASCO_116665-132",
        "Doc_title":" Molecular screening for cancer treatment optimization (MOSCATO 01)",
        "_version_":1606189009013309440},
      {
        "Meeting_name":" Patient stratification and drug combination strategy based on drug response and genomic information from PDX clinical trials (PCTs)",
        "Background":"['Cancer is a heterogeneous disease with various molecular lesions and drug response profiles within the same tumor type. Patient stratification in clinical trials based on molecular features has contributed to recent success of several targeted cancer drugs on molecular aberrations such as BCR-ABL translocation in CML, Her2 amplification in breast and gastric cancers, EGFR mutations and ALK fusions in lung cancer and BRAF mutation in melanoma. However, in most cancers, the molecular features which can be used for patient stratification are not as simple as a single genetic aberration. Multiple drug resistance mechanisms caused by various mutations in cancer signaling pathways can also increase the uncertainty of clinical outcomes.To increase the chance of success in human clinical studies, patient-derived xenograft (PDX) clinical trials (PCTs) have increasingly been used for predictive biomarker validation, resistance mechanism investigation and combination therapy selection. PDX tumor models have been demonstrated to have high correlations with human patients in tumor pathology, molecular characteristics and drug responses. Large scale PCTs have also shown consistency in results when compared to related human clinical trials.At GenenDesign, we have established over 1000 PDX tumor models and more than 100 resistance models against various cancer drugs. Many of these PDX models have been characterized at RNA/Exome sequence, gene expression, gene copy number and hot-spot mutation levels. We carried out our PDX clinical trials by testing multiple approved drugs and clinical drug candidates such as targeted inhibitors against FGFRs, c-Met/ALK, HER2, EGFR, cell cycle regulators, Ras/Raf pathway, PI3K/Akt pathway, as well as chemotherapy drugs in biomarker-driven multi-drug multi-arm expanded PDX clinical trials. So far, we have accumulated more than 3000 efficacy data sets and associated PD samples.Analysis of drug response and associated genomic information from PDX clinical trials yielded rich information for predictive biomarker identification and validation. At the same time, many potential resistance mechanisms were also revealed. These information can make human clinical trial better prepared, more efficient and focused. More importantly, testing of a targeted drug with multiple chemotherapies in the same models can also provide guidance on future combination selection strategy.']",
        "Doc_id":"AACR_2016-395",
        "Doc_title":" Patient stratification and drug combination strategy based on drug response and genomic information from PDX clinical trials (PCTs)",
        "_version_":1606188982216949760},
      {
        "Meeting_name":" Creating a superior, site-specific anti-HER2 antibody-drug conjugate (NG-HER2 ADC) for treatment of solid tumors",
        "Background":"['Antibody-drug conjugates (ADCs) have emerged as an important class of cancer therapeutics. The FDA approval of Kadcyla (T-DM1), a single agent for treatment of HER2-positive advanced metastatic breast cancer, was a significant milestone in the field of targeted therapy, as the first and only ADC for treatment of solid tumors. Despite the 3-month improvement over standard of care in the median survival, almost all the patients eventually became refractory to T-DM1. We have identified several possible areas for improvement', ' 1) The potency of T-DM1 as confirmed by the Phase III clinical data is restricted to high HER2 tumors which leaves moderate or low HER2 expressing patients without access to T-DM1 treatment; 2) The 48% overall response rate is indicative of intrinsic resistance to T-DM1 and all T-DM1 treated patients eventually relapse. 3) The randomized lysine conjugation in T-DM1 generates heterogeneity of the product. We have developed a novel, site-specific anti-HER2 ADC (NG-HER2 ADC) and evaluated it in comparative preclinical studies with T-DM1. The results show that the NG-HER2 ADC is  10 fold more potent than T-DM1 in HER2 3+ xenograft models of breast and gastric cancers. Our proprietary cleavable and permeable linker-payload can mediate bystander effect and this enables potent anti-tumor activity in non-HER2 amplified breast cancer and heterogeneous low HER2 NSCLC PDX models, where T-DM1 is ineffective. Our ADC can overcome T-DM1 resistance in in vitro and in vivo models.. Our site-specific ADC at HNSTD of 9 mg/kg in cynomolgus monkeys showed high AUC, long half-life and had normal clinical observations with no marked neutropenia. On the contrary, conventional conjugates with cleavable linker payloads typically have severe bone marrow toxicity as DLT above 5 mg/kg. The therapeutic index for NG-HER2 ADC is significantly greater than T-DM1 in all models tested. NG-HER2 ADC has a projected clinical efficacious dose of 1 mg/kg, compared to 3-5 mg/kg for T-DM1, based on PK/PD modeling. In addition, the activity of the NG-HER2 ADC shows increased infiltration of CD8 positive effector cells, an essential component for immuno-oncology (IO) efficacy, in a syngeneic HER2 overexpressing model. This property potentially allows the combination of the ADC with IO drugs to improve the long-term, overall survival. Our data provides preclinical proof of concept for NG-HER2 ADC with best-in-class potential and is currently being tested in preparation for clinical trials for treatment of HER2 solid tumors.']",
        "Doc_id":"AACR_2016-868",
        "Doc_title":" Creating a superior, site-specific anti-HER2 antibody-drug conjugate (NG-HER2 ADC) for treatment of solid tumors",
        "_version_":1606189030766018560},
      {
        "Meeting_name":" A study of the anatomic distribution of brain metastases in HER2+ breast cancer",
        "Background":"['Background', '  While only 20% of all breast cancer is HER2+, it represents a disproportionate majority of breast cancer brain metastases, and up to half of these patients will die of CNS disease.   Prophylactic cranial irradiation (PCI) reduces the risk of brain metastases and improves survival in small cell lung cancer, but at the cost of neurocognitive decline in 30-40%.  RTOG 0933 demonstrated a reduction in neurocognitive decline with hippocampal-avoidance (HA) whole brain radiation compared with historic controls.  HA-PCI may represent an approach to reduce the risk of symptomatic HER2+ brain metastases while simultaneously reducing the risk of neurotoxicity, presuming the incidence of metastases within the HA zone is low.  Methods', '  Patients with HER2+ breast cancer and brain metastases treated with whole brain radiation (WBRT) or stereotactic radiosurgery (SRS) from 1/2004-2/2012 were identified from registries in the Department of Radiation Oncology.  Pretreatment T1-weighted, postcontrast axial MRI images were reviewed, and metastases were scored as being within a 5 mm HA zone (as done in RTOG 0933), and further subdivided by whether (1) any portion was within the avoidance zone or (2) the nidus (assuming concentric growth of the metastasis) was within the HA zone.  Results', '  Seventy-three patients with 513 metastases were identified.  The median age was 52.2.  The median number of brain metastases per patient was 7.03 (range, 1-157).  40 of the patients were treated with WBRT and 21 were treated with SRS, with the remainder undergoing unknown or no radiation therapy.  Eleven patients (15.1%) and 14 metastases (2.7%) had any portion of the metastasis within the HA zone while only 5 patients (6.85%) and 5 metastases (0.97%) had the tumor nidus within the HA zone.    Conclusions', '  Metastases within the HA zone are uncommon.  Use of a 5 mm expansion from the hippocampus to create a HA zone for HA-PCI would be projected to result in a 1-3% excess risk of failure.  Such a low risk of failure would be acceptable, particularly with the ability to salvage such patients with techniques such as SRS.  A pilot study of HA-PCI for HER2+ metastatic breast cancer is in development.']",
        "Doc_id":"ASCO_130860-144",
        "Doc_title":" A study of the anatomic distribution of brain metastases in HER2+ breast cancer",
        "_version_":1606188975663349760},
      {
        "Meeting_name":" REGN1400, a fully-human ERBB3 antibody, potently inhibits tumor growth in preclinical models, both as a monotherapy and in combination with EGFR or HER2 blockers",
        "Background":"['ERBB3 is a member of the ERBB family of receptor tyrosine kinases, that includes EGFR and HER2, well-established drivers of tumorigenesis. Recent preclinical studies indicate that both EGFR and HER2 cooperate with ERBB3 to activate the phosphatidylinositol-3 kinase/Akt survival pathway and to promote tumor cell survival. Furthermore, ERBB3 activation has been demonstrated to mediate resistance to EGFR inhibitors in non-small cell lung cancer cell lines and to HER2 inhibitors in breast cancer cell lines. Consistent with these findings, anti-ERBB3 monoclonal antibodies have been shown to inhibit the growth of human tumor xenografts, demonstrating the importance of ERBB3 for tumor growth in vivo. REGN1400 is a fully-human anti-ERBB3 monoclonal antibody that binds human ERBB3 with high affinity (KD 50pM) and potently inhibits binding of the ERBB3 ligand neuregulin 1 (IC50 30pM). REGN1400 inhibited phosphorylation of ERBB3 and Akt in multiple human tumor cell lines in vitro, including A431 (epidermoid carcinoma), MDA-MB-175-VII (breast cancer) and FaDu (head and neck cancer). In addition, REGN1400 strongly inhibited the growth of these cell lines in vitro. Consistent with its potent effects on tumor cell growth in vitro, REGN1400 strongly inhibited the growth of A431 and FaDu tumor xenografts in a dose-dependent manner, providing 70% and 97% tumor growth inhibition, respectively. Inhibition of FaDu tumor growth by REGN1400 was accompanied by a significant decrease in tumor ERBB3 phosphorylation, as assessed by both western blot and immunohistochemistry, confirming target inhibition in vivo. While treatment of FaDu tumors with single agent REGN1400 provided almost complete tumor growth inhibition, but not regression, the combination of REGN1400 plus anti-EGFR antibody caused significant tumor regression. Furthermore, combination treatment with REGN1400 plus the anti-HER2 antibody trastuzumab inhibited the growth of BT474 breast tumor xenografts more potently than either single agent. These findings indicate that ERBB3-directed therapies might be more effective when combined with agents that inhibit other ERBB family members. Finally, gene profiling studies in REGN1400-treated tumor cells revealed upregulation of several genes that could promote resistance to REGN1400, e.g., ERBB3 itself and ERBB4. Further analysis of tumor gene expression changes induced by REGN1400 could provide insight into potentially useful combination regimens. In summary, REGN1400, a novel anti-ERBB3 antibody, exhibits significant antitumor activity in preclinical models, suggesting the possibility that it could provide benefit to patients with multiple types of cancer, either as a single agent or when combined with therapies targeting other ERBB family members.']",
        "Doc_id":"AACR_2012-2718",
        "Doc_title":" REGN1400, a fully-human ERBB3 antibody, potently inhibits tumor growth in preclinical models, both as a monotherapy and in combination with EGFR or HER2 blockers",
        "_version_":1606188991643648000},
      {
        "Meeting_name":" A phase I study of indoximod in combination with docetaxel in metastatic solid tumors.",
        "Background":"['Background', '  The indoleamine-2, 3-dioxygenase (IDO) pathway catabolizes tryptophan to create a state of immunosuppression. Indoximod (1-methyl-(D)-tryptophan, D-1MT) is an IDO pathway modulator. Preclinical studies in MMTV-neu mouse models have shown indoximod combined with chemotherapy was more effective in causing tumor regression than either agent alone. Based on this data, a phase IB trial was designed to study the safety of the combination of docetaxel (Doc) and indoximod. The primary goal of this trial was to determine the MTD for the combination of Doc and oral indoximod. Secondary endpoints were PK data and efficacy for indoximod/Doc.  Methods', '  This phase IB study consisted of 5 dose levels (DL). Doc was dosed IV q 3 wks at 60 mg/m2 in DL 1-4 and 75 mg/m2 at DL 5. Indoximod was dosed at 300, 600, 1,000, 2,000, and 1,200 mg PO BID continuously in DL 1-5 respectively. MTD was determined using a 3+3 design. The DLT rule was 1st cycle G3 non-heme AEs or G4 heme AEs despite supportive care or that delay therapy >14d. The PK of indoximod and Doc was analyzed using a HPLC assay. PK was measured on C1D1 and 8. Standard eligibility/exclusion criteria applied along with exclusion of patients previously treated with ipilumimab. Treatment was continued until disease progression, intolerance, or unacceptable side effects.  Results', ' Total # of patients treated at DL1-5 were 7, 6, 6, 2, and 6 respectively, with 22 total patients evaluable for response. DLTs included', ' G3 dehydration (at 300 mg), G5 neutropenic colitis (at 600 mg), G3 hypotension (at 2,000 mg) and G3 mucositis (at 2,000 mg). DL 5 was well tolerated and is the recommended phase II dose. The most frequent adverse events were fatigue (58.6%), anemia (51.7%), hyperglycemia (48.3%), infection (44.8%), and nausea (41.4%). There were 4 PRs (2 breast, 1 NSCLC, 1 thymic), 9 SD, and 9 PD. There were no drug-drug interactions, and PK was similar to Doc and indoximod single-agent studies.  Conclusions', ' The Doc+ indoximod combination was well tolerated with no increase in expected toxicities or unexpected PK interactions. It was active in a pretreated population of patients with metastatic solid tumors. The RP2D is 75 mg/m2 of Doc with 1,200 mg of indoximod BID for the current phase II metastatic breast cancer trial.  NCT01191216 Clinical trial information', ' NCT01191216.']",
        "Doc_id":"ASCO_113255-132",
        "Doc_title":" A phase I study of indoximod in combination with docetaxel in metastatic solid tumors.",
        "_version_":1606189013401600000},
      {
        "Meeting_name":" Multiplex assay in FFPE tissues to simultaneously quantify the human EGF receptor (HER1-4) family proteins",
        "Background":"[\"The human EGF receptor family (HER's) consists of two clinically validated drug targets (EGFR (HER1) and HER2), and two receptors (HER3 and HER4) which are the subject of intensive preclinical and early clinical investigation. Although drugs inhibiting both EGFR and HER2 show significant antitumor activity in the clinic, the acquisition of resistance is a hallmark of these and other targeted therapies. In the case of both targets, one of the emerging resistance mechanisms is the co-expression of other members of the EGFR superfamily. It was recently shown that HER2 co-expression mediates resistance in EGFR inhibitor (cetuximab) treated head and neck cancer (Sci Transl Med 7(3)99). Similarly, much attention has been paid to HER3 both as a bona fide drug target as well as a resistance mechanism (Oncogene 27, 3944). Finally, HER4, though less well studied may play a role in drug response (Breast Cancer Research 11\", 'R50). We have previously build HER1 and HER2 specific SRM assays. HER3 is usually expressed at much lower levels than EGFR and HER2 (often <10%). Yet, receptor crosstalk and heterodimerization can allow even very low levels of HER3 to exert a large impact on drug response. According to one report (Cancer Epidemiol Biomarkers Prev. 19(4)', '982), IHC analysis of HER3 may be inadequate to properly quantitate HER3 expression in FFPE tumor tissues. This antibody inadequacy may be a result of high sequence homology/identity between HER3 and other HER family members. Due to the critical need to accurately quantitate this receptor, we have used a mass spectrometric approach to develop a specific and quantitative SRM assay for HER3 from FFPE tumor tissue. These preclinical studies are being extended by assessing the expression levels of the complete HER family in two cohorts of clinical tumor tissue which had been treated with HER family antagonists. First, we measured HER3 expression in a set of neoadjuvant gefitinib treated NSCLC tumors. In this cohort, 12/15 tumor showed low but measurable levels of HER3 expression, ranging from 50-100 amol/ug tumor tissue. In a second tissue set, we measured HER3 expression in a cohort of advanced (Stage III-IV) breast cancer tissues which had undergone post resection adjuvant treatment with trastuzumab. These breast cancer samples demonstrated a higher level of expression of HER3, ranging from 50 - 250amol/ug tumor tissue, and 15/18 tumors were HER3 positive. In both studies, the relationship between HER family expression and response to either gefitinib or trastuzumab is currently under study. Analysis of HER4 in these cohorts is ongoing. It is critically important to understand mechanisms of resistance in patients undergoing targeted therapies, and Liquid Tissue-SRM promises to be a platform which can deliver extremely high sensitivity, absolute specificity as well as multiplexing capabilities to assess the four HER family targets in unison.']",
        "Doc_id":"AACR_2012-4567",
        "Doc_title":" Multiplex assay in FFPE tissues to simultaneously quantify the human EGF receptor (HER1-4) family proteins",
        "_version_":1606189005059129344},
      {
        "Meeting_name":" Elucidating the mechanisms of acquired resistance in lung adenocarcinomas",
        "Background":"['In lung adenocarcinomas, targeted therapy with the EGFR tyrosine kinase inhibitors (TKIs) erlotinib, gefitinib and afatinib is associated with longer progression free survival (PFS) and higher radiographic response (RR) rates when compared to standard first-line chemotherapy. In ALK rearranged lung cancers, targeted therapy with crizotinib is associated with PFS of approximately 9,7 months and RR of 60.8%. However, despite the initial success of these agents, all patients progress with a median PFS of 7 to 16 months. Acquired resistance in EGFR mutant tumors is driven by the occurrence of a secondary EGFR mutation (T790M) in about 50% of the cases and by MET amplification in 5 to 10 % of the cases. Other mechanisms include HER2 amplification, PTEN loss, phenotypic change to small cell histology, rare mutations in BRAF and AXL activation. Resistance to crizotinib, on the other hand, is caused by secondary mutations in the ALK kinase domain, by ALK or cKIT amplification or by alterations in EGFR and KRAS. Here, we made use of next generation sequencing techniques to better understand the mechanisms that drive resistance in lung adenocarcinomas treated with erlotinib or crizotinib. For this purpose, we used transbronchial or CT-guided rebiopsies from patients that had either prolonged stable disease or partial response to therapy, and developed radiographic progression under TKI therapy. Samples were analyzed by FISH and sequenced on a benchtop Illumina platform (MiSeq) in order to evaluate the presence of known mechanisms of resistance. Samples that were negative for any of the reported mechanisms were analyzed by genome, exome or trascriptome sequencing. From the sequencing output of the pan-negative samples, filtering of mutation candidates included', ' absence of the mutation in the pre-treatment sample (when available), expression of the candidate gene in lung adenocarcinomas, absence of the mutation in primary lung adenocarcinomas, high impact of the mutation at protein level (Polyphen), mutant allelic fraction in the tumor higher than 10%, among other factors. After filtering, validation of mutation calls was performed by Sanger sequencing. Sequencing of the erlotinib resistant samples revealed mutations in members of a functionally wide spectrum of protein families including the proteoglycan family, the ATP-binding cassette (ABC) transporters family, an Fms-related tyrosine kinase receptor and a member of the transforming growth factor beta family of cytokines. On the other hand, crizotinib resistant samples showed mutations in a cell surface receptor for macrophage-stimulating protein with tyrosine kinase activity, in a C2H2 type zinc finger gene, a semaphorin, a mitogen-activated protein kinase and a member of the SWI/SNF family of proteins. Our results evidence the possible contribution of a wide range of cellular pathways in the process of acquired resistance to EGFR and ALK inhibitors in lung adenocarcinomas.']",
        "Doc_id":"AACR_2014-956",
        "Doc_title":" Elucidating the mechanisms of acquired resistance in lung adenocarcinomas",
        "_version_":1606188999990312960},
      {
        "Meeting_name":" Establishment and molecular characterization of cell lines from Japanese patients with malignant pleural mesothelioma.",
        "Background":"['Malignant pleural mesothelioma (MPM) is a poor prognostic malignancy that is distinctly resistant to the conventional therapies. Cell lines are useful materials for studying the biological characteristics of the tumors, thus the establishment of MPM cell lines is valuable for exploring the new therapeutic strategies of MPM. We established 4 MPM cell lines (YUMC8, YUMC44, YUMC63 and YUMC64) from Japanese patients, consisting of 2 epithelioid and 2 sarcomatoid types for histological subtype. We analyzed the status of methylation, mutation, copy number gains (CNGs), and protein expression in representative genes and the sensitivity to several drugs in these 4 cell lines. We detected the complete methylation of P16 in 3 cell lines, in which the protein expression of p16 was lost. Methylation of RASSF1A was observed in 3 of 4 cell lines. Copy number gains (CNGs) in EGFR, HER2 and MET were not detected in all the cell lines. Mutations in various genes including EGFR, KRAS, HER2, BRAF, and PIK3CA, which are frequently detected in non-small cell lung cancer, were not detected in all 4 cell lines. As for microRNA, miR-34b/c was completely methylated in 2 of 4 MPM established cell lines. About cell adhesion molecules, E-cadherin expression was detected in two epithelioid type MPM cell lines, whereas N-cadherin expression was detected in all four established cell lines by Western blot analysis. Vimentin was strongly expressed in two sarcomatoid type MPM cell lines. All established MPM cell lines showed no dramatic responses to the drugs tested including NVP-AUY922, 17-DMAG, Trichostatin A and Vorinostat. Although new molecular findings were not observed in the process of the current characterization of these new MPM cell lines, they seem to be useful for the future extensive analyses of biological behavior of MPM, so as to the development of new therapeutic strategies.']",
        "Doc_id":"AACR_2013-2795",
        "Doc_title":" Establishment and molecular characterization of cell lines from Japanese patients with malignant pleural mesothelioma.",
        "_version_":1606189004427886592},
      {
        "Meeting_name":" Novel HER2 targeting antibody-drug conjugates based on DNA-interacting duocarmycin and an unique linker technology with great potential in breast cancer and NSCLC.",
        "Background":"['We have generated cleavable linker-duocarmycin payloads that previously have been shown to be highly stable in human plasma and to cause excellent in vitro and in vivo efficacy when conjugated to antibodies directed against multiple targets in different models. In our HER2 program, we have used these linker-duocarmycin payloads to generate HER2-targeting antibody-drug conjugates (ADCS) and prepare these for FIM studies. HER2 is a validated target in breast (BC) and gastric cancer (GC) that is currently used to target trastuzumab towards HER2-positive BC and GC tumors. We have generated a set of cysteine-coupled ADCs using newly developed duocarmycins conjugated to a therapeutic HER2/neu antibody. In vitro studies with the anti-Her2 ADCs showed that compared to the naked Ab, the ADCs tested have gained a more than 100-fold potency and more than two-fold efficacy in cell killing capacity. Studies in HER2 positive and negative cell lines indicated that cytotoxicity was HER2- mediated. HER2 binding and ADCC activity was not affected by conjugation. Single dose and multiple dose xenograft studies in mice using a human HER2-positive breast cancer cell line showed dose-dependent anti-tumor activity of the ADCs in vivo. Patient-derived xenografts (PDx) using primary tumors from HER2-positive breast cancer and NSCLC patients demonstrated the ability of the ADC to induce complete remission of tumors that remained unresponsive to the naked Ab trastuzumab. Also taken into account toxicology studies in rodents and cynomolgous monkeys, we conclude that we have generated a new class of HER2-based ADCs that have great potential to become effective treatment for HER2-positive tumors, including breast cancer and NSCLC. From a series of compounds, a preclinical candidate was selected that is currently being prepared for Phase I clinical trials that will start in 2014.']",
        "Doc_id":"AACR_2013-4329",
        "Doc_title":" Novel HER2 targeting antibody-drug conjugates based on DNA-interacting duocarmycin and an unique linker technology with great potential in breast cancer and NSCLC.",
        "_version_":1606188995724705792},
      {
        "Meeting_name":" RET fusion gene",
        "Background":"['A considerable proportion of lung adenocarcinomas, the most common histological type of lung cancer that comprises 40% of the total cases, develops through activation of oncogenes, for example, somatic mutations in EGFR or KRAS or fusion of ALK, in a mutually exclusive manner. Tyrosine kinase inhibitors targeting the EGFR and ALK proteins are effective in the treatment of lung adenocarcinomas that carry EGFR mutations and ALK fusions, respectively. We performed whole-transcriptome sequencing (RNA sequencing) of 30 lung adenocarcinoma specimens from Japanese individuals to identify new chimeric fusion transcripts that could be targets for therapy. Then, we identified KIF5B (kinesin family 5B)-RET fusion gene, as another druggable oncogene that is present in 2% (6/319) of lung adenocarcinomas (Kohno et al., Nat Med, 2012). The KIF5B-RET fusion leads to aberrant activation of RET kinase and is considered to be a new driver mutation segregating from mutations or fusions in EGFR, KRAS, HER2 and ALK. The RET fusion has preferentially been detected in well or moderately differentiated tumors of never smokers. The RET fusion in lung adenocarcinoma was also identified by three other groups', ' Dr. Ju et al of Seoul National University, Dr. Takeuchi et al of Japanese Foundation for Cancer Research, and Dr. Lipson et al of Foundation Medicine, USA. A clinical trial to address the therapeutic efficacy of a RET tyrosine kinase inhibitor, vandetanib, will be started in 2013 by Dr. Koichi Gotoh (kgoto@east.ncc.go.jp) of National Cancer Center Hospital East, Japan.']",
        "Doc_id":"AACR_2013-1214",
        "Doc_title":" RET fusion gene",
        "_version_":1606188998820102144},
      {
        "Meeting_name":" Phase I/IB multicenter study of afatinib in combination with capecitabine in patients (pts) with refractory solid tumors and pancreatico-biliary cancers.",
        "Background":"['Background', ' The epidermal growth factor receptor (EGFR)/HER2 pathway is overactive in several solid tumors, including gastroesophageal, hepatic, colorectal, and pancreatico-biliary cancers. Afatinib is an irreversible inhibitor of the Erb family approved for metastatic non-small cell lung cancer with EGFR mutations. Afatinib downregulates thymidine synthase (TS) the intracellular target of fluoropyrimidine chemotherapy such as capecitabine. Treatment of colorectal cancer cell lines with cytotoxic drugs can up-regulate EGFR expression, and increase sensitivity to EGFR inhibition. Based on this preclinical rationale, and given that capecitabine is commonly used in refractory gastrointestinal cancers, we have developed a phase I/Ib trial to evaluate the safety and maximum tolerated dose (MTD) of afatinib with capecitabine in advanced solid tumors, and assess preliminary antitumor activity in pts with refractory pancreatico-biliary cancers at MTD. Methods', ' Eligible pts have metastatic solid tumors (phase I) or pancreatico-biliary cancers (phase Ib), ECOG PS 0-2 (PS 0-1 phase Ib), any number of prior therapies (phase I), or  2 prior therapies (phase Ib), no prior erlotinib (phase Ib), and have archived paraffin embedded tumor tissue, or ability to undergo tumor biopsy at baseline. Tumor tissue is analyzed with UW-OncoPlex, a multiplexed gene sequencing panel of 200+ cancer-related genes, to identify predictive biomarkers of benefit. The study design is standard 3+3. Afatinib is administered orally (PO) daily (QD) in escalating doses of 20, 30 and 40 mg, with capecitabine at 1000 mg/m2 PO BID Days 1-14, in 21-day cycles (C). Dose limiting toxicity (DLT) is assessed in C1. Once the MTD is identified, the phase Ib expansion cohorts will enroll 15 pts each with refractory pancreatic and biliary cancers, with afatinib dosed at MTD and standard dose capecitabine. The study was activated in November 2015, and to date 4 pts were enrolled in cohort 1, 3 pts in cohort 2, and 2 pts in cohort 3. The phase I is ongoing and the phase Ib is expected to start enrollment in December 2016. Clinical trial information', ' NCT02451553']",
        "Doc_id":"ASCO_177198-195",
        "Doc_title":" Phase I/IB multicenter study of afatinib in combination with capecitabine in patients (pts) with refractory solid tumors and pancreatico-biliary cancers.",
        "_version_":1606189022590271488},
      {
        "Meeting_name":" Met-dependent positive and negative signaling cascades in gastric cancer cells",
        "Background":"['Signaling by the Met, hepatocyte growth factor (HGF) receptor tyrosine kinase (RTK) activates multiple downstream signaling pathways that promote cell migration and invasive growth. Cells that overexpress and are addicted to Met also require Met signaling to sustain cell survival. Thus, a number of specific small-molecule inhibitors have been developed to target Met in the clinic. Although several successes of RTK-targeted therapies are acknowledged, several have limited long-term success clinically, due to development of drug resistance. Initiation of RTK signaling cascades leads to the activation of a number of downstream signaling molecules, but prolonged activation also triggers negative feedback loops that function in part to abrogate this signaling. Hence, targeted inhibition of Met, in addition to suppressing Met-dependent signaling, may also release cells from negative feedback mechanisms and allow the reactivation of signaling pathways, that may promote resistance to Met inhibition. As MET amplification occurs in 10-20% of gastric cancers, to identify core Met dependent signaling pathways activated in Met dependent cancers we have used four different gastric cancer cell lines that exhibit amplification, overexpression, and constitutive activation of Met. Upon inhibition of Met with a small-molecule inhibitor, we observe abrogation of several downstream signaling pathways at both the protein phosphorylation and transcript level. Interestingly, as Met has been demonstrated to cross-talk with the EGF receptor family, we also observe a decrease in the phosphorylation of EGFR and HER3 upon treatment with Met inhibitor, and a decrease in expression of EGFR ligands. Conversely, Met inhibition results in an elevation in expression of HER3 transcript and protein in all 4 cell lines, implicating Met signaling in HER3 repression, and inhibition of Met may release HER3 from this negative regulation. As increases in HER3 phosphorylation and expression occur in other models (such as breast or lung cancer cell lines) upon treatment with EGFR, HER2, or AKT inhibitors, and high HER3 expression is strongly associated with tumor progression and poor prognosis in gastric cancer; hence, the loss of negative regulation of HER3, downstream from Met, may ultimately contribute to clinical efficacy, or lack thereof, of Met inhibitors.']",
        "Doc_id":"AACR_2012-1222",
        "Doc_title":" Met-dependent positive and negative signaling cascades in gastric cancer cells",
        "_version_":1606189002414620672},
      {
        "Meeting_name":" Comparison of genotype-specific progression free survival (PFS) outcomes in the control (ctrl) arms of randomized clinical trials (RCTs).",
        "Background":"['Background', ' PFS is often used as the primary outcome measure in RCTs involving patients (pts) with metastatic cancers. For RCTs evaluating new targeted agents, there is uncertainty about how somatic mutation status affects clinical outcomes under standard therapy. Our aim was to identify differences in genotype-specific PFS outcomes in the comparator arm of advanced solid tumor RCTs. Methods', ' A MEDLINE search was conducted to identify published RCT reports evaluating systemic therapies (tx) with PFS outcomes for wildtype (WT) versus (vs) mutant (MT) genotypes in the ctrl arm. Genotype-specific PFS data was available for cutaneous melanoma (BRAF), CRC (KRAS) and NSCLC (EGFR). Insufficient data was reported for other solid tumor genotypes, including HER2+ gastric, HPV+ SCC, PIK3CA breast, BRCA1/2 ovarian and KRAS NSCLC. We extracted data including sample size, type of tx, hazard ratios (HR), and genotype-specific median PFS (mPFS) for the ctrl arms. Trials were grouped according to type of tx, targeted (T) vs chemotherapy (C) and line of tx (first line (1L) vs non-1L). The t- test was used to compare mPFS difference and HRs for WT vs MT pts. Results', ' A total of 60 reports involving 29,631 pts were included in this analysis. For NSCLC, mPFS difference between WT and MT pts was 1.8 months (p = 0.01), in favor of EGFR MT pts receiving 1L C. For non-1L trials of T agents in NSCLC, mPFS difference was 6.7 months in favor of the EGFR MT pts (p = 0.05). In CRC and melanoma, there was no difference in mPFS for WT vs. MT genotypes. Mean difference in HRs between WT vs MT ctrl is listed in the Table below. Conclusions', 'EGFR MT NSCLC had a superior PFS under standard therapy with 1L C and non-1L T agents. For other groups analyzed, there was no difference in outcome under standard therapy according to genotype. Further reporting of RCTs that analyze outcome by genotype is required to establish standards for genotype-specific outcomes under standard therapy. Tumor type (# trials)Tx line and type (C or T)Mean HR difference, WT vs MT (95% CI)P valueNSCLC (28)1 L CNon-1 L CNon-1L T1.4 (1.1-1.6)1.6 (0.1-3.0)4.8 (1.6-7.9)0.020.300.04CRC (20)1L C1.0 (0.9-1.1)0.90Melanoma (12)1L C0.9 (0.0-6.7)0.92']",
        "Doc_id":"ASCO_168778-176",
        "Doc_title":" Comparison of genotype-specific progression free survival (PFS) outcomes in the control (ctrl) arms of randomized clinical trials (RCTs).",
        "_version_":1606189036124241921},
      {
        "Meeting_name":" Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E)",
        "Background":"['Background', ' Options are limited for pts with NSCLC following chemotherapy and E. PF299 is an oral irreversible small molecule inhibitor of the HER-1,-2, and -4 tyrosine kinases. Based on non-clinical and phase I NSCLC data, this ongoing phase II U.S. trial evaluates PF299 in pts with NSCLC (KRAS wild-type) who have progressive disease after at least 1 prior chemotherapy regimen and after E. Methods', ' Pts were enrolled by histology', ' adenocarcinoma (Arm A) and non-adenocarcinoma (Arm B), and received PF299 45 mg QD. Endpoints include objective response rate, duration of response, progression-free survival, survival, safety/tolerability, and pharmacokinetics. Pharmacodynamic endpoints include assessment of serum levels of HER2 and EGFR extracellular domains. Tissue and blood KRAS assays, and EGFR studies on available tissue, are also being performed. Forty-four and 22 response-evaluable pts were planned to be enrolled into Arms A and B respectively. Results', ' Thirty-four pts with progressive NSCLC (25 female, 14 smoker) have enrolled to date (Arm A', ' 30; Arm B', ' 4)', ' median duration of prior E', ' 11.5 months; median time since E', ' 2.5 months. Among 20 response-evaluable pts, stable disease (SD) was observed in 9/18 pts in Arm A, and 1/2 pts in Arm B', ' median duration of SD', ' 11.5 weeks [range 6+, 32+ weeks]. Observation of disease control included pts who had recently (8 weeks) discontinued E; and also pts whose tumor had known EGFR T790M mutations. At time of data cutoff, confirmation per RECIST of 2 partial responses is pending. The most common treatment-related AEs were skin and gastrointestinal disorders, with grade 3 AEs in 19% and 13% of pts, respectively. Two pts experienced grade 4 pulmonary embolus/dyspnea deemed possibly treatment-related, both in the setting of progressive disease. Conclusions', ' PF299 shows encouraging activity in NSCLC pts after failure of prior chemotherapy and E. The AE profile was predictable and consistent with the prior phase I trial. At submission, enrollment in the adenocarcinoma arm is complete and enrollment in the non-adenocarcinoma arm continues; updated efficacy data and tumor characterization will be presented.']",
        "Doc_id":"ASCO_32872-65",
        "Doc_title":" Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E)",
        "_version_":1606189024447299584},
      {
        "Meeting_name":" Prognostic index for patients with brain metastases from breast cancer",
        "Background":"['Background', \" Breast cancer (BC) is the second most common cause of brain metastases (BM). Various prognostic indexes such as RPA to predict survival in BM patients have been developed in patients enrolled in RTOG trials. However, they did not predict BC specific-survival with BM accurately because they had mostly included lung cancer patients. BC specific graded prognostic assessment (GPA) has been developed (Sperduto et al., IJROBP. 2010) and modified (ASCO 2010 abst. #1028) to reflect unique biologic feature of BC. The purpose of this study is to appraise and refine the Sperduto's BC-specific GPA index (S' GPA). Methods\", \" We retrospectively investigated 272 patients with BM from BC between 1995 and 2009 at Samsung Medical Center. 173 of 272 patients who had available clinical data with ER, PR, and HER2 status were included. We appraised the S' GPA index in our cohort. Since treatment with trastuzumab significantly enhanced survival of HER2 overexpressing BC patients with BM, we refined the S' GPA index as shown in the table. Then, we validated our refined BC-specific GPA index with external patients' cohort (n=140). Results\", \" Overall median survival time (MST) for 173 patients was 9.4 months. However, Sperduto's GPA index did not predict survival of BC with BM accurately in our patients' cohort. The patients with our refined GPA scores of 0-1.0, 1.5-2.0, 2.5-3.0, and 3.5-4.0 showed significant discrimination in MST with 6.0 (n=22), 8.6 (n=76), 11.4 (n=60), 14.1 (n=15) months (p=0.004), respectively. Our refined GPA index was validated with external patients' cohort at Yonsei Cancer Center. It did predict survival of BC with BM accurately in validation cohort according to refined GPA scores (pConclusions\", \" The Sperduto's GPA index was not appraisable for predicting survival of BC with BM in the era of trastuzumab. Refining the BC specific GPA index incorporated with trastuzumab treatment is proposed to be a prognostic tool with better predictive value.\"]",
        "Doc_id":"ASCO_76972-102",
        "Doc_title":" Prognostic index for patients with brain metastases from breast cancer",
        "_version_":1606189010569396225},
      {
        "Meeting_name":" Clonality of PIK3CA mutations (mut) and efficacy of PI3K/AKT/mTOR inhibitors (PAMi) in patients (pts) with metastatic breast cancer (MBC).",
        "Background":"['Background', ' PAMi are being developed in unselected populations with MBC, but not all pts derive equal benefit. Aim', ' to assess predictive factors influencing PAMi efficacy in MBC pts enrolled in phaseI/II clinical trials, with exploratory analysis according to PIK3CAmut allele fractions (MAF). Methods', ' MBC pts treated with PAMi and with genomic information were identified. MAF was corrected for tumor purity and categorized as clonal (cl; > 0.3) or subclonal (scl;  0.3). Efficacy of PAMi measured as clinical benefit rate [CBR', ' CR+PR+SD@4 months (m)] and time to treatment failure (TTF', ' time from PAMi start until discontinuation for any reason). Results', ' From Oct10-Sep15, 105 pts received 112 PAMi. Median (med) age 56; HR+/HER2- 74.3%; med number (N) of prior lines and MBC sites 2; visceral metastasis in 66%. Mut', ' PIK3CA 31%, AKT1 7%, NF2 4%. PIK3CA med MAF (N = 28) 0.5 (interquartile range 0.4-0.6), cl in 80% of samples. PAMi', ' AKTi 12%, pan-PI3Ki 12%, PI3K/mTORi 17%, mTORi 21%, PI3Ki 38%. Type of treatment', ' single agent 15%, +anti-HER2 19%, +endocrine therapy (ET) 52%, +chemotherapy (CT) 14%. Efficay of PAMi', ' CBR 56%, TTF 4.9m (95%CI 3.9-5.8). Overall, PIK3CAmut increased the likelihood of efficacy of PAMi (CBR 78% vs 45%, P = .001; TTF 7.4 vs 4.0m, HR 0.5 P = .006). In PI3Ki treated pts, having PIK3CAmut increased the likelihood of benefit (CBR 86.7% vs 46.4%, P = .02), with a trend for improved TTF (7.4 vs 4.9m, HR 1.7, P = .14). In PIK3CAmut pts treated with PI3Ki and with MAF counts available (N = 13), PIK3CA cl MAF associated with a trend for higher TTF (11.4 vs 5.6m, HR 2.3, P = .22). In multivariate models, PIK3CAmut, ET/CT combo, and receiving PAMi  2nd line associated with better TTF (all P < .005), but not tumor subtype, N/metastatic sites, type of PAMi, or PIK3CA clonality. Conclusions', ' PIK3CAmut associated with increased efficacy of PAMi, mainly with combos given in 1st/2nd line. The high proportion of PIK3CA cl MAF may suggest that PIK3CAmut is a truncal event in those tumors. Despite small numbers, pts with cl events had longer TTF while on matched targeted drugs. This association, described in EGFRmut lung cancer with selective inhibitors, needs confirmation in larger homogenous clinical trial cohorts.']",
        "Doc_id":"ASCO_163602-176",
        "Doc_title":" Clonality of PIK3CA mutations (mut) and efficacy of PI3K/AKT/mTOR inhibitors (PAMi) in patients (pts) with metastatic breast cancer (MBC).",
        "_version_":1606189011391479808},
      {
        "Meeting_name":" Sym013, novel pan-HER monoclonal antibody mixture, augments radiation response in human lung and head and neck tumors",
        "Background":"['Sym013 represents a novel HER family targeting approach consisting of a mixture of six monoclonal antibodies against EGFR, HER2, and HER3. Sym013 effectively induces rapid, simultaneous down-regulation of all HER members. Compared with single receptor or dual receptor targeting of the HER family, Sym013 provides broader inhibition and greater down-regulation efficacy. In this current study, we examined the capacity of Sym013 in combination with ionizing radiation to augment tumor response in lung (NSCLC) and head and neck (HNSCC) cancer model systems.The anti-proliferative effects of Sym013 were confirmed showing 30-60% growth inhibition across a variety of NSCLC and H&N cancer cell lines that express EGFR, HER2, and/or HER3. Furthermore, Sym013 inhibited the growth of tumor cells that exhibit resistance to cetuximab. Western blot analysis showed a dose-dependent down-regulation of HER family members and downstream MAPK and AKT signaling pathways following 24-hour treatment with Sym013. Clonogenic survival analysis revealed that Sym013 enhanced radiosensitivity in tumor cells following radiation exposure. We characterized the DNA damage profile following radiation via flow cytometric analysis of phosphorylated histone 2AX (H2AX) foci. This revealed a significant increase of H2AX following treatment with Sym013 and 2 Gy radiation when compared with Sym013 or radiation alone. Furthermore, combined treatment of Sym013 and radiation induced a significant G1 and G2 arrest. Using Annexin V/PI staining, we also found a significant increase in the apoptotic cell population following treatment of Sym013 and 6 Gy radiation. These results suggest that Sym013 augments radiation response via the induction of cell cycle arrest followed by the induction of apoptosis and cell death, likely reflecting inhibitory effects on DNA damage repair. Additional studies to examine the impact of Sym013 to augment radiation response as well as overcome acquired resistance to cetuximab in xenograft models are in progress. Overall, these data suggest the significant capacity of Sym013 to augment radiation response in lung and head and neck cancers. This unique antibody mixture warrants additional investigation as a promising novel HER family targeting strategy in cancer therapy.']",
        "Doc_id":"AACR_2014-4495",
        "Doc_title":" Sym013, novel pan-HER monoclonal antibody mixture, augments radiation response in human lung and head and neck tumors",
        "_version_":1606189001798057984},
      {
        "Meeting_name":" A cellular model of acquired resistance to rilotumumab (AMG 102) in glioblastoma.",
        "Background":"['Acquired drug resistance is a long-standing problem of cancer therapeutics. The issue has become even more vexing with the development of highly selective agents; resistance to gefitinib or erlotinib is acquired frequently in lung adenocarcinomas. Thus, anticipating acquired resistance and understanding its basis may help us develop strategies to prevent or circumvent occurrence. Through its receptor tyrosine kinase Met, hepatocyte growth factor (HGF) regulates mitogenesis, motogenesis, and morphogenesis during development and adulthood. HGF/Met signaling also contributes to cancer progression in many malignancies, including glioblastoma. Rilotumumab is a fully human neutralizing monoclonal antibody against HGF tested in multiple Phase 2 clinical trials, including mono therapy in renal cell carcinoma and glioblastoma, as well as combination trials in gastric, colorectal, small cell lung cancers and castrate resistant prostate cancer.To generate a cellular model of acquired resistance to rilotumumab, an HGF/Met dependent human glioblastoma-derived cell line (U87-MG) was grown in rilotumumab (600 nM) for 120 days. Growth rate, HGF secretion, Met content and Met activation state were 10-fold, 10,000-fold, 10-fold and 80-fold higher than the parental cell values, respectively. The HGF and MET coding sequences were normal in both parental and resistant cells. Quantitative PCR studies to determine mRNA levels of all HGF isoforms revealed a dramatic increase in full-length HGF transcript. CGH array studies indicated amplification within both HGF and MET genes. Xenograft studies confirmed that tumor growth was resistant to rilotumumab, however the resistant cell line and tumors remained sensitive to a highly selective Met tyrosine kinase inhibitor, suggesting that resistance was achieved via increased HGF/Met signaling rather than mutation or activation of alternate pathways. Microarray expression analysis demonstrated transcript profiles that were consistent with HGF/Met pathway activation. Thus the molecular basis of acquired resistance in this model differs from those prevalent in', ' [1] lung cancers treated with EGFR inhibitors and medulloblastomas treated with hedgehog inhibitors, where most cases acquire secondary mutations in the targeted kinase; [2] breast cancers treated with HER2 inhibitors, where PTEN loss, p27 downregulation, and activation of other receptors are primary causes; or [3] malignant melanoma treated with BRAF inhibitors, where increased signaling via multiple pathways lead to PI3K- and/or MEK-mediated reactivation of the MAPK pathway. In addition to the importance of HGF/Met pathway activity in selecting glioblastoma patients for HGF-targeted therapeutics, our results suggest that monitoring Met pathway activity could provide early indications of acquired resistance to these agents, and that Met kinase inhibitors may still be efficacious when resistance occurs.']",
        "Doc_id":"AACR_2013-5637",
        "Doc_title":" A cellular model of acquired resistance to rilotumumab (AMG 102) in glioblastoma.",
        "_version_":1606189011878019073},
      {
        "Meeting_name":" Treatment of advanced bronchoalveolar carcinoma with the Hsp90 inhibitor STA-9090.",
        "Background":"['Background', ' Treatment options for bronchoalveolar carcinoma (BAC) include conventional chemotherapy and erlotinib in tumors that harbor activating EGFR mutations. The chaperone Hsp90 regulates the folding, stability and activity of many signal transduction proteins important in NSCLC, including EGFR, KRAS, MET and HER2. STA-9090 is a potent, next-generation Hsp90 inhibitor that is structurally unrelated to the first-generation ansamycin class of Hsp90 inhibitors, such as 17-AAG and IPI-504, and has shown superior activity and an improved safety profile relative to these agents in preclinical studies. Methods', ' We report the case of a 66-year-old white male with metastatic BAC, treated with STA-9090 on a phase I study. Results', ' The patient was diagnosed with BAC in 2006. Molecular profiling showed wild type KRAS and EGFR, and EGFR was not amplified on FISH testing. Prior treatment included erlotinib, bevacizumab, carboplatin, paclitaxel, pemetrexed, and topotecan with progression of disease on each, and an investigational rexinoid with a three month stabilization of disease. He enrolled in a phase I solid tumor study of STA-9090, and began weekly infusions at 150 mg/m2 for 3 weeks (followed by a rest week). The treatment was well tolerated, with adverse events of mild diarrhea and moderate hypophosphatemia. Target lesions were reduced by 25% after cycle 4 (SD per RECIST), and that response was maintained. The dose of STA-9090 was increased to 180 mg/m2 starting at Cycle 8 and continues to be well-tolerated through Cycle 11. The 11 month treatment duration compares favorably with the average 2-3 month duration of prior regimens. Conclusions', ' Reduction in tumor size and prolonged stabilization, and a well-tolerated AE profile are encouraging and support the evaluation of STA-9090 in patients with NSCLC, including BAC. A phase II study of STA-9090 in patients with advanced NSCLC is ongoing.']",
        "Doc_id":"ASCO_53656-74",
        "Doc_title":" Treatment of advanced bronchoalveolar carcinoma with the Hsp90 inhibitor STA-9090.",
        "_version_":1606189015157964800},
      {
        "Meeting_name":" The retrospective study of single-agent capecitabine in the maintenance treatment of recurrent and metastatic breast cancer.",
        "Background":"['Background', ' Metastatic breast cancer ( MBC) is incurable. Although chemotherapy is important for MBC, optimal duration of chemotherapy for MBC is debatable. Maintenance therapy in NSCLC indicated survival benefit. However, similar therapy in MBC showed controversial results. In the study we evaluated maintenance chemotherapy of capecitabine in MBC. Methods', ' MBC patients receiving capecitabine-based therapy enrolled in the retrospective study if evaluated as CR/PR/SD. The patients continued capecitabine as maintenance therapy until PD or unacceptable toxicities. The maintenance treatment was administrated as', ' oral capecitabine 1,000 mg/ m2 twice daily on days 1 to 14 followed by a 7-day rest period of each 3-week cycle. The characteristics of patients were listed in the Table. Results', ' From September 2002 to September 2009, 64 eligible patients enrolled in the study with median age 50 years (range 26-71 years). The best responses after combination therapy were 2 (3.13%) CR, 29 (45.31%) PR, and 33 (51.56%) SD. Median duration of combination was 3 months (range 1-7.5 months). After maintenance therapy 32.2% of the patients obtained clinical benefit. 81.36% preserved the previous response. Median TTP of maintenance therapy was 4 months (range 1-20 months) . The most common toxicity in maintenance therapy was HFS (n=34, 53.13%) with 14.06% (n= 9) of patients suffered grades 3 HFS. Most toxicities were moderate and manageable. Conclusions', ' Capecitabine may be an optimal maintenance treatment in patients with MBC after effective combined therapy including capecitabine with well tolerance. Patient characteristicsCharacteristicsPatient No.% Menopause statusPremenopause3656.25%Postmenopause2843.75%ER/PR statusPositive4164.06%Negative2335.94%HER2 statusPositive57.81%Negative5585.94%Unknown46.25%Metastatic sitesLiver2132.81%Lung2335.94%Brain11.56%Bone3351.56%Soft tissue2335.94%Others812.5%No. of tumor sites12539.06%22234.38%31726.56%Setting of study treatmentFirst-line2945.31%Second-line2539.06%More than second-line1015.63%Capecitabine-based combined regimenTX4062.5%NX2437.5% .']",
        "Doc_id":"ASCO_47633-74",
        "Doc_title":" The retrospective study of single-agent capecitabine in the maintenance treatment of recurrent and metastatic breast cancer.",
        "_version_":1606189019863973888},
      {
        "Meeting_name":" Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma",
        "Background":"['Background', ' The ability to detect driver mutations like EGFR and EML4-ALK in tumor specimens from patients with lung cancer and administer agents targeting those molecular lesions has revolutionized the management of adenocarcinoma of the lung.   The availability of multiplexed assays to detect mutations permits the identification of multiple driver mutations from tumors at diagnosis.  The number of molecular lesions and new agents to target them continues to grow. To exploit this, we created the LCMC to determine 10 driver mutations in tumors from 1,000 patients and to give the results to clinicians for care and entry onto targeted therapeutic trials based on these findings. Methods', ' The 14 member LCMC is prospectively enrolling patients to test tumors from patients with lung adenocarcinoma in CLIA laboratories for KRAS, EGFR, HER2, BRAF, PIK3CA, AKT1, MEK1, and NRAS using standard multiplexed assays and fluorescence in situ hybridization (FISH) for ALK rearrangements and MET amplifications.  All are stage IIIB/IV, PS 0-2, have available tissue, and signed consent. Results', ' 830 patients have been registered with 50 enrolling monthly. We detected a driver mutation in 60% (252/422, 95% CI 55 to 65%) of tumors thus far. Mutations found', '  KRAS 107 (25%, 95% CI 21 to 30%), EGFR 98 (23%, 95% CI 19 to 27%), ALK rearrangements 14 (6%, 95% CI 4 to11%), BRAF 12 (3%, 95% CI 1 to 5%), PIK3CA 11 (3%, 95% CI 1 to 5%), MET amplifications 4 (2%, 95% CI 0.5 to 5%), HER2 3, (1%, 95% CI 0.1 to 2%), MEK1 2 (0.4%, 95% CI 0.1 to 2%), NRAS 1 (0.2%, 95% CI 0.01 to 1%), AKT1 0 (0%, 95% CI 0 to 1%).  95% of molecular lesions were mutually exclusive. Conclusions', ' We detected an actionable driver mutation in 60% of tumors from prospectively studied patients with lung adenocarcinoma. Results of EGFR mutation testing are given to treating physicians to select erlotinib as initial treatment per NCCN and ASCO guidelines. Patients with other driver mutations are offered participation in LCMC-linked trials of agents targeting the mutation identified, e.g. crizotinib with EML4-ALK.  At half of LCMC sites, multiplexed testing for all mutations is now routine practice in their pathology departments.  Supported by 1RC2CA148394-01.']",
        "Doc_id":"ASCO_81670-102",
        "Doc_title":" Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma",
        "_version_":1606188978064588801},
      {
        "Meeting_name":" Early detection of competing resistance mutations using plasma next-generation sequencing (NGS) in patients (pts) with EGFR-mutant NSCLC treated with osimertinib.",
        "Background":"['Background', ' In pts with EGFR+ NSCLC, genotyping of plasma cell-free DNA (cfDNA) has become a routine option for non-invasive detection of EGFRT790M. We hypothesized that serial NGS of cfDNA would allow early detection of co-existent resistance mutations during osimertinib treatment. Methods', ' Serial plasma samples were collected from pts with advanced EGFR+ NSCLC and T790M+ acquired resistance treated with osimertinib. Up to 4 specimens were analyzed, blinded to tumor genotype', ' baseline, initial 2 follow-ups, and progression. Plasma NGS was performed using enhanced tagged amplicon sequencing of hotspots and coding regions from 36 genes. Diagnostic accuracy was compared to tumor genotype (including NGS when available) and droplet digital PCR (ddPCR) of cfDNA. Results', ' 94 specimens from 26 pts underwent plasma NGS. Studying 26 baseline specimens, plasma NGS was more sensitive than ddPCR for known EGFR driver mutations (100% vs 88.5%). In 8 pts with pretreatment tumor NGS, 5 of 6 TP53 mutations were detected; one plasma positive/tissue negative result was seen across 36 genes, a PIK3CA mutation (0.6% AF) which was confirmed using ddPCR (99.6% specificity). Quantitative concordance of AF compared to ddPCR was high (R = 0.94). 21 pts had detectable EGFR driver mutations at resistance. Among 6 pts with maintained T790M, 4 acquired C797S and 2 of these additionally acquired low level KRAS mutations (G13D, Q61K). Among 15 pts with loss of T790M, 7 had competing non-EGFR alterations identified', ' MET amp, PIK3CA E545K, BRAF V600E (n = 2), HER2 amp, KRAS G12S, and FGFR1 amp. Resistance mutations detected at AF > 0.3% were confirmed with ddPCR. In 3 pts, a competing resistance mutation (1 KRAS, 2 BRAF) could be detected in plasma NGS pretreatment and reemerged as putative drivers at time of resistance. Conclusions', ' In this retrospective blinded validation, tagged amplicon-based plasma NGS was more sensitive than ddPCR with high specificity and quantitative concordance. In a subset of cases, serial plasma NGS can detect emergence of competing resistance mutations, creating an opportunity for the study of osimertinib-based targeted therapy combinations.']",
        "Doc_id":"ASCO_187023-199",
        "Doc_title":" Early detection of competing resistance mutations using plasma next-generation sequencing (NGS) in patients (pts) with EGFR-mutant NSCLC treated with osimertinib.",
        "_version_":1606189040012361729},
      {
        "Meeting_name":" A phase I study of daily BIBW 2992, an irreversible EGFR/HER-2 dual kinase inhibitor, in combination with weekly paclitaxel.",
        "Background":"['Background', ' BIBW 2992 is an oral, potent and irreversible inhibitor of both EGFR and HER2 receptor tyrosine kinases. The efficacy of cytotoxic agents can be enhanced by erbB inhibition. The primary objective of this Phase I open- label dose-escalation trial was to determine the maximum tolerated dose (MTD) of BIBW 2992 in combination with weekly paclitaxel. Methods', ' This study evaluated safety, pharmacokinetics (PK), and anti-tumor efficacy of daily BIBW 2992 combined with paclitaxel administered on Days 1, 8 and 15 of a 4-weekly cycle. The dose of paclitaxel was 80 mg/m2, and the BIBW 2992 starting dose was 20 mg, escalated in successive cohorts to 40 then 50 mg. After 6 cycles of combination therapy, patients benefiting and tolerating treatment were eligible to continue single agent BIBW 2992. Results', ' Sixteen patients with advanced solid tumors expressing erbB receptors and suitable for treatment with a taxane have been enrolled (6 male/10 female; median age', ' 59 [range', ' 39-72]; ECOG PS 0/1', ' 5/11). Two dose-limiting toxicities of fatigue and mucositis occurred at a BIBW 2992 dose of 50 mg. The most frequent adverse events were fatigue, rash, mucositis and diarrhea. Partial responses were seen in patients with non-small cell lung cancer (3), prostate cancer (1), oesophageal cancer (1) and cholangiocarcinoma (1). Eight patients have remained on treatment beyond 4 cycles. The PK data of paclitaxel (with and without BIBW 2992 administration) as well as of BIBW 2992 at steady state (in combination with paclitaxel) will be described. Conclusions', ' A BIBW 2992 dose of 40 mg daily in combination with weekly paclitaxel 80 mg/m2 is the likely recommended dose for Phase II study. Promising anti-tumor activity was seen with this combination. The addition of bevacizumab to BIBW 2992 with 80 mg/m2 weekly paclitaxel is now being evaluated. Adverse events of BIBW 2992 combined with paclitaxel were generally mild to moderate and manageable.']",
        "Doc_id":"ASCO_32776-65",
        "Doc_title":" A phase I study of daily BIBW 2992, an irreversible EGFR/HER-2 dual kinase inhibitor, in combination with weekly paclitaxel.",
        "_version_":1606189004576784384},
      {
        "Meeting_name":" A phase II, single-arm, efficacy and safety study of poziotinib (NOV120101) in Korean patients with advanced or metastatic lung adenocarcinoma who have acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.",
        "Background":"['Background', '  Poziotinib is an oral irreversible inhibitor of EGFR, HER2 and HER4, and has shown preclinical activity in lung cancer models with EGFR mutations including T790M. This phase II study was aimed to access the efficacy of poziotinib in patients with EGFR-mutant lung adenocarcinoma and acquired resistance to erlotinib or gefitinib.  Methods', '  Eligible patients had documented activating EGFRmutations and developed acquired resistance after treatment with erlotinib or gefitinib based on Jackman criteria. Patients received poziotinib at a dose of 16 mg once daily in 28-day cycles. The primary endpoint was PFS. All tumor responses were evaluated by independent review and, in a supportive manner, by investigator.  Results', '  A total of 39 patients were treated with poziotinib in this study (29 women, median age 62 years [range, 43-84]). Most patients received erlotinib or gefitinib as first-line (n = 27) or second-line therapy (n = 11). The median time on erlotinib or gefitinib was 13.1 months (range, 3.4-33.2). Genotyping using tumor biopsy acquired at study entry was determined in 37 patients; 19 patients had EGFR T790M mutation, 2 PIK3CA mutation and no MET-amplification. Partial response with poziotinib was confirmed in 3 patients (8%; 95% CI, 2-21). Twenty patients (51%; 95% CI, 35-68) had disease control of at least stable disease for  8 weeks. The median PFS and overall survival were 2.7 (95% CI, 1.8-3.7) and 15.0 months (95% CI, 9.5-not estimable), respectively. The most frequently reported AEs of grade 3 by preferred term were rash (59%), stomatitis (18%), and diarrhoea (10%). Two patients were discontinued due to treatment-related AEs (one grade 3 rash and one grade 3 myositis).  Conclusions', '  Poziotinib showed modest efficacy in patients with EGFR-mutant lung adenocarcinoma who had progressed on erlotinib or gefitinib. Obvious clinical evidence suggesting that poziotinib may overcome acquired resistance secondary to EGFR T790M mutation was not captured in this study. Clinical trial information', ' NCT01718847']",
        "Doc_id":"ASCO_153342-156",
        "Doc_title":" A phase II, single-arm, efficacy and safety study of poziotinib (NOV120101) in Korean patients with advanced or metastatic lung adenocarcinoma who have acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.",
        "_version_":1606189028360585216},
      {
        "Meeting_name":" Phase 2 study of tarloxotinib bromide (TRLX) in patients (pts) with EGFR-Mutant, T790M-Negative NSCLC progressing on an EGFR TKI.",
        "Background":"['Background', ' Additional treatment options are needed for pts with EGFR-mutant (MT) NSCLC who develop non-T790M-mediated resistance to EGFR TKIs. Sensitizing EGFR mutations are often heterozygous with co-expression of both wild type (WT) and MT EGFR, a genotype associated with poorer response to EGFR TKIs. Hypoxia-induced activation of WT EGFR signaling may be a mechanism of EGFR-TKI resistance in NSCLC. TRLX is a hypoxia-activated prodrug that releases an irreversible pan-ErbB TKI targeting WT EGFR, MT EGFR and HER2. Hypoxic tumor targeting using TRLX may allow a greater therapeutic index with greater intratumoral TKI exposure and less dose-limiting systemic toxicity compared to currently available EGFR TKIs. In xenograft models of NSCLC that co-express MT and WT EGFR, TRLX monotherapy reverses resistance to EGFR TKIs. A Phase 1 study in pts with advanced solid tumors established the maximum tolerated dose of 150 mg/m2 TRLX as a 1-hour weekly intravenous (IV) infusion. The most common treatment-related adverse events were dose-dependent and included rash, QT prolongation, nausea, infusion reaction, vomiting, diarrhea and fatigue. Methods', ' A multicenter Phase 2 trial is evaluating the safety and efficacy of single-agent TRLX in pts with EGFR-MT, T790M-negative NSCLC after progression on an EGFR TKI (NCT02454842). Eligible patients will have documentation of a sensitizing EGFR mutation and progression on EGFR TKI therapy with no evidence of T790M on a post-progression biopsy. Eligible patients must also have adequate pre-therapy tumor tissue available to enable tumor biomarker assessment, including assessment of EGFR signaling status using an EGFR-GRB2 proximity-ligation assay. TRLX (150 mg/m2) is administered by IV infusion over 60 minutes on Days 1, 8, 15 and 22 of a 28-day cycle. The primary endpoint is RECIST 1.1 response rate. Secondary endpoints include PFS, duration of response, OS, PK and safety, as well as evaluation of hypoxia PET imaging with [18F]HX-4, serum, and tissue biomarkers. The study design incorporates a Simon two-stage design (alpha = 0.10; beta = 0.10); up to 37 patients will be enrolled. Recruitment is ongoing. Clinical trial information', ' NCT02454842']",
        "Doc_id":"ASCO_171272-176",
        "Doc_title":" Phase 2 study of tarloxotinib bromide (TRLX) in patients (pts) with EGFR-Mutant, T790M-Negative NSCLC progressing on an EGFR TKI.",
        "_version_":1606189023655624704},
      {
        "Meeting_name":" Liquid biopsy in the clinic",
        "Background":"['Background', ' Liquid biopsy for plasma ctDNA NGS is a rapidly evolving science. Plasma ctDNA assays are commercially available and are increasingly adopted in the community with a paucity of evidence-based guidance. We set out to study the optimal timing and utility of plasma ctDNA NGS in clinic. Methods', ' Pts with advanced NSCLC who were driver unknown, defined as not having prior tissue NGS or clinical concern for tumor heterogeneity that may affect treatment decisions, were eligible. Peripheral blood was collected in a Streck tube (10mL), DNA extracted, and subjected to a bias-corrected hybrid-capture 21 gene targeted NGS assay in a CLIA lab with unique reads at 3000x and sensitive detection at variant allele frequency above 0.1% (ResolutionBio Bellevue, WA). Pts also had concurrent tissue NGS via MSK IMPACT. Clinical endpoints included detection of oncogenic drivers in plasma, ability to match pts to targeted therapy, concordance and turnaround time of plasma and tissue NGS. Results', ' Forty-one pts were prospectively accrued. Plasma ctDNA detected an oncogenic driver in 39% (16/41) of pts, of whom 17% (7/41) were matched to targeted therapy; including pts matched to clinical trials for HER2 exon 20 insertionYVMA, BRAF L597Q and MET exon14. Mean turnaround time for plasma was 7 days (4-12) and 28 days (20-43) for tissue. Plasma ctDNA was detected in 56% (23/41) of pts; detection was 40% (8/20) if blood was drawn on active therapy and 71% (15/21) if drawn off therapy, either at diagnosis or progression (Odds ratio 0.28, 95% CI 0.06 - 1.16; p = 0.06). All pts had concurrent tissue NGS; of the 10 samples resulted, there was 100% driver concordance between tissue and plasma in pts drawn off therapy. Conclusions', ' In pts who were driver unknown or who had clinical concern for tumor heterogeneity, plasma ctDNA NGS identified a variety of oncogenic drivers with a short turnaround time and matched them to targeted therapy. Plasma ctDNA detection was more frequent at diagnosis of metastatic disease or at progression. A positive finding of an oncogenic driver in plasma is highly specific, but a negative finding may still require tissue biopsy.']",
        "Doc_id":"ASCO_189219-199",
        "Doc_title":" Liquid biopsy in the clinic",
        "_version_":1606189007885041664},
      {
        "Meeting_name":" Prevalence of clinically meaningful prognostic variability in cancer",
        "Background":"['Background', '   Precise characterizations of tumor type to permit precision medicine are required for optimal outcomes and to facilitate payment reforms. ICD9 codes lump multiple cancer subtypes together (eg', ' all lung cancers ICD9 162.x). To enable comparisons of similar tumor types a new taxonomy system, amenable to computerized searching, has been created that embraces the complexity of cancer.  Methods', '   The Cancer Outcomes Tracking & Analysis nodal address system (CNA) embodies a prospective assessment of characteristics (diagnostic, prognostic and disease status), mapping all clinically relevant scenarios into defined entities (each evidence based to be distinct). CNAs start with tumor type and assign additional markers based on characteristics. (eg', ' in breast cancer, stage is included in the CNA; hormone receptor status also influences treatment; however if ER+, the prognostic value of PR is trumped [therefore ER+/PR irrelevant]).  Results', '   This expert panel grouping limited the number of CNAs from several trillion across all of oncology (if every combination were listed) to 517,422 entities. CNAs by cancer type', ' neuro-oncology 114,754, gastrointestinal 109,468, gynecologic 105,595, lymphoma 79,325, sarcoma 38,194, myeloma 23,949, head & neck 15,895, leukemia 9712, thoracic 8663, genitourinary 7117, breast 3061, non-malignant blood diseases 1031, unknown primary 379, and endocrine 261, demonstrating differing prognostic complexity. In 562 unselected breast cancer pts, 46% were assigned to 6 CNAs (all pts falling into 106 CNAs). The 6 common CNAs all involved adjuvant therapy, node negative, ER+, HER2 -, ECOG < 2, with 94 pts 5mm-5cm and Oncotype Dx 11-25, 51 pts DCIS histology, 34 pts 5mm-5cm and Oncotype Dx < 11, 32pts 5mm-5cm, age > 70, 26 pts 5mm-5cm, age < 70, and 21 pts 1mm-5mm. Rare CNAs were identified which can facilitate research subject identification.  Conclusions', '   The CNA taxonomy sorts cancer by clinically relevant characteristics facilitating clinical/financial analytics of similar complex tumor types, unlike the lumped ICD 9 codes. Cancer types have differing prevalence of theoretical variability but clusters of CNAs encompass the majority of pts.']",
        "Doc_id":"ASCO_147983-156",
        "Doc_title":" Prevalence of clinically meaningful prognostic variability in cancer",
        "_version_":1606189010232803328},
      {
        "Meeting_name":" Mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers.",
        "Background":"['Background', ' A high mutation burden a biomarker of response to immune checkpoint therapy in melanoma, non-small cell lung cancer, and colorectal cancer. It is unknown whether mutation burden is predictive of response in other cancer types, and whether it is identifiable using available clinical assays. Methods', ' Using data for 10,745 tumors from 33 solid cancer types in TCGA, we looked for a mutation burden threshold (iCAM) in each cancer type associated with gene expression signatures of a blocked immune response of robust CD8+T cell response and up-regulation of immune checkpoint genes. Results', ' A unique iCAM threshold was identified in nine cancers', ' melanoma and lung, colon, endometrial, and gastric adenocarcinoma; serous ovarian, bladder urothelial, cervical, and ER+ HER2 breast cancer. iCAM thresholds applied to published clinical data for patients treated with immune checkpoint therapy showed that iCAM+ patients had significantly better response. iCAM+ tumors can be identified from clinical-grade NGS assays with high accuracy . In a prospective melanoma cohort of patients treated with anti-PD-1 patients with iCAM+ tumors had significantly better objective response rates, progression free survival, and overall survival compared patients to iCAM tumors. Pattern of somatic mutations were different in iCAM+ and iCAM tumors, suggesting different mechanism of carcinogenesis in iCAM+ versus iCAM tumors. Higher fractions of leukocytes were NK (Natural Killer) cells and macrophages were M1 polarized, and a lower fraction of T cells were regulatory T cells in iCAM+ tumors compared to iCAM tumors. Over 75% of the genes significantly up-regulated in iCAM+ tumors in every cancer types were in the immune response pathway, confirming immune response to be the main differentiator in iCAM+ veruss iCAM tumors. Conclusions', ' In nine cancer types, a clinically useful mutation burden threshold (iCAM) associated with gene expression signatures of blocked immune response can identify likely responders to immune checkpoint therapy, and iCAM status is identifiable using currently available clinical NGS assays.']",
        "Doc_id":"ASCO_177495-194",
        "Doc_title":" Mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers.",
        "_version_":1606188977329537025},
      {
        "Meeting_name":" Comparison of afatinib and erlotinib as radiosensitizing agents in bladder cancer cells.",
        "Background":"['Erlotinib is a first-generation EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor and have well-established efficacy in non-small cell lung cancer patients with activating EGFR mutations. Afatinib, on the other hand, is a second-generation EGFR tyrosine kinase inhibitor with anti-HER2 activity and was found to be of benefit to patients with advanced lung adenocarcinoma who failed previous gefetinib or erlotinib. In previous study we have demonstrated the in vitro and in vivo radiosensitising activity of afatinib in a murine bladder cancer model. However, the radiosensitizing effect of afatinib and erlotinib, has never been compared in cancer cells including bladder cancer.We performed RTK (Receptor Tyrosine Kinase) antibody arrays to investigate the relative levels of phosphorylation in T24 human bladder cancer cell line. We found that EGFR and HER2 signals were activated after radiation10 Gy. Afatinib 100 nM suppressed both irradiation-induced EGFR and HER2 signals but erlotinib 100 nM only suppressed irradiation-induced EGFR signal.Clonogenic assay of T24 and NTUB1 human bladder cancer cell lines was then examined. Afatinib (100-500 nM) showed better radiosensitizing effect (radiation dose', ' 2-10 Gy) than erlotinib (300-1500 nM) in both T24 and NTUB1 cells by significantly decreasing the numbers of colonies 7 days after treatment. The effect is more prominent in high doses of afatinib.Flow cytometry was used to determine the distribution of cells among various cell cycle phases. T24 and NTUB1 cells were treated with vehicle, radiation 2.5 Gy, afatinib 200 nM, erlotinib 200 nM or the combination of radiation and afatinib or erlotinib. When compared with radiation or drug alone, treatment combining radiation and afatinib in T24 cells resulted in a significant increase of cells in sub-G1 phase but the phenomenon was not observed in the combination of erlotinib and radiation. A similar trend was found in NTUB1 cells. The results implicated that afatinib might enhance radiation effect by increasing apoptosis in bladder cancer cells.To study the DNA damage status after treatment, we checked intra-nuclear H2AX foci by mmunofluorescence microscopy. T24 and NTUB1 cells were treated with vehicle, radiation 2.5 Gy, afatinib 100 nM, erlotinib 100 nM or the combination of radiation and afatinib or erlotinib. Radiation alone significantly increased H2AX foci and combining radiation with afatinib further increased the foci in both T24 and NTUB1 cells. The enhancement was absent in the combination of radiation and erlotinib.Our data clearly show that afatinib, a new generation EGFR tyrosine kinase inhibitor with anti-HER2 activity, is superior to erlotinib as a radiosensitizer in the treatment of human bladder cancer cells.']",
        "Doc_id":"AACR_2013-4429",
        "Doc_title":" Comparison of afatinib and erlotinib as radiosensitizing agents in bladder cancer cells.",
        "_version_":1606189022982438912},
      {
        "Meeting_name":" Hitting the target",
        "Background":"['Background', ' Most chemotherapeutic agents kill via the mitochondrial pathway of apoptosis, but unfortunately there is a lack of effective predictive biomarkers to assess the optimal treatment for each patient. When effective death signaling is initiated by a targeted therapy, an increase in mitochondrial apoptotic sensitivity (or priming for death) can be observed within hours. We developed a new technique, Dynamic BH3 Profiling, that measures changes in priming induced by chemotherapy in cancer cells, without the requirement for prolonged ex vivo culture, and we assessed if it could be used as predictive assay to personalize cancer therapy in patients.Hypothesis ', ' Early apoptotic signaling detected via Dynamic BH3 Profiling can predict later cytotoxic cellular response.Results', ' Our first test was whether dynamic BH3 profiling performed following only 16 hours of drug exposure could predict cytotoxicity at a much later (72-96 hours) time point. We initiated our studies on a diverse panel of human cancer cell lines treated with a wide range of kinase inhibitors. These cell lines included solid tumors', ' NSCLC, breast cancer, melanoma and colon carcinoma; and hematological malignancies', ' multiple myeloma, CML, diffuse large B cell lymphoma and AML. We used different treatments (primary targets)', ' Gefitinib (EGFR inh), Imatinib (BCR-ABL inh), Lapatinib (HER2 inh), TAE-684 (ALK inh), MK-2206 (Akt inh), PLX-4032 (BRaf V600E inh), AZD6244 (MEK inh), BEZ235 (PI3K/mTOR inh) and others. We observed a significant correlation between the increase in priming following short-term exposure to the agents and cell death at 72-96 hours, demonstrating the predicting capacity of dynamic BH3 profiling in different cancer cells.We then tested if dynamic BH3 profiling can predict clinical response in cancer patients. For that purpose, we used samples from stable phase CML and ovarian adenocarcinoma patients of known clinical outcome to imatinib or carboplatin treatment respectively. In both cases we found that the induction of mitochondrial priming caused by short term (16 hr) ex vivo exposure to treatment predicted clinical response.Moreover, the ROC curve analysis demonstrated that Dynamic BH3 profiling is an excellent binary predictor of response in vitro and in the clinic.Conclusions', ' Our cell line and clinical experiments demonstrate the potential for Dynamic BH3 profiling to be used as a powerful real-time tool to predict chemotherapy response across many cancers and many agents, including combinations of agents. It is an excellent binary predictor in multiple cell lines and different types of primary samples. and could be used to recognize the best agent from a list of possible therapies for an individual tumor and improve cancer therapy.']",
        "Doc_id":"AACR_2014-2837",
        "Doc_title":" Hitting the target",
        "_version_":1606189015663378432},
      {
        "Meeting_name":" The dual action antibody MEHD7945A targeting EGFR and HER3 enhances chemotherapy induced cytotoxicity in vitro and in vivo",
        "Background":"['Dysregulation of the epidermal growth factor receptor family (EGFR, HER2, HER3, HER4) by mutation and/or overexpression plays an important role in tumorigenesis, and targeted agents directed against two members of the HER/ErbB family, epidermal growth factor receptor (EGFR/HER1), and HER2/ErbB2, are used in the treatment of cancer. Extensive crosstalk seen among these receptors implies that blocking signaling of more than one receptor may be more effective in inhibiting tumor growth and circumventing resistance mechanisms than targeting individual receptors. In particular, HER3 is considered a key mediator of resistance to many targeted agents. We generated a two-in-one antibody, MEHD7945A, that binds to EGFR and HER3 with high affinity, inhibits receptor function and is more broadly efficacious in various tumor types when compared to monospecific anti-EGFR or anti-HER3 antibodies. Given the ability of HER3 to potently activate the PI3K survival pathway, we investigated if antagonizing ligand-dependent HER signaling with MEHD7945A in the presence of chemotherapy augments cytotoxicity. We calculated combination index values the effects of combining MEHD7945A with commonly used chemotherapeutic agents in NSCLC and colorectal cell lines in vitro and in vivo. The NSCLC lines NCI-H292, NCI-H1666, NCI-H358 and HCC827 were treated with MEHD7945A plus gemcitabine over a wide range of drug concentrations. Cell proliferation data were analyzed using CalcuSyn software and all combination index values were <1, demonstrating that the combination of MEHD7945A and gemcitabine inhibited proliferation synergistically in these cells. To further explore the enhanced cytotoxic effect we evaluated the combination of MEHD7945A and gemcitabine, versus each single agent, in the NCI-H1975 NSCLC xenograft model, and observed enhanced tumor regression. Similar results were observed when MEHD7945A was combined with a range of chemotherapeutic agents, including pemetrexed, docetaxel and irinotecan in H1975, H441 or SW948 xenograft models. In summary, these in vitro and in vivo results demonstrate that MEHD7945A potentiates various cytotoxic agents in a variety of tumor types.']",
        "Doc_id":"AACR_2012-1212",
        "Doc_title":" The dual action antibody MEHD7945A targeting EGFR and HER3 enhances chemotherapy induced cytotoxicity in vitro and in vivo",
        "_version_":1606188995338829825},
      {
        "Meeting_name":" Phase I trial of BMS-690514 in combination with paclitaxel/carboplatin (PC) in patients with advanced or metastatic solid tumors.",
        "Background":"['Background', ' BMS-690514 is a potent, reversible oral inhibitor of EGFR, HER2, HER4, and VEGFR 1, 2, and 3. PC is a common chemotherapy regimen used in solid tumors. Methods', ' This phase I study was designed to determine the maximum tolerated dose (MTD) of BMS-690514 plus PC. Secondary endpoints included safety, antitumor efficacy, and PK. Pts with advanced or metastatic solid tumors (age  18 yrs, ECOG 1) received escalating doses of BMS-690514 plus fixed IV doses of PC (P', ' 200 mg/m2; C', ' AUC= 6 mg/mL min). BMS-690514 starting at 100 mg/d (days 4-19 of 21-day cycle) was escalated by 50 mg/d until MTD was defined. PK samples were collected on C1D4, C1D19, and C2D19. Results', ' BMS-690514 dose cohorts were (pts)', '100 mg (7), 150 mg (6), and 200 mg (4). The MTD of BMS-690514 was defined at 150 mg/d. DLTs were severe grade (Gr) 3 diarrhea 1 pt;100 mg, 1 pt; 150 mg, 2 pts; 200 mg. After determination of the MTD, 18 pts were included in an expansion cohort of BMS-609514 at the MTD of 150 mg plus PC. Of 30 pts enrolled on study to date, 22 were chemotherapy-naive. Tumor types included NSCLC (n=12, 8 evaluable), gastric (n=5, 2 evaluable), and other (n=13, 8 evaluable). Treatment-related Gr 3/4 AEs occurred in 13/30. Severe AEs of pulmonary embolism (2pts, 200 mg), neutropenia (2pts; 100 mg), acute renal failure (1pt; 100 mg), and reversible posterior leukoencephalopathy (1pt, 150 mg) led to treatment discontinuation. At the MTD of BMS-690514 plus PC, Gr 3/4 treatment-related AEs occurred in 8/19 pts, those occurring in 10% of pts included diarrhea (21%) and leukopenia (11%). At or below 150 mg BMS-690514 plus PC, the majority of AEs were mild-moderate and commonly (10%) included diarrhea, nausea, rash, fatigue, headache, and hypertension. Of 30 pts in this ongoing study, 9 partial responses (PR), 6 stable disease (SD), and 3 progressive disease (PD) were observed, 12 are not yet evaluable. Specifically, in NSCLC pts (n=8), PR=5, SD=1 and PD=2.The PK of BMS-690514 plus PC was comparable to that previously observed for BMS-690514 monotherapy. Conclusions', ' The MTD of BMS-609514 in combination with PC was 150 mg/d. This combination was generally well tolerated and demonstrated activity in a variety of tumor types, in particular in NSCLC.']",
        "Doc_id":"ASCO_53596-74",
        "Doc_title":" Phase I trial of BMS-690514 in combination with paclitaxel/carboplatin (PC) in patients with advanced or metastatic solid tumors.",
        "_version_":1606189014478487552},
      {
        "Meeting_name":" In vitro and in vivo antitumor activity of the next generation HSP90 inhibitor, AT13387, in both hormone-sensitive and castration-resistant prostate cancer models.",
        "Background":"['HSP90 is a molecular chaperone involved in the conformational maturation and function of a large number of client proteins that have been implicated in oncogenesis. The androgen receptor (AR), a key driver of prostate cancer growth and treatment resistance, is an HSP90 client and its function is dependent on HSP90 chaperone activity. The aim of this study was to evaluate the anti-tumour activity of AT13387, a novel second generation non-ansamycin HSP90 inhibitor, in prostate cancer models. AT13387 is currently being investigated in the clinic in GIST and NSCLC. It is a potent inhibitor of HSP90 (Kd 0.71 nM) and has previously been shown to inhibit proliferation and bring about the depletion of client proteins in a wide range of cell lines as well as inhibiting tumor growth in a number of xenograft models. In prostate cancer cell lines (VCaP, LNCaP, 22Rv1), AT13387 treatment depleted HSP90 clients such as AKT, HER-2 and CRAF, along with the induction of HSP72, confirming target inhibition. AT13387 treatment also resulted in depletion of mutant and wild-type AR, as well as the constitutively active truncated AR splice variant 7 (AR-V7). HSP90 inhibition disrupted AR nuclear localisation and AR transcriptional activity and resulted in down-regulation of AR-regulated genes in vitro. Inhibition of HSP90 translated into proliferative inhibition, with GI50 values in the range of 15-70 nM, and induction of apoptosis. AT13387 showed substantially greater potency than the first generation, natural product-based HSP90 inhibitor 17-AAG in modulating HSP90 client proteins, inhibiting cell growth and inducing cell death. The anti-tumor activity of AT13387 was demonstrated in vivo in a human xenograft model of castration-resistant prostate cancer. Our data suggest that HSP90 inhibition, through the use of more potent and better tolerated HSP90 inhibitors, will be active in multi drug resistant prostate cancer. These led to the design of a Phase I/II clinical trial of AT13387 with and without abiraterone acetate in castration-resistant prostate cancer no longer responding to abiraterone that is now accruing patients (NCT01685268).']",
        "Doc_id":"AACR_2013-2433",
        "Doc_title":" In vitro and in vivo antitumor activity of the next generation HSP90 inhibitor, AT13387, in both hormone-sensitive and castration-resistant prostate cancer models.",
        "_version_":1606189039014117376},
      {
        "Meeting_name":" A 3q amplification gene signature associated with triple negative breast cancer lung-specific metastasis",
        "Background":"['Triple negative breast cancers (TNBC), devoid of expression of the estrogen, progesterone and HER2 receptors, are among the most aggressive and deadly breast cancers, with high rates of tumor recurrence and metastatic spread. New prognostic markers are needed to identify patients who are at the highest risk for developing metastases, which might assist in tailoring treatment strategies. We previously identified 20 candidate driver genes in Chromosome 3q26-29, a critical amplified region in many human cancers including breast and lung cancer. The aim of this study was to assess the prognostic power of this 20-gene signature in TNBC patients. 855 breast tumors combined from four breast cancer cohorts (GSE12276, GSE2603, GSE2034 and NKI295) were used to evaluate the signature for prediction of organ-specific distant metastasis free survival (DMFS). The predictive ability of the 20-gene signature was evaluated by Cox proportional hazards model and was compared against other published breast cancer gene signatures including MammaPrint (70-gene), Veridex (76-gene), PAM50, 54 lung metastasis signature genes, HIF1 hypoxia pathway (8-gene), TGF  pathway (153-gene), BACH1 pathway metastasis gene signature (25-gene) and Gene Expression Prognostic Index Using Subtypes (GENIUS). The 20-gene signature was strongly associated with worse lung-specific metastasis-free survival (HR, 2.0, 95%CI, 1.4 to 2.87, P=0.00014) in TNBC patients (n = 131), independently of intrinsic subtype or published gene signatures and less so in non-TNBC patients (n = 724, HR, 1.3, 95%CI, 1.01 to 1.69, P=0.04). In conclusion, we discovered an amplified 20-gene signature in 3q26-29 that are associated with lung metastasis in patients with TNBC, suggesting on a potential role of 3q genes in the mechanism of lung-specific metastasis and incriminating cancer driver genes in this location as potential attractive novel therapeutic targets in this disease. The work is supported by the NIH Grant R01 CA102353 to PPM.']",
        "Doc_id":"AACR_2015-5282",
        "Doc_title":" A 3q amplification gene signature associated with triple negative breast cancer lung-specific metastasis",
        "_version_":1606189022107926528},
      {
        "Meeting_name":" Differential sensitivities to heat shock protein 90(HSP90) inhibitors in anaplastic lymphoma kinase(ALK)-positive non-small cell ling cancer(NSCLC) cells.",
        "Background":"['Objectives', ' HSP90 is an abundant cellular chaperone protein and its inhibition results in the instability and degradation of client proteins such as HER2, mutant KIT, mutant EGFR, and ALK. Recently, HSP90 inhibitors showed clinical activity against echinoderm microtubule-associated protein-like 4 (EML4)-ALK NSCLC. However, it is unknown whether HSP90 inhibitors remain sensitive against ALK-positive NSCLC cells that show acquired resistance to ALK inhibitors, such as crizotinib. Here, we evaluated the activity of two clinical stage HSP90 inhibitors in ALK-positive NSCLC cells that were sensitive and resistant to crizotinib.Methods', ' ALK-positive NSCLC cells that were crizotinib-sensitive (SNU-2292 and NCI-H3122) and crizotinib-resistant (SNU-2535 and H3122CR1) were used. In vitro cytotoxicities of HSP90 inhibitors alone (ganetespib and NVP-AUY922), or in combination with crizotinib, were evaluated against ALK-positive NSCLC cells using a modified MTT assay. Cell cycle and Annexin-V binding assays were evaluated by flow cytometry. Expression of ALK and its downstream effectors were detected by Western blot assay after exposure to HSP90 inhibitors  crizotinib.Results', ' HSP90 inhibitors were highly potent against crizotinib sensitive SNU-2292 and NCI-H3122 cell lines and displayed enhanced activity when combined with 0.1 M crizotinib. Consistent with previous reports, crizotinib resistant H3122 cells were 5x fold less sensitive to HSP90 inhibitors compared to parental H3122 cells, with IC50 still in the low nanomolar range. In a concentration dependent manner, the HSP90 inhibitors did not suppress ALK downstream signals in H3122CR1 and SNU-2535 cell lines compared to effects on NCI-H3122 and SNU-2292 cell lines. In addition, phospho-ALK signals were significantly diminished in Ba/F3 cells expressing EML4-ALK compared to cell lines expressing L1196M or G1269A after exposure to HSP90 inhibitors. Cell cycle analysis demonstrated HSP90 inhibitors and/or crizotinib significantly increased the sub-G1 populations of NCI-H3122 and SNU-2292 cells compared with those of H3122CR1 and SNU-2535. Similarly, apoptotic cells significantly increased in crizotinib-sensitive cells than in crizotinib-resistant cells treated with HSP90 inhibitors and/or crizotinib.Conclusions', ' HSP90 inhibitors showed differential sensitivities in ALK-positive NSCLC cells. Our results suggest that HSP90 inhibitors alone or in combination treatment with crizotinib are effective against crizotinib-sensitive, ALK-positive NSCLC cells.']",
        "Doc_id":"AACR_2013-3272",
        "Doc_title":" Differential sensitivities to heat shock protein 90(HSP90) inhibitors in anaplastic lymphoma kinase(ALK)-positive non-small cell ling cancer(NSCLC) cells.",
        "_version_":1606189032008581120},
      {
        "Meeting_name":" Molecular panel sequencing of pre-treatment samples to reveal mechanisms of innate resistance to 3rd generation EGFR TKI treatment in T790M-positive NSCLC patients.",
        "Background":"['Background', ' Resistance to early generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) inevitably develops in EGFR-mutant lung cancer. The secondary EGFR p.T790M mutation is the driving factor in 60% of cases and 3rd generation EGFR TKIs have been developed to overcome T790M-mediated resistance. However, besides T790M other genetic aberrations such as amplifications of MET may contribute to resistance to EGFR inhibition in the same patient. We here report on the systematic analysis of co-occurring genetic aberrations that may influence response to 3rd generation EGFR TKIs. Methods', ' Thirty-six patients were treated with 3rd generation EGFR TKIs in the setting of acquired resistance to EGFR inhibition in cancer centers in Germany and Switzerland. Pre-treatment samples were analyzed for co-occurring genetic aberrations in a subset of resistance-related genes including MET, HER2, RAS-gene family, PIK3CA, CTNNB1 and PTEN using next-generation sequencing and fluorescence in-situ hybridization assays. We investigated the association between clinical, epidemiological and molecular data and response to treatment (RECIST 1.1). Results', ' Co-occurring genetic aberrations were found in 68% of the pre-treatment samples where both, analyses by sequencing and FISH were feasible (N = 25). Efficacy of 3rd generation EGFR TKIs significantly dropped in the presence of high-level MET amplification as compared to wild-type MET (ORR, 0.0%; 95% CI, 0.0-60.4 vs. 70.0%; 95% CI, 45.7-87.2; p = 0.02; median PFS, 1.0 month; 95% CI, 0.37-1.72 months vs. 8.2 months; 95% CI, 1.69-14.77 months; p  0.001). No statistically significant association was found between treatment efficacy and the molecular status of the genes analyzed or the number of prior EGFR TKIs. Conclusions', ' Prevalence of additional genetic aberrations is frequent in the setting of acquired resistance to early generation EGFR TKIs and may not necessarily mediate resistance to 3rd generation EGFR TKIs. However, in our analysis high-level amplification of MET was associated with primary treatment failure and might be the main factor underlying resistance in this setting.']",
        "Doc_id":"ASCO_188296-199",
        "Doc_title":" Molecular panel sequencing of pre-treatment samples to reveal mechanisms of innate resistance to 3rd generation EGFR TKI treatment in T790M-positive NSCLC patients.",
        "_version_":1606189014406135808},
      {
        "Meeting_name":" Expression of cancer type amino acid transporter LAT1 is a prognosis prediction factor in breast carcinoma",
        "Background":"['Purpose', ' Amino acid transporters play important roles in cell survival and proliferation. L-Type amino acid transporter 1 (LAT1) is one of the major Na+-independent neutral amino acid transporters. LAT1 has an aspect of oncofetal protein. Recently, high levels of LAT1 expression have been reported in various tumors, such as prostate cancer, pancreas cancer, bile duct cancer, lung cancer and stomach cancer.We revealed LAT1 expression is an independent prognosis marker in stomach cancer, prostate cancer and pancreas cancer. The purpose of the present study was to investigate the LAT1 expression in breast carcinoma and relationship between LAT1 expression and prognosis.Materials & Methods', ' We enrolled 290 patients with invasive breast carcinoma surgically resected between 2006 and 2010 at Kitasato University Hospital and Toho University Omori Medical Center, Japan. We investigated LAT1 expression in the enrolled breast carcinoma cases by immunohistochemical staining. All cases were divided into two groups, 78 cases of triple negative carcinoma (TNBC) and 212 cases of non-triple negative carcinoma (NTNBC), with immunohistochemistry of estrogen and progesterone receptors and Her2. After LAT1 expression was compared between TNBC and NTNBC, correlations among LAT1 expression, Ki-67 labeling index (LI), CD98 expression, and clinicopathological findings was assessed.Results', ' TNBC showed significantly higher LAT1 expression than NTNBC. TNBC also showed significantly higher CD98 expression rather than NTNBC. LAT1 expression of extraductal invasive cancer cells was significantly higher than those of intraductal carcinoma cells. A significantly positive correlation was observed between LAT1 expression and CD98 expression. Further, a positive correlation between LAT1 expression and Ki-67 LI was found. Log-rank test in overall breast cancers revealed that high LAT1 expression group showed significantly poor prognosis, compared to low LAT1 group. In NTNBC, high LAT1expression cases possessed poorer prognosis than low LAT1 expression cases.Conclusion', ' In invasive ductal carcinoma of breast, LAT1 expression has a potential for a prognosis prediction factor. LAT1 offers a potential target for anti-cancer therapy by its inhibitor JPH203 which has been developed by us.']",
        "Doc_id":"AACR_2015-5286",
        "Doc_title":" Expression of cancer type amino acid transporter LAT1 is a prognosis prediction factor in breast carcinoma",
        "_version_":1606189014034939905},
      {
        "Meeting_name":" Ibrutinib regulates tumor microenvironment and enhances response to everolimus in renal cell carcinoma mouse models.",
        "Background":"['Introduction', ' Ibrutinib (ibr), a first-in-class, once-daily, oral inhibitor of Brutons tyrosine kinase (BTK), is indicated for the treatment of patients with CLL/SLL, MCL and WM. Ibr also inhibits EGFR/HER2 and has demonstrated efficacy against EGFR+ NSCLC and HER2+ breast cancer in vitro and in xenograft models (Gao 2014; Chen 2016). Further, ibr modulated host immunity and enhanced anti-PD-L1 activity in solid tumor models otherwise insensitive to BTK or HER kinase inhibition (Sagiv-Barfi 2015), suggesting that ibr may be active in renal cell carcinoma (RCC) via multiple mechanisms. Here we determined the impact of ibr alone and in combination with everolimus (eve) on tumor growth and the tumor microenvironment in syngeneic and xenograft RCC mouse models.']",
        "Doc_id":"AACR_2017-167",
        "Doc_title":" Ibrutinib regulates tumor microenvironment and enhances response to everolimus in renal cell carcinoma mouse models.",
        "_version_":1606189013042987008},
      {
        "Meeting_name":" A phase 1b trial of blood-brain barrier (BBB)-penetrant tyrosine kinase inhibitor (TKI) tesevatinib in combination with trastuzumab for patients with HER2+ metastatic breast cancer (MBC).",
        "Background":"['Background', '  Patients with HER2+ breast cancer (BC) have a high incidence of brain metastases (mets). Tesevatinib (formerly KD019) is a TKI with potent activity against EGFR, HER2, and SRC. In contrast to all of the approved anti-HER2 agents in BC, tesevatinib crosses the intact BBB in mouse and rat models and achieves levels in the brain similar to plasma levels. Single-agent trials of tesevatinib in NSCLC defined the maximum tolerated dose as 300 mg daily due to QTc prolongation.   Methods', '  This study was designed tofind the Recommended Phase 2 Dose for tesevatinib given daily combined with trastuzumab 6 mg/kg IV every 3 weeks. Secondary endpoints include pharmacokinetic evaluation of the combination. Eligible patients have HER2+ MBC with disease progression with or without brain mets. Three cohorts (tesevatinib 150 mg, 250 mg, and 300 mg/day) were planned. A 3 + 3 design was utilized for evaluating safety during the 21 days of Cycle (C) 1 to determine dose escalation.  Results', '  7 patients were enrolled into 2 dosing cohorts (median age 47). In Cohort 1 (150 mg) there was 1 patient with Gr 3 asymptomatic increased amylase, which resolved to Gr 1; not a DLT by protocol. There was 1 occurrence each of the following Gr 2 adverse events (AEs), all of which resolved', '  Gr 2 mouth sensitivity, acneiform rash, nausea, & vomiting. One patient in Cohort 1 missed doses of tesevatinib for 7/21 days (not due to AEs), and thus was not evaluable for dose escalation (but all AEs for this patient are included). The only Grade 2 or higher AE during C1 in Cohort 2 (250 mg) was a Gr 2 diarrhea that resolved to Gr 1 after 2 days with anti-diarrheal medications. Enrollment in the final dose cohort (300 mg) is ongoing.   Conclusions', '  The combination of tesevatinib and trastuzumab appears to be well tolerated with no QTc prolongation so far and enrollment into the final dose cohort in Phase 1b is proceeding. Tesevatinib is a TKI with anti-HER2 activity that freely crosses the BBB and therefore has promise in the treatment of brain mets in patients with HER2+ MBC. Clinical trial information', ' NCT02154529']",
        "Doc_id":"ASCO_150396-156",
        "Doc_title":" A phase 1b trial of blood-brain barrier (BBB)-penetrant tyrosine kinase inhibitor (TKI) tesevatinib in combination with trastuzumab for patients with HER2+ metastatic breast cancer (MBC).",
        "_version_":1606189035640848384},
      {
        "Meeting_name":" Massively parallel sequencing of clinical FFPE cancer specimens enables comprehensive genomic assessment of patient eligibility for targeted therapy",
        "Background":"['Molecular diagnostics are growing in importance to clinical oncology as an increasing number of therapies targeting specific molecular alterations become available. This trend has led to a proliferation of focused biomarker tests delivered using a variety of technologies, which are generally restricted in their breadth of mutational status assessment and constrained by scarce tissue material. We deployed massively parallel sequencing (or NGS) technology to develop a pan-cancer, comprehensive genomic profiling assay interrogating 189 relevant cancer genes, using minimal DNA from fixed surgical or biopsy specimens. With this assay we identify all classes of DNA alterations (base substitutions, insertions and deletions, copy number alterations and rearrangements at specific loci) in a single test with high sensitivity and specificity. To assess the potential for comprehensive genomic profiling to inform clinical decisions, we sequenced 58 archival FFPE tumor specimens, including 16 breast, 16 colon, 14 lung, and 12 renal cell cancers to an average of depth of 850x and considered the resultant mutation profiles in the context of current treatment guidelines and clinical trial information. In total, 121 mutations and 30 copy number alterations were identified, of which less than one third could be identified by traditional hotspot analysis. The observed mutation frequencies were consistent with published studies for these tissue types', ' 56% of breast cancers carried TP53 mutations, 38% had PIK3CA mutations, and 13% harbored HER2 amplifications. In colon cancers, 75% and 63% carried APC and TP53 mutations, while 38%, 31%, and 25% harbored KRAS, BRAF, and PIK3CA mutations respectively. Finally, 57% and 42% of NSCLCs carried mutations in TP53 and KRAS, while 17% of RCCs had mutations in VHL. Nearly 70% of the 58 cases carried one or more mutations that could plausibly confer sensitivity or resistance to approved or experimental targeted therapies. Of these potentially clinically actionable mutations, 57% occurred at known sites of oncogene activation, 27% involved gene amplification or deletion, 14% resulted in tumor suppressor loss, and one resulted in the EML4-ALK fusion gene. Our results demonstrate technical feasibility of comprehensive cancer gene characterization through massively parallel sequencing in clinical FFPE specimens. The prevalence and diversity of potentially actionable mutations we observed highlights the benefits of adopting this approach. As massively-parallel sequencing is the only practical means to detect all classes of somatic mutation in a small, clinically relevant sample, we suggest that this type of testing will be an essential ingredient in bringing targeted therapies to cancer patient care.']",
        "Doc_id":"AACR_2012-967",
        "Doc_title":" Massively parallel sequencing of clinical FFPE cancer specimens enables comprehensive genomic assessment of patient eligibility for targeted therapy",
        "_version_":1606188996277305345},
      {
        "Meeting_name":" A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2).",
        "Background":"['Background', ' NSCLC patients whose tumors harbor epidermal growth factor receptor EGFR/HER1 mutations represent a unique subpopulation with unparalleled responsiveness to EGFR tyrosine kinase inhibitors. A phase II study of BIBW 2992 - an oral, novel, potent irreversible inhibitor of EGFR and human HER2 - has completed accrual in Taiwan and the US. Methods', ' Patients with a stage IIIB/IV lung adenocarcinoma, EGFR mutations in exons 18-21 (by direct sequencing), chemo-nave or with progressive disease following first-line cytotoxic chemotherapy, measurable disease, and ECOG PS 0-2 received 50 mg or 40 mg BIBW 2992 qd until progression. Response was assessed at 4, 8 and 12 weeks, and at 8-weekly intervals thereafter; images were centrally reviewed. Analysis included primary endpoint objective response rate (ORR) and secondary endpoint progression-free survival (PFS). Results', ' 444 patients were tested for EGFR mutations and 129 received treatment. Tumor size reduction was seen in 90% of patients. ORR and disease control rate (DCR) was 62% and 94%, respectively, for del19; 52% and 85% for L858R; and 43% and 78% for other mutations based on investigator assessment. L858R mutation was seen in 54 (42%), del19 in 52 (40%) and other mutations in 23 (18%) patients. Median PFS was estimated to be 12 months (95% CI', ' 10-19.2) for the overall group, 12 months (95% CI', ' 10-19.2) in del19, 16.3 months (95% CI', '10-Inf) in L858R, and 15.6 months (95% CI', '10-19.2) when combined. The most common drug-related adverse events (AEs) were diarrhea and rash/acne, as reported in 95% of patients each and were Grade 3 in 18% and 19% of patients, respectively. No Grade 4 cases were reported for these events. Conclusions', ' Administration of BIBW 2992 resulted in a high ORR, DCR and PFS in NSCLC patients with EGFR mutations. Gastrointestinal and skin disorders were the most frequently observed AEs and were manageable with adequate supportive care and dose reduction. Updated response and PFS data based on independent imaging review will be presented.']",
        "Doc_id":"ASCO_50532-74",
        "Doc_title":" A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2).",
        "_version_":1606189025859731456},
      {
        "Meeting_name":" PD-L1 assessment in FNA (EBUS) dervied samples.",
        "Background":"['Background', ' Pembrolizumab therapy for non-small cell lung cancer requires PD-L1 immunohistochemistry (IHC). FDA approval was based on staining of resections or core biopsies. Little is known about PD-L1 expression in fine needle aspiration (FNA) specimens including EBUS of mediastinal lymph nodes. Methods', ' IHC was performed using the PD-L1 IHC 22C3 pharmDx test on formalin fixed paraffin embedded FNA cell blocks of 8 squamous cell carcinomas and 15 adenocarcinomas (ACA) (age', ' 42-84, mean', ' 63, median', ' 63; 11 female and 12 male). Mutation data (50 gene NGS panel, and ALK, ROS1, RET and MET FISH) was available for 14 ACA. Membranous PD-L1 staining of any intensity and extent was recorded in at least 100 tumor cells (tumor proportion score). The tumors were grouped as', ' no staining (<1%), low expression (1-49%) and high expression (50% or more). Results', ' Six (26%) tumors showed no staining, 6 (26%) low expression and 11 (48%) high expression (table 1). High PD-L1 expression was seen in 1 ALK, 1 braf, 1 EGFR, 1 Her2 exon20, 2 kras mutated tumors and 2 tumors with no or unknown mutation status, low PD-L1 expression in 1 braf and 1 EGFR mutated case and 1 tumor without mutation. No expression was seen in 1 ROS1, 1 kras mutated tumor and 1 tumor without mutation. One EBUS biopsy also had PD-L1 assessed on a transbronchial biopsy of the primary tumor showing similar staining (30% versus 20%). Conclusions', ' PD-L1 immunohistochemistry appears to be feasible using cell blocks of fine needle aspirates containing adeqaute number of viable tumor cells. The majority of ACA were also adequate for NGS mutation and FISH analysis. High PD-L1 expression was seen in approximately half the tumors, which is greater than has been observed in resections/core biopsies, this finding merits further study. High expression of PD-L1 was seen in both squamous cell carcinoma and adenocarcinoma, and tumors with and without common driver mutations. PD-L1 Expression according to histologic type.Histologic typeNo expressionLow expressionHigh expressionAdenocarcinoma (n15)4 (27%)3 (20%)8 (53%)Squamous cell carcinoma (n8)2 (25%)3 (37.5%)3 (37.5%)Total (n23)6 (26%)6 (26%)11 (48%)']",
        "Doc_id":"ASCO_193604-199",
        "Doc_title":" PD-L1 assessment in FNA (EBUS) dervied samples.",
        "_version_":1606189026168012800},
      {
        "Meeting_name":" Personalizing cancer therapy using dynamic BH3 profiling.",
        "Background":"['Personalizing cancer therapy using dynamic BH3 profiling.J. Montero, A. Letai.Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.Background', ' There are many targeted therapies that lack effective predictive biomarkers. Many of these agents kill via the mitochondrial pathway of apoptosis. Apoptosis can be considered as a threshold, and we have designed a tool, BH3 profiling, that can measure mitochondrial priming for death, essentially the proximity of a cell to the this threshold of apoptosis. When effective death signaling is initiated by a targeted therapy, dynamic BH3 profiling can be used to measure the increase in mitochondrial priming caused by the agent within hours, without the requirement for prolonged ex vivo culture. This means that death signaling induced by any number of distinct agents can be simultaneously compared on a single cell line or primary tumor sample.Hypothesis ', ' Early apoptotic signaling detected via dynamic BH3 profiling can predict later cytotoxic cellular response.Results', ' Our first test was whether dynamic BH3 profiling performed following only 16 hours of drug exposure could predict cytotoxicity at a much later (72-96 hours) time point. We initiated our studies on a diverse panel of cancer cell lines treated with a wide range of kinase inhibitors. These cell lines included', ' PC9 (NSCLC), K562 (CML), MCF7 (Breast Cancer), LP1 (Multiple Myeloma), DHL6 (Diffuse Large B cell lymphoma) and Sk5 mel (Melanoma) using nine different treatments (primary targets)', ' gefitinib (EGFR inh), imatinib (BCR-ABL inh), lapatinib (HER2 inh), PD173074 (FGFR inh), TAE-684 (ALK inh), MK-2206 (Akt inh), PLX-4032 (BRaf V600E inh), AZD6244 (MEK inh) and BEZ235 (PI3K/mTOR inh). We observed a significant correlation between the increase in priming and cell death, demonstrating the predicting capacity of dynamic BH3 profiling in different cancer cells.We also tested the predictive ability of dynamic BH3 profiling in chronic myelogenous leukemia (CML). We tested samples from stable phase CML patients of known clinical outcome who were either sensitive (underwent at least complete cytogenetic response) or refractory to clinical imatinib treatment. We found that the induction of mitochondrial priming caused by short term (16 hr) ex vivo exposure to imatinib predicted clinical response.Conclusions', ' Our cell line and clinical experiments demonstrate the potential for dynamic BH3 profiling to be used as a powerful real time predictive tool across many cancers and many agents, including combinations of agents. This tool could be used to identify niche populations sensitive to an individual agent. Alternatively, it could be used to recognize the best agent from a list of possible therapies for an individual tumor and improve cancer therapy.']",
        "Doc_id":"AACR_2013-4569",
        "Doc_title":" Personalizing cancer therapy using dynamic BH3 profiling.",
        "_version_":1606189017253019648},
      {
        "Meeting_name":" Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer.",
        "Background":"['Background', ' Abemaciclib is an oral selective CDK4 and CDK6 inhibitor administered on a continuous dosing schedule, which has demonstrated clinical activity and an acceptable safety profile in patients (pts) with heavily pre-treated HR+ metastatic breast cancer (MBC). Abemaciclib has been shown preclinically to cross the blood-brain barrier, providing rationale for testing this agent in pts with BM. Furthermore, as previously presented, levels of abemaciclib similar to plasma were detected in resected BM in a subset of pts with HR+, HER2- MBC in this study. Methods', ' Study I3Y-MC-JPBO is an open-label, Phase 2, Simon 2-Stage trial evaluating the safety and efficacy of abemaciclib 200 mg BID in pts with new or progressive BM secondary to HR+ MBC, NSCLC, or melanoma. Eligible pts in Part B (the focus of this presentation) include pts with HR+, HER2- MBC who have 1 measurable brain lesion. The primary objective was objective intracranial (IC) response rate as defined by Response Assessment in Neuro-Oncology BM response criteria. Secondary objectives (IC related) include best overall response, duration of response, disease control rate, and clinical benefit rate. Exploratory objectives include assessment of drug concentrations in resected tumors. Safety, tolerability, and PK of abemaciclib were also assessed. Stage 1 includes 23 pts; if < 2 of the 23 pts respond to abemaciclib, futility is met. However, if 2 respond, 33 additional pts are to be enrolled to Stage 2. Results', ' This Stage 1 efficacy analysis included 23 pts; 32 pts were included in the safety analysis. Although 5 pts were considered nonevaluable, 2 pts (8.7%) had confirmed partial response (PR) (meeting the predefined threshold for advancement to Stage 2); enrollment is ongoing. At the time of the analysis, the 2 pts with PR had completed 14 and 15 cycles each (21d cycles) of therapy. The majority of adverse events were gastrointestinal in nature, consistent with previous studies of abemaciclib. Conclusions', ' This study has provided preliminary evidence that abemaciclib penetrated BM in pts with HR+, HER2- MBC and had antitumor activity in this population. Final results will be presented following Stage 2 analyses. Clinical trial information', ' NCT02308020']",
        "Doc_id":"ASCO_182896-199",
        "Doc_title":" Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer.",
        "_version_":1606188997655134209},
      {
        "Meeting_name":" A phase II study to assess the efficacy and impact of BIBW 2992 on QTc interval in patients with solid tumors, including brain metastases and recurrent glioblastoma multiforme (GBM).",
        "Background":"['Background', ' BIBW 2992 is an oral, irreversible inhibitor of EGFR/HER1 and HER2. EGFR and HER2 are amplified and overexpressed in most epithelial cancers as well as 50%-60% of GBMs. In a phase I study, one patient with NSCLC and brain metastases showed a response in both systemic and CNS disease. Preclinical and retrospective ECG analyses did not suggest an effect of BIBW 2992 on QTc, although this has not been prospectively assessed according to ICH E14 Cardiac Assessment of New Drugs Guidelines. The primary objectives of this study are to evaluate the effect of BIBW 2992 on QTc interval and the efficacy in patients with GBM, and patients with eligible tumors with and without brain metastases. Methods', ' In this phase II open label study, patients 18 years, with tumors known to historically overexpress EGFR or HER2, including those with brain metastases, and GBM at 1st recurrence, adequate organ function and ECOG PS 0-2, are eligible for treatment with BIBW 2992 50 mg PO OD q28. Patients with a QTcF-interval >470 ms, a PR-interval >230 ms, a QRS-interval >120 ms and ST-segment and T/U-wave abnormalities at screening, as assessed by central cardiology review, are excluded. All concomitant medications and dose changes within the initial 14 days on BIBW 2992 treatment are recorded. Up to 60 patients are to be recruited and treated until disease progression. Time-matched 24-h electrocardiograms are being performed at baseline, prior to drug exposure, after single dose and at steady state, i.e. Days -1, +1 and +14. PK samples are to be drawn at single dose and at steady state coincident with ECGs The primary endpoints are QTcF interval and objective tumor response according to the Macdonald criteria for GBM patients and for patients with brain metastases, and the RECIST 1.0 for other patients. Secondary endpoints include prolongation of QTcF, PR and QRS interval of ECG, heart rate, T wave and U wave morphology, disease control rate, PFS, molecular determinants of response, adverse events and PK characteristics of BIBW 2992 after single dose and at steady state. To date, 40 patients have been treated and 33 patients have completed ECG assessments on Days -1, +1 and +14.']",
        "Doc_id":"ASCO_52527-74",
        "Doc_title":" A phase II study to assess the efficacy and impact of BIBW 2992 on QTc interval in patients with solid tumors, including brain metastases and recurrent glioblastoma multiforme (GBM).",
        "_version_":1606189020337930240},
      {
        "Meeting_name":" Insulin-like growth factor 1 (IGF1R)/insulin receptor (INSR) inhibitory activity of rociletinib (CO-1686) and its metabolites in nonclinical models",
        "Background":"['Rociletinib (CO-1686) is a novel, oral, targeted irreversible inhibitor of the cancer-causing mutant forms of EGFR currently being studied for the treatment of NSCLC. Rociletinib was designed to spare wild-type EGFR signaling. Heavily-pretreated T790M+ patients treated with rociletinib at 500 or 625mg BID demonstrated a 67% objective response rate (n = 56, Soria et al., ENA 2014). Adverse events (AEs) typical of wild-type EGFR inhibition, such as cutaneous toxicities, have not been observed. The most frequent AE in patients dosed with rociletinib is hyperglycemia (32% all grades/14% grade 3), which is typically managed with oral hypoglycemic therapy. Rociletinib does not directly play a role in hyperglycemia based on kinase and cellular profiling, toxicology studies performed in Sprague-Dawley rats and beagle dogs, and an oral glucose tolerance test (OGTT) in Sprague-Dawley rats. We examined the hypothesis that hyperglycemia may result from a metabolite of rociletinib. Metabolite profiling from in vitro hepatocyte incubations, as well as the analysis of plasma samples from healthy subjects and NSCLC patients, revealed three metabolites of interest referenced according to their protonated molecular ion', ' M460, M502, and M544. Metabolites M460 and M502 are present in higher levels in humans than in rats and dogs, whereas M544 levels are comparable between human and rat. In patients the levels of M502 are at least 5-fold greater than that of M460. All 3 metabolites demonstrated limited potency against EGFR, T790M EGFR, and HER2. Expanded cellular profiling revealed that M460 and M502 have 2-3 fold and 3-7 fold greater potency against INSR and IGF1R, respectively, as compared to rociletinib, whereas metabolite M544 demonstrated similar or reduced potency. Metabolite profiling in rats suggests that M502 is rapidly converted to M544 by acetylation, thus a rat OGTT was performed with a single dose of M502 at 1000 mg/kg to reach exposure levels comparable to those observed in rociletinib treated NSCLC patient samples. Metabolite M502 caused significant elevations in post-prandial glucose and insulin excursion. Taken together, the increased potency of M502 towards IGF1R and INSR, its absolute exposure in humans and the rat OGTT results suggest that M502 is likely to play a causative role in the hyperglycemia observed in patients. Additional data on the clinical implications of these findings, as well as the role of IGF1R pathway activation in resistance to EGFR inhibitors, will be presented.']",
        "Doc_id":"AACR_2015-793",
        "Doc_title":" Insulin-like growth factor 1 (IGF1R)/insulin receptor (INSR) inhibitory activity of rociletinib (CO-1686) and its metabolites in nonclinical models",
        "_version_":1606188977275011072},
      {
        "Meeting_name":" Molecular characterization of bladder cancer in smokers versus non-smokers.",
        "Background":"['Background', '  Bladder cancer (BC) is one of the most common malignancies of the urinary tract and is 4thmost common cancer among men. It is estimated that by the end of 2015, the US will have approximately 74,000 new BC cases, accounting for 16,000 cancer related deaths. Smoking is considered an important risk factor for BC; recent data demonstrate an increase in BC incidence in non-smokers as well. Molecular characterization of BC in non-smokers has not been well studied. To the best of our knowledge, no retrospective or prospective study examining the correlation between smoking status (smokers vs non-smokers) and specific genetic alterations in BC has been published to date.  Methods', '  676 consecutive BC profiled at a CLIA certified laboratory were evaluated for differences in molecular characterization between smokers and non-smokers. Smoking status, patient characteristics, age, sex and survival data were collected on a subgroup; compilation of etiology is ongoing for additional patients.   Results', '  30 patients were confirmed lifetime nonsmokers (NS) and 39 were confirmed smokers or reformed smokers (R/S). Identified trends included differences in the PI3 kinase, WNT and EGFR pathways. Percentage of PIK3CA mutations was higher in NS (43%) vs. R/S (11%), whereas the WNT pathway aberration (CTNNB1 and APC mutations) occurred more frequently in R/S. EGFR amplification occurred in 22% NS and 11% in R/S, while HER2 was amplified only in R/S (23% vs. 0%, p = 0.05). Additionally, 3 of 8 R/S had an ALK 2p23 rearrangement, found in ~5% non-small cell lung cancers. TP53 did not differ between the populations. Survival data for 31 patients (14 NS, 17 R/S) showed overall average survival in the NS cohort was 175 days longer than in the R/S cohort.  Conclusions', '  The difference in molecular biology between R/S and NS with BC suggests a different oncogenesis with potentially different treatment options. Increased incidence of PIK3CA mutations in NS may inform therapeutic options in this select group of BC patients with no smoking history. The results will need further verification in a larger group of BC patients in a prospective clinical study; more studies also need to be conducted to identify other mutational abnormalities between smokers vs. lifetime non-smokers.']",
        "Doc_id":"ASCO_149161-156",
        "Doc_title":" Molecular characterization of bladder cancer in smokers versus non-smokers.",
        "_version_":1606189021600415744},
      {
        "Meeting_name":" Implications of resistance patterns with NSCLC targeted agents",
        "Background":"['Introduction', ' Tyrosine kinase inhibitors (TKIs) can give regression of NSCLCs with mutations of EGFR, HER2 & BRAF and fusion genes for ALK, ROS1 & RET, but resistance develops in most patients.Methods', ' We reviewed available clinical data for insights on potential approaches to delay resistance.Results', ' Target absence is a major cause of intrinsic resistance. Most NSCLCs with target undergo at least some regression although the degree varies between patients due to largely unexplored factors. Many mechanisms of acquired resistance have been defined, including outgrowth of subclones with secondary mutations or alternative pathways, and pharmacological effects & sanctuaries. Available data suggest that resistant cells are present in small numbers in the initial tumor but that their growth is suppressed by the more rapidly growing parent tumor cells until this parent population is itself suppressed by TKI initiation. If TKI is stopped due to progression, there can be tumor flare as the initial parent cell population regrows rapidly. Exponential decay nonlinear regression analysis of patient survival curves suggests that TKI discontinuation at time of progression may partially synchronize patient deaths. Initial tumor progression may occur in a single site. Available data indicate that focal treatment (eg, radiation) to that site combined with continuation of initial TKI may give optimal control and reduce tumor flare. Of interest, progression may occur in many sites concurrently. Since there are many potential resistance mechanisms one might expect substantial discordance of resistance mechanisms between these sites, but preliminary data with 2nd line agents (eg, anti-T790M agents in EGFR-mutant patients and 2nd generation anti-ALK agents for acquired resistance to crizotinib) indicate response in most sites if any are sensitive, suggesting that all or most sites have a common resistance mechanism. This raises the possibility that an initial resistant site is seeding other distant tumor sites with resistant cells, in keeping with animal data. The probability of a resistant cell being present in an individual tumor deposit is proportional to the total number of tumor cells in that deposit. If 1 area of resistant tumor can seed other tumor areas with resistant cells, then (particularly in oligometastatic disease) we should consider clinical trials exploring', ' 1) at initiation of TKI therapy treating as many tumor sites as possible (particularly large tumors) with a modality (eg radiation) that is indifferent to the factors giving TKI resistance; 2) treating any progressing lesions as early as possible with intensive focal therapy, if feasible, rather than waiting until symptomatic or rather than treating only with low palliative doses.Conclusion', ' Extrapolation from available data suggests we should explore trials using multifocal radiation at initiation of TKIs for advanced NSCLC and early, intense treatment of areas of isolated progression.']",
        "Doc_id":"AACR_2015-763",
        "Doc_title":" Implications of resistance patterns with NSCLC targeted agents",
        "_version_":1606189020159672320},
      {
        "Meeting_name":" IDH1057, A novel, synthetic, small molecule inhibitor of heat shock protein 90(Hsp90)",
        "Background":"['Backgroud', ' The molecular chaperone Heat shock protein 90(Hsp90) governs the stabilization and activity of an array of over 100 client proteins, many of which are key signaling molecules involved in cell proliferation, survival, and transformation. A significant number of these client proteins are oncogenic in nature, including the protein kinases Her2, C-Raf, B-Raf, and AKT. We report here that IDH1057 is structurally distinct from a geldanamycin derivative, tanespimycin(17-AAG) as a novel and potent small molecule Hsp90 inhibitor that binds to the NH2-terminal ATP-binding pocket of Hsp90. Results', ' IDH1057 exhibited superior binding affinity for the ATPase domain of Hsp90(IDH1057, human Hsp90 FP IC50<150 nM) compared to 17-AAG(IC50 =456.3 nM) in vitro. IDH1057 also markedly inhibited proliferation in a broad panel of human tumor cell lines(IC50100 nM) and depleted Her2 in SKBR3 breast cancer cells(IC50<50 nM). 10 NSCLC cell lines were relatively sensitive to IDH1057, irrespective of EGFR, Her2 or KRAS mutational status. IDH1057 was also highly effective against cell lines that displayed resistance to erlotinib. IDH1057 efficiently inhibited cell proliferation in 8 breast cancer cell lines including triple-negative breast cancer(TNBC) cell lines such as BT-20, Hs578T and MDA-MB-231. Exposure to IDH1057 led to a rapid and dramatic degradation of key signaling molecules in BT474 cells. Based on these results, we examined in vivo anti-tumor activity of IDH1057 in BT474 breast cancer xenografts. Following once daily oral dosing of IDH1057 at 200mg/kg on a weekly 5-day-on and 2-day-off schedule for 4 weeks, this compound showed statistically significant tumor growth inhibition(TGI=84.5%) and was well-tolerated with no observable body weight loss. A2780 ovarian cancer xenografts in mice treated orally with IDH1057 also resulted in potent tumor growth inhibition. More importantly, IDH1057 displayed favorable oral PK profiles in mice. Additionally, we performed in vitro ADME assays to characterize a new series of small molecule inhibitors. IDH1057 exhibited high metabolic stability in liver microsomes from human, mouse and beagle(60%). Five human CYP isoforms were not significantly inhibited by IDH1057 at 10uM. IDH1057 had moderate permeability in MDCK permeability assay(Papp=4.7x106 cm/sec). Conclusion', ' Our results indicate that IDH1057 is a novel and fully synthetic Hsp90 inhibitor with strong anti-tumor activity in vitro and in vivo. IDH1057 is a promising and orally active drug candidate for cancer therapy.']",
        "Doc_id":"AACR_2012-2768",
        "Doc_title":" IDH1057, A novel, synthetic, small molecule inhibitor of heat shock protein 90(Hsp90)",
        "_version_":1606189019264188416},
      {
        "Meeting_name":" Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible, dual inhibitor of EGFR and HER2 plus best supportive care (BSC) versus placebo plus BSC in patients with NSCLC failing 1-2 lines of chemotherapy (CT) and erlotinib or gefitinib (LUX- Lung1)",
        "Background":"['Background', ' No approved therapy exists for NSCLC patients (pts) who have failed chemotherapy (CT) and the reversible epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), erlotinib (E) or gefitinib (G). The efficacy of BIBW 2992 (Tovok), a potent, irreversible inhibitor of EGFR and human epidermal growth factor receptor 2 (HER2) with preclinical activity against the secondary resistance mutation T790M, in pts progressing after initial clinical benefit on E/G is being assessed in this randomized trial. Methods', ' Pts with advanced adenocarcinoma of the lung (Stage IIIB/IV; ECOG 0-2), who have failed one or two lines of CT (including platinum) and progressed following at least 12 weeks of E or G are randomized in a 2', '1 ratio to receive BSC plus either oral BIBW 2992 50 mg qd or placebo until disease progression or unacceptable toxicity. Primary endpoint is overall survival, with progression-free survival, objective response and clinical benefit rate and duration, safety and quality of life being secondary endpoints. Enrollment of 400 pts is planned (HR=0.70, 85% power). An unblinded interim analysis of tumor response and safety by the independent Data Monitoring Committee (DMC) after the first 40 evaluable pts treated with BIBW 2992 will determine continuation to full accrual. Results', ' From May to November 2008, 145 pts have been randomized and 76 are still on treatment. Demographics (n=145)', ' median age 59 (range', ' 30-82); female 68%, current/ex-smokers 38%; metastatic disease 91%, ECOG 0-1 92%; Asian origin 68%. 50% had one prior line of CT. Main prior EGFR-TKI was G in Asians (70%) and E in non-Asians (85%). 40% of pts had achieved a PR or CR on previous treatment with E/G. Duration of prior E/G treatment was >24 weeks and >48 weeks in 80% and 40% of pts, respectively. As expected, diarrhea, rash, anorexia, stomatitis, paronychia, nausea and vomiting were the most frequently observed adverse events. Conclusions', ' The trial is continuing recruitment after DMC review of efficacy and safety and updated demographics and blinded safety data will be reported.']",
        "Doc_id":"ASCO_33860-65",
        "Doc_title":" Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible, dual inhibitor of EGFR and HER2 plus best supportive care (BSC) versus placebo plus BSC in patients with NSCLC failing 1-2 lines of chemotherapy (CT) and erlotinib or gefitinib (LUX- Lung1)",
        "_version_":1606189035163746304},
      {
        "Meeting_name":" Study of hTERT and IL-12 DNA immunotherapy using electroporation in patients with solid tumors after definitive surgery and adjuvant therapy.",
        "Background":"['Background', '  hTERT, the human catalytic reverse transcriptase subunit of telomerase, is highly expressed in breast, lung, and pancreatic cancers. Peptides derived from hTERT can be recognized on MHC by cytotoxic T cells and mediate tumor death. In preclinical studies, TERT DNA delivered with electroporation (EP) triggered an immune response in vivo that slowed tumor growth in HPV16-associated tumor-bearing mice. The advantages of DNA-based immunotherapy include (1) strong immunogenicity exceeding those achieved by viral vectors; (2) non infectiousness of the immunogen; (3) ability for repeated dosing; and (4) relatively low cost. EP can be used to optimally and safely deliver DNA in vivo by creating a transient electric field to enhance the cellular uptake of large molecules such as DNA. Addition of IL-12 to hTERT significantly enhanced immune responses in preclinical models. We hypothesized that generation of robust T-cell immunity by immunotherapy with hTERT + IL-12 can be clinically used to reduce the risk of relapse in high-risk cancer patients in the adjuvant setting.   Methods', '  This hypothesis is being tested in a phase 1 clinical trial (NCT02327468) sponsored by Inovio and opened at Abramson Cancer Center of the University of Pennsylvania. INO-1400 is a plasmid encoding hTERT. INO-9012 is a dual promoter plasmid encoding human IL-12 subunits p35 and p40. INO-1400 and INO-9012 are delivered IM followed by EP with the CELLECTRA device. This is an open-label, dose escalation study in patients with lung, pancreas, or breast carcinomas at high risk of relapse. Eligible patients must have early stage ER+ or HER2+, or any stage triple negative breast cancer; or Stage IB-IIIA NSCLC; or Stage I-III pancreatic cancer. Patients will enroll  4 and  16 weeks from completion of definitive surgery and adjuvant therapy into 1 of 6 cohorts (total N = 54)', ' dosing INO-1400 at 2 or 8 mg  INO-9012 at 0.5 or 2 mg, with EP, once every 4 weeks for 4 total treatments. Primary Endpoints', 'Safety and tolerability. Secondary Endpoints', '(1) Time to progression; (2) Antigen-specific T cell response by IFN- ELISpot and flow cytometry; (3) antigen-specific humoral responses by ELISA. Clinical trial information', ' NCT02327468']",
        "Doc_id":"ASCO_146214-156",
        "Doc_title":" Study of hTERT and IL-12 DNA immunotherapy using electroporation in patients with solid tumors after definitive surgery and adjuvant therapy.",
        "_version_":1606188991562907649},
      {
        "Meeting_name":" A phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of one line of chemotherapy (LUX-Lung 2).",
        "Background":"['Background', ' EGFR mutations are associated with exquisite sensitivity to EGFR TKIs in NSCLC. A phase II trial evaluating the efficacy of BIBW 2992 (Tovok), a novel, potent, irreversible, dual EGFR and HER2 TKI with preclinical activity in cell lines harboring activating (H3255, IC50=0.7 nM) and resistant (H1975, IC50=99 nM) EGFR mutations, is reported. Methods', ' Objective response rate is the primary endpoint of this 2-stage trial. Based on 16 or more unconfirmed PRs in an interim analysis of the first 40 2nd line patients (pts) completing 1 course (28 days), accrual will continue to a total of 120 1st and 2nd line pts (expected completion of accrual by May 2009. Data on 2nd line pts only are presented). Eligible pts have stage IIIB/IV lung adenocarcinoma, EGFR mutation in exons 18-21 (tested by direct sequencing), measurable disease, ECOG PS 0-2 and adequate end organ function. Pts receive 50 mg BIBW 2992 qd until progression. Tumor assessments are performed every 4 weeks for 12 weeks, then every 8 weeks. Results', ' Since Oct 2007, samples from 289 pts (222 from Taiwan and 67 from the US) have been sequenced. 100 had detectable EGFR mutations including del19 (n=39), L858R (n=45) and others (n=16). 69 pts have started treatment. The trial was moved to stage 2 after 21 of the first 38 treated pts had objective response at 28 days. Of 55 evaluable 2nd line pts, 29 (53%) had PR, and 23 (42%) had SD. Median follow up is 5.1 months. Most common related AEs were diarrhea and skin-related AEs, reported in 87% and 88% of pts, respectively. 27 pts (42.9 %) had dose reduction to 40 mg and 7 pts (11%) to 30 mg but only 1 pt permanently discontinued due to AEs. Diarrhea and rash were main causes of dose reduction. Conclusions', ' In the 2nd line setting, BIBW 2992 shows efficacy in NSCLC harboring EGFR activating mutations. Diarrhea and skin disorders, the most frequently observed AEs, are manageable with supportive care and dose reduction. Updated response and disease control rates and preliminary progression-free survival data will be presented. An international Phase III trial program investigating BIBW 2992 in NSCLC, LUX-Lung, is now recruiting.']",
        "Doc_id":"ASCO_33988-65",
        "Doc_title":" A phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of one line of chemotherapy (LUX-Lung 2).",
        "_version_":1606188988223193088},
      {
        "Meeting_name":" A phase I study of bevacizumab in combination with sunitinib, sorafenib, and erlotinib plus cetuximab, and trastuzumab plus lapatinib.",
        "Background":"['Background', ' Angiogenesis has a fundamental role in tumor growth and metastasis, and antiangiogenic agents, such as the monoclonal antibody bevacizumab (bev), have demonstrated clinical benefit for a variety of malignancies. We hypothesized that bev may be more effective when combined with other biological agents, and we performed a 4-arm phase I trial to assess safety, MTD, and correlates of anti-angiogenic activity of bev in combination with 1) sunitinib, 2) sorafenib, 3) erlotinib + cetuximab, 4) trastuzumab + lapatinib. Methods', ' Patients (pts) with advanced malignancy refractory to standard therapy were eligible. Pts received bev in the above combinations with stair-step dose escalation. Clinical correlates included DCE-MRI, plasma VEGF, plasma VEFGR2, and VEGF polymorphisms. Results', ' To date, 145 pts have been treated. Arm 1 enrollment was discontinued after an FDA alert regarding hemolytic anemia among pts treated with combination bev and sunitinib at other centers. No significant toxicities were observed among the 5 pts who enrolled at our center. On arm 2, the MTD was identified as bev 5 mg/kg days 1 and 15 with sorafenib 200 mg BID on a 28-day cycle. DLTs included G3 hypertension (3 pts), G3 hand-foot syndrome (2 pts), and G3 elevated transaminases (1 pt). Two PRs were achieved, including ovarian cancer (1 pt) and melanoma (1 pt). On arm 3, an MTD has not yet been identified. Current doses include bev 10 mg/kg days 1 and 15, cetuximab 400 mg/m2 loading and 250 mg/m2 maintenance weekly, erlotinib 150 mg daily, on a 28-day cycle. DLTs included G3 bleeding (1 pt), anemia (1 pt), bronchospasm (1 pt), and dyspnea (1 pt). One PR was achieved in NSCLC. On arm 4, an MTD has not yet been identified. Current doses include bev 10 mg/kg on day 1, trastuzumab 6 mg/kg loading and 4 mg/kg maintenance on day 1, lapatinib 1250 mg daily, on a 21-day cycle. DLTs included G3 diarrhea (1 pt). One CR and 4 PRs were observed in pts with HER2+ breast refractory to prior HER2 therapy. Conclusions', ' These bevacizumab combinations are well-tolerated and demonstrate preliminary evidence of antitumor activity. Updated clinical and biomarker data, including DCE-MRI, plasma VEGF/VEFGR2, and VEGF polymorphisms, will be presented.']",
        "Doc_id":"ASCO_51528-74",
        "Doc_title":" A phase I study of bevacizumab in combination with sunitinib, sorafenib, and erlotinib plus cetuximab, and trastuzumab plus lapatinib.",
        "_version_":1606189038372388864},
      {
        "Meeting_name":" Assessment of concentrations of abemaciclib and its major active metabolites in plasma, CSF, and brain tumor tissue in patients with brain metastases secondary to hormone receptor positive (HR+) breast cancer.",
        "Background":"['Background', ' Abemaciclib, an oral drug administered twice daily on a continuous schedule, is an inhibitor of both cyclin-dependent kinases (CDKs) 4 and 6. A Phase 1 study of abemaciclib showed evidence of single-agent activity in a cohort of patients with heavily pre-treated HR+ metastatic breast cancer (MBC). These findings, coupled with preclinical data demonstrating that abemaciclib crosses the blood-brain barrier, have led to investigation of abemaciclib in the current trial which includes patients with brain metastases secondary to HR+ MBC. Methods', ' Study JPBO (NCT02308020) is an open-label, Phase 2 trial evaluating the safety and efficacy of doses of abemaciclib up to 200 mg administered orally every 12 hours on Days 1 to 21 of a 21-day cycle in patients with brain metastases secondary to HR+ MBC, NSCLC, or melanoma. An exploratory objective of this study is to assess approximately 8 patients with brain metastases secondary to HR+ MBC, NSCLC, or melanoma for whom surgical resection is clinically indicated, and who agree to provide post-treatment (5 to 14 days after initiating abemaciclib) brain tumor tissue, with the goal of determining concentrations of abemaciclib and its metabolites in plasma, CSF, and brain metastases. These patients may resume treatment with abemaciclib post-operatively. Results', ' To date, a total of 3 patients (all with HR+, HER2- MBC) have provided post-treatment brain tumor tissue for analysis. All 3 patients were treated for > 5 days with abemaciclib prior to tumor resection; thus, it is anticipated that abemaciclib was at steady state at the time of surgical resection. Measurable levels of abemaciclib and active metabolites were detected in brain tumor tissue for all 3 patients. Unbound concentrations of abemaciclib in the plasma and tumor tissue were comparable and generally consistent with the CSF concentration for each of the patients. Conclusions', ' These early data suggest that abemaciclib penetrates human breast cancer brain metastases. Further data, related to safety and efficacy, from this ongoing study are necessary to determine the clinical relevance of these findings. Clinical trial information', ' NCT02308020']",
        "Doc_id":"ASCO_162841-176",
        "Doc_title":" Assessment of concentrations of abemaciclib and its major active metabolites in plasma, CSF, and brain tumor tissue in patients with brain metastases secondary to hormone receptor positive (HR+) breast cancer.",
        "_version_":1606188975414837249},
      {
        "Meeting_name":" Evaluation of genomic profiling in the GALAXY-1 (NCT01348126), a randomized Phase 2b study of ganetespib in combination with docetaxel versus docetaxel alone as second line therapy in patients with advanced NSCLC",
        "Background":"['Background', ' Inhibition of Hsp90, a key molecular chaperone required for activation of many oncoproteins, can lead to cancer cell death. Ganetespib (G) is a 2nd generation Hsp90 inhibitor (Hsp90i) that has single agent clinical activity in patients with ALK, KRAS, HER2, and BRAF mutations. G also inhibits pathways implicated in resistance to taxanes, including hypoxia pathways (HIF-1) as well as cell-cycle and DNA repair pathways. Combination of G with docetaxel (D) has shown synergy in NSCLC xenografts and prolongation of progression-free survival (PFS) and overall survival (OS) of patients with NSCLC adenocarcinoma in interim analyses of the GALAXY-1 trial. Methods', ' Patients enrolled in GALAXY-1 (n=253) receive D 75 mg/m2 on D1 of a 3-week treatment cycle; combination arm patients receive G 150 mg/m2 on D1 and D15 in addition. The co-primary endpoints are PFS in patients with elevated baseline level of serum LDH and PFS in the mutant KRAS population. PFS and OS in all adenocarcinoma patients are key secondary endpoints. Genomic profiling using Affymetrix Oncoscan was performed on archival tissues obtained at baseline, with the goal of determining biomarkers predictive of ganetespib activityResults', ' Tumor tissue samples from 65 patients and 26 matched normal tissues were processed on the Affymetrix OncoScan FFPE Express 2.0 Services assay. The OncoScan FFPE Express 2.0 assay contains 332941 copy number probes. After removing samples with average call rates lower than 90%, 296522 markers on chromosome 1-22 were selected for copy number analyses. For preliminary evaluation of interactions between copy number aberrations and treatment response in the G arm, a genome scale Kaplan-Meier Estimates PFS analysis at each of 296522 markers was performed.Conclusions', ' Genomic profiling using OncoScan is utilized in the GALAXY-1 trial to identify biomarkers of response/resistance to ganetespib administered in combination with docetaxel. Complete analyses will be presented at the meeting.Note', ' This abstract was not presented at the meeting.']",
        "Doc_id":"AACR_2014-4657",
        "Doc_title":" Evaluation of genomic profiling in the GALAXY-1 (NCT01348126), a randomized Phase 2b study of ganetespib in combination with docetaxel versus docetaxel alone as second line therapy in patients with advanced NSCLC",
        "_version_":1606188982768500736},
      {
        "Meeting_name":" Astrocytic elevated gene 1 (AEG1) a target for pharmacological anticancer intervention",
        "Background":"[\"AEG1 is highly expressed in solid tumors; hyperexpression confers multidrug resistance, increased tumor proliferation, angiogenesis, metastatic potential and poor outcome in most solid tumors. AEG1 activates multiple protumorogenic signal transduction pathways like PIK3/ALT, NFKB, MAMPK, WNT and is a rational target for therapeutic intervention in solid tumors.Also AEG1 functionality is instrumental in the natural history of brain tumors. Our data in NSCLCs confirm AEG1 overexpression as the main parameter (uni and multivariate analysis) indicative of outcome to targeted and cytotoxic therapy. We designed an in silico model based on inhibition of AEG1-p65 crosstalk, identifying a possible interacting interface between the 2 proteins that could be modeled as a three-dimensional structure. This interface was further reduced and transformed into a 3-point pharmacophore for virtual screening comparing both molecular interaction fields and the pharmacophore. A total of 217.000 chemical entities (CEs) were tested in this model giving a Hercules affinity ranking. Sixty CEs with the highest Hercules ranking were identified for a second (16 CEs) and third (5 CEs) selection to implement the first round of in vitro studies in our human solid tumor panel. Twenty analogs were generated to seek for a lead according to prospective selection criteria. PB0412-3 (PB3), a small molecule polyheterocyclic compound, was selected for further development. PB3 displays antitumor activity in the human solid tumor panel (median IC50 1.3 uM) and PB3-induced growth inhibition appears independent of EGFR, KRAS & p53 mutational status, Her2 amplification, PIK3 mutations and BRCA1 expression;tumor cell lines bearing highest AEG1-mRNA expression levels were sensititive to PB3. Median IC50 in our glioblastoma (GBM) panel was 60 nM with no impact of MGMT methylation status on PB3's molar potency (MP). IC50s delta solid vs brain tumors were significant (p<.0001) representing a 25-fold increase in MP. Data from nitrosureas in the same GBM panel indicate PB3 is 250 times more potent than BCNU and temozolamide. Median IC50s in human non cancer lines is 2 uM. PB3 was re-screened in the in silico model; PB3 fully matches the AEG1 binder pharmacophore model and was screened in the Chemical Space web tool; results confirm PB3 as first-in-class CE. Functional studies are ongoing; preliminary data in PC9 NSCLC cell line demonstrate significant PB3-induced downregulation of AEG1 mRNA expression. Expansion of the CNS tumor panel, cell kinetics, drug-induced cell death & in vivo/PK-PD studies in SC orthotopic models is ongoing. To the best of our knowledge, this is the first successful attempt at the Pharmacological intervention against the AEG1 pathway. A dual developmental plan for PB3 as local brain drug delivery and systemic therapy is proposed.\"]",
        "Doc_id":"AACR_2014-4601",
        "Doc_title":" Astrocytic elevated gene 1 (AEG1) a target for pharmacological anticancer intervention",
        "_version_":1606188992202539008},
      {
        "Meeting_name":" CheckMate 649",
        "Background":"['Background', ' Pts with adv G/GEJ cancer have an OS of  1 y, indicating an unmet medical need for new first-line treatments (Tx). Expression of the PD-1 ligands PD-L1/PD-L2 is observed in up to 40% of pts with G/GEJ cancer and is associated with poor prognosis. In a phase 3 study of the PD-1 inhibitor nivo vs placebo in pts with adv CTX-refractory (CTX-R;  2 lines) G/GEJ cancer, nivo reduced the risk of death by 37% (HR, 0.63; P< 0.0001) and increased the OS rate at 12 mo (27% vs 11%; Kang YK, et al. J Clin Oncol. 2017;35 (suppl 4S) [abstract 2]). In a phase 1/2 study in pts with CTX-R G/GEJ/esophageal cancer (79%  2 prior Tx lines), nivo 1 mg/kg + ipi 3 mg/kg had a manageable safety profile and resulted in 26% ORR (44% ORR in pts with PD-L1+ tumors), a median OS of 6.9 mo, and a 34% OS rate at 12 mo (Janjigian Y, et al. ASCO, 2016 [abstract 4010]). In the phase 1 CheckMate 012 trial, nivo + CTX had clinical activity and manageable safety in pts with NSCLC (Rizvi NA, et al. J Clin Oncol. 2016;34', '2969-2979). These positive results support investigation of nivo, nivo + ipi, and nivo + CTX in earlier lines of Tx for G/GEJ cancer. The open-label, phase 3 CheckMate 649 trial will evaluate nivo + ipi and nivo + CTX vs CTX alone as first-line Tx for pts with adv G/GEJ cancer (NCT02872116). Methods', ' 1266 pts aged  18 y with untreated, inoperable adv/metastatic G/GEJ cancer (histologically confirmed adenocarcinoma) regardless of PD-L1 status will be randomized to receive either nivo + ipi, nivo + CTX (capecitabine/oxaliplatin [XELOX] or fluorouracil/leucovorin/oxaliplatin [FOLFOX]), or investigator choice of XELOX or FOLFOX. Tumor tissue for determination of PD-L1 status (Dako assay) must be provided from  6 mo before study Tx. No prior systemic Tx, including HER2 inhibitors, are allowed. Pts with known HER2+ status, suspected autoimmune disease, grade > 1 peripheral neuropathy, or active infection are excluded. Primary endpoint is OS in pts with PD-L1+ ( 1%) tumors. Other endpoints include OS in all pts; PFS and time to symptom deterioration in all pts and in pts with PD-L1+ tumors; and safety. Clinical trial information', ' NCT02872116']",
        "Doc_id":"ASCO_185304-199",
        "Doc_title":" CheckMate 649",
        "_version_":1606189039851929600},
      {
        "Meeting_name":" CDK4/6 inhibitor PD-0332991 (palbociclib) promotes cell death and synergizes with CPT-11 in colorectal cancer under hypoxia in vitro",
        "Background":"['We recently reported that a family of nucleoside analogues (sangivamycin-like molecules) can sensitize tumor cells to TRAIL through dual blockade of CDK1 and GSK3-beta (Mayes et al., Cancer Research, 2011). We further reported that CDK inhibitors can destabilize HIF1-alpha regardless of VHL or p53 status or the presence of hypoxia (Warfel et al., Cell Cycle, 2013). In order to translate this knowledge into a cancer therapeutic strategy, we investigated the effects of CDK inhibition in colorectal cancer (CRC) cell lines with or without chemotherapy. PD-0332991 (Palbociclib) is a specific inhibitor of CDK4/6 that has been tested in numerous clinical trials for breast cancer, NSCLC, GBM, lymphoma, leukemia, in combination with 5-FU and oxaliplatin in solid malignancies (NCT01522989) or with cetuximab in head and neck cancer (NCT02101034). Palbociclib was approved by the FDA in 2015 in combination with letrozole as initial endocrine therapy for post-menopausal women with ER(+)/Her2(-) breast cancer. Little is known about the effects of CDK4/6 inhibition in CRC. We investigated the therapeutic effect and anti-proliferative mechanism of CDK4/6 inhibition in CRC. We used CellTiter-Glo assays to detect CRC cell viability and determined IC50 values (50% inhibitory concentration) of single drug through nonlinear regression analysis by GraphPad Prism software. The combination index (CI) of multiple drug combinations was identified with Compusyn analysis. We found that Palbociclib promotes cell death of CRC cells under hypoxia but not under normoxia where Palbociclib inhibited cell proliferation via the pRb pathway. These results suggest that the CDK4/6 inhibitor could regulate cell fate of CRC via different molecular mechanisms under hypoxia versus normoxia. We further found that Palbociclib can upregulate ERK/MAPK signaling under hypoxia, as compared with normoxia. The IC50 values of Palbociclib were generally higher under hypoxia (Mean  SD', ' 10.54  3.35 M, N = 5) versus normoxia (Mean  SD', ' 6.61  0.85 M, N = 5) in CRC cell lines. Thus, hypoxia promotes resistance of CRC cells toward the cytotoxic activity of the CDK4/6 inhibitor. We found that Palbociclib synergizes with CPT-11 much better than with either 5-FU or oxaliplatin against CRC cell lines with different molecular subtypes. Based on our findings that Palbociclib can promote cell death of CRC cells under hypoxia and synergizes with CPT11, further investigation is needed to assess the novel combination therapy against CRC.']",
        "Doc_id":"AACR_2016-2840",
        "Doc_title":" CDK4/6 inhibitor PD-0332991 (palbociclib) promotes cell death and synergizes with CPT-11 in colorectal cancer under hypoxia in vitro",
        "_version_":1606188976429858816},
      {
        "Meeting_name":" Ex-vivo analysis of the isoform selective histone deacetylase inhibitor entinostat in triple-negative breast cancer tumors.",
        "Background":"['Background', ' Triple-negative (ER, PR, HER2 negative) breast cancer represents an unmet need for which novel agents and approaches are essential. Entinostat is an orally available, class 1 isoform selective histone deacetylase inhibitor currently in multiple phase 2 clinical studies including advanced NSCLC and breast cancer. Studies in vitro and in vivo in the triple negative cell line model MDA-MB-231 have established single agent activity of entinostat in inhibiting tumor growth as well preventing bone metastases. In addition, entinostat induces expression of ER in MDA-MB-231 in vivo and is synergistic with endocrine therapy agents to inhibit tumor growth of ER negative cancer cells. The aim of these studies was to confirm the activity of entinostat in triple negative breast cancers using human breast tumor explants. Methods', ' Cytotoxicity of entinostat was determined by the Oncotech Extreme Drug Resistance (EDR) proliferation assay using ten cryopreserved breast tumor explants known to lack estrogen receptor, progesterone receptor and HER2/neu expression (i.e. Triple negative) by immunohistochemistry. Results', ' Dose response curves of entinostat were analyzed and compared to paclitaxel at 2.45 M in ten triple negative breast tumor explants in the EDR assay. Entinostat was broadly effective in all of the tumors tested, with most samples showing dose-dependent response for the range of concentrations analyzed (0.003 - 10 M). Two of the breast tumors that were most sensitive to entinostat (IC50 30- 100nM) were also sensitive to paclitaxel. In contrast, entinostat effectively inhibited (IC50 10-270nM) the growth of eight of the tumors that were resistant to paclitaxel (i.e. < 50% growth inhibition). Overall, all breast tumors tested were sensitive to entinostat at clinically achievable concentrations regardless of paclitaxel resistance indicating entinostat may improve the treatment outcome of triple negative breast cancer patients. Conclusions', \" Entinostat is an effective agent at inhibiting the growth of triple negative breast tumors with clinically relevant IC50's ranging from 10nM to 270nM. A pre-surgical clinical study to assess the activity of entinostat in triple negative breast cancer patients is planned.\"]",
        "Doc_id":"ASCO_35480-65",
        "Doc_title":" Ex-vivo analysis of the isoform selective histone deacetylase inhibitor entinostat in triple-negative breast cancer tumors.",
        "_version_":1606188997718048768},
      {
        "Meeting_name":" NOSH-aspirin inhibits breast cancer cell growth",
        "Background":"['Introduction', ' We recently reported the synthesis and characterization of NOSH-aspirin a highly potent hybrid; that releases both nitric oxide (NO) and hydrogen sulfide (H2S) two important signalling molecules of physiological relevance. The present study was undertaken to unravel some of the underlying mechanisms of its action. Methods', ' Cell lines', ' MCF-7 (ER+), MDA-MB-231 (ER-, PR-, does not over express Her2), HMEpC, normal human mammary epithelial; Cell growth', ' MTT; Cell cycle phase distribution', ' Apoptosis and cell cycle', ' Flow cytometry; Proliferation', ' PCNA; ROS', ' measured hydrogen peroxide and super oxide by flow cytometry using DCFDA and DHE dyes. Xenografts', ' NuNu mice (N=5/group) implanted with MCF-7 and MDA-MB 231, after 10 days randomly divided animals and gavaged daily with NOSH-ASA (100 mg/kg body weight) or vehicle. Tumor volume and animal weight were recorded every 3 days. After 4 weeks of treatment, mice were sacrificed, tumors excised, weighed, and fixed in 10% buffered formalin. Results', \" NOSH-aspirin's IC50 in nM at 24h for cell growth inhibition were MCF-7 (28520), MDA-MB-231 (989), HMEpC (20,0003,000); aspirin's IC50 in all cell lines was greater than 5,000,000 nM at 24h. Cell proliferation at 2xIC50 was decreased 314 % in ER+ cells and 27.8 2% in ER- cells. This was accompanied by a G0-G1 phase cell cycle arrest (59.5% at IC50 for ER+ cells and 66.3% at IC50 for ER- cells). NOSH-aspirin at the doses studied, did not cause appreciable apoptosis at 24hr, at 2xIC50 the values being 32.73% in ER(+) and 242% in ER(-) cells. These results are in line with our data showing that in PC9 lung cancer cells stably expressing cytochrome c-GFP (used for mitochondrial cytochrome c release) NOSH-aspirin caused partial release of cytochrome c up to 3 hours when followed in real -time by fluorescence microscopy and image analysis. NOSH-ASA increased intracellular H2O2 and superoxide anions. Pretreatment of cells with N-acetylcysteine, blocked these. Xenografts\", ' NOSH-aspirin had no effect on the weight of the mice and there were no overt signs of toxicity. Tumor volume was reduced as a function of treatment time. The growth rate of ER(-) xenografts was significantly greater than that of ER(+) ones and NOSH-aspirin had a greater effect on the ER(-) vs ER(+) xenografts. Tumor mass for each group were, ER(+)', ' 0.460.056g untreated and 0.210.035g treated, (55% reduction, P=0.022), ER(-)', ' 1.20.33g untreated and 0.110.058g treated (91% reduction, P=0.006). NOSH-aspirin inhibited growth of these cancer cell xenografts as a result of reduced proliferation (decreased PCNA expression), and induction apoptosis (increased number of TUNEL positive cells), and induction of ROS. Conclusions', ' NOSH-aspirin preferentially affects cancer cells and has potent anti-cancer properties. It targets parameters important in determining cellular mass and merits further evaluation.Citation Format', ' Diandra E. Nesbitt, Mitali Chattopadhyay, Federica Vannini, Thuy-Tien C. Le, Ravinder Kodela, Niharika Nath, Khosrow Kashfi. NOSH-aspirin inhibits breast cancer cell growth', ' an effect modulated through reactive oxygen species and independent of the ER status. [abstract]. In', ' Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA)', ' AACR; Cancer Res 2013;73(8 Suppl)', 'Abstract nr 4793. doi', '10.1158/1538-7445.AM2013-4793']",
        "Doc_id":"AACR_2013-4793",
        "Doc_title":" NOSH-aspirin inhibits breast cancer cell growth",
        "_version_":1606189033901260800},
      {
        "Meeting_name":" Phase II, open-label trial to assess the effect of continuous oral afatinib (BIBW 2992) at a daily dose of 50 mg on QTc, pharmacokinetics, and efficacy in relapsed or refractory solid tumors including brain metastases and glioblastoma that is not amenable to other therapy.",
        "Background":"['Background', '  Afatinib (BIBW 2992) is an oral, irreversible ErbB family blocker. This trial prospectively evaluated the possible proarrhythmic potential of afatinib by assessing QTc interval, as well as its PK and clinical efficacy.   Methods', '  Patients (pts) with tumors known to overexpress EGFR or HER2, including those with brain metastases and GBM were eligible for treatment with daily afatinib 50mg. Pts with a QTcF-interval >470 ms, a PR-interval >230 ms, a QRS-interval >120 ms and ST-segment and T/U-wave abnormalities at screening, as assessed by central cardiology review, were excluded. 60 pts were treated. Time-matched 24-h ECGs were performed prior to drug exposure, after single dose and at steady state. Pharmacokinetic (PK) samples were drawn on days coincident with ECGs.  Results', '    49 of 60 pts were analyzed for the QTcF. The largest mean time matched QTcF change from baseline to Day 14 was 1.6 ms (90% CI 2.1, 5.2) at 1 h post dosing. The analysis of the relationship between the afatinib concentrations and time-matched QTcF changes from baseline revealed a statistically significant negative slope and a predicted negative QTcF change from baseline (90% CI -2.83, 2.55 ms).  No relevant effect of afatinib on other cardiac intervals was detected. The overall AE profile was consistent with the known safety profile of afatinib. The median tmax value for afatinib was approximately 3 h after a single dose (Day 1) and at steady state (Day 14). The gMean accumulation ratio was 2.05 based on Cmax values and 2.67 based on AUC values. Efficacy was assessed in 60 pts including NSCLC (35%), breast cancer (10%), GBM (7%) & GI tumors (32%). Two pts had brain metastases. 42% of the pts received > 4 treatment cycles, 18% > 6 cycles, and one pt 19 cycles.  Conclusions', '  Afatinib at doses of 50 mg daily did not suggest any drug-induced QT/QTcF prolonging effects compared with baseline. Afatinib showed clinical efficacy in this patient population.']",
        "Doc_id":"ASCO_83371-102",
        "Doc_title":" Phase II, open-label trial to assess the effect of continuous oral afatinib (BIBW 2992) at a daily dose of 50 mg on QTc, pharmacokinetics, and efficacy in relapsed or refractory solid tumors including brain metastases and glioblastoma that is not amenable to other therapy.",
        "_version_":1606189041454153729},
      {
        "Meeting_name":" A phase 1, open-label study to evaluate the safety and pharmacokinetics of the anti ErbB3 antibody, KTN3379, alone or in combination with targeted therapies in patients with advanced tumors.",
        "Background":"['Background', '  KTN3379 is a human monoclonal antibody against a unique epitope of human epidermal growth factor receptor-3 (ErbB3) blocking ligand (neuregulin (NRG)) dependent and independent activation. This trial assessed safety and pharmacokinetics (PK) of KTN3379 alone or with each of four targeted agents in advanced cancers and evaluated potential biomarkers of KTN3379 activity.  Methods', '  Part I evaluated KTN3379 in a single agent dose escalation design. Part II evaluated KTN3379 with each of cetuximab, erlotinib, vemurafenib and trastuzumab in patients with refractory SCCHN, CRC, NSCLC, melanoma and HER2+ breast cancer (n = 6 each). Dose limiting toxicities (DLT) were evaluated in the first treatment cycle, RECIST tumor measurements every 3rd treatment cycle and PK and blood pharmacodynamic (PD) assessments each treatment cycle. Archival tumor tissue was evaluated for biomarkers and correlated with KTN3379 activity.  Results', '  In Part I, no DLTs were observed in the 16 patients treated with KTN3379 at doses of 5 up to its maximally administered dose of 20 mg/kg IV every 3 weeks. PK parameters were linear, supported every 3-week dosing, and trough blood levels following dosing of KTN3379 at 10-20 mg/kg were consistent with maximum antitumor activity in preclinical models. Grade 3 or higher treatment related AE was reported in 1 patient (diarrhea). Other treatment related AEs were low grade diarrhea (n = 5), mucositis (n = 3), rash (n = 3), anemia (n = 2), and fatigue (n = 2). Patients in Part II to date had a similar profile, with low grade diarrhea, mucositis and rash being the most common AEs. In both Parts, elevations of soluble ErbB3 were noted after treatment. Other blood biomarkers and NRG expression are being evaluated. The best tumor response to date has been stable disease.  Conclusions', '  Doses of 10-20 mg/kg exceed target blood concentrations. KTN3379 doses of 20 mg/kg with other targeted agents are safe and PK supports 3-week dosing. KTN3379 has the potential to benefit patients in combination with other targeted agents against ErbB family members, and NRG may be a predictive biomarker of response to KTN3379 in future studies. Clinical trial information', ' NCT02014909']",
        "Doc_id":"ASCO_152253-156",
        "Doc_title":" A phase 1, open-label study to evaluate the safety and pharmacokinetics of the anti ErbB3 antibody, KTN3379, alone or in combination with targeted therapies in patients with advanced tumors.",
        "_version_":1606188982656303104}]
  }}
